[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAxA-YhnL7gcpnWUACcFDoUoyrRee8gOMkZFZOxvSp2Y":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":36,"phaseBuckets":85,"rows":92},"University of Wisconsin, Madison",[4],1155,false,214,29,2580350,91,778,[14,17,20,23,25,28,30,33],{"name":15,"count":16},"Breast Cancer",33,{"name":18,"count":19},"Prostate Cancer",31,{"name":21,"count":22},"Healthy",27,{"name":24,"count":22},"Obesity",{"name":26,"count":27},"Smoking Cessation",26,{"name":29,"count":27},"Smoking",{"name":31,"count":32},"Nicotine Dependence",20,{"name":34,"count":35},"Asthma",18,[37,42,47,52,57,61,66,71,76,81],{"nctId":38,"briefTitle":39,"date":40,"intervention":41},"NCT03600350","pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer","2022-11-07","pTVG-HP",{"nctId":43,"briefTitle":44,"date":45,"intervention":46},"NCT04489732","MSC in Patients With Xerostomia Post XRT in Head and Neck Cancer","2022-11-22","Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells",{"nctId":48,"briefTitle":49,"date":50,"intervention":51},"NCT03958383","IT-hu14.18-IL2 With Radiation, Nivolumab and Ipilimumab for Melanoma","2024-01-06","hu14.18-IL2",{"nctId":53,"briefTitle":54,"date":55,"intervention":56},"NCT03725761","Sacituzumab Govitecan in Patients With Metastatic Castration-Resistant Prostate Cancer Progressing on Second Generation AR-Directed Therapy","2024-04-18","Sacituzumab Govitecan",{"nctId":58,"briefTitle":59,"date":60,"intervention":41},"NCT04090528","pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer","2024-11-24",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT03943901","Split-Dose R-CHOP for Older Adults With DLBCL","2025-01-13","Rituximab",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT05820711","Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy","2025-12-09","MSC",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05477823","Imaging and Genomic Biomarkers to Predict Response in Prostate Cancer","2026-04-02","Androgen deprivation therapy",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06122610","Using Novel Imaging to More Safely Treat Neuroendocrine Tumors","2026-06","64Cu-Dotatate",{"nctId":82,"briefTitle":83,"date":79,"intervention":84},"NCT04573231","Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer","18F-DCFPyL",[86,87,88,89,90,91],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[93,244,315,378,405,423,450,468,503,530,591,669,728,776,819,851,884,919,952,994,1024,1055,1089,1125,1165,1194,1216,1247,1282,1304,1331,1354,1378,1396,1414,1432,1450,1468,1486,1508,1528,1553,1571,1589,1607,1625,1643,1661,1687,1705,1727,1753,1771,1789,1812,1838,1856,1882,1951,2010,2079,2111,2151,2196,2225,2247,2268,2286,2312,2330,2348,2368,2394,2412,2436,2458,2478,2507,2525,2549,2567,2592,2626,2659,2677,2695,2715,2738,2771,2794,2817,2842,2879,2910,2946,2972,3020,3051,3088,3110,3132,3154,3190,3227,3255,3280,3308,3326,3350,3373,3391,3417,3435,3453,3471,3489,3514,3539,3557,3581,3606,3629,3652,3683,3701,3719,3737,3755,3773,3791,3809,3827,3845,3863,3881,3899,3923,3941,3965,3990,4008,4034,4052,4070,4088,4112,4136,4161,4179,4202,4227,4245,4263,4288,4306,4333,4351,4369,4387,4412,4430,4448,4476,4494,4512,4530,4548,4566,4594,4617,4641,4659,4685,4703,4721,4739,4763,4781,4805,4831,4849,4872,4894,4917,4940,4958,4981,5006,5033,5056,5082,5105,5127,5150,5168,5194,5263,5302,5340,5373,5399,5440,5471,5501,5528,5561,5591,5613,5644,5666,5690,5708,5732,5757,5775,5793,5814,5832,5857,5875,5899,5917,5940,5964,5991,6009,6034,6060,6083,6101,6122,6147,6171,6194,6212,6235,6253,6277,6304,6327,6345,6363,6388,6410,6434,6460,6485,6508,6532,6550,6574,6597,6621,6647,6671,6694,6718,6741,6759,6777,6795,6818,6841,6865,6886,6911,6929,6952,6970,6995,7013,7040,7063,7086,7113,7131,7149,7167,7192,7210,7236,7254,7279,7302,7326,7344,7368,7389,7414,7436,7454,7472,7490,7508,7526,7544,7562,7580,7598,7616,7639,7657,7682,7707,7725,7748,7771,7789,7812,7830,7854,7879,7897,7919,7937,7960,7982,8000,8018,8042,8066,8097,8121,8139,8161,8186,8208,8235,8253,8276,8297,8320,8344,8365,8387,8412,8430,8453,8471,8489,8514,8543,8561,8579,8597,8620,8644,8662,8680,8703,8721,8746,8764,8782,8800,8822,8844,8862,8888,8906,8924,8948,8971,8996,9019,9043,9066,9088,9111,9133,9155,9178,9200,9221,9239,9257,9279,9302,9324,9346,9375,9393,9411,9429,9447,9472,9496,9520,9547,9565,9587,9614,9632,9656,9735,9765,9794,9836,9867,9901,9934,9958,9980,10017,10047,10077,10103,10125,10147,10170,10192,10218,10236,10254,10278,10300,10323,10341,10364,10389,10407,10430,10452,10473,10495,10519,10540,10563,10581,10599,10617,10640,10658,10676,10694,10712,10730,10748,10776,10794,10812,10830,10853,10876,10898,10923,10941,10959,10982,11006,11024,11046,11069,11091,11114,11137,11160,11183,11205,11223,11249,11271,11294,11317],{"intervention":94,"totalTrials":95,"cells":96},"Nicotine patch",12,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":233},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":232,"soonestReadout":181},[108,117,129,140,151,165,176,187,198,208,220],{"nctId":109,"briefTitle":110,"status":111,"phases":112,"primaryCompletion":113,"completion":113,"start":79,"enrollment":114,"conditions":115,"interventions":116},"NCT07419425","My Path to Quit Tobacco","NOT_YET_RECRUITING",[90],"2030-01",1550,[26],[94],{"nctId":118,"briefTitle":119,"status":120,"phases":121,"primaryCompletion":122,"completion":122,"start":123,"enrollment":124,"conditions":125,"interventions":127},"NCT01783912","Helping Those With Mental Illness Quit Smoking","COMPLETED",[90],"2014-06","2012-12",270,[29,31,126],"Mental Disorders",[128],"Nicotine Patch",{"nctId":130,"briefTitle":131,"status":120,"phases":132,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":136,"interventions":138},"NCT03176784","UW Quitting Using Intensive Treatment Study (QUITS)",[90],"2020-07-09","2017-11-11",1251,[137],"Tobacco Dependence",[139,94],"Varenicline",{"nctId":141,"briefTitle":142,"status":120,"phases":143,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":148,"interventions":149},"NCT01087905","Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines",[90],"2011-02","2011-11","2010-04",987,[29,26],[94,150],"Nicotine gum",{"nctId":152,"briefTitle":153,"status":120,"phases":154,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":159},"NCT00332644","Smoking Cessation Medications: Efficacy, Mechanisms and Algorithms",[90],"2010-08","2004-09",1504,[31],[160,161,162,163,164],"nicotine patch","nicotine lozenge","nicotine patch + nicotine lozenge","bupropion","bupropion + lozenge",{"nctId":166,"briefTitle":167,"status":120,"phases":168,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":173,"interventions":174},"NCT01553084","A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers",[90],"2015-11","2017-08","2012-05",1086,[26,29,31],[139,175,128],"Nicotine lozenge",{"nctId":177,"briefTitle":178,"status":179,"phases":180,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":184,"interventions":186},"NCT06474299","The Avenues Study: Dual Use Cessation","RECRUITING",[90],"2028-07","2024-09-24",500,[26,185],"Electronic Cigarette Use",[139,94],{"nctId":188,"briefTitle":189,"status":120,"phases":190,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":194,"interventions":196},"NCT03538938","Improving Quitline Support Study",[90],"2023-08-15","2018-06-07",1316,[195],"Tobacco Use Cessation",[94,197],"Nicotine Patch and Nicotine Lozenge",{"nctId":199,"briefTitle":200,"status":120,"phases":201,"primaryCompletion":202,"completion":203,"start":156,"enrollment":204,"conditions":205,"interventions":206},"NCT00296647","Smoking Cessation Intervention: Effectiveness in Primary Care",[90],"2009-07","2010-12",1346,[137],[160,160,161,163,207,164],"patch + lozenge",{"nctId":209,"briefTitle":210,"status":120,"phases":211,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":217},"NCT01122238","Identifying Treatments to Motivate Smokers to Quit",[90],"2014-05","2010-06",517,[29,26,216,31],"Motivation",[128,218,219],"Nicotine Gum","Nicotine Patch + Nicotine Gum",{"nctId":221,"briefTitle":222,"status":120,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":229},"NCT02301403","A Comparative Effectiveness RCT of Optimized Cessation Treatments",[90],"2017-12","2018-02","2015-01",623,[26],[94,230,231],"Preparation Nicotine Mini-Lozenges","Combination NRT",2,{"trials":234,"activeCount":99},[235],{"nctId":236,"briefTitle":237,"status":120,"phases":238,"primaryCompletion":239,"completion":239,"start":240,"enrollment":241,"conditions":242,"interventions":243},"NCT02164383","A Quit Smoking Study Using Smartphones",[91],"2016-05","2014-10",30,[26,29,31],[94],{"intervention":139,"totalTrials":245,"cells":246},7,{"EARLY_PHASE1":247,"PHASE1":249,"PHASE2":251,"PHASE3":253,"PHASE4":255,"NA":313},{"trials":248,"activeCount":99},[],{"trials":250,"activeCount":99},[],{"trials":252,"activeCount":99},[],{"trials":254,"activeCount":99},[],{"trials":256,"activeCount":312,"soonestReadout":181},[257,267,271,282,286,290,301],{"nctId":258,"briefTitle":259,"status":120,"phases":260,"primaryCompletion":261,"completion":144,"start":262,"enrollment":263,"conditions":264,"interventions":265},"NCT00828113","Long-term Varenicline Treatment for Smoking Cessation",[90],"2010-09","2009-01",101,[29],[266,266],"varenicline",{"nctId":130,"briefTitle":131,"status":120,"phases":268,"primaryCompletion":133,"completion":133,"start":134,"enrollment":135,"conditions":269,"interventions":270},[90],[137],[139,94],{"nctId":272,"briefTitle":273,"status":120,"phases":274,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":278,"interventions":280},"NCT04199117","Health Systems Reach Interventions Project",[90],"2024-10-16","2020-03-11",210,[279,26],"Smoking, Cigarette",[139,281],"Combination nicotine patch and nicotine mini-lozenge treatment",{"nctId":166,"briefTitle":167,"status":120,"phases":283,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":284,"interventions":285},[90],[26,29,31],[139,175,128],{"nctId":177,"briefTitle":178,"status":179,"phases":287,"primaryCompletion":181,"completion":181,"start":182,"enrollment":183,"conditions":288,"interventions":289},[90],[26,185],[139,94],{"nctId":291,"briefTitle":292,"status":120,"phases":293,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":297,"interventions":298},"NCT02681510","UW-CTRI Triple Medication Smoking Cessation Study",[90],"2016-06-13","2016-02",36,[29],[139,299,300],"Nicotine Transdermal Patch","Nicotine Mini",{"nctId":302,"briefTitle":303,"status":120,"phases":304,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":308,"interventions":310},"NCT06218823","Tobacco Treatment Comparison for Cancer Care",[90],"2025-08-04","2024-03-01",52,[26,309],"Cancer",[311,139],"Transdermal Nicotine Patch",1,{"trials":314,"activeCount":99},[],{"intervention":316,"totalTrials":317,"cells":318},"Paclitaxel",4,{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":363,"PHASE4":365,"NA":376},{"trials":320,"activeCount":99},[],{"trials":322,"activeCount":99},[],{"trials":324,"activeCount":99},[325,339,349],{"nctId":326,"briefTitle":327,"status":120,"phases":328,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":333,"interventions":336},"NCT03490292","Avelumab With Chemoradiation for Stage II\u002FIII Resectable Esophageal and Gastroesophageal Cancer",[87,88],"2022-01-19","2023-07-12","2018-05-29",22,[334,335],"Resectable Esophageal Cancer","GastroEsophageal Cancer",[337,338,316],"Avelumab combined with Chemoradiation","Carboplatin",{"nctId":340,"briefTitle":341,"status":342,"phases":343,"start":344,"conditions":345,"interventions":347},"NCT00004265","Paclitaxel in Treating Patients With Recurrent or Refractory Non-small Cell Lung Cancer","UNKNOWN",[88],"1999-02",[346],"Lung Cancer",[348],"paclitaxel",{"nctId":350,"briefTitle":351,"status":120,"phases":352,"primaryCompletion":353,"completion":354,"start":355,"enrollment":9,"conditions":356,"interventions":358},"NCT03301350","Neoadjuvant Carbo\u002FPaclitaxel Followed by Doxorubicin\u002FCyclophosphamide in Breast Cancer",[88],"2020-03-23","2022-02-07","2017-11-07",[15,357],"Triple Negative Breast Cancer",[338,316,359,360,361,362],"Doxorubicin","Cyclophosphamide","Pegfilgrastim","Filgrastim",{"trials":364,"activeCount":99},[],{"trials":366,"activeCount":312,"soonestReadout":79},[367],{"nctId":368,"briefTitle":369,"status":179,"phases":370,"primaryCompletion":79,"completion":79,"start":371,"enrollment":372,"conditions":373,"interventions":375},"NCT03096418","Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response",[90],"2017-03-13",50,[374],"Breast Neoplasm Female",[316],{"trials":377,"activeCount":99},[],{"intervention":379,"totalTrials":312,"cells":380},"TAP Anesthesia",{"EARLY_PHASE1":381,"PHASE1":383,"PHASE2":385,"PHASE3":387,"PHASE4":389,"NA":403},{"trials":382,"activeCount":99},[],{"trials":384,"activeCount":99},[],{"trials":386,"activeCount":99},[],{"trials":388,"activeCount":99},[],{"trials":390,"activeCount":312,"soonestReadout":395},[391],{"nctId":392,"briefTitle":393,"status":179,"phases":394,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":398,"interventions":401},"NCT06213454","Transversus Abdominis Plane Block Compared to Local Anesthetic Wound Infiltration in Gynecologic Oncology Surgery",[90],"2026-08","2024-03-26",80,[399,400],"Analgesia","Surgery",[379,402],"Surgeon-Initiated Local Anesthetic",{"trials":404,"activeCount":99},[],{"intervention":402,"totalTrials":312,"cells":406},{"EARLY_PHASE1":407,"PHASE1":409,"PHASE2":411,"PHASE3":413,"PHASE4":415,"NA":421},{"trials":408,"activeCount":99},[],{"trials":410,"activeCount":99},[],{"trials":412,"activeCount":99},[],{"trials":414,"activeCount":99},[],{"trials":416,"activeCount":312,"soonestReadout":395},[417],{"nctId":392,"briefTitle":393,"status":179,"phases":418,"primaryCompletion":395,"completion":395,"start":396,"enrollment":397,"conditions":419,"interventions":420},[90],[399,400],[379,402],{"trials":422,"activeCount":99},[],{"intervention":424,"totalTrials":312,"cells":425},"Nicotine Pouches",{"EARLY_PHASE1":426,"PHASE1":428,"PHASE2":430,"PHASE3":432,"PHASE4":434,"NA":448},{"trials":427,"activeCount":99},[],{"trials":429,"activeCount":99},[],{"trials":431,"activeCount":99},[],{"trials":433,"activeCount":99},[],{"trials":435,"activeCount":312,"soonestReadout":440},[436],{"nctId":437,"briefTitle":438,"status":179,"phases":439,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":444,"interventions":446},"NCT06595459","The Options 2 Study",[90],"2029-01-01","2029-07-30","2025-05-21",300,[445,26],"Smoker",[424,447],"Mini Nicotine lozenges",{"trials":449,"activeCount":99},[],{"intervention":447,"totalTrials":312,"cells":451},{"EARLY_PHASE1":452,"PHASE1":454,"PHASE2":456,"PHASE3":458,"PHASE4":460,"NA":466},{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":99},[],{"trials":457,"activeCount":99},[],{"trials":459,"activeCount":99},[],{"trials":461,"activeCount":312,"soonestReadout":440},[462],{"nctId":437,"briefTitle":438,"status":179,"phases":463,"primaryCompletion":440,"completion":441,"start":442,"enrollment":443,"conditions":464,"interventions":465},[90],[445,26],[424,447],{"trials":467,"activeCount":99},[],{"intervention":469,"totalTrials":232,"cells":470},"Envarsus XR",{"EARLY_PHASE1":471,"PHASE1":473,"PHASE2":475,"PHASE3":477,"PHASE4":488,"NA":501},{"trials":472,"activeCount":99},[],{"trials":474,"activeCount":99},[],{"trials":476,"activeCount":99},[],{"trials":478,"activeCount":312,"soonestReadout":483},[479],{"nctId":480,"briefTitle":481,"status":179,"phases":482,"primaryCompletion":483,"completion":483,"start":484,"enrollment":32,"conditions":485,"interventions":487},"NCT03769298","CIRTEN-Simultaneous Pancreas-Kidney Transplant Recipients",[88,89],"2026-12","2019-02-27",[486],"Kidney Pancreas Transplantation",[469],{"trials":489,"activeCount":99},[490],{"nctId":491,"briefTitle":492,"status":120,"phases":493,"primaryCompletion":494,"completion":494,"start":495,"enrollment":496,"conditions":497,"interventions":499},"NCT03864926","Envarsus in Delayed Graft Function (E-DGF)",[90],"2022-07-22","2019-03-18",100,[498],"Delayed Graft Function",[469,500],"Tacrolimus",{"trials":502,"activeCount":99},[],{"intervention":504,"totalTrials":312,"cells":505},"Letermovir",{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":512,"PHASE4":526,"NA":528},{"trials":507,"activeCount":99},[],{"trials":509,"activeCount":99},[],{"trials":511,"activeCount":99},[],{"trials":513,"activeCount":312,"soonestReadout":518},[514],{"nctId":515,"briefTitle":516,"status":179,"phases":517,"primaryCompletion":518,"completion":518,"start":519,"enrollment":520,"conditions":521,"interventions":525},"NCT06407232","Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients",[89],"2026-09","2024-08-08",90,[522,523,524],"Cytomegalovirus Infections","Kidney Transplant Infection","Pancreas Transplant",[504],{"trials":527,"activeCount":99},[],{"trials":529,"activeCount":99},[],{"intervention":531,"totalTrials":317,"cells":532},"Nivolumab",{"EARLY_PHASE1":533,"PHASE1":535,"PHASE2":537,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":534,"activeCount":99},[],{"trials":536,"activeCount":99},[],{"trials":538,"activeCount":317,"soonestReadout":40},[539,554,564,571],{"nctId":540,"briefTitle":541,"status":179,"phases":542,"primaryCompletion":483,"completion":543,"start":544,"enrollment":307,"conditions":545,"interventions":548},"NCT04150640","Oxaliplatin and Liposomal Irinotecan (Plus Trastuzumab for HER2-positive Disease) in Advanced Esophageal and Gastric Adenocarcinoma",[88],"2027-12","2020-07-13",[546,547],"Esophageal Adenocarcinoma","Gastric Adenocarcinoma",[549,550,551,552,553,531],"Nal-IRI","Oxaliplatin","5-FU","Trastuzumab","Pembrolizumab",{"nctId":48,"briefTitle":49,"status":555,"phases":556,"primaryCompletion":50,"completion":557,"start":558,"enrollment":559,"conditions":560,"interventions":562},"ACTIVE_NOT_RECRUITING",[87,88],"2026-08-15","2020-01-30",8,[561],"Melanoma",[51,531,563],"Ipilimumab",{"nctId":38,"briefTitle":39,"status":555,"phases":565,"primaryCompletion":40,"completion":543,"start":566,"enrollment":567,"conditions":568,"interventions":569},[88],"2018-09-10",19,[18],[41,531,570],"GM-CSF",{"nctId":572,"briefTitle":573,"status":179,"phases":574,"primaryCompletion":483,"completion":575,"start":576,"enrollment":577,"conditions":578,"interventions":579},"NCT04989946","Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer",[87,88],"2028-12","2021-12-16",60,[18],[580,581,531,582,583,584],"Degarelix","pTVG-AR","Cemiplimab","Fianlimab","FLT PET\u002FCT",{"trials":586,"activeCount":99},[],{"trials":588,"activeCount":99},[],{"trials":590,"activeCount":99},[],{"intervention":553,"totalTrials":592,"cells":593},6,{"EARLY_PHASE1":594,"PHASE1":607,"PHASE2":624,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":595,"activeCount":312,"soonestReadout":600},[596],{"nctId":597,"briefTitle":598,"status":555,"phases":599,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":603,"interventions":605},"NCT06308913","Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma",[86],"2026-10","2024-09-18",10,[604],"Head and Neck Squamous Cell Carcinoma",[606,553],"INCB081776",{"trials":608,"activeCount":99},[609],{"nctId":610,"briefTitle":611,"status":120,"phases":612,"primaryCompletion":613,"completion":614,"start":615,"enrollment":616,"conditions":617,"interventions":623},"NCT02837263","PI Pembro in Combination With Stereotactic Body Radiotherapy for Liver Metastatic Colorectal Cancer",[87],"2021-11-02","2023-05-31","2016-08-11",15,[618,619,620,621,622],"Colorectal Cancer","Colorectal Adenocarcinoma","Stage IVA Colorectal Cancer","Stage IVB Colorectal Cancer","Metastatic Carcinoma in the Liver",[553],{"trials":625,"activeCount":232,"soonestReadout":60},[626,630,648],{"nctId":540,"briefTitle":541,"status":179,"phases":627,"primaryCompletion":483,"completion":543,"start":544,"enrollment":307,"conditions":628,"interventions":629},[88],[546,547],[549,550,551,552,553,531],{"nctId":631,"briefTitle":632,"status":120,"phases":633,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":638,"interventions":646},"NCT02499835","Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer",[87,88],"2021-08-09","2023-07-27","2015-07-01",66,[639,640,641,642,643,644,645],"Hormone-Resistant Prostate Cancer","Metastatic Malignant Neoplasm in the Bone","Metastatic Malignant Neoplasm in the Soft Tissues","Metastatic Prostate Carcinoma","Prostate Adenocarcinoma","Recurrent Prostate Carcinoma","Stage IV Prostate Cancer",[553,647],"pTVG-HP Plasmid DNA Vaccine",{"nctId":58,"briefTitle":59,"status":555,"phases":649,"primaryCompletion":60,"completion":600,"start":650,"enrollment":577,"conditions":651,"interventions":654},[88],"2019-10-21",[652,653,18],"Castration-resistant Prostate Cancer","Metastatic Cancer",[41,581,553],{"trials":656,"activeCount":99},[],{"trials":658,"activeCount":99},[],{"trials":660,"activeCount":312,"soonestReadout":543},[661],{"nctId":662,"briefTitle":663,"status":179,"phases":664,"primaryCompletion":543,"completion":543,"start":665,"enrollment":32,"conditions":666,"interventions":668},"NCT07343596","Study to Identify Biomarkers of Oral Cavity Cancer Response to Neoadjuvant Immunotherapy Prior to Definitive Surgery",[91],"2026-04-15",[667],"Oral Cavity Cancer",[553],{"intervention":670,"totalTrials":317,"cells":671},"Bevacizumab",{"EARLY_PHASE1":672,"PHASE1":674,"PHASE2":676,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":673,"activeCount":99},[],{"trials":675,"activeCount":99},[],{"trials":677,"activeCount":232,"soonestReadout":181},[678,689,703,713],{"nctId":679,"briefTitle":680,"status":681,"phases":682,"primaryCompletion":683,"completion":683,"start":684,"enrollment":685,"conditions":686,"interventions":688},"NCT01743950","A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab","TERMINATED",[88],"2024-12-24","2012-12-03",49,[687],"Glioma",[670],{"nctId":690,"briefTitle":691,"status":555,"phases":692,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":696,"interventions":698},"NCT04587128","Early-Line Anti-EGFR Therapy to Facilitate Retreatment for Select Patients With mCRC",[88],"2029-10","2020-10-19",34,[697],"Metastatic Colorectal Cancer",[699,700,701,702,670],"Panitumumab","Cetuximab","Irinotecan","FOLFIRI Protocol",{"nctId":704,"briefTitle":705,"status":120,"phases":706,"primaryCompletion":707,"completion":707,"start":708,"enrollment":263,"conditions":709,"interventions":712},"NCT02192970","Bevacizumab Against Recurrent Retinal Detachment",[88],"2019-11-11","2015-01-21",[710,711],"Retinal Detachment","Proliferative Vitreoretinopathy",[670],{"nctId":714,"briefTitle":715,"status":179,"phases":716,"primaryCompletion":181,"completion":181,"start":717,"enrollment":372,"conditions":718,"interventions":719},"NCT05854498","Liposomal Irinotecan With TAS102 and Bevacizumab for Patients With Metastatic Colorectal Cancer",[88],"2023-10-13",[697],[720,721,670],"Liposomal irinotecan","TAS102",{"trials":723,"activeCount":99},[],{"trials":725,"activeCount":99},[],{"trials":727,"activeCount":99},[],{"intervention":700,"totalTrials":317,"cells":729},{"EARLY_PHASE1":730,"PHASE1":743,"PHASE2":745,"PHASE3":770,"PHASE4":772,"NA":774},{"trials":731,"activeCount":312,"soonestReadout":736},[732],{"nctId":733,"briefTitle":734,"status":555,"phases":735,"primaryCompletion":736,"completion":736,"start":737,"enrollment":616,"conditions":738,"interventions":741},"NCT05816785","Pilot Study of Imatinib Cetuximab Combo for H & N Cancer",[86],"2026-10-31","2023-04-18",[739,740],"Head and Neck Cancer","Squamous Cell Carcinoma of Head and Neck",[700,742],"Imatinib",{"trials":744,"activeCount":99},[],{"trials":746,"activeCount":312,"soonestReadout":693},[747,756,760],{"nctId":748,"briefTitle":749,"status":120,"phases":750,"primaryCompletion":751,"completion":751,"start":752,"enrollment":616,"conditions":753,"interventions":755},"NCT03769311","Cetuximab in Head and Neck Cancer Patients",[88],"2022-03-15","2019-04-17",[739,754],"Squamous Cell Carcinoma",[700],{"nctId":690,"briefTitle":691,"status":555,"phases":757,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":758,"interventions":759},[88],[697],[699,700,701,702,670],{"nctId":761,"briefTitle":762,"status":681,"phases":763,"primaryCompletion":764,"completion":764,"start":765,"enrollment":592,"conditions":766,"interventions":768},"NCT00580073","Phase II Trial of Neoadjuvant FOLFOX4 and Cetuximab for Localized Adenocarcinoma of Rectum",[88],"2009-11","2007-12",[767],"Rectal Cancer",[769,700],"FOLFOX4",{"trials":771,"activeCount":99},[],{"trials":773,"activeCount":99},[],{"trials":775,"activeCount":99},[],{"intervention":777,"totalTrials":778,"cells":779},"Prazosin",3,{"EARLY_PHASE1":780,"PHASE1":782,"PHASE2":784,"PHASE3":813,"PHASE4":815,"NA":817},{"trials":781,"activeCount":99},[],{"trials":783,"activeCount":99},[],{"trials":785,"activeCount":232,"soonestReadout":483},[786,796,805],{"nctId":787,"briefTitle":788,"status":120,"phases":789,"primaryCompletion":790,"completion":790,"start":791,"enrollment":792,"conditions":793,"interventions":795},"NCT02966340","Repurposing alpha1 Noradrenergic Antagonists for Alcoholism Treatment",[87,88],"2018-03-12","2016-11-01",70,[794],"Alcoholism",[777],{"nctId":797,"briefTitle":798,"status":179,"phases":799,"primaryCompletion":483,"completion":483,"start":800,"enrollment":296,"conditions":801,"interventions":804},"NCT06629090","Brain Blood Vessel Responses to Changes in Blood Flow: Younger Cohort",[88],"2025-12-17",[802,803],"Magnetic Resonance Imaging","Cerebrovascular Circulation",[777],{"nctId":806,"briefTitle":807,"status":179,"phases":808,"primaryCompletion":809,"completion":809,"start":810,"enrollment":296,"conditions":811,"interventions":812},"NCT06629077","Brain Blood Vessel Responses to Changes in Blood Flow",[88],"2027-01","2026-02-26",[802,803],[777],{"trials":814,"activeCount":99},[],{"trials":816,"activeCount":99},[],{"trials":818,"activeCount":99},[],{"intervention":41,"totalTrials":778,"cells":820},{"EARLY_PHASE1":821,"PHASE1":823,"PHASE2":825,"PHASE3":845,"PHASE4":847,"NA":849},{"trials":822,"activeCount":99},[],{"trials":824,"activeCount":99},[],{"trials":826,"activeCount":232,"soonestReadout":40},[827,831,835],{"nctId":38,"briefTitle":39,"status":555,"phases":828,"primaryCompletion":40,"completion":543,"start":566,"enrollment":567,"conditions":829,"interventions":830},[88],[18],[41,531,570],{"nctId":58,"briefTitle":59,"status":555,"phases":832,"primaryCompletion":60,"completion":600,"start":650,"enrollment":577,"conditions":833,"interventions":834},[88],[652,653,18],[41,581,553],{"nctId":836,"briefTitle":837,"status":120,"phases":838,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":842,"interventions":843},"NCT01341652","Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer",[88],"2020-06-30","2011-05-23",99,[18],[41,844],"rhGM-CSF",{"trials":846,"activeCount":99},[],{"trials":848,"activeCount":99},[],{"trials":850,"activeCount":99},[],{"intervention":581,"totalTrials":778,"cells":852},{"EARLY_PHASE1":853,"PHASE1":855,"PHASE2":868,"PHASE3":878,"PHASE4":880,"NA":882},{"trials":854,"activeCount":99},[],{"trials":856,"activeCount":99},[857],{"nctId":858,"briefTitle":859,"status":120,"phases":860,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":865,"interventions":866},"NCT02411786","A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +\u002F-GMCSF",[87],"2019-05-01","2020-11-28","2015-08-24",40,[18],[581,867],"gm-csf",{"trials":869,"activeCount":232,"soonestReadout":60},[870,874],{"nctId":58,"briefTitle":59,"status":555,"phases":871,"primaryCompletion":60,"completion":600,"start":650,"enrollment":577,"conditions":872,"interventions":873},[88],[652,653,18],[41,581,553],{"nctId":572,"briefTitle":573,"status":179,"phases":875,"primaryCompletion":483,"completion":575,"start":576,"enrollment":577,"conditions":876,"interventions":877},[87,88],[18],[580,581,531,582,583,584],{"trials":879,"activeCount":99},[],{"trials":881,"activeCount":99},[],{"trials":883,"activeCount":99},[],{"intervention":885,"totalTrials":232,"cells":886},"Saline",{"EARLY_PHASE1":887,"PHASE1":889,"PHASE2":900,"PHASE3":913,"PHASE4":915,"NA":917},{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":312,"soonestReadout":543},[891],{"nctId":892,"briefTitle":893,"status":179,"phases":894,"primaryCompletion":543,"completion":543,"start":895,"enrollment":577,"conditions":896,"interventions":898},"NCT06692192","The RECAP2 Study: Midazolam and Psilocybin",[87],"2025-08-07",[897],"Psilocybin",[897,897,899,885],"Midazolam",{"trials":901,"activeCount":312,"soonestReadout":906},[902],{"nctId":903,"briefTitle":904,"status":179,"phases":905,"primaryCompletion":906,"completion":906,"start":907,"enrollment":864,"conditions":908,"interventions":912},"NCT06665594","Effect of TXA on Reducing Bruising After Filler Injection",[88],"2026-11","2025-12-05",[909,910,911],"Facial Filler Injections","Hyaluronic Acid","Tranexamic Acid",[911,885],{"trials":914,"activeCount":99},[],{"trials":916,"activeCount":99},[],{"trials":918,"activeCount":99},[],{"intervention":920,"totalTrials":232,"cells":921},"18F-fluorofuranylnorprogesterone",{"EARLY_PHASE1":922,"PHASE1":924,"PHASE2":926,"PHASE3":946,"PHASE4":948,"NA":950},{"trials":923,"activeCount":99},[],{"trials":925,"activeCount":99},[],{"trials":927,"activeCount":232,"soonestReadout":395},[928,938],{"nctId":929,"briefTitle":930,"status":179,"phases":931,"primaryCompletion":809,"completion":113,"start":932,"enrollment":933,"conditions":934,"interventions":935},"NCT06086704","Study of 18F-FFNP Breast PET\u002FMRI",[88],"2024-09-25",53,[15],[920,936,937],"Anastrozole","FDA-approved gadolinium-based intravenous contrast agent",{"nctId":939,"briefTitle":940,"status":179,"phases":941,"primaryCompletion":395,"completion":395,"start":942,"enrollment":559,"conditions":943,"interventions":945},"NCT06067503","Biomarkers to Detect Endocrine Therapy Resistance",[88],"2024-04-30",[653,15,944],"Lobular Breast Carcinoma",[920],{"trials":947,"activeCount":99},[],{"trials":949,"activeCount":99},[],{"trials":951,"activeCount":99},[],{"intervention":953,"totalTrials":778,"cells":954},"Prednisone",{"EARLY_PHASE1":955,"PHASE1":957,"PHASE2":959,"PHASE3":970,"PHASE4":972,"NA":992},{"trials":956,"activeCount":99},[],{"trials":958,"activeCount":99},[],{"trials":960,"activeCount":312,"soonestReadout":64},[961],{"nctId":62,"briefTitle":63,"status":555,"phases":962,"primaryCompletion":64,"completion":963,"start":964,"enrollment":22,"conditions":965,"interventions":968},[88],"2027-02","2021-02-17",[966,967,309],"Diffuse Large B Cell Lymphoma","DLBCL",[65,360,359,969,953,361],"Vincristine",{"trials":971,"activeCount":99},[],{"trials":973,"activeCount":99},[974,983],{"nctId":975,"briefTitle":976,"status":120,"phases":977,"primaryCompletion":262,"completion":262,"start":978,"enrollment":95,"conditions":979,"interventions":981},"NCT00204737","Short Course Glucocorticoid Treatment for PTSD",[90],"2004-12",[980],"Post-traumatic Stress Disorder",[982],"prednisone",{"nctId":984,"briefTitle":985,"status":120,"phases":986,"primaryCompletion":987,"completion":987,"start":988,"enrollment":241,"conditions":989,"interventions":991},"NCT04542278","Preoperative Steroids in Autoimmune Thyroid Disease",[90],"2022-10-04","2020-11-13",[990],"Thyroid Diseases",[953],{"trials":993,"activeCount":99},[],{"intervention":911,"totalTrials":232,"cells":995},{"EARLY_PHASE1":996,"PHASE1":998,"PHASE2":1000,"PHASE3":1006,"PHASE4":1008,"NA":1022},{"trials":997,"activeCount":99},[],{"trials":999,"activeCount":99},[],{"trials":1001,"activeCount":312,"soonestReadout":906},[1002],{"nctId":903,"briefTitle":904,"status":179,"phases":1003,"primaryCompletion":906,"completion":906,"start":907,"enrollment":864,"conditions":1004,"interventions":1005},[88],[909,910,911],[911,885],{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[1010],{"nctId":1011,"briefTitle":1012,"status":1013,"phases":1014,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":99,"conditions":1017,"interventions":1019},"NCT04373603","Use of Tranexamic Acid in Facial Fillers","WITHDRAWN",[90],"2023-07","2022-07",[1018],"Injection Site Bruising",[1020,1021],"Tranexamic acid","Hyaluronic acid",{"trials":1023,"activeCount":99},[],{"intervention":936,"totalTrials":232,"cells":1025},{"EARLY_PHASE1":1026,"PHASE1":1028,"PHASE2":1030,"PHASE3":1036,"PHASE4":1038,"NA":1053},{"trials":1027,"activeCount":99},[],{"trials":1029,"activeCount":99},[],{"trials":1031,"activeCount":312,"soonestReadout":809},[1032],{"nctId":929,"briefTitle":930,"status":179,"phases":1033,"primaryCompletion":809,"completion":113,"start":932,"enrollment":933,"conditions":1034,"interventions":1035},[88],[15],[920,936,937],{"trials":1037,"activeCount":99},[],{"trials":1039,"activeCount":99},[1040],{"nctId":1041,"briefTitle":1042,"status":120,"phases":1043,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":332,"conditions":1046,"interventions":1048},"NCT06253702","Brain Blood Flow Responses to Stress: Sex Differences",[90],"2025-05-31","2024-07-24",[1047],"Cerebrovascular Disorders",[1049,1050,1051,936,1052],"Indomethacin","Orilissa","Testosterone gel","Estradiol",{"trials":1054,"activeCount":99},[],{"intervention":359,"totalTrials":778,"cells":1056},{"EARLY_PHASE1":1057,"PHASE1":1059,"PHASE2":1061,"PHASE3":1083,"PHASE4":1085,"NA":1087},{"trials":1058,"activeCount":99},[],{"trials":1060,"activeCount":99},[],{"trials":1062,"activeCount":312,"soonestReadout":64},[1063,1075,1079],{"nctId":1064,"briefTitle":1065,"status":120,"phases":1066,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":241,"conditions":1070,"interventions":1072},"NCT00581776","Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma",[88],"2012-11","2015-05","2005-05",[1071],"Mantle Cell Lymphoma",[1073,65,360,359,969,1074],"Bortezomib","Dexamethasone",{"nctId":350,"briefTitle":351,"status":120,"phases":1076,"primaryCompletion":353,"completion":354,"start":355,"enrollment":9,"conditions":1077,"interventions":1078},[88],[15,357],[338,316,359,360,361,362],{"nctId":62,"briefTitle":63,"status":555,"phases":1080,"primaryCompletion":64,"completion":963,"start":964,"enrollment":22,"conditions":1081,"interventions":1082},[88],[966,967,309],[65,360,359,969,953,361],{"trials":1084,"activeCount":99},[],{"trials":1086,"activeCount":99},[],{"trials":1088,"activeCount":99},[],{"intervention":361,"totalTrials":778,"cells":1090},{"EARLY_PHASE1":1091,"PHASE1":1093,"PHASE2":1109,"PHASE3":1119,"PHASE4":1121,"NA":1123},{"trials":1092,"activeCount":99},[],{"trials":1094,"activeCount":99},[1095],{"nctId":1096,"briefTitle":1097,"status":681,"phases":1098,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":35,"conditions":1102,"interventions":1106},"NCT02943733","Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic NETs",[87],"2020-11-07","2022-01-31","2017-08-22",[1103,1104,309,1105],"Neuroendocrine Tumors","Neoplasms","Tumors",[1107,1108,362,361],"TAS-102","Temozolomide",{"trials":1110,"activeCount":312,"soonestReadout":64},[1111,1115],{"nctId":350,"briefTitle":351,"status":120,"phases":1112,"primaryCompletion":353,"completion":354,"start":355,"enrollment":9,"conditions":1113,"interventions":1114},[88],[15,357],[338,316,359,360,361,362],{"nctId":62,"briefTitle":63,"status":555,"phases":1116,"primaryCompletion":64,"completion":963,"start":964,"enrollment":22,"conditions":1117,"interventions":1118},[88],[966,967,309],[65,360,359,969,953,361],{"trials":1120,"activeCount":99},[],{"trials":1122,"activeCount":99},[],{"trials":1124,"activeCount":99},[],{"intervention":51,"totalTrials":778,"cells":1126},{"EARLY_PHASE1":1127,"PHASE1":1129,"PHASE2":1144,"PHASE3":1159,"PHASE4":1161,"NA":1163},{"trials":1128,"activeCount":99},[],{"trials":1130,"activeCount":99},[1131],{"nctId":1132,"briefTitle":1133,"status":1013,"phases":1134,"primaryCompletion":1135,"completion":1135,"start":790,"enrollment":99,"conditions":1136,"interventions":1141},"NCT03209869","Treatment of Relapsed or Refractory Neuroblastoma and Osteosarcoma With Expanded Haploidentical NK Cells and Hu14.18-IL2",[87],"2022-09-07",[1137,1138,1139,1140],"Neuroblastoma","Relapsed Neuroblastoma","Recurrent Neuroblastoma","Osteosarcoma",[1142,1143],"Ex vivo Expanded and Activated Haploidentical Donor NK Cells","Hu14.18-IL2",{"trials":1145,"activeCount":312,"soonestReadout":50},[1146,1150],{"nctId":48,"briefTitle":49,"status":555,"phases":1147,"primaryCompletion":50,"completion":557,"start":558,"enrollment":559,"conditions":1148,"interventions":1149},[87,88],[561],[51,531,563],{"nctId":1151,"briefTitle":1152,"status":120,"phases":1153,"primaryCompletion":1154,"completion":1154,"start":1155,"enrollment":1156,"conditions":1157,"interventions":1158},"NCT00590824","Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma",[88],"2018-09-20","2007-12-17",23,[561],[51,51],{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"intervention":580,"totalTrials":232,"cells":1166},{"EARLY_PHASE1":1167,"PHASE1":1180,"PHASE2":1182,"PHASE3":1188,"PHASE4":1190,"NA":1192},{"trials":1168,"activeCount":99},[1169],{"nctId":1170,"briefTitle":1171,"status":120,"phases":1172,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":241,"conditions":1176,"interventions":1177},"NCT03358563","Pilot Trial of Chemohormonal Therapy Followed by Prostatectomy in High Risk Prostate Cancer",[86],"2021-08-10","2022-09-02","2018-01-17",[18],[1178,580,1179],"Docetaxel","Bicalutamide",{"trials":1181,"activeCount":99},[],{"trials":1183,"activeCount":312,"soonestReadout":483},[1184],{"nctId":572,"briefTitle":573,"status":179,"phases":1185,"primaryCompletion":483,"completion":575,"start":576,"enrollment":577,"conditions":1186,"interventions":1187},[87,88],[18],[580,581,531,582,583,584],{"trials":1189,"activeCount":99},[],{"trials":1191,"activeCount":99},[],{"trials":1193,"activeCount":99},[],{"intervention":969,"totalTrials":232,"cells":1195},{"EARLY_PHASE1":1196,"PHASE1":1198,"PHASE2":1200,"PHASE3":1210,"PHASE4":1212,"NA":1214},{"trials":1197,"activeCount":99},[],{"trials":1199,"activeCount":99},[],{"trials":1201,"activeCount":312,"soonestReadout":64},[1202,1206],{"nctId":1064,"briefTitle":1065,"status":120,"phases":1203,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":241,"conditions":1204,"interventions":1205},[88],[1071],[1073,65,360,359,969,1074],{"nctId":62,"briefTitle":63,"status":555,"phases":1207,"primaryCompletion":64,"completion":963,"start":964,"enrollment":22,"conditions":1208,"interventions":1209},[88],[966,967,309],[65,360,359,969,953,361],{"trials":1211,"activeCount":99},[],{"trials":1213,"activeCount":99},[],{"trials":1215,"activeCount":99},[],{"intervention":550,"totalTrials":232,"cells":1217},{"EARLY_PHASE1":1218,"PHASE1":1220,"PHASE2":1222,"PHASE3":1241,"PHASE4":1243,"NA":1245},{"trials":1219,"activeCount":99},[],{"trials":1221,"activeCount":99},[],{"trials":1223,"activeCount":312,"soonestReadout":483},[1224,1228],{"nctId":540,"briefTitle":541,"status":179,"phases":1225,"primaryCompletion":483,"completion":543,"start":544,"enrollment":307,"conditions":1226,"interventions":1227},[88],[546,547],[549,550,551,552,553,531],{"nctId":1229,"briefTitle":1230,"status":120,"phases":1231,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1234,"conditions":1235,"interventions":1238},"NCT00634751","CO07204-Phase I\u002FII of Oxaliplatin, Capecitabine & Sorafenib for Advanced Pancreatic & Biliary Carcinoma",[87,88],"2010-07","2008-02",48,[1236,1237],"Pancreatic Neoplasms","Bile Duct Neoplasms",[550,1239,1240],"Capecitabine","Sorafenib",{"trials":1242,"activeCount":99},[],{"trials":1244,"activeCount":99},[],{"trials":1246,"activeCount":99},[],{"intervention":1248,"totalTrials":232,"cells":1249},"Celecoxib",{"EARLY_PHASE1":1250,"PHASE1":1252,"PHASE2":1254,"PHASE3":1276,"PHASE4":1278,"NA":1280},{"trials":1251,"activeCount":99},[],{"trials":1253,"activeCount":99},[],{"trials":1255,"activeCount":312,"soonestReadout":518},[1256,1267],{"nctId":1257,"briefTitle":1258,"status":179,"phases":1259,"primaryCompletion":518,"completion":518,"start":1260,"enrollment":1261,"conditions":1262,"interventions":1264},"NCT06505187","Celecoxib for ENT Pain Management",[88],"2025-02-28",84,[1263],"Parotidectomy",[1248,1265,1266],"Tylenol","Oxycodone",{"nctId":1268,"briefTitle":1269,"status":1013,"phases":1270,"primaryCompletion":1271,"completion":1271,"start":1272,"enrollment":99,"conditions":1273,"interventions":1275},"NCT03185871","Celecoxib Window of Opportunity Trial to Assess Tumor and Stroma Responses",[88],"2018-10-10","2017-09-20",[1274],"Breast Carcinoma",[1248],{"trials":1277,"activeCount":99},[],{"trials":1279,"activeCount":99},[],{"trials":1281,"activeCount":99},[],{"intervention":570,"totalTrials":232,"cells":1283},{"EARLY_PHASE1":1284,"PHASE1":1286,"PHASE2":1292,"PHASE3":1298,"PHASE4":1300,"NA":1302},{"trials":1285,"activeCount":99},[],{"trials":1287,"activeCount":99},[1288],{"nctId":858,"briefTitle":859,"status":120,"phases":1289,"primaryCompletion":861,"completion":862,"start":863,"enrollment":864,"conditions":1290,"interventions":1291},[87],[18],[581,867],{"trials":1293,"activeCount":312,"soonestReadout":40},[1294],{"nctId":38,"briefTitle":39,"status":555,"phases":1295,"primaryCompletion":40,"completion":543,"start":566,"enrollment":567,"conditions":1296,"interventions":1297},[88],[18],[41,531,570],{"trials":1299,"activeCount":99},[],{"trials":1301,"activeCount":99},[],{"trials":1303,"activeCount":99},[],{"intervention":699,"totalTrials":232,"cells":1305},{"EARLY_PHASE1":1306,"PHASE1":1308,"PHASE2":1310,"PHASE3":1325,"PHASE4":1327,"NA":1329},{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":312,"soonestReadout":693},[1312,1316],{"nctId":690,"briefTitle":691,"status":555,"phases":1313,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":1314,"interventions":1315},[88],[697],[699,700,701,702,670],{"nctId":1317,"briefTitle":1318,"status":681,"phases":1319,"primaryCompletion":1320,"completion":1320,"start":1321,"enrollment":1322,"conditions":1323,"interventions":1324},"NCT01128387","Trial of Panitumumab\u002FCisplatin\u002FFluorouracil Combined With Radiation in Esophageal Cancer",[87,88],"2016-10","2010-05",11,[309],[699],{"trials":1326,"activeCount":99},[],{"trials":1328,"activeCount":99},[],{"trials":1330,"activeCount":99},[],{"intervention":1332,"totalTrials":312,"cells":1333},"FDG PET\u002FMRI",{"EARLY_PHASE1":1334,"PHASE1":1336,"PHASE2":1338,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1335,"activeCount":99},[],{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":312,"soonestReadout":906},[1340],{"nctId":1341,"briefTitle":1342,"status":179,"phases":1343,"primaryCompletion":906,"completion":906,"start":1344,"enrollment":616,"conditions":1345,"interventions":1347},"NCT07066709","Painful Post-Operative Hip Study",[88],"2026-01-21",[1346],"Unilateral Hip Arthroscopy",[1332],{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":99},[],{"intervention":1355,"totalTrials":312,"cells":1356},"Nivolumab and Relatlimab",{"EARLY_PHASE1":1357,"PHASE1":1359,"PHASE2":1361,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1358,"activeCount":99},[],{"trials":1360,"activeCount":99},[],{"trials":1362,"activeCount":312,"soonestReadout":1367},[1363],{"nctId":1364,"briefTitle":1365,"status":179,"phases":1366,"primaryCompletion":1367,"completion":1367,"start":79,"enrollment":616,"conditions":1368,"interventions":1371},"NCT07281924","Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis",[87,88],"2030-12",[1369,1370],"Metastatic Melanoma","Liver Metastases",[1355],{"trials":1373,"activeCount":99},[],{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":99},[],{"intervention":549,"totalTrials":312,"cells":1379},{"EARLY_PHASE1":1380,"PHASE1":1382,"PHASE2":1384,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1381,"activeCount":99},[],{"trials":1383,"activeCount":99},[],{"trials":1385,"activeCount":312,"soonestReadout":483},[1386],{"nctId":540,"briefTitle":541,"status":179,"phases":1387,"primaryCompletion":483,"completion":543,"start":544,"enrollment":307,"conditions":1388,"interventions":1389},[88],[546,547],[549,550,551,552,553,531],{"trials":1391,"activeCount":99},[],{"trials":1393,"activeCount":99},[],{"trials":1395,"activeCount":99},[],{"intervention":551,"totalTrials":312,"cells":1397},{"EARLY_PHASE1":1398,"PHASE1":1400,"PHASE2":1402,"PHASE3":1408,"PHASE4":1410,"NA":1412},{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"trials":1403,"activeCount":312,"soonestReadout":483},[1404],{"nctId":540,"briefTitle":541,"status":179,"phases":1405,"primaryCompletion":483,"completion":543,"start":544,"enrollment":307,"conditions":1406,"interventions":1407},[88],[546,547],[549,550,551,552,553,531],{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":99},[],{"trials":1413,"activeCount":99},[],{"intervention":552,"totalTrials":312,"cells":1415},{"EARLY_PHASE1":1416,"PHASE1":1418,"PHASE2":1420,"PHASE3":1426,"PHASE4":1428,"NA":1430},{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":99},[],{"trials":1421,"activeCount":312,"soonestReadout":483},[1422],{"nctId":540,"briefTitle":541,"status":179,"phases":1423,"primaryCompletion":483,"completion":543,"start":544,"enrollment":307,"conditions":1424,"interventions":1425},[88],[546,547],[549,550,551,552,553,531],{"trials":1427,"activeCount":99},[],{"trials":1429,"activeCount":99},[],{"trials":1431,"activeCount":99},[],{"intervention":1265,"totalTrials":312,"cells":1433},{"EARLY_PHASE1":1434,"PHASE1":1436,"PHASE2":1438,"PHASE3":1444,"PHASE4":1446,"NA":1448},{"trials":1435,"activeCount":99},[],{"trials":1437,"activeCount":99},[],{"trials":1439,"activeCount":312,"soonestReadout":518},[1440],{"nctId":1257,"briefTitle":1258,"status":179,"phases":1441,"primaryCompletion":518,"completion":518,"start":1260,"enrollment":1261,"conditions":1442,"interventions":1443},[88],[1263],[1248,1265,1266],{"trials":1445,"activeCount":99},[],{"trials":1447,"activeCount":99},[],{"trials":1449,"activeCount":99},[],{"intervention":1266,"totalTrials":312,"cells":1451},{"EARLY_PHASE1":1452,"PHASE1":1454,"PHASE2":1456,"PHASE3":1462,"PHASE4":1464,"NA":1466},{"trials":1453,"activeCount":99},[],{"trials":1455,"activeCount":99},[],{"trials":1457,"activeCount":312,"soonestReadout":518},[1458],{"nctId":1257,"briefTitle":1258,"status":179,"phases":1459,"primaryCompletion":518,"completion":518,"start":1260,"enrollment":1261,"conditions":1460,"interventions":1461},[88],[1263],[1248,1265,1266],{"trials":1463,"activeCount":99},[],{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"intervention":563,"totalTrials":312,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1480,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":99},[],{"trials":1473,"activeCount":99},[],{"trials":1475,"activeCount":312,"soonestReadout":50},[1476],{"nctId":48,"briefTitle":49,"status":555,"phases":1477,"primaryCompletion":50,"completion":557,"start":558,"enrollment":559,"conditions":1478,"interventions":1479},[87,88],[561],[51,531,563],{"trials":1481,"activeCount":99},[],{"trials":1483,"activeCount":99},[],{"trials":1485,"activeCount":99},[],{"intervention":84,"totalTrials":312,"cells":1487},{"EARLY_PHASE1":1488,"PHASE1":1490,"PHASE2":1492,"PHASE3":1502,"PHASE4":1504,"NA":1506},{"trials":1489,"activeCount":99},[],{"trials":1491,"activeCount":99},[],{"trials":1493,"activeCount":312,"soonestReadout":79},[1494],{"nctId":82,"briefTitle":83,"status":179,"phases":1495,"primaryCompletion":79,"completion":79,"start":1496,"enrollment":1497,"conditions":1498,"interventions":1501},[88],"2021-05-24",13,[15,1499,1500],"HER2-negative Breast Cancer","Metastatic Breast Cancer",[84],{"trials":1503,"activeCount":99},[],{"trials":1505,"activeCount":99},[],{"trials":1507,"activeCount":99},[],{"intervention":56,"totalTrials":312,"cells":1509},{"EARLY_PHASE1":1510,"PHASE1":1512,"PHASE2":1514,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1511,"activeCount":99},[],{"trials":1513,"activeCount":99},[],{"trials":1515,"activeCount":312,"soonestReadout":55},[1516],{"nctId":53,"briefTitle":54,"status":555,"phases":1517,"primaryCompletion":55,"completion":1518,"start":1519,"enrollment":19,"conditions":1520,"interventions":1521},[88],"2027-09","2018-10-24",[18],[56],{"trials":1523,"activeCount":99},[],{"trials":1525,"activeCount":99},[],{"trials":1527,"activeCount":99},[],{"intervention":1529,"totalTrials":312,"cells":1530},"ASTX727 + retifanlimab",{"EARLY_PHASE1":1531,"PHASE1":1533,"PHASE2":1535,"PHASE3":1547,"PHASE4":1549,"NA":1551},{"trials":1532,"activeCount":99},[],{"trials":1534,"activeCount":99},[],{"trials":1536,"activeCount":312,"soonestReadout":1541},[1537],{"nctId":1538,"briefTitle":1539,"status":111,"phases":1540,"primaryCompletion":1541,"completion":1541,"start":79,"enrollment":19,"conditions":1542,"interventions":1546},"NCT07472322","ASTX727 & Retifanlimab-dlwr for Advanced Merkel Cell After Progression on Anti-PD-(L)1",[87,88],"2031-05",[1543,1544,1545],"Merkel Cell Carcinoma","Merkel Cell Carcinoma, Stage III","Merkel Cell Carcinoma, Stage IV",[1529],{"trials":1548,"activeCount":99},[],{"trials":1550,"activeCount":99},[],{"trials":1552,"activeCount":99},[],{"intervention":937,"totalTrials":312,"cells":1554},{"EARLY_PHASE1":1555,"PHASE1":1557,"PHASE2":1559,"PHASE3":1565,"PHASE4":1567,"NA":1569},{"trials":1556,"activeCount":99},[],{"trials":1558,"activeCount":99},[],{"trials":1560,"activeCount":312,"soonestReadout":809},[1561],{"nctId":929,"briefTitle":930,"status":179,"phases":1562,"primaryCompletion":809,"completion":113,"start":932,"enrollment":933,"conditions":1563,"interventions":1564},[88],[15],[920,936,937],{"trials":1566,"activeCount":99},[],{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[],{"intervention":582,"totalTrials":312,"cells":1572},{"EARLY_PHASE1":1573,"PHASE1":1575,"PHASE2":1577,"PHASE3":1583,"PHASE4":1585,"NA":1587},{"trials":1574,"activeCount":99},[],{"trials":1576,"activeCount":99},[],{"trials":1578,"activeCount":312,"soonestReadout":483},[1579],{"nctId":572,"briefTitle":573,"status":179,"phases":1580,"primaryCompletion":483,"completion":575,"start":576,"enrollment":577,"conditions":1581,"interventions":1582},[87,88],[18],[580,581,531,582,583,584],{"trials":1584,"activeCount":99},[],{"trials":1586,"activeCount":99},[],{"trials":1588,"activeCount":99},[],{"intervention":583,"totalTrials":312,"cells":1590},{"EARLY_PHASE1":1591,"PHASE1":1593,"PHASE2":1595,"PHASE3":1601,"PHASE4":1603,"NA":1605},{"trials":1592,"activeCount":99},[],{"trials":1594,"activeCount":99},[],{"trials":1596,"activeCount":312,"soonestReadout":483},[1597],{"nctId":572,"briefTitle":573,"status":179,"phases":1598,"primaryCompletion":483,"completion":575,"start":576,"enrollment":577,"conditions":1599,"interventions":1600},[87,88],[18],[580,581,531,582,583,584],{"trials":1602,"activeCount":99},[],{"trials":1604,"activeCount":99},[],{"trials":1606,"activeCount":99},[],{"intervention":584,"totalTrials":312,"cells":1608},{"EARLY_PHASE1":1609,"PHASE1":1611,"PHASE2":1613,"PHASE3":1619,"PHASE4":1621,"NA":1623},{"trials":1610,"activeCount":99},[],{"trials":1612,"activeCount":99},[],{"trials":1614,"activeCount":312,"soonestReadout":483},[1615],{"nctId":572,"briefTitle":573,"status":179,"phases":1616,"primaryCompletion":483,"completion":575,"start":576,"enrollment":577,"conditions":1617,"interventions":1618},[87,88],[18],[580,581,531,582,583,584],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[],{"intervention":701,"totalTrials":312,"cells":1626},{"EARLY_PHASE1":1627,"PHASE1":1629,"PHASE2":1631,"PHASE3":1637,"PHASE4":1639,"NA":1641},{"trials":1628,"activeCount":99},[],{"trials":1630,"activeCount":99},[],{"trials":1632,"activeCount":312,"soonestReadout":693},[1633],{"nctId":690,"briefTitle":691,"status":555,"phases":1634,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":1635,"interventions":1636},[88],[697],[699,700,701,702,670],{"trials":1638,"activeCount":99},[],{"trials":1640,"activeCount":99},[],{"trials":1642,"activeCount":99},[],{"intervention":702,"totalTrials":312,"cells":1644},{"EARLY_PHASE1":1645,"PHASE1":1647,"PHASE2":1649,"PHASE3":1655,"PHASE4":1657,"NA":1659},{"trials":1646,"activeCount":99},[],{"trials":1648,"activeCount":99},[],{"trials":1650,"activeCount":312,"soonestReadout":693},[1651],{"nctId":690,"briefTitle":691,"status":555,"phases":1652,"primaryCompletion":693,"completion":693,"start":694,"enrollment":695,"conditions":1653,"interventions":1654},[88],[697],[699,700,701,702,670],{"trials":1656,"activeCount":99},[],{"trials":1658,"activeCount":99},[],{"trials":1660,"activeCount":99},[],{"intervention":1662,"totalTrials":312,"cells":1663},"Calfactant",{"EARLY_PHASE1":1664,"PHASE1":1666,"PHASE2":1668,"PHASE3":1681,"PHASE4":1683,"NA":1685},{"trials":1665,"activeCount":99},[],{"trials":1667,"activeCount":99},[],{"trials":1669,"activeCount":312,"soonestReadout":1674},[1670],{"nctId":1671,"briefTitle":1672,"status":111,"phases":1673,"primaryCompletion":1674,"completion":1674,"start":518,"enrollment":1675,"conditions":1676,"interventions":1679},"NCT06855043","Little Lungs Study",[87,88],"2029-03",24,[1677,1678],"Invasive Mechanical Ventilation","Severe Respiratory Distress Syndrome",[1662,1680],"Budesonide",{"trials":1682,"activeCount":99},[],{"trials":1684,"activeCount":99},[],{"trials":1686,"activeCount":99},[],{"intervention":1680,"totalTrials":312,"cells":1688},{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1699,"PHASE4":1701,"NA":1703},{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":312,"soonestReadout":1674},[1695],{"nctId":1671,"briefTitle":1672,"status":111,"phases":1696,"primaryCompletion":1674,"completion":1674,"start":518,"enrollment":1675,"conditions":1697,"interventions":1698},[87,88],[1677,1678],[1662,1680],{"trials":1700,"activeCount":99},[],{"trials":1702,"activeCount":99},[],{"trials":1704,"activeCount":99},[],{"intervention":1706,"totalTrials":312,"cells":1707},"Probiotic",{"EARLY_PHASE1":1708,"PHASE1":1710,"PHASE2":1712,"PHASE3":1721,"PHASE4":1723,"NA":1725},{"trials":1709,"activeCount":99},[],{"trials":1711,"activeCount":99},[],{"trials":1713,"activeCount":312,"soonestReadout":1674},[1714],{"nctId":1715,"briefTitle":1716,"status":111,"phases":1717,"primaryCompletion":1674,"completion":1674,"start":79,"enrollment":864,"conditions":1718,"interventions":1720},"NCT07413744","The Gut - PRO Study",[88],[1719],"Alzheimer Disease",[1706],{"trials":1722,"activeCount":99},[],{"trials":1724,"activeCount":99},[],{"trials":1726,"activeCount":99},[],{"intervention":1728,"totalTrials":312,"cells":1729},"Caffeine citrate",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1747,"PHASE4":1749,"NA":1751},{"trials":1731,"activeCount":99},[],{"trials":1733,"activeCount":99},[],{"trials":1735,"activeCount":312,"soonestReadout":1740},[1736],{"nctId":1737,"briefTitle":1738,"status":179,"phases":1739,"primaryCompletion":1740,"completion":1741,"start":79,"enrollment":1742,"conditions":1743,"interventions":1746},"NCT07262060","Improving Preterm Kidney Outcomes With Caffeine",[88],"2030-03","2030-09",114,[1744,1745],"Kidney Injury","Pre-Term",[1728],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[],{"intervention":720,"totalTrials":312,"cells":1754},{"EARLY_PHASE1":1755,"PHASE1":1757,"PHASE2":1759,"PHASE3":1765,"PHASE4":1767,"NA":1769},{"trials":1756,"activeCount":99},[],{"trials":1758,"activeCount":99},[],{"trials":1760,"activeCount":312,"soonestReadout":181},[1761],{"nctId":714,"briefTitle":715,"status":179,"phases":1762,"primaryCompletion":181,"completion":181,"start":717,"enrollment":372,"conditions":1763,"interventions":1764},[88],[697],[720,721,670],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[],{"intervention":721,"totalTrials":312,"cells":1772},{"EARLY_PHASE1":1773,"PHASE1":1775,"PHASE2":1777,"PHASE3":1783,"PHASE4":1785,"NA":1787},{"trials":1774,"activeCount":99},[],{"trials":1776,"activeCount":99},[],{"trials":1778,"activeCount":312,"soonestReadout":181},[1779],{"nctId":714,"briefTitle":715,"status":179,"phases":1780,"primaryCompletion":181,"completion":181,"start":717,"enrollment":372,"conditions":1781,"interventions":1782},[88],[697],[720,721,670],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[],{"intervention":1790,"totalTrials":312,"cells":1791},"FAPI tracer",{"EARLY_PHASE1":1792,"PHASE1":1794,"PHASE2":1796,"PHASE3":1806,"PHASE4":1808,"NA":1810},{"trials":1793,"activeCount":99},[],{"trials":1795,"activeCount":99},[],{"trials":1797,"activeCount":312,"soonestReadout":1518},[1798],{"nctId":1799,"briefTitle":1800,"status":179,"phases":1801,"primaryCompletion":1518,"completion":1518,"start":1802,"enrollment":372,"conditions":1803,"interventions":1805},"NCT06940427","Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis",[88],"2025-11-19",[1804],"Fibrosis Lung",[1790],{"trials":1807,"activeCount":99},[],{"trials":1809,"activeCount":99},[],{"trials":1811,"activeCount":99},[],{"intervention":1813,"totalTrials":312,"cells":1814},"Everolimus 0.5 MG once per day",{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1832,"PHASE4":1834,"NA":1836},{"trials":1816,"activeCount":99},[],{"trials":1818,"activeCount":99},[],{"trials":1820,"activeCount":312,"soonestReadout":518},[1821],{"nctId":1822,"briefTitle":1823,"status":555,"phases":1824,"primaryCompletion":518,"completion":518,"start":1825,"enrollment":1826,"conditions":1827,"interventions":1830},"NCT05835999","Everolimus Aging Study",[88],"2023-03-24",106,[1828,1829],"Aging","Insulin Resistance",[1813,1831],"Everolimus 5 MG once per week",{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"intervention":1831,"totalTrials":312,"cells":1839},{"EARLY_PHASE1":1840,"PHASE1":1842,"PHASE2":1844,"PHASE3":1850,"PHASE4":1852,"NA":1854},{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[],{"trials":1845,"activeCount":312,"soonestReadout":518},[1846],{"nctId":1822,"briefTitle":1823,"status":555,"phases":1847,"primaryCompletion":518,"completion":518,"start":1825,"enrollment":1826,"conditions":1848,"interventions":1849},[88],[1828,1829],[1813,1831],{"trials":1851,"activeCount":99},[],{"trials":1853,"activeCount":99},[],{"trials":1855,"activeCount":99},[],{"intervention":1857,"totalTrials":312,"cells":1858},"CBD",{"EARLY_PHASE1":1859,"PHASE1":1861,"PHASE2":1863,"PHASE3":1876,"PHASE4":1878,"NA":1880},{"trials":1860,"activeCount":99},[],{"trials":1862,"activeCount":99},[],{"trials":1864,"activeCount":312,"soonestReadout":1869},[1865],{"nctId":1866,"briefTitle":1867,"status":179,"phases":1868,"primaryCompletion":1869,"completion":1869,"start":1870,"enrollment":32,"conditions":1871,"interventions":1875},"NCT06840899","CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury",[88],"2027-05","2026-02-13",[1872,1873,1874],"Supra-sacral Spinal Cord Injury","Spinal Cord Injury","Urinary Incontinence",[1857],{"trials":1877,"activeCount":99},[],{"trials":1879,"activeCount":99},[],{"trials":1881,"activeCount":99},[],{"intervention":65,"totalTrials":592,"cells":1883},{"EARLY_PHASE1":1884,"PHASE1":1886,"PHASE2":1888,"PHASE3":1921,"PHASE4":1923,"NA":1925},{"trials":1885,"activeCount":99},[],{"trials":1887,"activeCount":99},[],{"trials":1889,"activeCount":312,"soonestReadout":64},[1890,1903,1907,1917],{"nctId":1891,"briefTitle":1892,"status":120,"phases":1893,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":296,"conditions":1896,"interventions":1900},"NCT01754857","Bendamustine and Rituximab Induction Therapy and Maintenance Rituximab and Lenalidomide in Previously Untreated CLL\u002FSLL",[88],"2022-06-30","2013-11-12",[1897,1898,1899],"Lymphoid Leukemia","Small Lymphocytic Lymphoma","Lymphoma, Non-Hodgkin",[1901,65,1902],"Bendamustine","Lenalidomide",{"nctId":1064,"briefTitle":1065,"status":120,"phases":1904,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":241,"conditions":1905,"interventions":1906},[88],[1071],[1073,65,360,359,969,1074],{"nctId":1908,"briefTitle":1909,"status":120,"phases":1910,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":695,"conditions":1914,"interventions":1916},"NCT00974233","Study of Bendamustine\u002FRituxan Induction Chemotherapy With Revlimid Maintenance for Relapsed\u002FRefractory CLL and SLL",[88],"2013-07","2015-04","2009-10",[1915,1898],"Chronic Lymphocytic Leukemia",[1901,65,1902],{"nctId":62,"briefTitle":63,"status":555,"phases":1918,"primaryCompletion":64,"completion":963,"start":964,"enrollment":22,"conditions":1919,"interventions":1920},[88],[966,967,309],[65,360,359,969,953,361],{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[1927,1937],{"nctId":1928,"briefTitle":1929,"status":1013,"phases":1930,"primaryCompletion":1931,"completion":1931,"start":1932,"enrollment":99,"conditions":1933,"interventions":1935},"NCT00167791","Rituximab Desensitization Therapy for Patients on the Waiting List for Kidney Transplant",[91],"2008-03","2005-07",[1934],"End Stage Renal Disease",[1936],"rituximab",{"nctId":1938,"briefTitle":1939,"status":120,"phases":1940,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1322,"conditions":1944,"interventions":1946},"NCT02652468","TCR-α\u002Fβ and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed Lymphoma",[91],"2018-09-01","2021-09-17","2016-03-10",[1945],"Lymphoma",[1947,1948,360,1949,1950,500,65],"Fludarabine Phosphate","Mesna","T Cell-Depleted Hematopoietic Stem Cell Transplantation","Mycophenolate Mofetil",{"intervention":360,"totalTrials":1952,"cells":1953},5,{"EARLY_PHASE1":1954,"PHASE1":1956,"PHASE2":1958,"PHASE3":2000,"PHASE4":2002,"NA":2004},{"trials":1955,"activeCount":99},[],{"trials":1957,"activeCount":99},[],{"trials":1959,"activeCount":312,"soonestReadout":64},[1960,1964,1968,1996],{"nctId":1064,"briefTitle":1065,"status":120,"phases":1961,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":241,"conditions":1962,"interventions":1963},[88],[1071],[1073,65,360,359,969,1074],{"nctId":350,"briefTitle":351,"status":120,"phases":1965,"primaryCompletion":353,"completion":354,"start":355,"enrollment":9,"conditions":1966,"interventions":1967},[88],[15,357],[338,316,359,360,361,362],{"nctId":1969,"briefTitle":1970,"status":120,"phases":1971,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":32,"conditions":1975,"interventions":1988},"NCT01707004","Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia",[88],"2017-07-22","2017-10-07","2013-05-16",[1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987],"Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome","Adult Acute Myeloid Leukemia in Remission","Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities","Adult Acute Myeloid Leukemia With Del(5q)","Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)","Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)","Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)","Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)","de Novo Myelodysplastic Syndromes","Previously Treated Myelodysplastic Syndromes","Recurrent Adult Acute Myeloid Leukemia","Secondary Acute Myeloid Leukemia",[1989,1990,1991,1992,1993,1994,1995],"decitabine","fludarabine phosphate","busulfan","cyclophosphamide","tacrolimus","mycophenolate mofetil","filgrastim",{"nctId":62,"briefTitle":63,"status":555,"phases":1997,"primaryCompletion":64,"completion":963,"start":964,"enrollment":22,"conditions":1998,"interventions":1999},[88],[966,967,309],[65,360,359,969,953,361],{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[2006],{"nctId":1938,"briefTitle":1939,"status":120,"phases":2007,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1322,"conditions":2008,"interventions":2009},[91],[1945],[1947,1948,360,1949,1950,500,65],{"intervention":897,"totalTrials":592,"cells":2011},{"EARLY_PHASE1":2012,"PHASE1":2014,"PHASE2":2071,"PHASE3":2073,"PHASE4":2075,"NA":2077},{"trials":2013,"activeCount":99},[],{"trials":2015,"activeCount":778,"soonestReadout":2020},[2016,2028,2038,2047,2060,2067],{"nctId":2017,"briefTitle":2018,"status":179,"phases":2019,"primaryCompletion":2020,"completion":2021,"start":2022,"enrollment":2023,"conditions":2024,"interventions":2027},"NCT05866471","The ENHANCE Study: taVNS and Psilocybin",[87],"2027-11","2028-01","2025-01-27",108,[21,2025,2026],"Psychedelic Experiences","Vagus Nerve Stimulation",[897],{"nctId":2029,"briefTitle":2030,"status":111,"phases":2031,"primaryCompletion":2032,"completion":2032,"start":79,"enrollment":2033,"conditions":2034,"interventions":2036},"NCT07360301","Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study",[87],"2028-02",120,[2035,2025],"Well-Being, Psychological",[897,2037],"Clonidine",{"nctId":2039,"briefTitle":2040,"status":120,"phases":2041,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":592,"conditions":2044,"interventions":2046},"NCT05592379","Consciousness, Psilocybin, and Well-Being",[87],"2025-02-19","2023-11-07",[21,2025,2045],"Sleep",[897,2037],{"nctId":2048,"briefTitle":2049,"status":681,"phases":2050,"primaryCompletion":2051,"completion":2051,"start":2052,"enrollment":1952,"conditions":2053,"interventions":2059},"NCT05322954","Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder",[87],"2024-03-07","2023-03-03",[2054,2055,2056,2057,2058],"Methamphetamine Use Disorder","Substance-Related Disorders","Chemically-Induced Disorders","Substance Use Disorders","Stimulant-Use Disorder",[897],{"nctId":2061,"briefTitle":2062,"status":120,"phases":2063,"primaryCompletion":2064,"completion":2064,"start":122,"enrollment":95,"conditions":2065,"interventions":2066},"NCT02163707","UW Psilocybin Pharmacokinetics Study",[87],"2015-12",[21],[897],{"nctId":892,"briefTitle":893,"status":179,"phases":2068,"primaryCompletion":543,"completion":543,"start":895,"enrollment":577,"conditions":2069,"interventions":2070},[87],[897],[897,897,899,885],{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"trials":2076,"activeCount":99},[],{"trials":2078,"activeCount":99},[],{"intervention":899,"totalTrials":232,"cells":2080},{"EARLY_PHASE1":2081,"PHASE1":2083,"PHASE2":2089,"PHASE3":2091,"PHASE4":2093,"NA":2109},{"trials":2082,"activeCount":99},[],{"trials":2084,"activeCount":312,"soonestReadout":543},[2085],{"nctId":892,"briefTitle":893,"status":179,"phases":2086,"primaryCompletion":543,"completion":543,"start":895,"enrollment":577,"conditions":2087,"interventions":2088},[87],[897],[897,897,899,885],{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"trials":2094,"activeCount":99},[2095],{"nctId":2096,"briefTitle":2097,"status":120,"phases":2098,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":2101,"conditions":2102,"interventions":2105},"NCT03284307","UNderstanding CONSciousness Connectedness and Intraoperative Unresponsiveness Study",[90],"2020-03-12","2017-08-10",35,[2103,2104],"Unconsciousness","Consciousness",[2106,2107,2108,899],"Dexmedetomidine","Ketamine","Propofol",{"trials":2110,"activeCount":99},[],{"intervention":2112,"totalTrials":232,"cells":2113},"Zoledronate",{"EARLY_PHASE1":2114,"PHASE1":2116,"PHASE2":2134,"PHASE3":2145,"PHASE4":2147,"NA":2149},{"trials":2115,"activeCount":99},[],{"trials":2117,"activeCount":312,"soonestReadout":483},[2118],{"nctId":2119,"briefTitle":2120,"status":179,"phases":2121,"primaryCompletion":483,"completion":543,"start":2122,"enrollment":332,"conditions":2123,"interventions":2133},"NCT02508038","Alpha\u002FBeta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors",[87],"2016-02-12",[2124,2125,2126,2127,2128,2129,2130,2131,2132,1140,1137],"Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Hodgkin Lymphoma","Non-Hodgkin Lymphoma","Myelodysplastic Syndrome","Myeloproliferative Syndrome","Rhabdomyosarcoma","Ewing Sarcoma","Primitive Neuroectodermal Tumor",[2112],{"trials":2135,"activeCount":99},[2136],{"nctId":2137,"briefTitle":2138,"status":120,"phases":2139,"primaryCompletion":2140,"completion":2140,"start":2141,"enrollment":2142,"conditions":2143,"interventions":2144},"NCT00213980","Bone Mineral Density Effects of Zoledronate in Postmenopausal Women With Breast Cancer",[88],"2008-04","2000-01",68,[15],[2112],{"trials":2146,"activeCount":99},[],{"trials":2148,"activeCount":99},[],{"trials":2150,"activeCount":99},[],{"intervention":2152,"totalTrials":232,"cells":2153},"Sirolimus",{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2168,"PHASE3":2190,"PHASE4":2192,"NA":2194},{"trials":2155,"activeCount":99},[],{"trials":2157,"activeCount":312,"soonestReadout":2162},[2158],{"nctId":2159,"briefTitle":2160,"status":179,"phases":2161,"primaryCompletion":2162,"completion":575,"start":2163,"enrollment":2164,"conditions":2165,"interventions":2166},"NCT05949658","Rapalog Pharmacology (RAP PAC) Study",[87],"2027-03","2024-05-15",72,[1828],[2152,2167],"Everolimus",{"trials":2169,"activeCount":99},[2170],{"nctId":2171,"briefTitle":2172,"status":120,"phases":2173,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":2176,"interventions":2179},"NCT00078559","Combination Immunosuppressive Therapy to Prevent Kidney Transplant Rejection in Adults",[87,88],"2010-02","2003-11",[2177,2178],"Kidney Transplantation","Kidney Disease",[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],"Alemtuzumab","Methylprednisolone","Acetaminophen","Diphenhydramine","Trimethoprim","Valgancyclovir","Acyclovir","Pentamidine","Clotrimazole","Nystatin",{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[],{"intervention":1179,"totalTrials":232,"cells":2197},{"EARLY_PHASE1":2198,"PHASE1":2204,"PHASE2":2217,"PHASE3":2219,"PHASE4":2221,"NA":2223},{"trials":2199,"activeCount":99},[2200],{"nctId":1170,"briefTitle":1171,"status":120,"phases":2201,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":241,"conditions":2202,"interventions":2203},[86],[18],[1178,580,1179],{"trials":2205,"activeCount":312,"soonestReadout":2210},[2206],{"nctId":2207,"briefTitle":2208,"status":179,"phases":2209,"primaryCompletion":2210,"completion":2211,"start":2212,"enrollment":397,"conditions":2213,"interventions":2216},"NCT05521698","A Randomized Trial of Bicalutamide in Non-Muscle Invasive Bladder Cancer",[87],"2028-06-01","2028-12-01","2026-05",[2214,2215],"Non-Muscle Invasive Bladder Urothelial Carcinoma","Recurrent Non-Muscle Invasive Bladder Urothelial Carcinoma",[1179],{"trials":2218,"activeCount":99},[],{"trials":2220,"activeCount":99},[],{"trials":2222,"activeCount":99},[],{"trials":2224,"activeCount":99},[],{"intervention":2037,"totalTrials":232,"cells":2226},{"EARLY_PHASE1":2227,"PHASE1":2229,"PHASE2":2239,"PHASE3":2241,"PHASE4":2243,"NA":2245},{"trials":2228,"activeCount":99},[],{"trials":2230,"activeCount":312,"soonestReadout":2032},[2231,2235],{"nctId":2029,"briefTitle":2030,"status":111,"phases":2232,"primaryCompletion":2032,"completion":2032,"start":79,"enrollment":2033,"conditions":2233,"interventions":2234},[87],[2035,2025],[897,2037],{"nctId":2039,"briefTitle":2040,"status":120,"phases":2236,"primaryCompletion":2042,"completion":2042,"start":2043,"enrollment":592,"conditions":2237,"interventions":2238},[87],[21,2025,2045],[897,2037],{"trials":2240,"activeCount":99},[],{"trials":2242,"activeCount":99},[],{"trials":2244,"activeCount":99},[],{"trials":2246,"activeCount":99},[],{"intervention":80,"totalTrials":312,"cells":2248},{"EARLY_PHASE1":2249,"PHASE1":2251,"PHASE2":2260,"PHASE3":2262,"PHASE4":2264,"NA":2266},{"trials":2250,"activeCount":99},[],{"trials":2252,"activeCount":312,"soonestReadout":79},[2253],{"nctId":77,"briefTitle":78,"status":179,"phases":2254,"primaryCompletion":79,"completion":79,"start":2255,"enrollment":602,"conditions":2256,"interventions":2258},[87],"2025-03-07",[1103,2257],"Somatostatin Receptor-positive Neuroendocrine Tumor",[80,2259],"177Lu-Dotatate",{"trials":2261,"activeCount":99},[],{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[],{"trials":2267,"activeCount":99},[],{"intervention":2259,"totalTrials":312,"cells":2269},{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2278,"PHASE3":2280,"PHASE4":2282,"NA":2284},{"trials":2271,"activeCount":99},[],{"trials":2273,"activeCount":312,"soonestReadout":79},[2274],{"nctId":77,"briefTitle":78,"status":179,"phases":2275,"primaryCompletion":79,"completion":79,"start":2255,"enrollment":602,"conditions":2276,"interventions":2277},[87],[1103,2257],[80,2259],{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[],{"trials":2283,"activeCount":99},[],{"trials":2285,"activeCount":99},[],{"intervention":2287,"totalTrials":312,"cells":2288},"S-(+)-methamphetamine",{"EARLY_PHASE1":2289,"PHASE1":2291,"PHASE2":2304,"PHASE3":2306,"PHASE4":2308,"NA":2310},{"trials":2290,"activeCount":99},[],{"trials":2292,"activeCount":312,"soonestReadout":2297},[2293],{"nctId":2294,"briefTitle":2295,"status":111,"phases":2296,"primaryCompletion":2297,"completion":2297,"start":79,"enrollment":2298,"conditions":2299,"interventions":2301},"NCT06746831","Methamphetamine Isomer Pharmacology in Humans",[87],"2028-03",17,[2300],"Methamphetamine",[2287,2302,2303],"R-(-)-methamphetamine","1:1 racemic mixture of two isomers",{"trials":2305,"activeCount":99},[],{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"trials":2311,"activeCount":99},[],{"intervention":2302,"totalTrials":312,"cells":2313},{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2322,"PHASE3":2324,"PHASE4":2326,"NA":2328},{"trials":2315,"activeCount":99},[],{"trials":2317,"activeCount":312,"soonestReadout":2297},[2318],{"nctId":2294,"briefTitle":2295,"status":111,"phases":2319,"primaryCompletion":2297,"completion":2297,"start":79,"enrollment":2298,"conditions":2320,"interventions":2321},[87],[2300],[2287,2302,2303],{"trials":2323,"activeCount":99},[],{"trials":2325,"activeCount":99},[],{"trials":2327,"activeCount":99},[],{"trials":2329,"activeCount":99},[],{"intervention":2303,"totalTrials":312,"cells":2331},{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2333,"activeCount":99},[],{"trials":2335,"activeCount":312,"soonestReadout":2297},[2336],{"nctId":2294,"briefTitle":2295,"status":111,"phases":2337,"primaryCompletion":2297,"completion":2297,"start":79,"enrollment":2298,"conditions":2338,"interventions":2339},[87],[2300],[2287,2302,2303],{"trials":2341,"activeCount":99},[],{"trials":2343,"activeCount":99},[],{"trials":2345,"activeCount":99},[],{"trials":2347,"activeCount":99},[],{"intervention":70,"totalTrials":312,"cells":2349},{"EARLY_PHASE1":2350,"PHASE1":2352,"PHASE2":2360,"PHASE3":2362,"PHASE4":2364,"NA":2366},{"trials":2351,"activeCount":99},[],{"trials":2353,"activeCount":312,"soonestReadout":69},[2354],{"nctId":67,"briefTitle":68,"status":555,"phases":2355,"primaryCompletion":69,"completion":2021,"start":2356,"enrollment":1156,"conditions":2357,"interventions":2359},[87],"2023-07-17",[739,2358],"Xerostomia",[70],{"trials":2361,"activeCount":99},[],{"trials":2363,"activeCount":99},[],{"trials":2365,"activeCount":99},[],{"trials":2367,"activeCount":99},[],{"intervention":2369,"totalTrials":312,"cells":2370},"Mesenchymal Stromal Cells (MSC) Dose Level 0",{"EARLY_PHASE1":2371,"PHASE1":2373,"PHASE2":2386,"PHASE3":2388,"PHASE4":2390,"NA":2392},{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":312,"soonestReadout":2379},[2375],{"nctId":2376,"briefTitle":2377,"status":179,"phases":2378,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":296,"conditions":2381,"interventions":2384},"NCT06392711","Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia",[87],"2028-11","2024-10-04",[2358,2382,2383],"Graft-versus-host-disease","Sjogren's Disease",[2369,2385],"Mesenchymal Stromal Cells (MSC) Dose Level 1",{"trials":2387,"activeCount":99},[],{"trials":2389,"activeCount":99},[],{"trials":2391,"activeCount":99},[],{"trials":2393,"activeCount":99},[],{"intervention":2385,"totalTrials":312,"cells":2395},{"EARLY_PHASE1":2396,"PHASE1":2398,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2410},{"trials":2397,"activeCount":99},[],{"trials":2399,"activeCount":312,"soonestReadout":2379},[2400],{"nctId":2376,"briefTitle":2377,"status":179,"phases":2401,"primaryCompletion":2379,"completion":2379,"start":2380,"enrollment":296,"conditions":2402,"interventions":2403},[87],[2358,2382,2383],[2369,2385],{"trials":2405,"activeCount":99},[],{"trials":2407,"activeCount":99},[],{"trials":2409,"activeCount":99},[],{"trials":2411,"activeCount":99},[],{"intervention":2413,"totalTrials":312,"cells":2414},"TCRαβ+\u002FCD19+ depleted Hematopoietic stem cell (HSC) graft",{"EARLY_PHASE1":2415,"PHASE1":2417,"PHASE2":2428,"PHASE3":2430,"PHASE4":2432,"NA":2434},{"trials":2416,"activeCount":99},[],{"trials":2418,"activeCount":312,"soonestReadout":2423},[2419],{"nctId":2420,"briefTitle":2421,"status":111,"phases":2422,"primaryCompletion":2423,"completion":2424,"start":79,"enrollment":95,"conditions":2425,"interventions":2427},"NCT04806347","Alpha\u002FBeta T-cell Depleted Blood-forming Stem Cell Transplant From Related or Unrelated Donors for Blood Diseases in Children and Young Adults",[87],"2029-05","2030-05",[2426],"Blood Disease",[2413],{"trials":2429,"activeCount":99},[],{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[],{"intervention":2437,"totalTrials":312,"cells":2438},"90Y-NM600",{"EARLY_PHASE1":2439,"PHASE1":2441,"PHASE2":2450,"PHASE3":2452,"PHASE4":2454,"NA":2456},{"trials":2440,"activeCount":99},[],{"trials":2442,"activeCount":312,"soonestReadout":2447},[2443],{"nctId":2444,"briefTitle":2445,"status":179,"phases":2446,"primaryCompletion":2447,"completion":2447,"start":79,"enrollment":577,"conditions":2448,"interventions":2449},"NCT07197671","Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer",[87],"2028-09",[653],[2437],{"trials":2451,"activeCount":99},[],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"intervention":46,"totalTrials":312,"cells":2459},{"EARLY_PHASE1":2460,"PHASE1":2462,"PHASE2":2470,"PHASE3":2472,"PHASE4":2474,"NA":2476},{"trials":2461,"activeCount":99},[],{"trials":2463,"activeCount":312,"soonestReadout":45},[2464],{"nctId":43,"briefTitle":44,"status":555,"phases":2465,"primaryCompletion":45,"completion":2212,"start":2466,"enrollment":592,"conditions":2467,"interventions":2469},[87],"2022-02-18",[2468],"Xerostomia Following Radiotherapy",[46],{"trials":2471,"activeCount":99},[],{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":99},[],{"intervention":2479,"totalTrials":312,"cells":2480},"pTVG-HP DNA vaccine",{"EARLY_PHASE1":2481,"PHASE1":2483,"PHASE2":2499,"PHASE3":2501,"PHASE4":2503,"NA":2505},{"trials":2482,"activeCount":99},[],{"trials":2484,"activeCount":312,"soonestReadout":2489},[2485],{"nctId":2486,"briefTitle":2487,"status":179,"phases":2488,"primaryCompletion":2489,"completion":2489,"start":2490,"enrollment":2491,"conditions":2492,"interventions":2497},"NCT07090148","Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC",[87],"2030-10","2026-03-03",14,[2493,2494,2495,2496],"Prostate Cancer Patients","Non-castrate Prostate Cancer","Recurrent Prostate Cancer","Oligometastatic Prostate Cancer (OMPC)",[2479,2498],"Anti-PD-1 monoclonal antibody",{"trials":2500,"activeCount":99},[],{"trials":2502,"activeCount":99},[],{"trials":2504,"activeCount":99},[],{"trials":2506,"activeCount":99},[],{"intervention":2498,"totalTrials":312,"cells":2508},{"EARLY_PHASE1":2509,"PHASE1":2511,"PHASE2":2517,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2510,"activeCount":99},[],{"trials":2512,"activeCount":312,"soonestReadout":2489},[2513],{"nctId":2486,"briefTitle":2487,"status":179,"phases":2514,"primaryCompletion":2489,"completion":2489,"start":2490,"enrollment":2491,"conditions":2515,"interventions":2516},[87],[2493,2494,2495,2496],[2479,2498],{"trials":2518,"activeCount":99},[],{"trials":2520,"activeCount":99},[],{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"intervention":2526,"totalTrials":312,"cells":2527},"Psilocybin with facilitated counseling",{"EARLY_PHASE1":2528,"PHASE1":2530,"PHASE2":2541,"PHASE3":2543,"PHASE4":2545,"NA":2547},{"trials":2529,"activeCount":99},[],{"trials":2531,"activeCount":312,"soonestReadout":79},[2532],{"nctId":2533,"briefTitle":2534,"status":179,"phases":2535,"primaryCompletion":79,"completion":2536,"start":2537,"enrollment":602,"conditions":2538,"interventions":2540},"NCT04161066","Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine",[87],"2026-07","2021-01-13",[2539],"Opioid Use Disorder",[2526],{"trials":2542,"activeCount":99},[],{"trials":2544,"activeCount":99},[],{"trials":2546,"activeCount":99},[],{"trials":2548,"activeCount":99},[],{"intervention":2167,"totalTrials":312,"cells":2550},{"EARLY_PHASE1":2551,"PHASE1":2553,"PHASE2":2559,"PHASE3":2561,"PHASE4":2563,"NA":2565},{"trials":2552,"activeCount":99},[],{"trials":2554,"activeCount":312,"soonestReadout":2162},[2555],{"nctId":2159,"briefTitle":2160,"status":179,"phases":2556,"primaryCompletion":2162,"completion":575,"start":2163,"enrollment":2164,"conditions":2557,"interventions":2558},[87],[1828],[2152,2167],{"trials":2560,"activeCount":99},[],{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"intervention":2568,"totalTrials":312,"cells":2569},"Lopinavir \u002F Ritonavir",{"EARLY_PHASE1":2570,"PHASE1":2572,"PHASE2":2584,"PHASE3":2586,"PHASE4":2588,"NA":2590},{"trials":2571,"activeCount":99},[],{"trials":2573,"activeCount":312,"soonestReadout":2578},[2574],{"nctId":2575,"briefTitle":2576,"status":179,"phases":2577,"primaryCompletion":2578,"completion":2578,"start":2579,"enrollment":2580,"conditions":2581,"interventions":2583},"NCT05334004","Lopinavir\u002FRitonavir in PLWH With High-Grade AIN",[87],"2027-06","2023-12-19",21,[2582],"High-Grade Anal Intraepithelial Neoplasia",[2568],{"trials":2585,"activeCount":99},[],{"trials":2587,"activeCount":99},[],{"trials":2589,"activeCount":99},[],{"trials":2591,"activeCount":99},[],{"intervention":1049,"totalTrials":778,"cells":2593},{"EARLY_PHASE1":2594,"PHASE1":2612,"PHASE2":2614,"PHASE3":2616,"PHASE4":2618,"NA":2624},{"trials":2595,"activeCount":312,"soonestReadout":2600},[2596,2604],{"nctId":2597,"briefTitle":2598,"status":111,"phases":2599,"primaryCompletion":2600,"completion":2600,"start":2536,"enrollment":2164,"conditions":2601,"interventions":2603},"NCT07218653","Human Cerebrovascular Blood Flow and Sex Differences in Metabolic Syndrome",[86],"2031-07",[2602],"Metabolic Syndrome",[1049],{"nctId":2605,"briefTitle":2606,"status":120,"phases":2607,"primaryCompletion":2608,"completion":2608,"start":2609,"enrollment":397,"conditions":2610,"interventions":2611},"NCT02653638","Blood Brain Flow and Exercise",[86],"2019-04","2016-06",[803],[1049],{"trials":2613,"activeCount":99},[],{"trials":2615,"activeCount":99},[],{"trials":2617,"activeCount":99},[],{"trials":2619,"activeCount":99},[2620],{"nctId":1041,"briefTitle":1042,"status":120,"phases":2621,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":332,"conditions":2622,"interventions":2623},[90],[1047],[1049,1050,1051,936,1052],{"trials":2625,"activeCount":99},[],{"intervention":2627,"totalTrials":232,"cells":2628},"Tamoxifen",{"EARLY_PHASE1":2629,"PHASE1":2640,"PHASE2":2642,"PHASE3":2653,"PHASE4":2655,"NA":2657},{"trials":2630,"activeCount":312,"soonestReadout":483},[2631],{"nctId":2632,"briefTitle":2633,"status":179,"phases":2634,"primaryCompletion":483,"completion":543,"start":2635,"enrollment":95,"conditions":2636,"interventions":2639},"NCT04174352","FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer",[86],"2020-10-20",[2637,2638],"ERα+ Breast Cancer","ESR1 Gene Mutation",[2627],{"trials":2641,"activeCount":99},[],{"trials":2643,"activeCount":99},[2644],{"nctId":2645,"briefTitle":2646,"status":120,"phases":2647,"completion":2648,"start":2649,"enrollment":496,"conditions":2650,"interventions":2652},"NCT00214110","Tamoxifen Therapy in Amyotrophic Lateral Sclerosis [ALS]",[88],"2005-01","2001-01",[2651],"Amyotrophic Lateral Sclerosis (ALS)",[2627],{"trials":2654,"activeCount":99},[],{"trials":2656,"activeCount":99},[],{"trials":2658,"activeCount":99},[],{"intervention":742,"totalTrials":312,"cells":2660},{"EARLY_PHASE1":2661,"PHASE1":2667,"PHASE2":2669,"PHASE3":2671,"PHASE4":2673,"NA":2675},{"trials":2662,"activeCount":312,"soonestReadout":736},[2663],{"nctId":733,"briefTitle":734,"status":555,"phases":2664,"primaryCompletion":736,"completion":736,"start":737,"enrollment":616,"conditions":2665,"interventions":2666},[86],[739,740],[700,742],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[],{"trials":2674,"activeCount":99},[],{"trials":2676,"activeCount":99},[],{"intervention":606,"totalTrials":312,"cells":2678},{"EARLY_PHASE1":2679,"PHASE1":2685,"PHASE2":2687,"PHASE3":2689,"PHASE4":2691,"NA":2693},{"trials":2680,"activeCount":312,"soonestReadout":600},[2681],{"nctId":597,"briefTitle":598,"status":555,"phases":2682,"primaryCompletion":600,"completion":600,"start":601,"enrollment":602,"conditions":2683,"interventions":2684},[86],[604],[606,553],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"trials":2692,"activeCount":99},[],{"trials":2694,"activeCount":99},[],{"intervention":75,"totalTrials":312,"cells":2696},{"EARLY_PHASE1":2697,"PHASE1":2705,"PHASE2":2707,"PHASE3":2709,"PHASE4":2711,"NA":2713},{"trials":2698,"activeCount":312,"soonestReadout":74},[2699],{"nctId":72,"briefTitle":73,"status":555,"phases":2700,"primaryCompletion":74,"completion":2701,"start":2702,"enrollment":241,"conditions":2703,"interventions":2704},[86],"2027-08","2023-03-08",[18],[75],{"trials":2706,"activeCount":99},[],{"trials":2708,"activeCount":99},[],{"trials":2710,"activeCount":99},[],{"trials":2712,"activeCount":99},[],{"trials":2714,"activeCount":99},[],{"intervention":2716,"totalTrials":312,"cells":2717},"3'-Deoxy-3'-[18F]-fluorothymidine",{"EARLY_PHASE1":2718,"PHASE1":2728,"PHASE2":2730,"PHASE3":2732,"PHASE4":2734,"NA":2736},{"trials":2719,"activeCount":312,"soonestReadout":2724},[2720],{"nctId":2721,"briefTitle":2722,"status":111,"phases":2723,"primaryCompletion":2724,"completion":2724,"start":2536,"enrollment":616,"conditions":2725,"interventions":2727},"NCT07609225","Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy",[86],"2029-07",[2726],"Metastatic Castration-resistant Prostate Cancer",[2716],{"trials":2729,"activeCount":99},[],{"trials":2731,"activeCount":99},[],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"intervention":2739,"totalTrials":232,"cells":2740},"Indocyanine green",{"EARLY_PHASE1":2741,"PHASE1":2743,"PHASE2":2745,"PHASE3":2747,"PHASE4":2749,"NA":2751},{"trials":2742,"activeCount":99},[],{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[],{"trials":2750,"activeCount":99},[],{"trials":2752,"activeCount":312,"soonestReadout":2162},[2753,2763],{"nctId":2754,"briefTitle":2755,"status":120,"phases":2756,"primaryCompletion":2757,"completion":2757,"start":2758,"enrollment":2759,"conditions":2760,"interventions":2762},"NCT05094102","Intraoperative Evaluation of Axillary Lymphatics",[91],"2023-04-27","2022-05-05",9,[2761,400,15],"Lymphedema",[2739],{"nctId":2764,"briefTitle":2765,"status":555,"phases":2766,"primaryCompletion":2162,"completion":2297,"start":2767,"enrollment":496,"conditions":2768,"interventions":2770},"NCT05593523","Fluorescence-based Detection of Inflammation and Necrosis to Inform Surgical Decision-making and Enhance Outcomes",[],"2023-03-09",[2769],"Burn Wound",[2739],{"intervention":2772,"totalTrials":312,"cells":2773},"PET\u002FMRI using [18F]FEPPA tracer",{"EARLY_PHASE1":2774,"PHASE1":2776,"PHASE2":2778,"PHASE3":2780,"PHASE4":2782,"NA":2784},{"trials":2775,"activeCount":99},[],{"trials":2777,"activeCount":99},[],{"trials":2779,"activeCount":99},[],{"trials":2781,"activeCount":99},[],{"trials":2783,"activeCount":99},[],{"trials":2785,"activeCount":312,"soonestReadout":2790},[2786],{"nctId":2787,"briefTitle":2788,"status":179,"phases":2789,"primaryCompletion":2790,"completion":2790,"start":2791,"enrollment":496,"conditions":2792,"interventions":2793},"NCT06299592","Comparison of Microglial Activation in Severe Asthma and Healthy Controls",[],"2028-08","2024-03-06",[34],[2772],{"intervention":2795,"totalTrials":312,"cells":2796},"Whole lung antigen challenge",{"EARLY_PHASE1":2797,"PHASE1":2799,"PHASE2":2801,"PHASE3":2803,"PHASE4":2805,"NA":2807},{"trials":2798,"activeCount":99},[],{"trials":2800,"activeCount":99},[],{"trials":2802,"activeCount":99},[],{"trials":2804,"activeCount":99},[],{"trials":2806,"activeCount":99},[],{"trials":2808,"activeCount":312,"soonestReadout":2813},[2809],{"nctId":2810,"briefTitle":2811,"status":179,"phases":2812,"primaryCompletion":2813,"completion":2813,"start":2814,"enrollment":372,"conditions":2815,"interventions":2816},"NCT04307667","Microglia Activation in Asthma",[],"2028-08-01","2019-12-17",[34],[2795],{"intervention":2818,"totalTrials":312,"cells":2819},"FDG radiotracer",{"EARLY_PHASE1":2820,"PHASE1":2822,"PHASE2":2824,"PHASE3":2826,"PHASE4":2828,"NA":2830},{"trials":2821,"activeCount":99},[],{"trials":2823,"activeCount":99},[],{"trials":2825,"activeCount":99},[],{"trials":2827,"activeCount":99},[],{"trials":2829,"activeCount":99},[],{"trials":2831,"activeCount":312,"soonestReadout":2578},[2832],{"nctId":2833,"briefTitle":2834,"status":179,"phases":2835,"primaryCompletion":2578,"completion":2578,"start":2836,"enrollment":2837,"conditions":2838,"interventions":2841},"NCT06171659","FDG PET\u002FMR Imaging of Peripheral Pain Generators",[],"2024-11-19",128,[2839,2840],"Pain","Nociceptive Pain",[2818],{"intervention":2108,"totalTrials":778,"cells":2843},{"EARLY_PHASE1":2844,"PHASE1":2846,"PHASE2":2848,"PHASE3":2850,"PHASE4":2852,"NA":2877},{"trials":2845,"activeCount":99},[],{"trials":2847,"activeCount":99},[],{"trials":2849,"activeCount":99},[],{"trials":2851,"activeCount":99},[],{"trials":2853,"activeCount":99},[2854,2865,2869],{"nctId":2855,"briefTitle":2856,"status":681,"phases":2857,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":32,"conditions":2860,"interventions":2863},"NCT03283150","Deep Brain Stimulation (DBS) Sedation",[90],"2022-01-20","2017-12-01",[2861,2862],"Brain","Sedation",[2864,2108,2106],"Remifentanil",{"nctId":2096,"briefTitle":2097,"status":120,"phases":2866,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":2101,"conditions":2867,"interventions":2868},[90],[2103,2104],[2106,2107,2108,899],{"nctId":2870,"briefTitle":2871,"status":120,"phases":2872,"primaryCompletion":203,"completion":203,"start":2873,"enrollment":841,"conditions":2874,"interventions":2876},"NCT00535613","Propofol in Emergence Agitation",[90],"2007-08",[2875],"Emergence Agitation",[2108],{"trials":2878,"activeCount":99},[],{"intervention":2106,"totalTrials":778,"cells":2880},{"EARLY_PHASE1":2881,"PHASE1":2883,"PHASE2":2885,"PHASE3":2887,"PHASE4":2889,"NA":2908},{"trials":2882,"activeCount":99},[],{"trials":2884,"activeCount":99},[],{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[],{"trials":2890,"activeCount":99},[2891,2895,2899],{"nctId":2855,"briefTitle":2856,"status":681,"phases":2892,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":32,"conditions":2893,"interventions":2894},[90],[2861,2862],[2864,2108,2106],{"nctId":2096,"briefTitle":2097,"status":120,"phases":2896,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":2101,"conditions":2897,"interventions":2898},[90],[2103,2104],[2106,2107,2108,899],{"nctId":2900,"briefTitle":2901,"status":120,"phases":2902,"primaryCompletion":2903,"completion":2903,"start":1067,"enrollment":592,"conditions":2904,"interventions":2907},"NCT01721460","Effects of Dexmedetomidine on Activity in the Subthalamic Nucleus",[90],"2015-06",[2905,2906],"Parkinson's Disease","Deep Brain Stimulation Surgery",[2106],{"trials":2909,"activeCount":99},[],{"intervention":2107,"totalTrials":778,"cells":2911},{"EARLY_PHASE1":2912,"PHASE1":2922,"PHASE2":2934,"PHASE3":2936,"PHASE4":2938,"NA":2944},{"trials":2913,"activeCount":99},[2914],{"nctId":2915,"briefTitle":2916,"status":2917,"phases":2918,"primaryCompletion":1518,"completion":1518,"start":518,"enrollment":1952,"conditions":2919,"interventions":2921},"NCT06378528","Ketamine-assisted Psychotherapy for Adolescent PTSD (KAP)","SUSPENDED",[86],[2920],"Posttraumatic Stress Disorder",[2107],{"trials":2923,"activeCount":99},[2924],{"nctId":2925,"briefTitle":2926,"status":1013,"phases":2927,"primaryCompletion":2790,"completion":2790,"start":2928,"enrollment":99,"conditions":2929,"interventions":2933},"NCT06919198","The Dreamy Jet Study",[87],"2025-09",[2862,2930,2931,2932],"Blood Drawing Procedure","Immunization","IV Placement",[2107],{"trials":2935,"activeCount":99},[],{"trials":2937,"activeCount":99},[],{"trials":2939,"activeCount":99},[2940],{"nctId":2096,"briefTitle":2097,"status":120,"phases":2941,"primaryCompletion":2099,"completion":2099,"start":2100,"enrollment":2101,"conditions":2942,"interventions":2943},[90],[2103,2104],[2106,2107,2108,899],{"trials":2945,"activeCount":99},[],{"intervention":161,"totalTrials":778,"cells":2947},{"EARLY_PHASE1":2948,"PHASE1":2950,"PHASE2":2952,"PHASE3":2954,"PHASE4":2956,"NA":2970},{"trials":2949,"activeCount":99},[],{"trials":2951,"activeCount":99},[],{"trials":2953,"activeCount":99},[],{"trials":2955,"activeCount":99},[],{"trials":2957,"activeCount":99},[2958,2962,2966],{"nctId":152,"briefTitle":153,"status":120,"phases":2959,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":2960,"interventions":2961},[90],[31],[160,161,162,163,164],{"nctId":166,"briefTitle":167,"status":120,"phases":2963,"primaryCompletion":169,"completion":170,"start":171,"enrollment":172,"conditions":2964,"interventions":2965},[90],[26,29,31],[139,175,128],{"nctId":199,"briefTitle":200,"status":120,"phases":2967,"primaryCompletion":202,"completion":203,"start":156,"enrollment":204,"conditions":2968,"interventions":2969},[90],[137],[160,160,161,163,207,164],{"trials":2971,"activeCount":99},[],{"intervention":2973,"totalTrials":778,"cells":2974},"Liposomal bupivacaine",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2979,"PHASE3":2981,"PHASE4":2983,"NA":3018},{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[],{"trials":2982,"activeCount":99},[],{"trials":2984,"activeCount":99},[2985,2994,3006],{"nctId":2986,"briefTitle":2987,"status":681,"phases":2988,"primaryCompletion":2989,"completion":2989,"start":2990,"enrollment":232,"conditions":2991,"interventions":2993},"NCT04254692","Optimizing Recovery in Abdominoplasty",[90],"2021-01-21","2021-01-05",[2992],"Postoperative Pain",[2973],{"nctId":2995,"briefTitle":2996,"status":120,"phases":2997,"primaryCompletion":2998,"completion":2999,"start":3000,"enrollment":496,"conditions":3001,"interventions":3004},"NCT04928339","Pecto-Intercostal Fascial Plane Block Study",[90],"2023-09-03","2023-11-30","2022-03-28",[3002,3003],"Cardiac Surgery","Opioid Use, Unspecified",[3005,2973],"Bupivacaine",{"nctId":3007,"briefTitle":3008,"status":120,"phases":3009,"primaryCompletion":3010,"completion":3011,"start":3012,"enrollment":577,"conditions":3013,"interventions":3016},"NCT04897841","Obstetric Liposomal Bupivacaine Via Surgical Transversus Abdominis Plane Block for Post Cesarean Pain Control",[90],"2022-08-31","2022-10-13","2021-10-11",[3014,2839,3015],"Cesarean Section Complications","Opioid Use",[2973,3017],"Bupivacaine Hydrochloride",{"trials":3019,"activeCount":99},[],{"intervention":3021,"totalTrials":232,"cells":3022},"Raloxifene",{"EARLY_PHASE1":3023,"PHASE1":3025,"PHASE2":3027,"PHASE3":3029,"PHASE4":3039,"NA":3049},{"trials":3024,"activeCount":99},[],{"trials":3026,"activeCount":99},[],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[3031],{"nctId":3032,"briefTitle":3033,"status":120,"phases":3034,"primaryCompletion":3035,"completion":3035,"start":3036,"enrollment":32,"conditions":3037,"interventions":3038},"NCT00065767","Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease",[88,89],"2005-03","2001-09",[1719],[3021],{"trials":3040,"activeCount":99},[3041],{"nctId":3042,"briefTitle":3043,"status":120,"phases":3044,"primaryCompletion":1067,"completion":1067,"start":261,"enrollment":27,"conditions":3045,"interventions":3047},"NCT01166958","Enhancing Osteoporosis Therapy: Can We Open the Anabolic Window?",[90],[3046],"Osteoporosis",[3048,3021],"Teriparatide",{"trials":3050,"activeCount":99},[],{"intervention":3052,"totalTrials":232,"cells":3053},"Tamsulosin",{"EARLY_PHASE1":3054,"PHASE1":3056,"PHASE2":3058,"PHASE3":3060,"PHASE4":3074,"NA":3086},{"trials":3055,"activeCount":99},[],{"trials":3057,"activeCount":99},[],{"trials":3059,"activeCount":99},[],{"trials":3061,"activeCount":99},[3062],{"nctId":3063,"briefTitle":3064,"status":120,"phases":3065,"primaryCompletion":3066,"completion":3067,"start":3068,"enrollment":3069,"conditions":3070,"interventions":3073},"NCT02486653","Prevention of Post-operative Urinary Retention",[89],"2018-04-01","2018-05-02","2015-08",158,[3071,3072],"Urinary Retention","Urinary Tract Infections",[3052],{"trials":3075,"activeCount":99},[3076],{"nctId":3077,"briefTitle":3078,"status":120,"phases":3079,"primaryCompletion":3080,"completion":3080,"start":1067,"enrollment":3081,"conditions":3082,"interventions":3084},"NCT01741454","Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction",[90],"2018-03-30",181,[3083],"Ureteral Obstruction",[3052,3085],"Tolterodine ER",{"trials":3087,"activeCount":99},[],{"intervention":150,"totalTrials":232,"cells":3089},{"EARLY_PHASE1":3090,"PHASE1":3092,"PHASE2":3094,"PHASE3":3096,"PHASE4":3098,"NA":3108},{"trials":3091,"activeCount":99},[],{"trials":3093,"activeCount":99},[],{"trials":3095,"activeCount":99},[],{"trials":3097,"activeCount":99},[],{"trials":3099,"activeCount":99},[3100,3104],{"nctId":141,"briefTitle":142,"status":120,"phases":3101,"primaryCompletion":144,"completion":145,"start":146,"enrollment":147,"conditions":3102,"interventions":3103},[90],[29,26],[94,150],{"nctId":209,"briefTitle":210,"status":120,"phases":3105,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":3106,"interventions":3107},[90],[29,26,216,31],[128,218,219],{"trials":3109,"activeCount":99},[],{"intervention":163,"totalTrials":232,"cells":3111},{"EARLY_PHASE1":3112,"PHASE1":3114,"PHASE2":3116,"PHASE3":3118,"PHASE4":3120,"NA":3130},{"trials":3113,"activeCount":99},[],{"trials":3115,"activeCount":99},[],{"trials":3117,"activeCount":99},[],{"trials":3119,"activeCount":99},[],{"trials":3121,"activeCount":99},[3122,3126],{"nctId":152,"briefTitle":153,"status":120,"phases":3123,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":3124,"interventions":3125},[90],[31],[160,161,162,163,164],{"nctId":199,"briefTitle":200,"status":120,"phases":3127,"primaryCompletion":202,"completion":203,"start":156,"enrollment":204,"conditions":3128,"interventions":3129},[90],[137],[160,160,161,163,207,164],{"trials":3131,"activeCount":99},[],{"intervention":164,"totalTrials":232,"cells":3133},{"EARLY_PHASE1":3134,"PHASE1":3136,"PHASE2":3138,"PHASE3":3140,"PHASE4":3142,"NA":3152},{"trials":3135,"activeCount":99},[],{"trials":3137,"activeCount":99},[],{"trials":3139,"activeCount":99},[],{"trials":3141,"activeCount":99},[],{"trials":3143,"activeCount":99},[3144,3148],{"nctId":152,"briefTitle":153,"status":120,"phases":3145,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":3146,"interventions":3147},[90],[31],[160,161,162,163,164],{"nctId":199,"briefTitle":200,"status":120,"phases":3149,"primaryCompletion":202,"completion":203,"start":156,"enrollment":204,"conditions":3150,"interventions":3151},[90],[137],[160,160,161,163,207,164],{"trials":3153,"activeCount":99},[],{"intervention":3155,"totalTrials":232,"cells":3156},"Lidocaine",{"EARLY_PHASE1":3157,"PHASE1":3166,"PHASE2":3168,"PHASE3":3170,"PHASE4":3172,"NA":3188},{"trials":3158,"activeCount":99},[3159],{"nctId":3160,"briefTitle":3161,"status":120,"phases":3162,"primaryCompletion":3163,"completion":3163,"start":1232,"enrollment":864,"conditions":3164,"interventions":3165},"NCT01445756","Topical Lidocaine for Pain Control With Intrauterine Device (IUD) Insertion",[86],"2011-06",[2839],[3155],{"trials":3167,"activeCount":99},[],{"trials":3169,"activeCount":99},[],{"trials":3171,"activeCount":99},[],{"trials":3173,"activeCount":99},[3174],{"nctId":3175,"briefTitle":3176,"status":120,"phases":3177,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3181,"interventions":3184},"NCT01342510","Combination of Magnesium and Lidocaine for the Pretreatment of Pain That is Caused by the Injection of Propofol",[90],"2012-04","2011-04",200,[3182,3183],"General Anesthesia","Intravenous Anesthesia",[3185,3155,3186,3187],"Magnesium Sulfate","Control","Lidocaine\u002FMagnesium",{"trials":3189,"activeCount":99},[],{"intervention":3191,"totalTrials":232,"cells":3192},"Ascorbic Acid",{"EARLY_PHASE1":3193,"PHASE1":3195,"PHASE2":3209,"PHASE3":3211,"PHASE4":3213,"NA":3225},{"trials":3194,"activeCount":99},[],{"trials":3196,"activeCount":99},[3197],{"nctId":3198,"briefTitle":3199,"status":1013,"phases":3200,"primaryCompletion":3201,"completion":3201,"start":3202,"enrollment":99,"conditions":3203,"interventions":3206},"NCT03066115","Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation",[87],"2021-12-01","2020-12-01",[3204,3205],"Hypoxia","Hypercapnia",[3207,3208,3191],"L-NMMA","Ketorolac",{"trials":3210,"activeCount":99},[],{"trials":3212,"activeCount":99},[],{"trials":3214,"activeCount":99},[3215],{"nctId":3216,"briefTitle":3217,"status":2917,"phases":3218,"primaryCompletion":3219,"completion":3220,"start":2212,"enrollment":520,"conditions":3221,"interventions":3223},"NCT04756063","Parenteral Ascorbic Acid Repletion in TransplantatIon",[90],"2031-03","2032-03",[3222],"Liver Transplant Failure and Rejection",[3224],"Ascorbic acid",{"trials":3226,"activeCount":99},[],{"intervention":1052,"totalTrials":232,"cells":3228},{"EARLY_PHASE1":3229,"PHASE1":3231,"PHASE2":3233,"PHASE3":3245,"PHASE4":3247,"NA":3253},{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[],{"trials":3234,"activeCount":99},[3235],{"nctId":3236,"briefTitle":3237,"status":681,"phases":3238,"primaryCompletion":3239,"completion":3240,"start":3241,"enrollment":2298,"conditions":3242,"interventions":3244},"NCT01083641","Estrogen for Triple Negative Breast Cancer",[88],"2013-06","2015-03","2010-01",[3243],"Female Breast Cancer",[1052],{"trials":3246,"activeCount":99},[],{"trials":3248,"activeCount":99},[3249],{"nctId":1041,"briefTitle":1042,"status":120,"phases":3250,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":332,"conditions":3251,"interventions":3252},[90],[1047],[1049,1050,1051,936,1052],{"trials":3254,"activeCount":99},[],{"intervention":3256,"totalTrials":312,"cells":3257},"Acetazolamide",{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3262,"PHASE3":3264,"PHASE4":3266,"NA":3278},{"trials":3259,"activeCount":99},[],{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[],{"trials":3265,"activeCount":99},[],{"trials":3267,"activeCount":99},[3268],{"nctId":3269,"briefTitle":3270,"status":120,"phases":3271,"primaryCompletion":3272,"completion":3272,"start":3273,"enrollment":1322,"conditions":3274,"interventions":3277},"NCT03377049","Acetazolamide Challenge With Perfusion in the Prediction of Cerebral Vasospasm",[90],"2022-07-15","2019-07-28",[3275,3276],"Subarachnoid Hemorrhage, Aneurysmal","Vasospasm, Cerebral",[3256],{"trials":3279,"activeCount":99},[],{"intervention":3281,"totalTrials":312,"cells":3282},"Shingrix",{"EARLY_PHASE1":3283,"PHASE1":3285,"PHASE2":3287,"PHASE3":3289,"PHASE4":3291,"NA":3306},{"trials":3284,"activeCount":99},[],{"trials":3286,"activeCount":99},[],{"trials":3288,"activeCount":99},[],{"trials":3290,"activeCount":99},[],{"trials":3292,"activeCount":99},[3293],{"nctId":3294,"briefTitle":3295,"status":120,"phases":3296,"primaryCompletion":3297,"completion":3298,"start":3299,"enrollment":16,"conditions":3300,"interventions":3305},"NCT03798691","Immunogenicity of Herpes Zoster Subunit Vaccine in Inflammatory Bowel Disease Patients Treated With Vedolizumab",[90],"2023-10-12","2024-09-10","2019-05-28",[3301,3302,3303,3304],"Inflammatory Bowel Diseases","Crohn Disease","Ulcerative Colitis","Herpes Zoster",[3281],{"trials":3307,"activeCount":99},[],{"intervention":3085,"totalTrials":312,"cells":3309},{"EARLY_PHASE1":3310,"PHASE1":3312,"PHASE2":3314,"PHASE3":3316,"PHASE4":3318,"NA":3324},{"trials":3311,"activeCount":99},[],{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":99},[],{"trials":3317,"activeCount":99},[],{"trials":3319,"activeCount":99},[3320],{"nctId":3077,"briefTitle":3078,"status":120,"phases":3321,"primaryCompletion":3080,"completion":3080,"start":1067,"enrollment":3081,"conditions":3322,"interventions":3323},[90],[3083],[3052,3085],{"trials":3325,"activeCount":99},[],{"intervention":3327,"totalTrials":312,"cells":3328},"Chemodenervation",{"EARLY_PHASE1":3329,"PHASE1":3331,"PHASE2":3333,"PHASE3":3335,"PHASE4":3337,"NA":3348},{"trials":3330,"activeCount":99},[],{"trials":3332,"activeCount":99},[],{"trials":3334,"activeCount":99},[],{"trials":3336,"activeCount":99},[],{"trials":3338,"activeCount":99},[3339],{"nctId":3340,"briefTitle":3341,"status":120,"phases":3342,"primaryCompletion":3343,"completion":3343,"start":3344,"enrollment":616,"conditions":3345,"interventions":3347},"NCT04148872","Mixed Methods Investigation of Chronic Facial Paralysis in Individuals With Synkinesis",[90],"2021-08-24","2019-10-24",[3346],"Synkinesis",[3327],{"trials":3349,"activeCount":99},[],{"intervention":3351,"totalTrials":312,"cells":3352},"Quadratus Lumborum Block",{"EARLY_PHASE1":3353,"PHASE1":3355,"PHASE2":3357,"PHASE3":3359,"PHASE4":3361,"NA":3371},{"trials":3354,"activeCount":99},[],{"trials":3356,"activeCount":99},[],{"trials":3358,"activeCount":99},[],{"trials":3360,"activeCount":99},[],{"trials":3362,"activeCount":99},[3363],{"nctId":3364,"briefTitle":3365,"status":681,"phases":3366,"primaryCompletion":2099,"completion":2099,"start":3367,"enrollment":2491,"conditions":3368,"interventions":3370},"NCT03794882","Impact of Quadratus Lumborum Block on Recovery Profile After Ventral Hernia Repair",[90],"2019-05-06",[3369,3015],"Pain, Postoperative",[3351],{"trials":3372,"activeCount":99},[],{"intervention":2864,"totalTrials":312,"cells":3374},{"EARLY_PHASE1":3375,"PHASE1":3377,"PHASE2":3379,"PHASE3":3381,"PHASE4":3383,"NA":3389},{"trials":3376,"activeCount":99},[],{"trials":3378,"activeCount":99},[],{"trials":3380,"activeCount":99},[],{"trials":3382,"activeCount":99},[],{"trials":3384,"activeCount":99},[3385],{"nctId":2855,"briefTitle":2856,"status":681,"phases":3386,"primaryCompletion":2858,"completion":2858,"start":2859,"enrollment":32,"conditions":3387,"interventions":3388},[90],[2861,2862],[2864,2108,2106],{"trials":3390,"activeCount":99},[],{"intervention":3392,"totalTrials":312,"cells":3393},"Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt",{"EARLY_PHASE1":3394,"PHASE1":3396,"PHASE2":3398,"PHASE3":3400,"PHASE4":3402,"NA":3415},{"trials":3395,"activeCount":99},[],{"trials":3397,"activeCount":99},[],{"trials":3399,"activeCount":99},[],{"trials":3401,"activeCount":99},[],{"trials":3403,"activeCount":99},[3404],{"nctId":3405,"briefTitle":3406,"status":120,"phases":3407,"primaryCompletion":212,"completion":212,"start":213,"enrollment":3408,"conditions":3409,"interventions":3410},"NCT01116986","Identifying Optimal Smoking Cessation Intervention Components (Cessation)",[90],637,[29,26,31],[3392,3411,3412,3413,3414],"Short Term Nicotine Patch + Nicotine Gum during the quit attempt","Pre-Quit Nicotine Gum","Pre-Quit Nicotine Patch","Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum",{"trials":3416,"activeCount":99},[],{"intervention":3411,"totalTrials":312,"cells":3418},{"EARLY_PHASE1":3419,"PHASE1":3421,"PHASE2":3423,"PHASE3":3425,"PHASE4":3427,"NA":3433},{"trials":3420,"activeCount":99},[],{"trials":3422,"activeCount":99},[],{"trials":3424,"activeCount":99},[],{"trials":3426,"activeCount":99},[],{"trials":3428,"activeCount":99},[3429],{"nctId":3405,"briefTitle":3406,"status":120,"phases":3430,"primaryCompletion":212,"completion":212,"start":213,"enrollment":3408,"conditions":3431,"interventions":3432},[90],[29,26,31],[3392,3411,3412,3413,3414],{"trials":3434,"activeCount":99},[],{"intervention":3412,"totalTrials":312,"cells":3436},{"EARLY_PHASE1":3437,"PHASE1":3439,"PHASE2":3441,"PHASE3":3443,"PHASE4":3445,"NA":3451},{"trials":3438,"activeCount":99},[],{"trials":3440,"activeCount":99},[],{"trials":3442,"activeCount":99},[],{"trials":3444,"activeCount":99},[],{"trials":3446,"activeCount":99},[3447],{"nctId":3405,"briefTitle":3406,"status":120,"phases":3448,"primaryCompletion":212,"completion":212,"start":213,"enrollment":3408,"conditions":3449,"interventions":3450},[90],[29,26,31],[3392,3411,3412,3413,3414],{"trials":3452,"activeCount":99},[],{"intervention":3413,"totalTrials":312,"cells":3454},{"EARLY_PHASE1":3455,"PHASE1":3457,"PHASE2":3459,"PHASE3":3461,"PHASE4":3463,"NA":3469},{"trials":3456,"activeCount":99},[],{"trials":3458,"activeCount":99},[],{"trials":3460,"activeCount":99},[],{"trials":3462,"activeCount":99},[],{"trials":3464,"activeCount":99},[3465],{"nctId":3405,"briefTitle":3406,"status":120,"phases":3466,"primaryCompletion":212,"completion":212,"start":213,"enrollment":3408,"conditions":3467,"interventions":3468},[90],[29,26,31],[3392,3411,3412,3413,3414],{"trials":3470,"activeCount":99},[],{"intervention":3414,"totalTrials":312,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3479,"PHASE4":3481,"NA":3487},{"trials":3474,"activeCount":99},[],{"trials":3476,"activeCount":99},[],{"trials":3478,"activeCount":99},[],{"trials":3480,"activeCount":99},[],{"trials":3482,"activeCount":99},[3483],{"nctId":3405,"briefTitle":3406,"status":120,"phases":3484,"primaryCompletion":212,"completion":212,"start":213,"enrollment":3408,"conditions":3485,"interventions":3486},[90],[29,26,31],[3392,3411,3412,3413,3414],{"trials":3488,"activeCount":99},[],{"intervention":3490,"totalTrials":312,"cells":3491},"Abaloparatide",{"EARLY_PHASE1":3492,"PHASE1":3494,"PHASE2":3496,"PHASE3":3498,"PHASE4":3500,"NA":3512},{"trials":3493,"activeCount":99},[],{"trials":3495,"activeCount":99},[],{"trials":3497,"activeCount":99},[],{"trials":3499,"activeCount":99},[],{"trials":3501,"activeCount":99},[3502],{"nctId":3503,"briefTitle":3504,"status":120,"phases":3505,"primaryCompletion":3506,"completion":3506,"start":3507,"enrollment":3508,"conditions":3509,"interventions":3511},"NCT04167163","Abaloparatide Before Total Knee Arthroplasty",[90],"2025-04-03","2020-01-10",58,[3046,3510],"Arthroplasties, Knee Replacement",[3490],{"trials":3513,"activeCount":99},[],{"intervention":3515,"totalTrials":312,"cells":3516},"Transdermal Lidocaine Patch",{"EARLY_PHASE1":3517,"PHASE1":3519,"PHASE2":3521,"PHASE3":3523,"PHASE4":3525,"NA":3537},{"trials":3518,"activeCount":99},[],{"trials":3520,"activeCount":99},[],{"trials":3522,"activeCount":99},[],{"trials":3524,"activeCount":99},[],{"trials":3526,"activeCount":99},[3527],{"nctId":3528,"briefTitle":3529,"status":120,"phases":3530,"primaryCompletion":3531,"completion":3532,"start":3533,"enrollment":637,"conditions":3534,"interventions":3535},"NCT03810235","The OBstetric Lidocaine Patch (OBLido) Trial",[90],"2019-09-09","2019-11-30","2019-02-15",[3369],[3515,3536],"Transdermal Hydrocolloid Placebo Patch",{"trials":3538,"activeCount":99},[],{"intervention":3536,"totalTrials":312,"cells":3540},{"EARLY_PHASE1":3541,"PHASE1":3543,"PHASE2":3545,"PHASE3":3547,"PHASE4":3549,"NA":3555},{"trials":3542,"activeCount":99},[],{"trials":3544,"activeCount":99},[],{"trials":3546,"activeCount":99},[],{"trials":3548,"activeCount":99},[],{"trials":3550,"activeCount":99},[3551],{"nctId":3528,"briefTitle":3529,"status":120,"phases":3552,"primaryCompletion":3531,"completion":3532,"start":3533,"enrollment":637,"conditions":3553,"interventions":3554},[90],[3369],[3515,3536],{"trials":3556,"activeCount":99},[],{"intervention":3558,"totalTrials":312,"cells":3559},"Cidofovir",{"EARLY_PHASE1":3560,"PHASE1":3562,"PHASE2":3564,"PHASE3":3566,"PHASE4":3568,"NA":3579},{"trials":3561,"activeCount":99},[],{"trials":3563,"activeCount":99},[],{"trials":3565,"activeCount":99},[],{"trials":3567,"activeCount":99},[],{"trials":3569,"activeCount":99},[3570],{"nctId":3571,"briefTitle":3572,"status":120,"phases":3573,"primaryCompletion":3574,"completion":3574,"start":3575,"enrollment":567,"conditions":3576,"interventions":3578},"NCT00205374","Use of Cidofovir for Recurrent Respiratory Papillomatosis",[90],"2009-12","1999-11",[3577],"Recurrent Respiratory Papillomatosis",[3558],{"trials":3580,"activeCount":99},[],{"intervention":3582,"totalTrials":312,"cells":3583},"Ramipril",{"EARLY_PHASE1":3584,"PHASE1":3586,"PHASE2":3588,"PHASE3":3590,"PHASE4":3592,"NA":3604},{"trials":3585,"activeCount":99},[],{"trials":3587,"activeCount":99},[],{"trials":3589,"activeCount":99},[],{"trials":3591,"activeCount":99},[],{"trials":3593,"activeCount":99},[3594],{"nctId":3595,"briefTitle":3596,"status":120,"phases":3597,"primaryCompletion":3598,"completion":3598,"start":3599,"enrollment":2491,"conditions":3600,"interventions":3603},"NCT00980785","Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's",[90],"2011-07-26","2009-04-09",[3601,3602],"Alzheimer's Disease","Hypertension",[3582],{"trials":3605,"activeCount":99},[],{"intervention":3607,"totalTrials":312,"cells":3608},"Nicotine Mini-Lozenge",{"EARLY_PHASE1":3609,"PHASE1":3611,"PHASE2":3613,"PHASE3":3615,"PHASE4":3617,"NA":3627},{"trials":3610,"activeCount":99},[],{"trials":3612,"activeCount":99},[],{"trials":3614,"activeCount":99},[],{"trials":3616,"activeCount":99},[],{"trials":3618,"activeCount":99},[3619],{"nctId":3620,"briefTitle":3621,"status":120,"phases":3622,"primaryCompletion":3623,"completion":3623,"start":226,"enrollment":3624,"conditions":3625,"interventions":3626},"NCT02354872","Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit",[90],"2019-03-19",577,[29,216,26],[3607],{"trials":3628,"activeCount":99},[],{"intervention":3630,"totalTrials":312,"cells":3631},"Adjuvanted Recombinant Zoster Vaccine",{"EARLY_PHASE1":3632,"PHASE1":3634,"PHASE2":3636,"PHASE3":3638,"PHASE4":3640,"NA":3650},{"trials":3633,"activeCount":99},[],{"trials":3635,"activeCount":99},[],{"trials":3637,"activeCount":99},[],{"trials":3639,"activeCount":99},[],{"trials":3641,"activeCount":99},[3642],{"nctId":3643,"briefTitle":3644,"status":1013,"phases":3645,"primaryCompletion":1518,"completion":1518,"start":3646,"enrollment":99,"conditions":3647,"interventions":3649},"NCT06224270","Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications",[90],"2024-10",[3301,3648],"IBD",[3630],{"trials":3651,"activeCount":99},[],{"intervention":3653,"totalTrials":312,"cells":3654},"Preparation Varenicline and Standard Duration Varenicline",{"EARLY_PHASE1":3655,"PHASE1":3657,"PHASE2":3659,"PHASE3":3661,"PHASE4":3663,"NA":3681},{"trials":3656,"activeCount":99},[],{"trials":3658,"activeCount":99},[],{"trials":3660,"activeCount":99},[],{"trials":3662,"activeCount":99},[],{"trials":3664,"activeCount":99},[3665],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3668,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3672,"interventions":3673},"NCT04188873","Cessation Screening Project",[90],"2025-05-08","2020-12-10",529,[31],[3653,3674,3675,3676,3677,3678,3679,3680],"Preparation Varenicline and Extended Duration Varenicline","Standard Duration Varenicline","Extended Duration Varenicline","Preparation Combination NRT and Standard Duration Combination NRT","Preparation Combination NRT and Extended Duration Combination NRT","Standard Duration Combination NRT","Extended Duration Combination NRT",{"trials":3682,"activeCount":99},[],{"intervention":3674,"totalTrials":312,"cells":3684},{"EARLY_PHASE1":3685,"PHASE1":3687,"PHASE2":3689,"PHASE3":3691,"PHASE4":3693,"NA":3699},{"trials":3686,"activeCount":99},[],{"trials":3688,"activeCount":99},[],{"trials":3690,"activeCount":99},[],{"trials":3692,"activeCount":99},[],{"trials":3694,"activeCount":99},[3695],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3696,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3697,"interventions":3698},[90],[31],[3653,3674,3675,3676,3677,3678,3679,3680],{"trials":3700,"activeCount":99},[],{"intervention":3675,"totalTrials":312,"cells":3702},{"EARLY_PHASE1":3703,"PHASE1":3705,"PHASE2":3707,"PHASE3":3709,"PHASE4":3711,"NA":3717},{"trials":3704,"activeCount":99},[],{"trials":3706,"activeCount":99},[],{"trials":3708,"activeCount":99},[],{"trials":3710,"activeCount":99},[],{"trials":3712,"activeCount":99},[3713],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3714,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3715,"interventions":3716},[90],[31],[3653,3674,3675,3676,3677,3678,3679,3680],{"trials":3718,"activeCount":99},[],{"intervention":3676,"totalTrials":312,"cells":3720},{"EARLY_PHASE1":3721,"PHASE1":3723,"PHASE2":3725,"PHASE3":3727,"PHASE4":3729,"NA":3735},{"trials":3722,"activeCount":99},[],{"trials":3724,"activeCount":99},[],{"trials":3726,"activeCount":99},[],{"trials":3728,"activeCount":99},[],{"trials":3730,"activeCount":99},[3731],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3732,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3733,"interventions":3734},[90],[31],[3653,3674,3675,3676,3677,3678,3679,3680],{"trials":3736,"activeCount":99},[],{"intervention":3677,"totalTrials":312,"cells":3738},{"EARLY_PHASE1":3739,"PHASE1":3741,"PHASE2":3743,"PHASE3":3745,"PHASE4":3747,"NA":3753},{"trials":3740,"activeCount":99},[],{"trials":3742,"activeCount":99},[],{"trials":3744,"activeCount":99},[],{"trials":3746,"activeCount":99},[],{"trials":3748,"activeCount":99},[3749],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3750,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3751,"interventions":3752},[90],[31],[3653,3674,3675,3676,3677,3678,3679,3680],{"trials":3754,"activeCount":99},[],{"intervention":3678,"totalTrials":312,"cells":3756},{"EARLY_PHASE1":3757,"PHASE1":3759,"PHASE2":3761,"PHASE3":3763,"PHASE4":3765,"NA":3771},{"trials":3758,"activeCount":99},[],{"trials":3760,"activeCount":99},[],{"trials":3762,"activeCount":99},[],{"trials":3764,"activeCount":99},[],{"trials":3766,"activeCount":99},[3767],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3768,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3769,"interventions":3770},[90],[31],[3653,3674,3675,3676,3677,3678,3679,3680],{"trials":3772,"activeCount":99},[],{"intervention":3679,"totalTrials":312,"cells":3774},{"EARLY_PHASE1":3775,"PHASE1":3777,"PHASE2":3779,"PHASE3":3781,"PHASE4":3783,"NA":3789},{"trials":3776,"activeCount":99},[],{"trials":3778,"activeCount":99},[],{"trials":3780,"activeCount":99},[],{"trials":3782,"activeCount":99},[],{"trials":3784,"activeCount":99},[3785],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3786,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3787,"interventions":3788},[90],[31],[3653,3674,3675,3676,3677,3678,3679,3680],{"trials":3790,"activeCount":99},[],{"intervention":3680,"totalTrials":312,"cells":3792},{"EARLY_PHASE1":3793,"PHASE1":3795,"PHASE2":3797,"PHASE3":3799,"PHASE4":3801,"NA":3807},{"trials":3794,"activeCount":99},[],{"trials":3796,"activeCount":99},[],{"trials":3798,"activeCount":99},[],{"trials":3800,"activeCount":99},[],{"trials":3802,"activeCount":99},[3803],{"nctId":3666,"briefTitle":3667,"status":120,"phases":3804,"primaryCompletion":3669,"completion":3669,"start":3670,"enrollment":3671,"conditions":3805,"interventions":3806},[90],[31],[3653,3674,3675,3676,3677,3678,3679,3680],{"trials":3808,"activeCount":99},[],{"intervention":281,"totalTrials":312,"cells":3810},{"EARLY_PHASE1":3811,"PHASE1":3813,"PHASE2":3815,"PHASE3":3817,"PHASE4":3819,"NA":3825},{"trials":3812,"activeCount":99},[],{"trials":3814,"activeCount":99},[],{"trials":3816,"activeCount":99},[],{"trials":3818,"activeCount":99},[],{"trials":3820,"activeCount":99},[3821],{"nctId":272,"briefTitle":273,"status":120,"phases":3822,"primaryCompletion":275,"completion":275,"start":276,"enrollment":277,"conditions":3823,"interventions":3824},[90],[279,26],[139,281],{"trials":3826,"activeCount":99},[],{"intervention":162,"totalTrials":312,"cells":3828},{"EARLY_PHASE1":3829,"PHASE1":3831,"PHASE2":3833,"PHASE3":3835,"PHASE4":3837,"NA":3843},{"trials":3830,"activeCount":99},[],{"trials":3832,"activeCount":99},[],{"trials":3834,"activeCount":99},[],{"trials":3836,"activeCount":99},[],{"trials":3838,"activeCount":99},[3839],{"nctId":152,"briefTitle":153,"status":120,"phases":3840,"primaryCompletion":155,"completion":155,"start":156,"enrollment":157,"conditions":3841,"interventions":3842},[90],[31],[160,161,162,163,164],{"trials":3844,"activeCount":99},[],{"intervention":3185,"totalTrials":312,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3851,"PHASE3":3853,"PHASE4":3855,"NA":3861},{"trials":3848,"activeCount":99},[],{"trials":3850,"activeCount":99},[],{"trials":3852,"activeCount":99},[],{"trials":3854,"activeCount":99},[],{"trials":3856,"activeCount":99},[3857],{"nctId":3175,"briefTitle":3176,"status":120,"phases":3858,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3859,"interventions":3860},[90],[3182,3183],[3185,3155,3186,3187],{"trials":3862,"activeCount":99},[],{"intervention":3186,"totalTrials":312,"cells":3864},{"EARLY_PHASE1":3865,"PHASE1":3867,"PHASE2":3869,"PHASE3":3871,"PHASE4":3873,"NA":3879},{"trials":3866,"activeCount":99},[],{"trials":3868,"activeCount":99},[],{"trials":3870,"activeCount":99},[],{"trials":3872,"activeCount":99},[],{"trials":3874,"activeCount":99},[3875],{"nctId":3175,"briefTitle":3176,"status":120,"phases":3876,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3877,"interventions":3878},[90],[3182,3183],[3185,3155,3186,3187],{"trials":3880,"activeCount":99},[],{"intervention":3187,"totalTrials":312,"cells":3882},{"EARLY_PHASE1":3883,"PHASE1":3885,"PHASE2":3887,"PHASE3":3889,"PHASE4":3891,"NA":3897},{"trials":3884,"activeCount":99},[],{"trials":3886,"activeCount":99},[],{"trials":3888,"activeCount":99},[],{"trials":3890,"activeCount":99},[],{"trials":3892,"activeCount":99},[3893],{"nctId":3175,"briefTitle":3176,"status":120,"phases":3894,"primaryCompletion":3178,"completion":3178,"start":3179,"enrollment":3180,"conditions":3895,"interventions":3896},[90],[3182,3183],[3185,3155,3186,3187],{"trials":3898,"activeCount":99},[],{"intervention":3900,"totalTrials":312,"cells":3901},"5% Topical Benzoyl Peroxide Gel",{"EARLY_PHASE1":3902,"PHASE1":3904,"PHASE2":3906,"PHASE3":3908,"PHASE4":3910,"NA":3921},{"trials":3903,"activeCount":99},[],{"trials":3905,"activeCount":99},[],{"trials":3907,"activeCount":99},[],{"trials":3909,"activeCount":99},[],{"trials":3911,"activeCount":99},[3912],{"nctId":3913,"briefTitle":3914,"status":120,"phases":3915,"primaryCompletion":3916,"completion":3916,"start":3917,"enrollment":577,"conditions":3918,"interventions":3920},"NCT04300010","Blue Light Therapy of C. Acnes",[90],"2021-01-22","2020-10-05",[3919],"Acne",[3900],{"trials":3922,"activeCount":99},[],{"intervention":1021,"totalTrials":312,"cells":3924},{"EARLY_PHASE1":3925,"PHASE1":3927,"PHASE2":3929,"PHASE3":3931,"PHASE4":3933,"NA":3939},{"trials":3926,"activeCount":99},[],{"trials":3928,"activeCount":99},[],{"trials":3930,"activeCount":99},[],{"trials":3932,"activeCount":99},[],{"trials":3934,"activeCount":99},[3935],{"nctId":1011,"briefTitle":1012,"status":1013,"phases":3936,"primaryCompletion":1015,"completion":1015,"start":1016,"enrollment":99,"conditions":3937,"interventions":3938},[90],[1018],[1020,1021],{"trials":3940,"activeCount":99},[],{"intervention":3942,"totalTrials":312,"cells":3943},"Natrecor",{"EARLY_PHASE1":3944,"PHASE1":3946,"PHASE2":3948,"PHASE3":3950,"PHASE4":3952,"NA":3963},{"trials":3945,"activeCount":99},[],{"trials":3947,"activeCount":99},[],{"trials":3949,"activeCount":99},[],{"trials":3951,"activeCount":99},[],{"trials":3953,"activeCount":99},[3954],{"nctId":3955,"briefTitle":3956,"status":120,"phases":3957,"primaryCompletion":3958,"completion":3958,"start":3959,"enrollment":245,"conditions":3960,"interventions":3962},"NCT00205426","Natrecor for Pulmonary Hypertension in Lung Transplants",[90],"2006-05","2005-08",[3961],"Pulmonary Hypertension",[3942],{"trials":3964,"activeCount":99},[],{"intervention":3966,"totalTrials":312,"cells":3967},"Omalizumab",{"EARLY_PHASE1":3968,"PHASE1":3970,"PHASE2":3972,"PHASE3":3974,"PHASE4":3976,"NA":3988},{"trials":3969,"activeCount":99},[],{"trials":3971,"activeCount":99},[],{"trials":3973,"activeCount":99},[],{"trials":3975,"activeCount":99},[],{"trials":3977,"activeCount":99},[3978],{"nctId":3979,"briefTitle":3980,"status":120,"phases":3981,"primaryCompletion":3982,"completion":3982,"start":3983,"enrollment":95,"conditions":3984,"interventions":3986},"NCT02966314","Treatment of Idiopathic Angioedema With Xolair as Add-on Therapy",[90],"2020-01-06","2017-03-30",[3985],"Idiopathic Angioedema",[3966,3987],"Placebos",{"trials":3989,"activeCount":99},[],{"intervention":3987,"totalTrials":312,"cells":3991},{"EARLY_PHASE1":3992,"PHASE1":3994,"PHASE2":3996,"PHASE3":3998,"PHASE4":4000,"NA":4006},{"trials":3993,"activeCount":99},[],{"trials":3995,"activeCount":99},[],{"trials":3997,"activeCount":99},[],{"trials":3999,"activeCount":99},[],{"trials":4001,"activeCount":99},[4002],{"nctId":3979,"briefTitle":3980,"status":120,"phases":4003,"primaryCompletion":3982,"completion":3982,"start":3983,"enrollment":95,"conditions":4004,"interventions":4005},[90],[3985],[3966,3987],{"trials":4007,"activeCount":99},[],{"intervention":4009,"totalTrials":312,"cells":4010},"Standard dose Influenza vaccine",{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4019,"NA":4032},{"trials":4012,"activeCount":99},[],{"trials":4014,"activeCount":99},[],{"trials":4016,"activeCount":99},[],{"trials":4018,"activeCount":99},[],{"trials":4020,"activeCount":99},[4021],{"nctId":4022,"briefTitle":4023,"status":120,"phases":4024,"primaryCompletion":4025,"completion":4026,"start":1320,"enrollment":4027,"conditions":4028,"interventions":4030},"NCT02461758","Trial of High Dose vs. Standard Dose Influenza Vaccine in Inflammatory Bowel Disease Patients",[90],"2018-06","2018-07",81,[4029],"Inflammatory Bowel Disease (IBD)",[4009,4031],"High dose influenza vaccine",{"trials":4033,"activeCount":99},[],{"intervention":4031,"totalTrials":312,"cells":4035},{"EARLY_PHASE1":4036,"PHASE1":4038,"PHASE2":4040,"PHASE3":4042,"PHASE4":4044,"NA":4050},{"trials":4037,"activeCount":99},[],{"trials":4039,"activeCount":99},[],{"trials":4041,"activeCount":99},[],{"trials":4043,"activeCount":99},[],{"trials":4045,"activeCount":99},[4046],{"nctId":4022,"briefTitle":4023,"status":120,"phases":4047,"primaryCompletion":4025,"completion":4026,"start":1320,"enrollment":4027,"conditions":4048,"interventions":4049},[90],[4029],[4009,4031],{"trials":4051,"activeCount":99},[],{"intervention":1050,"totalTrials":312,"cells":4053},{"EARLY_PHASE1":4054,"PHASE1":4056,"PHASE2":4058,"PHASE3":4060,"PHASE4":4062,"NA":4068},{"trials":4055,"activeCount":99},[],{"trials":4057,"activeCount":99},[],{"trials":4059,"activeCount":99},[],{"trials":4061,"activeCount":99},[],{"trials":4063,"activeCount":99},[4064],{"nctId":1041,"briefTitle":1042,"status":120,"phases":4065,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":332,"conditions":4066,"interventions":4067},[90],[1047],[1049,1050,1051,936,1052],{"trials":4069,"activeCount":99},[],{"intervention":1051,"totalTrials":312,"cells":4071},{"EARLY_PHASE1":4072,"PHASE1":4074,"PHASE2":4076,"PHASE3":4078,"PHASE4":4080,"NA":4086},{"trials":4073,"activeCount":99},[],{"trials":4075,"activeCount":99},[],{"trials":4077,"activeCount":99},[],{"trials":4079,"activeCount":99},[],{"trials":4081,"activeCount":99},[4082],{"nctId":1041,"briefTitle":1042,"status":120,"phases":4083,"primaryCompletion":1044,"completion":1044,"start":1045,"enrollment":332,"conditions":4084,"interventions":4085},[90],[1047],[1049,1050,1051,936,1052],{"trials":4087,"activeCount":99},[],{"intervention":4089,"totalTrials":312,"cells":4090},"Peripheral Nerve Blockade",{"EARLY_PHASE1":4091,"PHASE1":4093,"PHASE2":4095,"PHASE3":4097,"PHASE4":4099,"NA":4110},{"trials":4092,"activeCount":99},[],{"trials":4094,"activeCount":99},[],{"trials":4096,"activeCount":99},[],{"trials":4098,"activeCount":99},[],{"trials":4100,"activeCount":99},[4101],{"nctId":4102,"briefTitle":4103,"status":681,"phases":4104,"primaryCompletion":4105,"completion":4105,"start":4106,"enrollment":4107,"conditions":4108,"interventions":4109},"NCT03182933","Liposomal Bupivacaine Versus Standard Bupivacaine in the Adductor Canal for Total Knee Arthroplasty",[90],"2018-07-16","2017-05-30",64,[2839],[4089],{"trials":4111,"activeCount":99},[],{"intervention":4113,"totalTrials":312,"cells":4114},"Aromatase Inhibitor",{"EARLY_PHASE1":4115,"PHASE1":4117,"PHASE2":4119,"PHASE3":4121,"PHASE4":4123,"NA":4134},{"trials":4116,"activeCount":99},[],{"trials":4118,"activeCount":99},[],{"trials":4120,"activeCount":99},[],{"trials":4122,"activeCount":99},[],{"trials":4124,"activeCount":99},[4125],{"nctId":4126,"briefTitle":4127,"status":120,"phases":4128,"primaryCompletion":4129,"completion":4129,"start":262,"enrollment":95,"conditions":4130,"interventions":4133},"NCT00766532","Do Aromatase Inhibitors (AIs) Decrease Intestinal Calcium Absorption?",[90],"2010-10",[15,3046,4131,4132],"Osteopenia","Fracture",[4113],{"trials":4135,"activeCount":99},[],{"intervention":4137,"totalTrials":312,"cells":4138},"Active bupropion + counseling",{"EARLY_PHASE1":4139,"PHASE1":4141,"PHASE2":4143,"PHASE3":4145,"PHASE4":4147,"NA":4159},{"trials":4140,"activeCount":99},[],{"trials":4142,"activeCount":99},[],{"trials":4144,"activeCount":99},[],{"trials":4146,"activeCount":99},[],{"trials":4148,"activeCount":99},[4149],{"nctId":4150,"briefTitle":4151,"status":120,"phases":4152,"primaryCompletion":4153,"completion":4154,"start":2649,"enrollment":4155,"conditions":4156,"interventions":4157},"NCT01621009","Bupropion SR Plus Counseling for Smoking Cessation",[90],"2002-10","2003-10",463,[137,29],[4137,4158],"Active bupropion, No counseling",{"trials":4160,"activeCount":99},[],{"intervention":4158,"totalTrials":312,"cells":4162},{"EARLY_PHASE1":4163,"PHASE1":4165,"PHASE2":4167,"PHASE3":4169,"PHASE4":4171,"NA":4177},{"trials":4164,"activeCount":99},[],{"trials":4166,"activeCount":99},[],{"trials":4168,"activeCount":99},[],{"trials":4170,"activeCount":99},[],{"trials":4172,"activeCount":99},[4173],{"nctId":4150,"briefTitle":4151,"status":120,"phases":4174,"primaryCompletion":4153,"completion":4154,"start":2649,"enrollment":4155,"conditions":4175,"interventions":4176},[90],[137,29],[4137,4158],{"trials":4178,"activeCount":99},[],{"intervention":4180,"totalTrials":312,"cells":4181},"multimodal:acetaminophen, gabapentin, ketamine, bupivacaine",{"EARLY_PHASE1":4182,"PHASE1":4184,"PHASE2":4186,"PHASE3":4188,"PHASE4":4190,"NA":4200},{"trials":4183,"activeCount":99},[],{"trials":4185,"activeCount":99},[],{"trials":4187,"activeCount":99},[],{"trials":4189,"activeCount":99},[],{"trials":4191,"activeCount":99},[4192],{"nctId":4193,"briefTitle":4194,"status":120,"phases":4195,"primaryCompletion":224,"completion":224,"start":4196,"enrollment":4197,"conditions":4198,"interventions":4199},"NCT01868425","ACL Repair and Multimodal Analgesia",[90],"2013-04",112,[2839],[4180],{"trials":4201,"activeCount":99},[],{"intervention":4203,"totalTrials":312,"cells":4204},"Nicotine Mini-Lozenge for 11 Months",{"EARLY_PHASE1":4205,"PHASE1":4207,"PHASE2":4209,"PHASE3":4211,"PHASE4":4213,"NA":4225},{"trials":4206,"activeCount":99},[],{"trials":4208,"activeCount":99},[],{"trials":4210,"activeCount":99},[],{"trials":4212,"activeCount":99},[],{"trials":4214,"activeCount":99},[4215],{"nctId":4216,"briefTitle":4217,"status":120,"phases":4218,"primaryCompletion":4219,"completion":4219,"start":4220,"enrollment":4221,"conditions":4222,"interventions":4223},"NCT02564315","The Long-Term Quitting (Smoking Cessation) Study",[90],"2019-11-05","2015-10-30",1154,[26],[4203,4224],"Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge",{"trials":4226,"activeCount":99},[],{"intervention":4224,"totalTrials":312,"cells":4228},{"EARLY_PHASE1":4229,"PHASE1":4231,"PHASE2":4233,"PHASE3":4235,"PHASE4":4237,"NA":4243},{"trials":4230,"activeCount":99},[],{"trials":4232,"activeCount":99},[],{"trials":4234,"activeCount":99},[],{"trials":4236,"activeCount":99},[],{"trials":4238,"activeCount":99},[4239],{"nctId":4216,"briefTitle":4217,"status":120,"phases":4240,"primaryCompletion":4219,"completion":4219,"start":4220,"enrollment":4221,"conditions":4241,"interventions":4242},[90],[26],[4203,4224],{"trials":4244,"activeCount":99},[],{"intervention":197,"totalTrials":312,"cells":4246},{"EARLY_PHASE1":4247,"PHASE1":4249,"PHASE2":4251,"PHASE3":4253,"PHASE4":4255,"NA":4261},{"trials":4248,"activeCount":99},[],{"trials":4250,"activeCount":99},[],{"trials":4252,"activeCount":99},[],{"trials":4254,"activeCount":99},[],{"trials":4256,"activeCount":99},[4257],{"nctId":188,"briefTitle":189,"status":120,"phases":4258,"primaryCompletion":191,"completion":191,"start":192,"enrollment":193,"conditions":4259,"interventions":4260},[90],[195],[94,197],{"trials":4262,"activeCount":99},[],{"intervention":4264,"totalTrials":312,"cells":4265},"Levodopa",{"EARLY_PHASE1":4266,"PHASE1":4268,"PHASE2":4270,"PHASE3":4272,"PHASE4":4274,"NA":4286},{"trials":4267,"activeCount":99},[],{"trials":4269,"activeCount":99},[],{"trials":4271,"activeCount":99},[],{"trials":4273,"activeCount":99},[],{"trials":4275,"activeCount":99},[4276],{"nctId":4277,"briefTitle":4278,"status":120,"phases":4279,"primaryCompletion":4280,"completion":4280,"start":4281,"enrollment":4282,"conditions":4283,"interventions":4285},"NCT02560389","Dopamine Enhancement of Fear Extinction Learning in PTSD (1R21MH108753)",[90],"2018-05-01","2016-03",103,[4284],"Stress Disorder, Post Traumatic",[4264],{"trials":4287,"activeCount":99},[],{"intervention":207,"totalTrials":312,"cells":4289},{"EARLY_PHASE1":4290,"PHASE1":4292,"PHASE2":4294,"PHASE3":4296,"PHASE4":4298,"NA":4304},{"trials":4291,"activeCount":99},[],{"trials":4293,"activeCount":99},[],{"trials":4295,"activeCount":99},[],{"trials":4297,"activeCount":99},[],{"trials":4299,"activeCount":99},[4300],{"nctId":199,"briefTitle":200,"status":120,"phases":4301,"primaryCompletion":202,"completion":203,"start":156,"enrollment":204,"conditions":4302,"interventions":4303},[90],[137],[160,160,161,163,207,164],{"trials":4305,"activeCount":99},[],{"intervention":4307,"totalTrials":312,"cells":4308},"Bromfenac",{"EARLY_PHASE1":4309,"PHASE1":4311,"PHASE2":4313,"PHASE3":4315,"PHASE4":4317,"NA":4331},{"trials":4310,"activeCount":99},[],{"trials":4312,"activeCount":99},[],{"trials":4314,"activeCount":99},[],{"trials":4316,"activeCount":99},[],{"trials":4318,"activeCount":99},[4319],{"nctId":4320,"briefTitle":4321,"status":120,"phases":4322,"primaryCompletion":4323,"completion":4323,"start":4324,"enrollment":4325,"conditions":4326,"interventions":4329},"NCT04343222","Control of Pain in Intravitreal Injections Using Topical NSAIDs",[90],"2019-12-19","2019-06-27",46,[4327,4328],"Intravitreal Injections","IVI",[4307,4330],"Artificial tears",{"trials":4332,"activeCount":99},[],{"intervention":4330,"totalTrials":312,"cells":4334},{"EARLY_PHASE1":4335,"PHASE1":4337,"PHASE2":4339,"PHASE3":4341,"PHASE4":4343,"NA":4349},{"trials":4336,"activeCount":99},[],{"trials":4338,"activeCount":99},[],{"trials":4340,"activeCount":99},[],{"trials":4342,"activeCount":99},[],{"trials":4344,"activeCount":99},[4345],{"nctId":4320,"briefTitle":4321,"status":120,"phases":4346,"primaryCompletion":4323,"completion":4323,"start":4324,"enrollment":4325,"conditions":4347,"interventions":4348},[90],[4327,4328],[4307,4330],{"trials":4350,"activeCount":99},[],{"intervention":299,"totalTrials":312,"cells":4352},{"EARLY_PHASE1":4353,"PHASE1":4355,"PHASE2":4357,"PHASE3":4359,"PHASE4":4361,"NA":4367},{"trials":4354,"activeCount":99},[],{"trials":4356,"activeCount":99},[],{"trials":4358,"activeCount":99},[],{"trials":4360,"activeCount":99},[],{"trials":4362,"activeCount":99},[4363],{"nctId":291,"briefTitle":292,"status":120,"phases":4364,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":4365,"interventions":4366},[90],[29],[139,299,300],{"trials":4368,"activeCount":99},[],{"intervention":300,"totalTrials":312,"cells":4370},{"EARLY_PHASE1":4371,"PHASE1":4373,"PHASE2":4375,"PHASE3":4377,"PHASE4":4379,"NA":4385},{"trials":4372,"activeCount":99},[],{"trials":4374,"activeCount":99},[],{"trials":4376,"activeCount":99},[],{"trials":4378,"activeCount":99},[],{"trials":4380,"activeCount":99},[4381],{"nctId":291,"briefTitle":292,"status":120,"phases":4382,"primaryCompletion":294,"completion":294,"start":295,"enrollment":296,"conditions":4383,"interventions":4384},[90],[29],[139,299,300],{"trials":4386,"activeCount":99},[],{"intervention":4388,"totalTrials":312,"cells":4389},"Tumescent solution with dilute lidocaine and epinephrine",{"EARLY_PHASE1":4390,"PHASE1":4392,"PHASE2":4394,"PHASE3":4396,"PHASE4":4398,"NA":4410},{"trials":4391,"activeCount":99},[],{"trials":4393,"activeCount":99},[],{"trials":4395,"activeCount":99},[],{"trials":4397,"activeCount":99},[],{"trials":4399,"activeCount":99},[4400],{"nctId":4401,"briefTitle":4402,"status":120,"phases":4403,"primaryCompletion":4404,"completion":4404,"start":4405,"enrollment":864,"conditions":4406,"interventions":4408},"NCT01602692","A Comparison of Tumescence in Breast Reduction Surgery",[90],"2014-07","2012-08",[3369,4407],"Postoperative Nausea and Vomiting",[4388,4409],"Tumescent Solution with dilute epinephrine",{"trials":4411,"activeCount":99},[],{"intervention":4409,"totalTrials":312,"cells":4413},{"EARLY_PHASE1":4414,"PHASE1":4416,"PHASE2":4418,"PHASE3":4420,"PHASE4":4422,"NA":4428},{"trials":4415,"activeCount":99},[],{"trials":4417,"activeCount":99},[],{"trials":4419,"activeCount":99},[],{"trials":4421,"activeCount":99},[],{"trials":4423,"activeCount":99},[4424],{"nctId":4401,"briefTitle":4402,"status":120,"phases":4425,"primaryCompletion":4404,"completion":4404,"start":4405,"enrollment":864,"conditions":4426,"interventions":4427},[90],[3369,4407],[4388,4409],{"trials":4429,"activeCount":99},[],{"intervention":219,"totalTrials":312,"cells":4431},{"EARLY_PHASE1":4432,"PHASE1":4434,"PHASE2":4436,"PHASE3":4438,"PHASE4":4440,"NA":4446},{"trials":4433,"activeCount":99},[],{"trials":4435,"activeCount":99},[],{"trials":4437,"activeCount":99},[],{"trials":4439,"activeCount":99},[],{"trials":4441,"activeCount":99},[4442],{"nctId":209,"briefTitle":210,"status":120,"phases":4443,"primaryCompletion":212,"completion":212,"start":213,"enrollment":214,"conditions":4444,"interventions":4445},[90],[29,26,216,31],[128,218,219],{"trials":4447,"activeCount":99},[],{"intervention":4449,"totalTrials":312,"cells":4450},"Tacrolimus withdrawal",{"EARLY_PHASE1":4451,"PHASE1":4453,"PHASE2":4455,"PHASE3":4457,"PHASE4":4459,"NA":4474},{"trials":4452,"activeCount":99},[],{"trials":4454,"activeCount":99},[],{"trials":4456,"activeCount":99},[],{"trials":4458,"activeCount":99},[],{"trials":4460,"activeCount":99},[4461],{"nctId":4462,"briefTitle":4463,"status":1013,"phases":4464,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":99,"conditions":4467,"interventions":4469},"NCT02130817","Belatacept in Kidney Transplantation of Moderately Sensitized Patients",[90],"2015-10-09","2014-09-24",[1934,4468],"Antibody Mediated Rejection",[4470,4449,4471,4472,4473],"Belatacept","Thymoglobulin","Myfortic","Steroids",{"trials":4475,"activeCount":99},[],{"intervention":4471,"totalTrials":312,"cells":4477},{"EARLY_PHASE1":4478,"PHASE1":4480,"PHASE2":4482,"PHASE3":4484,"PHASE4":4486,"NA":4492},{"trials":4479,"activeCount":99},[],{"trials":4481,"activeCount":99},[],{"trials":4483,"activeCount":99},[],{"trials":4485,"activeCount":99},[],{"trials":4487,"activeCount":99},[4488],{"nctId":4462,"briefTitle":4463,"status":1013,"phases":4489,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":99,"conditions":4490,"interventions":4491},[90],[1934,4468],[4470,4449,4471,4472,4473],{"trials":4493,"activeCount":99},[],{"intervention":4472,"totalTrials":312,"cells":4495},{"EARLY_PHASE1":4496,"PHASE1":4498,"PHASE2":4500,"PHASE3":4502,"PHASE4":4504,"NA":4510},{"trials":4497,"activeCount":99},[],{"trials":4499,"activeCount":99},[],{"trials":4501,"activeCount":99},[],{"trials":4503,"activeCount":99},[],{"trials":4505,"activeCount":99},[4506],{"nctId":4462,"briefTitle":4463,"status":1013,"phases":4507,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":99,"conditions":4508,"interventions":4509},[90],[1934,4468],[4470,4449,4471,4472,4473],{"trials":4511,"activeCount":99},[],{"intervention":4473,"totalTrials":312,"cells":4513},{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4518,"PHASE3":4520,"PHASE4":4522,"NA":4528},{"trials":4515,"activeCount":99},[],{"trials":4517,"activeCount":99},[],{"trials":4519,"activeCount":99},[],{"trials":4521,"activeCount":99},[],{"trials":4523,"activeCount":99},[4524],{"nctId":4462,"briefTitle":4463,"status":1013,"phases":4525,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":99,"conditions":4526,"interventions":4527},[90],[1934,4468],[4470,4449,4471,4472,4473],{"trials":4529,"activeCount":99},[],{"intervention":230,"totalTrials":312,"cells":4531},{"EARLY_PHASE1":4532,"PHASE1":4534,"PHASE2":4536,"PHASE3":4538,"PHASE4":4540,"NA":4546},{"trials":4533,"activeCount":99},[],{"trials":4535,"activeCount":99},[],{"trials":4537,"activeCount":99},[],{"trials":4539,"activeCount":99},[],{"trials":4541,"activeCount":99},[4542],{"nctId":221,"briefTitle":222,"status":120,"phases":4543,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":4544,"interventions":4545},[90],[26],[94,230,231],{"trials":4547,"activeCount":99},[],{"intervention":231,"totalTrials":312,"cells":4549},{"EARLY_PHASE1":4550,"PHASE1":4552,"PHASE2":4554,"PHASE3":4556,"PHASE4":4558,"NA":4564},{"trials":4551,"activeCount":99},[],{"trials":4553,"activeCount":99},[],{"trials":4555,"activeCount":99},[],{"trials":4557,"activeCount":99},[],{"trials":4559,"activeCount":99},[4560],{"nctId":221,"briefTitle":222,"status":120,"phases":4561,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":4562,"interventions":4563},[90],[26],[94,230,231],{"trials":4565,"activeCount":99},[],{"intervention":4567,"totalTrials":312,"cells":4568},"Paravertebral block using local anesthetic",{"EARLY_PHASE1":4569,"PHASE1":4571,"PHASE2":4573,"PHASE3":4575,"PHASE4":4577,"NA":4592},{"trials":4570,"activeCount":99},[],{"trials":4572,"activeCount":99},[],{"trials":4574,"activeCount":99},[],{"trials":4576,"activeCount":99},[],{"trials":4578,"activeCount":99},[4579],{"nctId":4580,"briefTitle":4581,"status":681,"phases":4582,"primaryCompletion":4583,"completion":4583,"start":4584,"enrollment":4585,"conditions":4586,"interventions":4591},"NCT03187080","Enhanced Recovery Strategies in Elective Breast Surgery",[90],"2021-06-15","2017-10-19",113,[4587,4588,4589,3015,4590],"Pain, Acute","Nausea","Vomiting, Postoperative","Satisfaction",[4567],{"trials":4593,"activeCount":99},[],{"intervention":4595,"totalTrials":312,"cells":4596},"Tranexamic Acid Irrigation",{"EARLY_PHASE1":4597,"PHASE1":4599,"PHASE2":4601,"PHASE3":4603,"PHASE4":4605,"NA":4615},{"trials":4598,"activeCount":99},[],{"trials":4600,"activeCount":99},[],{"trials":4602,"activeCount":99},[],{"trials":4604,"activeCount":99},[],{"trials":4606,"activeCount":99},[4607],{"nctId":4608,"briefTitle":4609,"status":1013,"phases":4610,"primaryCompletion":4611,"completion":4611,"start":4612,"enrollment":99,"conditions":4613,"interventions":4614},"NCT04372940","Tranexamic Acid in Gender Mastectomy",[90],"2024-01","2023-01",[400],[4595],{"trials":4616,"activeCount":99},[],{"intervention":4618,"totalTrials":312,"cells":4619},"Short Term Combination Nicotine Replacement Therapy",{"EARLY_PHASE1":4620,"PHASE1":4622,"PHASE2":4624,"PHASE3":4626,"PHASE4":4628,"NA":4639},{"trials":4621,"activeCount":99},[],{"trials":4623,"activeCount":99},[],{"trials":4625,"activeCount":99},[],{"trials":4627,"activeCount":99},[],{"trials":4629,"activeCount":99},[4630],{"nctId":4631,"briefTitle":4632,"status":120,"phases":4633,"primaryCompletion":212,"completion":212,"start":213,"enrollment":4634,"conditions":4635,"interventions":4637},"NCT01120704","Evaluation of Treatments to Improve Smoking Cessation Medication Adherence",[90],544,[29,26,4636,31,216],"Adherence",[4618,4638],"Long Term Combination Nicotine Replacement Therapy",{"trials":4640,"activeCount":99},[],{"intervention":4638,"totalTrials":312,"cells":4642},{"EARLY_PHASE1":4643,"PHASE1":4645,"PHASE2":4647,"PHASE3":4649,"PHASE4":4651,"NA":4657},{"trials":4644,"activeCount":99},[],{"trials":4646,"activeCount":99},[],{"trials":4648,"activeCount":99},[],{"trials":4650,"activeCount":99},[],{"trials":4652,"activeCount":99},[4653],{"nctId":4631,"briefTitle":4632,"status":120,"phases":4654,"primaryCompletion":212,"completion":212,"start":213,"enrollment":4634,"conditions":4655,"interventions":4656},[90],[29,26,4636,31,216],[4618,4638],{"trials":4658,"activeCount":99},[],{"intervention":4660,"totalTrials":312,"cells":4661},"nutritional supplement",{"EARLY_PHASE1":4662,"PHASE1":4664,"PHASE2":4666,"PHASE3":4668,"PHASE4":4670,"NA":4683},{"trials":4663,"activeCount":99},[],{"trials":4665,"activeCount":99},[],{"trials":4667,"activeCount":99},[],{"trials":4669,"activeCount":99},[],{"trials":4671,"activeCount":99},[4672],{"nctId":4673,"briefTitle":4674,"status":120,"phases":4675,"primaryCompletion":4676,"completion":4676,"start":4677,"enrollment":372,"conditions":4678,"interventions":4681},"NCT00204958","Glutamine Popsicles in Bone Marrow Transplant (BMT)\u002FHematopoietic Stem Cell Transplant (HSCT) Patients",[90],"2007-05","2004-02",[4679,4680],"Bone Marrow Transplantation","Hematopoietic Stem Cell Transplantion",[4660,4682],"glutamine popsicle",{"trials":4684,"activeCount":99},[],{"intervention":4682,"totalTrials":312,"cells":4686},{"EARLY_PHASE1":4687,"PHASE1":4689,"PHASE2":4691,"PHASE3":4693,"PHASE4":4695,"NA":4701},{"trials":4688,"activeCount":99},[],{"trials":4690,"activeCount":99},[],{"trials":4692,"activeCount":99},[],{"trials":4694,"activeCount":99},[],{"trials":4696,"activeCount":99},[4697],{"nctId":4673,"briefTitle":4674,"status":120,"phases":4698,"primaryCompletion":4676,"completion":4676,"start":4677,"enrollment":372,"conditions":4699,"interventions":4700},[90],[4679,4680],[4660,4682],{"trials":4702,"activeCount":99},[],{"intervention":3005,"totalTrials":312,"cells":4704},{"EARLY_PHASE1":4705,"PHASE1":4707,"PHASE2":4709,"PHASE3":4711,"PHASE4":4713,"NA":4719},{"trials":4706,"activeCount":99},[],{"trials":4708,"activeCount":99},[],{"trials":4710,"activeCount":99},[],{"trials":4712,"activeCount":99},[],{"trials":4714,"activeCount":99},[4715],{"nctId":2995,"briefTitle":2996,"status":120,"phases":4716,"primaryCompletion":2998,"completion":2999,"start":3000,"enrollment":496,"conditions":4717,"interventions":4718},[90],[3002,3003],[3005,2973],{"trials":4720,"activeCount":99},[],{"intervention":311,"totalTrials":312,"cells":4722},{"EARLY_PHASE1":4723,"PHASE1":4725,"PHASE2":4727,"PHASE3":4729,"PHASE4":4731,"NA":4737},{"trials":4724,"activeCount":99},[],{"trials":4726,"activeCount":99},[],{"trials":4728,"activeCount":99},[],{"trials":4730,"activeCount":99},[],{"trials":4732,"activeCount":99},[4733],{"nctId":302,"briefTitle":303,"status":120,"phases":4734,"primaryCompletion":305,"completion":305,"start":306,"enrollment":307,"conditions":4735,"interventions":4736},[90],[26,309],[311,139],{"trials":4738,"activeCount":99},[],{"intervention":4740,"totalTrials":312,"cells":4741},"nicotine",{"EARLY_PHASE1":4742,"PHASE1":4744,"PHASE2":4746,"PHASE3":4748,"PHASE4":4750,"NA":4761},{"trials":4743,"activeCount":99},[],{"trials":4745,"activeCount":99},[],{"trials":4747,"activeCount":99},[],{"trials":4749,"activeCount":99},[],{"trials":4751,"activeCount":99},[4752],{"nctId":4753,"briefTitle":4754,"status":120,"phases":4755,"primaryCompletion":4756,"completion":4756,"start":4757,"enrollment":4758,"conditions":4759,"interventions":4760},"NCT03262233","Stress Neuroadaptation in Tobacco Dependence",[90],"2018-02-20","2015-04-01",226,[31],[4740],{"trials":4762,"activeCount":99},[],{"intervention":3048,"totalTrials":312,"cells":4764},{"EARLY_PHASE1":4765,"PHASE1":4767,"PHASE2":4769,"PHASE3":4771,"PHASE4":4773,"NA":4779},{"trials":4766,"activeCount":99},[],{"trials":4768,"activeCount":99},[],{"trials":4770,"activeCount":99},[],{"trials":4772,"activeCount":99},[],{"trials":4774,"activeCount":99},[4775],{"nctId":3042,"briefTitle":3043,"status":120,"phases":4776,"primaryCompletion":1067,"completion":1067,"start":261,"enrollment":27,"conditions":4777,"interventions":4778},[90],[3046],[3048,3021],{"trials":4780,"activeCount":99},[],{"intervention":4782,"totalTrials":312,"cells":4783},"Recombinant hepatitis B vaccine with CpG adjuvant",{"EARLY_PHASE1":4784,"PHASE1":4786,"PHASE2":4788,"PHASE3":4790,"PHASE4":4792,"NA":4803},{"trials":4785,"activeCount":99},[],{"trials":4787,"activeCount":99},[],{"trials":4789,"activeCount":99},[],{"trials":4791,"activeCount":99},[],{"trials":4793,"activeCount":99},[4794],{"nctId":4795,"briefTitle":4796,"status":120,"phases":4797,"primaryCompletion":4798,"completion":4798,"start":4799,"enrollment":685,"conditions":4800,"interventions":4802},"NCT04456504","HepB-CpG Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders",[90],"2023-12-06","2020-09-15",[4801],"Healthcare Worker, Hepatitis B Vaccine, Nonresponder",[4782],{"trials":4804,"activeCount":99},[],{"intervention":4806,"totalTrials":312,"cells":4807},"Omeprazole",{"EARLY_PHASE1":4808,"PHASE1":4810,"PHASE2":4812,"PHASE3":4814,"PHASE4":4816,"NA":4829},{"trials":4809,"activeCount":99},[],{"trials":4811,"activeCount":99},[],{"trials":4813,"activeCount":99},[],{"trials":4815,"activeCount":99},[],{"trials":4817,"activeCount":99},[4818],{"nctId":4819,"briefTitle":4820,"status":120,"phases":4821,"primaryCompletion":4822,"completion":203,"start":4823,"enrollment":1156,"conditions":4824,"interventions":4828},"NCT00582972","Does Omeprazole Decrease Intestinal Calcium Absorption?",[90],"2008-12","2008-01",[3046,4825,4826,4827],"Achlorhydria","GERD","Hip Fracture",[4806],{"trials":4830,"activeCount":99},[],{"intervention":3017,"totalTrials":312,"cells":4832},{"EARLY_PHASE1":4833,"PHASE1":4835,"PHASE2":4837,"PHASE3":4839,"PHASE4":4841,"NA":4847},{"trials":4834,"activeCount":99},[],{"trials":4836,"activeCount":99},[],{"trials":4838,"activeCount":99},[],{"trials":4840,"activeCount":99},[],{"trials":4842,"activeCount":99},[4843],{"nctId":3007,"briefTitle":3008,"status":120,"phases":4844,"primaryCompletion":3010,"completion":3011,"start":3012,"enrollment":577,"conditions":4845,"interventions":4846},[90],[3014,2839,3015],[2973,3017],{"trials":4848,"activeCount":99},[],{"intervention":4850,"totalTrials":312,"cells":4851},"Nicotine Replacement Product",{"EARLY_PHASE1":4852,"PHASE1":4854,"PHASE2":4856,"PHASE3":4858,"PHASE4":4860,"NA":4870},{"trials":4853,"activeCount":99},[],{"trials":4855,"activeCount":99},[],{"trials":4857,"activeCount":99},[],{"trials":4859,"activeCount":99},[],{"trials":4861,"activeCount":99},[4862],{"nctId":4863,"briefTitle":4864,"status":120,"phases":4865,"primaryCompletion":4866,"completion":4866,"start":4867,"enrollment":1156,"conditions":4868,"interventions":4869},"NCT06051474","Treating Caregivers Who Smoke at AFCH",[90],"2025-04-18","2024-03-05",[29,26],[4850],{"trials":4871,"activeCount":99},[],{"intervention":4873,"totalTrials":312,"cells":4874},"Exenatide",{"EARLY_PHASE1":4875,"PHASE1":4877,"PHASE2":4879,"PHASE3":4881,"PHASE4":4883,"NA":4892},{"trials":4876,"activeCount":99},[],{"trials":4878,"activeCount":99},[],{"trials":4880,"activeCount":99},[],{"trials":4882,"activeCount":99},[],{"trials":4884,"activeCount":99},[4885],{"nctId":4886,"briefTitle":4887,"status":120,"phases":4888,"primaryCompletion":146,"completion":146,"start":4823,"enrollment":4889,"conditions":4890,"interventions":4891},"NCT00623545","Bioenergetic Alterations After Exenatide Administration",[90],28,[21],[4873],{"trials":4893,"activeCount":99},[],{"intervention":4895,"totalTrials":312,"cells":4896},"Botox",{"EARLY_PHASE1":4897,"PHASE1":4899,"PHASE2":4901,"PHASE3":4903,"PHASE4":4905,"NA":4915},{"trials":4898,"activeCount":99},[],{"trials":4900,"activeCount":99},[],{"trials":4902,"activeCount":99},[],{"trials":4904,"activeCount":99},[],{"trials":4906,"activeCount":99},[4907],{"nctId":4908,"briefTitle":4909,"status":681,"phases":4910,"primaryCompletion":4911,"completion":4911,"start":4911,"enrollment":312,"conditions":4912,"interventions":4914},"NCT05006417","Botox for the Treatment of Recurrent Chronic Exertional Compartment Syndrome",[90],"2022-11-23",[4913],"Compartment Syndrome of Leg",[4895],{"trials":4916,"activeCount":99},[],{"intervention":4918,"totalTrials":312,"cells":4919},"bupropion + nicotine gum",{"EARLY_PHASE1":4920,"PHASE1":4922,"PHASE2":4924,"PHASE3":4926,"PHASE4":4928,"NA":4938},{"trials":4921,"activeCount":99},[],{"trials":4923,"activeCount":99},[],{"trials":4925,"activeCount":99},[],{"trials":4927,"activeCount":99},[],{"trials":4929,"activeCount":99},[4930],{"nctId":4931,"briefTitle":4932,"status":120,"phases":4933,"primaryCompletion":4153,"completion":4153,"start":2649,"enrollment":4934,"conditions":4935,"interventions":4936},"NCT01621022","Bupropion Alone or Combined With Nicotine Gum",[90],608,[137],[4918,4937],"Active bupropion-Placebo gum",{"trials":4939,"activeCount":99},[],{"intervention":4937,"totalTrials":312,"cells":4941},{"EARLY_PHASE1":4942,"PHASE1":4944,"PHASE2":4946,"PHASE3":4948,"PHASE4":4950,"NA":4956},{"trials":4943,"activeCount":99},[],{"trials":4945,"activeCount":99},[],{"trials":4947,"activeCount":99},[],{"trials":4949,"activeCount":99},[],{"trials":4951,"activeCount":99},[4952],{"nctId":4931,"briefTitle":4932,"status":120,"phases":4953,"primaryCompletion":4153,"completion":4153,"start":2649,"enrollment":4934,"conditions":4954,"interventions":4955},[90],[137],[4918,4937],{"trials":4957,"activeCount":99},[],{"intervention":4959,"totalTrials":312,"cells":4960},"buprenorphine\u002Fnaloxone",{"EARLY_PHASE1":4961,"PHASE1":4963,"PHASE2":4965,"PHASE3":4967,"PHASE4":4977,"NA":4979},{"trials":4962,"activeCount":99},[],{"trials":4964,"activeCount":99},[],{"trials":4966,"activeCount":99},[],{"trials":4968,"activeCount":99},[4969],{"nctId":4970,"briefTitle":4971,"status":120,"phases":4972,"primaryCompletion":295,"completion":295,"start":4973,"enrollment":1675,"conditions":4974,"interventions":4976},"NCT01843751","Dane County Drug Court Study for Addicted Offenders",[89],"2013-03",[4975],"Opioid Dependence",[4959],{"trials":4978,"activeCount":99},[],{"trials":4980,"activeCount":99},[],{"intervention":4982,"totalTrials":312,"cells":4983},"Naltrexone",{"EARLY_PHASE1":4984,"PHASE1":4986,"PHASE2":4988,"PHASE3":4990,"PHASE4":5002,"NA":5004},{"trials":4985,"activeCount":99},[],{"trials":4987,"activeCount":99},[],{"trials":4989,"activeCount":99},[],{"trials":4991,"activeCount":99},[4992],{"nctId":4993,"briefTitle":4994,"status":120,"phases":4995,"primaryCompletion":4996,"completion":4996,"start":4997,"enrollment":4998,"conditions":4999,"interventions":5001},"NCT01856712","Oral vs. Injectable Naltrexone for Hospitalized Veterans With Alcohol Dependence",[89],"2016-01","2013-05",54,[5000],"Alcohol Dependence",[4982],{"trials":5003,"activeCount":99},[],{"trials":5005,"activeCount":99},[],{"intervention":5007,"totalTrials":312,"cells":5008},"Lidocaine patch",{"EARLY_PHASE1":5009,"PHASE1":5011,"PHASE2":5013,"PHASE3":5015,"PHASE4":5029,"NA":5031},{"trials":5010,"activeCount":99},[],{"trials":5012,"activeCount":99},[],{"trials":5014,"activeCount":99},[],{"trials":5016,"activeCount":99},[5017],{"nctId":5018,"briefTitle":5019,"status":120,"phases":5020,"primaryCompletion":5021,"completion":5021,"start":5022,"enrollment":5023,"conditions":5024,"interventions":5028},"NCT04822597","Pain Control for Breast Cancer Patients Receiving Injection of Radioactive Tracer",[89],"2022-05-09","2021-04-23",167,[15,5025,5026,5027],"Sentinel Lymph Node","Breast Neoplasms","Breast Cancer Female",[5007],{"trials":5030,"activeCount":99},[],{"trials":5032,"activeCount":99},[],{"intervention":5034,"totalTrials":312,"cells":5035},"BTX-A",{"EARLY_PHASE1":5036,"PHASE1":5038,"PHASE2":5040,"PHASE3":5042,"PHASE4":5052,"NA":5054},{"trials":5037,"activeCount":99},[],{"trials":5039,"activeCount":99},[],{"trials":5041,"activeCount":99},[],{"trials":5043,"activeCount":99},[5044],{"nctId":5045,"briefTitle":5046,"status":681,"phases":5047,"primaryCompletion":3178,"completion":1067,"start":5048,"enrollment":232,"conditions":5049,"interventions":5051},"NCT01262339","BTX-A Treatment for Palmar Hyperhidrosis",[88,89],"2010-11",[5050],"Primary Focal Hyperhidrosis of the Hands",[5034],{"trials":5053,"activeCount":99},[],{"trials":5055,"activeCount":99},[],{"intervention":5057,"totalTrials":312,"cells":5058},"Methadone",{"EARLY_PHASE1":5059,"PHASE1":5061,"PHASE2":5063,"PHASE3":5065,"PHASE4":5078,"NA":5080},{"trials":5060,"activeCount":99},[],{"trials":5062,"activeCount":99},[],{"trials":5064,"activeCount":99},[],{"trials":5066,"activeCount":99},[5067],{"nctId":5068,"briefTitle":5069,"status":120,"phases":5070,"primaryCompletion":5071,"completion":5072,"start":5073,"enrollment":5074,"conditions":5075,"interventions":5076},"NCT01082679","Treatment for Opioid Dependent Offenders",[88,89],"2011-03","2011-05","2009-06",16,[4975],[5057,5077],"buprenorphine",{"trials":5079,"activeCount":99},[],{"trials":5081,"activeCount":99},[],{"intervention":5083,"totalTrials":312,"cells":5084},"eflornithine",{"EARLY_PHASE1":5085,"PHASE1":5087,"PHASE2":5089,"PHASE3":5091,"PHASE4":5101,"NA":5103},{"trials":5086,"activeCount":99},[],{"trials":5088,"activeCount":99},[],{"trials":5090,"activeCount":99},[],{"trials":5092,"activeCount":99},[5093],{"nctId":5094,"briefTitle":5095,"status":120,"phases":5096,"primaryCompletion":5097,"conditions":5098,"interventions":5100},"NCT00005884","Eflornithine to Prevent Skin Cancer in Patients With Previously Treated Early Stage Skin Cancer",[89],"2000-12",[5099],"Non-melanomatous Skin Cancer",[5083],{"trials":5102,"activeCount":99},[],{"trials":5104,"activeCount":99},[],{"intervention":5106,"totalTrials":312,"cells":5107},"Pioglitazone",{"EARLY_PHASE1":5108,"PHASE1":5110,"PHASE2":5112,"PHASE3":5114,"PHASE4":5123,"NA":5125},{"trials":5109,"activeCount":99},[],{"trials":5111,"activeCount":99},[],{"trials":5113,"activeCount":99},[],{"trials":5115,"activeCount":99},[5116],{"nctId":5117,"briefTitle":5118,"status":1013,"phases":5119,"primaryCompletion":171,"completion":171,"start":155,"enrollment":99,"conditions":5120,"interventions":5122},"NCT01184144","Endometriosis: Immunomodulation",[88,89],[5121],"Endometriosis",[5106],{"trials":5124,"activeCount":99},[],{"trials":5126,"activeCount":99},[],{"intervention":5128,"totalTrials":312,"cells":5129},"Transdermal estradiol",{"EARLY_PHASE1":5130,"PHASE1":5132,"PHASE2":5134,"PHASE3":5136,"PHASE4":5146,"NA":5148},{"trials":5131,"activeCount":99},[],{"trials":5133,"activeCount":99},[],{"trials":5135,"activeCount":99},[],{"trials":5137,"activeCount":99},[5138],{"nctId":5139,"briefTitle":5140,"status":120,"phases":5141,"primaryCompletion":765,"completion":765,"start":3036,"enrollment":5142,"conditions":5143,"interventions":5144},"NCT00066157","Alzheimer's Disease: Therapeutic Potential of Estrogen",[88,89],42,[1719],[5128,5145],"Medroxyprogesterone",{"trials":5147,"activeCount":99},[],{"trials":5149,"activeCount":99},[],{"intervention":5145,"totalTrials":312,"cells":5151},{"EARLY_PHASE1":5152,"PHASE1":5154,"PHASE2":5156,"PHASE3":5158,"PHASE4":5164,"NA":5166},{"trials":5153,"activeCount":99},[],{"trials":5155,"activeCount":99},[],{"trials":5157,"activeCount":99},[],{"trials":5159,"activeCount":99},[5160],{"nctId":5139,"briefTitle":5140,"status":120,"phases":5161,"primaryCompletion":765,"completion":765,"start":3036,"enrollment":5142,"conditions":5162,"interventions":5163},[88,89],[1719],[5128,5145],{"trials":5165,"activeCount":99},[],{"trials":5167,"activeCount":99},[],{"intervention":5169,"totalTrials":312,"cells":5170},"Epidural analgesia",{"EARLY_PHASE1":5171,"PHASE1":5173,"PHASE2":5175,"PHASE3":5177,"PHASE4":5190,"NA":5192},{"trials":5172,"activeCount":99},[],{"trials":5174,"activeCount":99},[],{"trials":5176,"activeCount":99},[],{"trials":5178,"activeCount":99},[5179],{"nctId":5180,"briefTitle":5181,"status":120,"phases":5182,"primaryCompletion":5183,"completion":5183,"start":5184,"enrollment":5185,"conditions":5186,"interventions":5189},"NCT02423876","Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery",[89],"2022-01-03","2015-03-17",104,[5187,5188,2839],"Intraoperative Complication","Malignant Female Reproductive System Neoplasm",[5169],{"trials":5191,"activeCount":99},[],{"trials":5193,"activeCount":99},[],{"intervention":1178,"totalTrials":592,"cells":5195},{"EARLY_PHASE1":5196,"PHASE1":5202,"PHASE2":5215,"PHASE3":5257,"PHASE4":5259,"NA":5261},{"trials":5197,"activeCount":99},[5198],{"nctId":1170,"briefTitle":1171,"status":120,"phases":5199,"primaryCompletion":1173,"completion":1174,"start":1175,"enrollment":241,"conditions":5200,"interventions":5201},[86],[18],[1178,580,1179],{"trials":5203,"activeCount":99},[5204],{"nctId":5205,"briefTitle":5206,"status":120,"phases":5207,"primaryCompletion":5208,"completion":5208,"start":5209,"enrollment":2491,"conditions":5210,"interventions":5212},"NCT02146222","VEGFR\u002FPDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors",[87],"2016-12","2014-09",[5211],"Unspecified Adult Solid Tumor, Protocol Specific",[5213,5214],"VEGFR\u002FPDGFR dual kinase inhibitor X-82","docetaxel",{"trials":5216,"activeCount":99},[5217,5228,5237,5247],{"nctId":5218,"briefTitle":5219,"status":120,"phases":5220,"primaryCompletion":5221,"completion":5222,"start":5223,"enrollment":397,"conditions":5224,"interventions":5226},"NCT01671332","Docetaxel +\u002F- Suramin in 2nd Line Advanced Non-Small Cell Lung Cancer",[88],"2015-06-11","2016-06-16","2012-06",[5225],"Carcinoma, Non Small Cell Lung",[1178,5227,1178],"Suramin",{"nctId":5229,"briefTitle":5230,"status":120,"phases":5231,"primaryCompletion":5232,"completion":5232,"start":5233,"enrollment":317,"conditions":5234,"interventions":5235},"NCT00064012","Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer",[88],"2004-07","2003-05",[346],[5236,5214],"bortezomib",{"nctId":5238,"briefTitle":5239,"status":120,"phases":5240,"completion":5241,"start":5242,"enrollment":296,"conditions":5243,"interventions":5246},"NCT00214058","Weekly Carboplatin\u002FDocetaxel for Recurrent Ovarian\u002FPeritoneal Cancer",[88],"2006-02","2002-08",[5244,5245],"Ovarian Carcinoma","Primary Peritoneal Carcinoma",[338,1178],{"nctId":5248,"briefTitle":5249,"status":342,"phases":5250,"start":5251,"conditions":5252,"interventions":5254},"NCT00004264","Docetaxel, Cisplatin, and Amifostine in Treating Patients With Advanced Non-small Cell Lung Cancer",[87,88],"1997-07",[5253,346],"Drug\u002FAgent Toxicity by Tissue\u002FOrgan",[5255,5256,5214],"amifostine trihydrate","cisplatin",{"trials":5258,"activeCount":99},[],{"trials":5260,"activeCount":99},[],{"trials":5262,"activeCount":99},[],{"intervention":338,"totalTrials":317,"cells":5264},{"EARLY_PHASE1":5265,"PHASE1":5267,"PHASE2":5269,"PHASE3":5296,"PHASE4":5298,"NA":5300},{"trials":5266,"activeCount":99},[],{"trials":5268,"activeCount":99},[],{"trials":5270,"activeCount":99},[5271,5275,5279,5292],{"nctId":326,"briefTitle":327,"status":120,"phases":5272,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":5273,"interventions":5274},[87,88],[334,335],[337,338,316],{"nctId":350,"briefTitle":351,"status":120,"phases":5276,"primaryCompletion":353,"completion":354,"start":355,"enrollment":9,"conditions":5277,"interventions":5278},[88],[15,357],[338,316,359,360,361,362],{"nctId":5280,"briefTitle":5281,"status":120,"phases":5282,"primaryCompletion":5283,"completion":5284,"start":5285,"enrollment":695,"conditions":5286,"interventions":5288},"NCT00002974","Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma",[88],"2001-07","2003-04","1996-07",[5287],"Sarcoma",[5289,5290,5291],"carboplatin","etoposide","ifosfamide",{"nctId":5238,"briefTitle":5239,"status":120,"phases":5293,"completion":5241,"start":5242,"enrollment":296,"conditions":5294,"interventions":5295},[88],[5244,5245],[338,1178],{"trials":5297,"activeCount":99},[],{"trials":5299,"activeCount":99},[],{"trials":5301,"activeCount":99},[],{"intervention":5236,"totalTrials":317,"cells":5303},{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5316,"PHASE3":5334,"PHASE4":5336,"NA":5338},{"trials":5305,"activeCount":99},[],{"trials":5307,"activeCount":99},[5308],{"nctId":5309,"briefTitle":5310,"status":120,"phases":5311,"primaryCompletion":4154,"start":5312,"conditions":5313,"interventions":5314},"NCT00023855","PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors",[87],"2001-06",[5211],[5236,5315],"doxorubicin hydrochloride",{"trials":5317,"activeCount":99},[5318,5322,5330],{"nctId":1064,"briefTitle":1065,"status":120,"phases":5319,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":241,"conditions":5320,"interventions":5321},[88],[1071],[1073,65,360,359,969,1074],{"nctId":5323,"briefTitle":5324,"status":120,"phases":5325,"primaryCompletion":5326,"completion":5326,"start":4822,"enrollment":35,"conditions":5327,"interventions":5328},"NCT00798720","Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer",[88],"2012-10",[5225],[5329,5236],"vorinostat",{"nctId":5229,"briefTitle":5230,"status":120,"phases":5331,"primaryCompletion":5232,"completion":5232,"start":5233,"enrollment":317,"conditions":5332,"interventions":5333},[88],[346],[5236,5214],{"trials":5335,"activeCount":99},[],{"trials":5337,"activeCount":99},[],{"trials":5339,"activeCount":99},[],{"intervention":1901,"totalTrials":778,"cells":5341},{"EARLY_PHASE1":5342,"PHASE1":5344,"PHASE2":5346,"PHASE3":5367,"PHASE4":5369,"NA":5371},{"trials":5343,"activeCount":99},[],{"trials":5345,"activeCount":99},[],{"trials":5347,"activeCount":99},[5348,5359,5363],{"nctId":5349,"briefTitle":5350,"status":681,"phases":5351,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":2580,"conditions":5354,"interventions":5357},"NCT03311126","Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma",[88],"2023-07-31","2017-09-29",[1071,5355,5356],"Non-hodgkin Lymphoma","Non Hodgkin Lymphoma",[1901,5358],"Obinutuzumab",{"nctId":1891,"briefTitle":1892,"status":120,"phases":5360,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":296,"conditions":5361,"interventions":5362},[88],[1897,1898,1899],[1901,65,1902],{"nctId":1908,"briefTitle":1909,"status":120,"phases":5364,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":695,"conditions":5365,"interventions":5366},[88],[1915,1898],[1901,65,1902],{"trials":5368,"activeCount":99},[],{"trials":5370,"activeCount":99},[],{"trials":5372,"activeCount":99},[],{"intervention":362,"totalTrials":778,"cells":5374},{"EARLY_PHASE1":5375,"PHASE1":5377,"PHASE2":5383,"PHASE3":5393,"PHASE4":5395,"NA":5397},{"trials":5376,"activeCount":99},[],{"trials":5378,"activeCount":99},[5379],{"nctId":1096,"briefTitle":1097,"status":681,"phases":5380,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":35,"conditions":5381,"interventions":5382},[87],[1103,1104,309,1105],[1107,1108,362,361],{"trials":5384,"activeCount":99},[5385,5389],{"nctId":350,"briefTitle":351,"status":120,"phases":5386,"primaryCompletion":353,"completion":354,"start":355,"enrollment":9,"conditions":5387,"interventions":5388},[88],[15,357],[338,316,359,360,361,362],{"nctId":1969,"briefTitle":1970,"status":120,"phases":5390,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":32,"conditions":5391,"interventions":5392},[88],[1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987],[1989,1990,1991,1992,1993,1994,1995],{"trials":5394,"activeCount":99},[],{"trials":5396,"activeCount":99},[],{"trials":5398,"activeCount":99},[],{"intervention":1239,"totalTrials":778,"cells":5400},{"EARLY_PHASE1":5401,"PHASE1":5403,"PHASE2":5419,"PHASE3":5434,"PHASE4":5436,"NA":5438},{"trials":5402,"activeCount":99},[],{"trials":5404,"activeCount":99},[5405],{"nctId":5406,"briefTitle":5407,"status":120,"phases":5408,"primaryCompletion":5409,"completion":5410,"start":5411,"enrollment":2580,"conditions":5412,"interventions":5417},"NCT01918644","Neoadjuvant SBRT With Concomitant Capecitabine in Resectable Pancreatic Cancer",[87],"2019-12-04","2022-04-26","2014-04-08",[5413,5414,5415,5416],"Stage IA Pancreatic Cancer","Stage IB Pancreatic Cancer","Stage IIA Pancreatic Cancer","Stage IIB Pancreatic Cancer",[5418],"capecitabine",{"trials":5420,"activeCount":99},[5421,5430],{"nctId":5422,"briefTitle":5423,"status":120,"phases":5424,"primaryCompletion":5425,"completion":5425,"start":5426,"enrollment":9,"conditions":5427,"interventions":5428},"NCT00574171","Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma",[88],"2009-08","2007-09",[697],[5429,1239],"lapatinib",{"nctId":1229,"briefTitle":1230,"status":120,"phases":5431,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1234,"conditions":5432,"interventions":5433},[87,88],[1236,1237],[550,1239,1240],{"trials":5435,"activeCount":99},[],{"trials":5437,"activeCount":99},[],{"trials":5439,"activeCount":99},[],{"intervention":5441,"totalTrials":232,"cells":5442},"Simvastatin",{"EARLY_PHASE1":5443,"PHASE1":5445,"PHASE2":5447,"PHASE3":5465,"PHASE4":5467,"NA":5469},{"trials":5444,"activeCount":99},[],{"trials":5446,"activeCount":99},[],{"trials":5448,"activeCount":99},[5449,5458],{"nctId":5450,"briefTitle":5451,"status":120,"phases":5452,"primaryCompletion":5453,"completion":5453,"start":5454,"enrollment":5455,"conditions":5456,"interventions":5457},"NCT00939822","Statin Effects on Beta-Amyloid and Cerebral Perfusion in Adults at Risk for Alzheimer's Disease",[88],"2013-09","2009-03",88,[3601],[5441],{"nctId":5459,"briefTitle":5460,"status":120,"phases":5461,"primaryCompletion":5073,"completion":5073,"start":5462,"enrollment":4282,"conditions":5463,"interventions":5464},"NCT00486044","Evaluating Simvastatin's Potential Role in Therapy",[88],"2005-02",[1719],[5441],{"trials":5466,"activeCount":99},[],{"trials":5468,"activeCount":99},[],{"trials":5470,"activeCount":99},[],{"intervention":5472,"totalTrials":232,"cells":5473},"pTVG-HP with rhGM-CSF",{"EARLY_PHASE1":5474,"PHASE1":5476,"PHASE2":5485,"PHASE3":5495,"PHASE4":5497,"NA":5499},{"trials":5475,"activeCount":99},[],{"trials":5477,"activeCount":99},[5478],{"nctId":5479,"briefTitle":5480,"status":120,"phases":5481,"primaryCompletion":5482,"completion":5482,"start":3035,"enrollment":332,"conditions":5483,"interventions":5484},"NCT00582140","Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer",[87],"2008-08",[18],[5472,5472,5472],{"trials":5486,"activeCount":99},[5487],{"nctId":5488,"briefTitle":5489,"status":120,"phases":5490,"primaryCompletion":5491,"completion":5491,"start":5492,"enrollment":2298,"conditions":5493,"interventions":5494},"NCT00849121","Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer",[88],"2014-02-17","2009-03-16",[18],[5472,5472],{"trials":5496,"activeCount":99},[],{"trials":5498,"activeCount":99},[],{"trials":5500,"activeCount":99},[],{"intervention":5502,"totalTrials":232,"cells":5503},"sorafenib",{"EARLY_PHASE1":5504,"PHASE1":5506,"PHASE2":5516,"PHASE3":5522,"PHASE4":5524,"NA":5526},{"trials":5505,"activeCount":99},[],{"trials":5507,"activeCount":99},[5508],{"nctId":5509,"briefTitle":5510,"status":120,"phases":5511,"primaryCompletion":5512,"completion":5512,"start":5513,"enrollment":1675,"conditions":5514,"interventions":5515},"NCT00954278","Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer",[87],"2015-12-23","2009-07-28",[5225],[5502],{"trials":5517,"activeCount":99},[5518],{"nctId":1229,"briefTitle":1230,"status":120,"phases":5519,"primaryCompletion":1232,"completion":1232,"start":1233,"enrollment":1234,"conditions":5520,"interventions":5521},[87,88],[1236,1237],[550,1239,1240],{"trials":5523,"activeCount":99},[],{"trials":5525,"activeCount":99},[],{"trials":5527,"activeCount":99},[],{"intervention":5529,"totalTrials":232,"cells":5530},"Campath-1H",{"EARLY_PHASE1":5531,"PHASE1":5533,"PHASE2":5535,"PHASE3":5555,"PHASE4":5557,"NA":5559},{"trials":5532,"activeCount":99},[],{"trials":5534,"activeCount":99},[],{"trials":5536,"activeCount":99},[5537,5546],{"nctId":5538,"briefTitle":5539,"status":120,"phases":5540,"primaryCompletion":1932,"completion":5541,"start":5542,"enrollment":9,"conditions":5543,"interventions":5545},"NCT00365846","\"A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52) Therapy in Primary Renal Allograft Transplantation\"",[88],"2006-07","2000-08",[5544],"Renal Transplant",[5529],{"nctId":5547,"briefTitle":5548,"status":681,"phases":5549,"primaryCompletion":5550,"completion":171,"start":5551,"enrollment":16,"conditions":5552,"interventions":5554},"NCT00167661","Campath-1H Induction to Allow Steroid Free Immunosuppression in Pediatric Renal Transplantation",[87,88],"2011-12","2004-06",[5553],"Disorder Related to Renal Transplantation",[5529],{"trials":5556,"activeCount":99},[],{"trials":5558,"activeCount":99},[],{"trials":5560,"activeCount":99},[],{"intervention":5562,"totalTrials":232,"cells":5563},"perillyl alcohol",{"EARLY_PHASE1":5564,"PHASE1":5566,"PHASE2":5568,"PHASE3":5585,"PHASE4":5587,"NA":5589},{"trials":5565,"activeCount":99},[],{"trials":5567,"activeCount":99},[],{"trials":5569,"activeCount":99},[5570,5578],{"nctId":5571,"briefTitle":5572,"status":120,"phases":5573,"primaryCompletion":5574,"start":5575,"conditions":5576,"interventions":5577},"NCT00003238","Perillyl Alcohol in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy",[88],"2001-10","1998-02",[18],[5562],{"nctId":5579,"briefTitle":5580,"status":120,"phases":5581,"primaryCompletion":5582,"completion":5582,"start":5582,"conditions":5583,"interventions":5584},"NCT00003219","Perillyl Alcohol in Treating Patients With Metastatic Breast Cancer",[88],"1998-05",[15],[5562],{"trials":5586,"activeCount":99},[],{"trials":5588,"activeCount":99},[],{"trials":5590,"activeCount":99},[],{"intervention":1902,"totalTrials":232,"cells":5592},{"EARLY_PHASE1":5593,"PHASE1":5595,"PHASE2":5597,"PHASE3":5607,"PHASE4":5609,"NA":5611},{"trials":5594,"activeCount":99},[],{"trials":5596,"activeCount":99},[],{"trials":5598,"activeCount":99},[5599,5603],{"nctId":1891,"briefTitle":1892,"status":120,"phases":5600,"primaryCompletion":1894,"completion":1894,"start":1895,"enrollment":296,"conditions":5601,"interventions":5602},[88],[1897,1898,1899],[1901,65,1902],{"nctId":1908,"briefTitle":1909,"status":120,"phases":5604,"primaryCompletion":1911,"completion":1912,"start":1913,"enrollment":695,"conditions":5605,"interventions":5606},[88],[1915,1898],[1901,65,1902],{"trials":5608,"activeCount":99},[],{"trials":5610,"activeCount":99},[],{"trials":5612,"activeCount":99},[],{"intervention":5614,"totalTrials":232,"cells":5615},"Lithium carbonate",{"EARLY_PHASE1":5616,"PHASE1":5618,"PHASE2":5620,"PHASE3":5638,"PHASE4":5640,"NA":5642},{"trials":5617,"activeCount":99},[],{"trials":5619,"activeCount":99},[],{"trials":5621,"activeCount":99},[5622,5630],{"nctId":5623,"briefTitle":5624,"status":681,"phases":5625,"primaryCompletion":5626,"completion":3178,"start":4823,"enrollment":1952,"conditions":5627,"interventions":5629},"NCT00582712","An Initial Study of Lithium in Patients With Medullary Thyroid Cancer",[88],"2009-05",[5628],"Medullary Thyroid Cancer",[5614],{"nctId":5631,"briefTitle":5632,"status":120,"phases":5633,"primaryCompletion":5073,"completion":5073,"start":5634,"enrollment":616,"conditions":5635,"interventions":5636},"NCT00501540","Lithium for Low-Grade Neuroendocrine Tumors",[88],"2007-07",[1103],[5637],"Lithium Carbonate",{"trials":5639,"activeCount":99},[],{"trials":5641,"activeCount":99},[],{"trials":5643,"activeCount":99},[],{"intervention":5645,"totalTrials":312,"cells":5646},"PS-341, doxorubicin",{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5651,"PHASE3":5660,"PHASE4":5662,"NA":5664},{"trials":5648,"activeCount":99},[],{"trials":5650,"activeCount":99},[],{"trials":5652,"activeCount":99},[5653],{"nctId":5654,"briefTitle":5655,"status":681,"phases":5656,"primaryCompletion":1913,"completion":1913,"start":5657,"enrollment":317,"conditions":5658,"interventions":5659},"NCT00574236","Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer",[88],"2006-08",[1500],[5645],{"trials":5661,"activeCount":99},[],{"trials":5663,"activeCount":99},[],{"trials":5665,"activeCount":99},[],{"intervention":5667,"totalTrials":312,"cells":5668},"Velcade",{"EARLY_PHASE1":5669,"PHASE1":5671,"PHASE2":5673,"PHASE3":5684,"PHASE4":5686,"NA":5688},{"trials":5670,"activeCount":99},[],{"trials":5672,"activeCount":99},[],{"trials":5674,"activeCount":99},[5675],{"nctId":5676,"briefTitle":5677,"status":120,"phases":5678,"primaryCompletion":5679,"completion":122,"start":144,"enrollment":864,"conditions":5680,"interventions":5682},"NCT01281917","Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma",[88],"2013-10",[5681],"Non-Hodgkins Lymphoma",[5667,5683],"Temsirolimus",{"trials":5685,"activeCount":99},[],{"trials":5687,"activeCount":99},[],{"trials":5689,"activeCount":99},[],{"intervention":5683,"totalTrials":312,"cells":5691},{"EARLY_PHASE1":5692,"PHASE1":5694,"PHASE2":5696,"PHASE3":5702,"PHASE4":5704,"NA":5706},{"trials":5693,"activeCount":99},[],{"trials":5695,"activeCount":99},[],{"trials":5697,"activeCount":99},[5698],{"nctId":5676,"briefTitle":5677,"status":120,"phases":5699,"primaryCompletion":5679,"completion":122,"start":144,"enrollment":864,"conditions":5700,"interventions":5701},[88],[5681],[5667,5683],{"trials":5703,"activeCount":99},[],{"trials":5705,"activeCount":99},[],{"trials":5707,"activeCount":99},[],{"intervention":5709,"totalTrials":312,"cells":5710},"Difluoromethylornithine",{"EARLY_PHASE1":5711,"PHASE1":5713,"PHASE2":5715,"PHASE3":5726,"PHASE4":5728,"NA":5730},{"trials":5712,"activeCount":99},[],{"trials":5714,"activeCount":99},[],{"trials":5716,"activeCount":99},[5717],{"nctId":5718,"briefTitle":5719,"status":120,"phases":5720,"primaryCompletion":765,"completion":765,"start":5721,"enrollment":307,"conditions":5722,"interventions":5725},"NCT00204789","Difluoromethylornithine (DFMO) Chemoprevention of Skin Cancer in Organ Transplant Recipients",[88],"2003-07",[5723,5724],"Post-solid Organ Transplant","Skin Neoplasms",[5709],{"trials":5727,"activeCount":99},[],{"trials":5729,"activeCount":99},[],{"trials":5731,"activeCount":99},[],{"intervention":5733,"totalTrials":312,"cells":5734},"Lorazepam 1 mg",{"EARLY_PHASE1":5735,"PHASE1":5737,"PHASE2":5739,"PHASE3":5751,"PHASE4":5753,"NA":5755},{"trials":5736,"activeCount":99},[],{"trials":5738,"activeCount":99},[],{"trials":5740,"activeCount":99},[5741],{"nctId":5742,"briefTitle":5743,"status":1013,"phases":5744,"primaryCompletion":5745,"completion":5745,"start":5746,"enrollment":99,"conditions":5747,"interventions":5749},"NCT06496854","Prescribing Lorazepam for IUD Insertion: Pilot Feasibility Study",[88],"2026-01","2025-10",[2839,5748],"IUD",[5733,5750],"Ibuprofen 800 mg",{"trials":5752,"activeCount":99},[],{"trials":5754,"activeCount":99},[],{"trials":5756,"activeCount":99},[],{"intervention":5750,"totalTrials":312,"cells":5758},{"EARLY_PHASE1":5759,"PHASE1":5761,"PHASE2":5763,"PHASE3":5769,"PHASE4":5771,"NA":5773},{"trials":5760,"activeCount":99},[],{"trials":5762,"activeCount":99},[],{"trials":5764,"activeCount":99},[5765],{"nctId":5742,"briefTitle":5743,"status":1013,"phases":5766,"primaryCompletion":5745,"completion":5745,"start":5746,"enrollment":99,"conditions":5767,"interventions":5768},[88],[2839,5748],[5733,5750],{"trials":5770,"activeCount":99},[],{"trials":5772,"activeCount":99},[],{"trials":5774,"activeCount":99},[],{"intervention":337,"totalTrials":312,"cells":5776},{"EARLY_PHASE1":5777,"PHASE1":5779,"PHASE2":5781,"PHASE3":5787,"PHASE4":5789,"NA":5791},{"trials":5778,"activeCount":99},[],{"trials":5780,"activeCount":99},[],{"trials":5782,"activeCount":99},[5783],{"nctId":326,"briefTitle":327,"status":120,"phases":5784,"primaryCompletion":329,"completion":330,"start":331,"enrollment":332,"conditions":5785,"interventions":5786},[87,88],[334,335],[337,338,316],{"trials":5788,"activeCount":99},[],{"trials":5790,"activeCount":99},[],{"trials":5792,"activeCount":99},[],{"intervention":5794,"totalTrials":312,"cells":5795},"Novasoy",{"EARLY_PHASE1":5796,"PHASE1":5798,"PHASE2":5800,"PHASE3":5808,"PHASE4":5810,"NA":5812},{"trials":5797,"activeCount":99},[],{"trials":5799,"activeCount":99},[],{"trials":5801,"activeCount":99},[5802],{"nctId":5803,"briefTitle":5804,"status":120,"phases":5805,"primaryCompletion":3574,"completion":3574,"start":2648,"enrollment":2164,"conditions":5806,"interventions":5807},"NCT00205179","Alzheimer's Disease: Potential Benefit of Isoflavones",[88],[3601],[5794],{"trials":5809,"activeCount":99},[],{"trials":5811,"activeCount":99},[],{"trials":5813,"activeCount":99},[],{"intervention":5358,"totalTrials":312,"cells":5815},{"EARLY_PHASE1":5816,"PHASE1":5818,"PHASE2":5820,"PHASE3":5826,"PHASE4":5828,"NA":5830},{"trials":5817,"activeCount":99},[],{"trials":5819,"activeCount":99},[],{"trials":5821,"activeCount":99},[5822],{"nctId":5349,"briefTitle":5350,"status":681,"phases":5823,"primaryCompletion":5352,"completion":5352,"start":5353,"enrollment":2580,"conditions":5824,"interventions":5825},[88],[1071,5355,5356],[1901,5358],{"trials":5827,"activeCount":99},[],{"trials":5829,"activeCount":99},[],{"trials":5831,"activeCount":99},[],{"intervention":5833,"totalTrials":312,"cells":5834},"sipuleucel-T",{"EARLY_PHASE1":5835,"PHASE1":5837,"PHASE2":5839,"PHASE3":5851,"PHASE4":5853,"NA":5855},{"trials":5836,"activeCount":99},[],{"trials":5838,"activeCount":99},[],{"trials":5840,"activeCount":99},[5841],{"nctId":5842,"briefTitle":5843,"status":120,"phases":5844,"primaryCompletion":5845,"completion":5846,"start":5847,"enrollment":35,"conditions":5848,"interventions":5849},"NCT01706458","Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer",[88],"2017-06-12","2020-08-13","2013-05-20",[18],[5833,5850],"DNA Vaccine",{"trials":5852,"activeCount":99},[],{"trials":5854,"activeCount":99},[],{"trials":5856,"activeCount":99},[],{"intervention":5850,"totalTrials":312,"cells":5858},{"EARLY_PHASE1":5859,"PHASE1":5861,"PHASE2":5863,"PHASE3":5869,"PHASE4":5871,"NA":5873},{"trials":5860,"activeCount":99},[],{"trials":5862,"activeCount":99},[],{"trials":5864,"activeCount":99},[5865],{"nctId":5842,"briefTitle":5843,"status":120,"phases":5866,"primaryCompletion":5845,"completion":5846,"start":5847,"enrollment":35,"conditions":5867,"interventions":5868},[88],[18],[5833,5850],{"trials":5870,"activeCount":99},[],{"trials":5872,"activeCount":99},[],{"trials":5874,"activeCount":99},[],{"intervention":5876,"totalTrials":312,"cells":5877},"Docetaxel plus doxercalciferol",{"EARLY_PHASE1":5878,"PHASE1":5880,"PHASE2":5882,"PHASE3":5893,"PHASE4":5895,"NA":5897},{"trials":5879,"activeCount":99},[],{"trials":5881,"activeCount":99},[],{"trials":5883,"activeCount":99},[5884],{"nctId":5885,"briefTitle":5886,"status":681,"phases":5887,"completion":5888,"start":5889,"enrollment":792,"conditions":5890,"interventions":5891},"NCT00582582","Study of Docetaxel With Doxercalciferol or Placebo for Advanced Prostate Cancer",[88],"2007-04","2002-04",[18],[5876,5892],"Docetaxel plus placebo",{"trials":5894,"activeCount":99},[],{"trials":5896,"activeCount":99},[],{"trials":5898,"activeCount":99},[],{"intervention":5892,"totalTrials":312,"cells":5900},{"EARLY_PHASE1":5901,"PHASE1":5903,"PHASE2":5905,"PHASE3":5911,"PHASE4":5913,"NA":5915},{"trials":5902,"activeCount":99},[],{"trials":5904,"activeCount":99},[],{"trials":5906,"activeCount":99},[5907],{"nctId":5885,"briefTitle":5886,"status":681,"phases":5908,"completion":5888,"start":5889,"enrollment":792,"conditions":5909,"interventions":5910},[88],[18],[5876,5892],{"trials":5912,"activeCount":99},[],{"trials":5914,"activeCount":99},[],{"trials":5916,"activeCount":99},[],{"intervention":5918,"totalTrials":312,"cells":5919},"TAK-700",{"EARLY_PHASE1":5920,"PHASE1":5922,"PHASE2":5924,"PHASE3":5934,"PHASE4":5936,"NA":5938},{"trials":5921,"activeCount":99},[],{"trials":5923,"activeCount":99},[],{"trials":5925,"activeCount":99},[5926],{"nctId":5927,"briefTitle":5928,"status":681,"phases":5929,"primaryCompletion":2064,"completion":5930,"start":4997,"enrollment":559,"conditions":5931,"interventions":5933},"NCT01816048","NaF Positron Emission Tomography\u002FComputed Tomography (PET\u002FCT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis",[88],"2016-11",[5932,18],"Prostatic Neoplasms",[5918],{"trials":5935,"activeCount":99},[],{"trials":5937,"activeCount":99},[],{"trials":5939,"activeCount":99},[],{"intervention":5941,"totalTrials":312,"cells":5942},"PSMA-based 18F-DCFPyL PET tracer",{"EARLY_PHASE1":5943,"PHASE1":5945,"PHASE2":5947,"PHASE3":5958,"PHASE4":5960,"NA":5962},{"trials":5944,"activeCount":99},[],{"trials":5946,"activeCount":99},[],{"trials":5948,"activeCount":99},[5949],{"nctId":5950,"briefTitle":5951,"status":681,"phases":5952,"primaryCompletion":5953,"completion":5953,"start":5954,"enrollment":616,"conditions":5955,"interventions":5957},"NCT03302156","PSMA PET and MRI in Gynecological Cancers",[88],"2020-01-20","2017-11-15",[5956],"Gynecologic Cancer",[5941],{"trials":5959,"activeCount":99},[],{"trials":5961,"activeCount":99},[],{"trials":5963,"activeCount":99},[],{"intervention":5965,"totalTrials":312,"cells":5966},"Low Dose FMT Capsule DE",{"EARLY_PHASE1":5967,"PHASE1":5969,"PHASE2":5971,"PHASE3":5985,"PHASE4":5987,"NA":5989},{"trials":5968,"activeCount":99},[],{"trials":5970,"activeCount":99},[],{"trials":5972,"activeCount":99},[5973],{"nctId":5974,"briefTitle":5975,"status":120,"phases":5976,"primaryCompletion":5977,"completion":5977,"start":5978,"enrollment":312,"conditions":5979,"interventions":5983},"NCT03621657","The GRAFT Study: Gut RecolonizAtion by Fecal Transplantation",[88],"2020-02-27","2019-03-21",[5980,5981,5982],"Clostridium Difficile Infection","C.Difficile Diarrhea","CDI",[5965,5984],"Single Dose FMT Capsule DE",{"trials":5986,"activeCount":99},[],{"trials":5988,"activeCount":99},[],{"trials":5990,"activeCount":99},[],{"intervention":5984,"totalTrials":312,"cells":5992},{"EARLY_PHASE1":5993,"PHASE1":5995,"PHASE2":5997,"PHASE3":6003,"PHASE4":6005,"NA":6007},{"trials":5994,"activeCount":99},[],{"trials":5996,"activeCount":99},[],{"trials":5998,"activeCount":99},[5999],{"nctId":5974,"briefTitle":5975,"status":120,"phases":6000,"primaryCompletion":5977,"completion":5977,"start":5978,"enrollment":312,"conditions":6001,"interventions":6002},[88],[5980,5981,5982],[5965,5984],{"trials":6004,"activeCount":99},[],{"trials":6006,"activeCount":99},[],{"trials":6008,"activeCount":99},[],{"intervention":6010,"totalTrials":312,"cells":6011},"platelet rich plasma",{"EARLY_PHASE1":6012,"PHASE1":6014,"PHASE2":6016,"PHASE3":6028,"PHASE4":6030,"NA":6032},{"trials":6013,"activeCount":99},[],{"trials":6015,"activeCount":99},[],{"trials":6017,"activeCount":99},[6018],{"nctId":6019,"briefTitle":6020,"status":120,"phases":6021,"primaryCompletion":6022,"completion":6022,"start":6023,"enrollment":9,"conditions":6024,"interventions":6027},"NCT01843504","Platelet-Rich Plasma (PRP) Injection for the Treatment of Chronic Patellar Tendinopathy",[88],"2024-02-29","2014-01",[6025,6026],"Chronic Patellar Tendinopathy","Chronic PT",[6010],{"trials":6029,"activeCount":99},[],{"trials":6031,"activeCount":99},[],{"trials":6033,"activeCount":99},[],{"intervention":6035,"totalTrials":312,"cells":6036},"CPC - Capsaicin, Phenylephrine, Caffeine",{"EARLY_PHASE1":6037,"PHASE1":6039,"PHASE2":6041,"PHASE3":6054,"PHASE4":6056,"NA":6058},{"trials":6038,"activeCount":99},[],{"trials":6040,"activeCount":99},[],{"trials":6042,"activeCount":99},[6043],{"nctId":6044,"briefTitle":6045,"status":120,"phases":6046,"primaryCompletion":6047,"completion":6048,"start":6049,"enrollment":6050,"conditions":6051,"interventions":6053},"NCT04972123","The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope",[88],"2023-08-25","2023-08-31","2021-07-20",143,[6052],"Syncope, Vasovagal",[6035],{"trials":6055,"activeCount":99},[],{"trials":6057,"activeCount":99},[],{"trials":6059,"activeCount":99},[],{"intervention":6061,"totalTrials":312,"cells":6062},"NKTR-214",{"EARLY_PHASE1":6063,"PHASE1":6065,"PHASE2":6067,"PHASE3":6077,"PHASE4":6079,"NA":6081},{"trials":6064,"activeCount":99},[],{"trials":6066,"activeCount":99},[],{"trials":6068,"activeCount":99},[6069],{"nctId":6070,"briefTitle":6071,"status":681,"phases":6072,"primaryCompletion":987,"completion":987,"start":6073,"enrollment":1952,"conditions":6074,"interventions":6075},"NCT04936841","Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma",[88],"2021-08-05",[739],[6061,6076],"anti-PD-1 therapy",{"trials":6078,"activeCount":99},[],{"trials":6080,"activeCount":99},[],{"trials":6082,"activeCount":99},[],{"intervention":6076,"totalTrials":312,"cells":6084},{"EARLY_PHASE1":6085,"PHASE1":6087,"PHASE2":6089,"PHASE3":6095,"PHASE4":6097,"NA":6099},{"trials":6086,"activeCount":99},[],{"trials":6088,"activeCount":99},[],{"trials":6090,"activeCount":99},[6091],{"nctId":6070,"briefTitle":6071,"status":681,"phases":6092,"primaryCompletion":987,"completion":987,"start":6073,"enrollment":1952,"conditions":6093,"interventions":6094},[88],[739],[6061,6076],{"trials":6096,"activeCount":99},[],{"trials":6098,"activeCount":99},[],{"trials":6100,"activeCount":99},[],{"intervention":6102,"totalTrials":312,"cells":6103},"conjugated linoleic acid",{"EARLY_PHASE1":6104,"PHASE1":6106,"PHASE2":6108,"PHASE3":6116,"PHASE4":6118,"NA":6120},{"trials":6105,"activeCount":99},[],{"trials":6107,"activeCount":99},[],{"trials":6109,"activeCount":99},[6110],{"nctId":6111,"briefTitle":6112,"status":120,"phases":6113,"primaryCompletion":3035,"completion":3035,"start":5232,"enrollment":933,"conditions":6114,"interventions":6115},"NCT00204932","Effects of CLA Supplements on Body Weight and Fat Oxidation",[88],[24],[6102],{"trials":6117,"activeCount":99},[],{"trials":6119,"activeCount":99},[],{"trials":6121,"activeCount":99},[],{"intervention":6123,"totalTrials":312,"cells":6124},"Horse Chestnut Seed Extract",{"EARLY_PHASE1":6125,"PHASE1":6127,"PHASE2":6129,"PHASE3":6141,"PHASE4":6143,"NA":6145},{"trials":6126,"activeCount":99},[],{"trials":6128,"activeCount":99},[],{"trials":6130,"activeCount":99},[6131],{"nctId":6132,"briefTitle":6133,"status":120,"phases":6134,"primaryCompletion":156,"completion":6135,"start":6136,"enrollment":6137,"conditions":6138,"interventions":6140},"NCT00213928","Horse Chestnut Seed Extract for Lymphedema",[88],"2008-09","2002-05",56,[6139],"Lymphedema of Arm",[6123],{"trials":6142,"activeCount":99},[],{"trials":6144,"activeCount":99},[],{"trials":6146,"activeCount":99},[],{"intervention":6148,"totalTrials":312,"cells":6149},"PRP",{"EARLY_PHASE1":6150,"PHASE1":6152,"PHASE2":6154,"PHASE3":6165,"PHASE4":6167,"NA":6169},{"trials":6151,"activeCount":99},[],{"trials":6153,"activeCount":99},[],{"trials":6155,"activeCount":99},[6156],{"nctId":6157,"briefTitle":6158,"status":120,"phases":6159,"primaryCompletion":6160,"completion":6160,"start":6161,"enrollment":241,"conditions":6162,"interventions":6164},"NCT03136965","Platelet-Rich Plasma Therapy for Patellar Tendinopathy",[88],"2022-08-15","2017-04-25",[6163],"Patellar Tendinitis",[6148],{"trials":6166,"activeCount":99},[],{"trials":6168,"activeCount":99},[],{"trials":6170,"activeCount":99},[],{"intervention":6172,"totalTrials":312,"cells":6173},"Mycophenolic Acid",{"EARLY_PHASE1":6174,"PHASE1":6176,"PHASE2":6178,"PHASE3":6188,"PHASE4":6190,"NA":6192},{"trials":6175,"activeCount":99},[],{"trials":6177,"activeCount":99},[],{"trials":6179,"activeCount":99},[6180],{"nctId":6181,"briefTitle":6182,"status":681,"phases":6183,"primaryCompletion":4405,"completion":4405,"start":6184,"enrollment":5074,"conditions":6185,"interventions":6186},"NCT01053221","Mycophenolic Acid Monotherapy in Recipients of HLA-identical Living-Related Transplantation",[88],"2006-03",[2177],[6172,6187],"Standard of Care: CNI and MPA",{"trials":6189,"activeCount":99},[],{"trials":6191,"activeCount":99},[],{"trials":6193,"activeCount":99},[],{"intervention":6187,"totalTrials":312,"cells":6195},{"EARLY_PHASE1":6196,"PHASE1":6198,"PHASE2":6200,"PHASE3":6206,"PHASE4":6208,"NA":6210},{"trials":6197,"activeCount":99},[],{"trials":6199,"activeCount":99},[],{"trials":6201,"activeCount":99},[6202],{"nctId":6181,"briefTitle":6182,"status":681,"phases":6203,"primaryCompletion":4405,"completion":4405,"start":6184,"enrollment":5074,"conditions":6204,"interventions":6205},[88],[2177],[6172,6187],{"trials":6207,"activeCount":99},[],{"trials":6209,"activeCount":99},[],{"trials":6211,"activeCount":99},[],{"intervention":6213,"totalTrials":312,"cells":6214},"Bort, Dex, and Dox with ALCAR",{"EARLY_PHASE1":6215,"PHASE1":6217,"PHASE2":6219,"PHASE3":6229,"PHASE4":6231,"NA":6233},{"trials":6216,"activeCount":99},[],{"trials":6218,"activeCount":99},[],{"trials":6220,"activeCount":99},[6221],{"nctId":6222,"briefTitle":6223,"status":120,"phases":6224,"primaryCompletion":203,"completion":1911,"start":4677,"enrollment":6225,"conditions":6226,"interventions":6228},"NCT00581919","Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma",[88],32,[6227],"Multiple Myeloma",[6213],{"trials":6230,"activeCount":99},[],{"trials":6232,"activeCount":99},[],{"trials":6234,"activeCount":99},[],{"intervention":1074,"totalTrials":312,"cells":6236},{"EARLY_PHASE1":6237,"PHASE1":6239,"PHASE2":6241,"PHASE3":6247,"PHASE4":6249,"NA":6251},{"trials":6238,"activeCount":99},[],{"trials":6240,"activeCount":99},[],{"trials":6242,"activeCount":99},[6243],{"nctId":1064,"briefTitle":1065,"status":120,"phases":6244,"primaryCompletion":1067,"completion":1068,"start":1069,"enrollment":241,"conditions":6245,"interventions":6246},[88],[1071],[1073,65,360,359,969,1074],{"trials":6248,"activeCount":99},[],{"trials":6250,"activeCount":99},[],{"trials":6252,"activeCount":99},[],{"intervention":6254,"totalTrials":312,"cells":6255},"Losartan",{"EARLY_PHASE1":6256,"PHASE1":6258,"PHASE2":6260,"PHASE3":6271,"PHASE4":6273,"NA":6275},{"trials":6257,"activeCount":99},[],{"trials":6259,"activeCount":99},[],{"trials":6261,"activeCount":99},[6262],{"nctId":6263,"briefTitle":6264,"status":120,"phases":6265,"primaryCompletion":2903,"completion":2903,"start":5223,"enrollment":6266,"conditions":6267,"interventions":6269},"NCT01637623","Study of Cardiovascular Disease and Obstructive Sleep Apnea",[88],87,[6268,3602],"Severe Obstructive Sleep Apnea (Apnea Hypopnea Index > 30 Events\u002FHour)",[6254,6270],"Allopurinol",{"trials":6272,"activeCount":99},[],{"trials":6274,"activeCount":99},[],{"trials":6276,"activeCount":99},[],{"intervention":6278,"totalTrials":312,"cells":6279},"Vancomycin",{"EARLY_PHASE1":6280,"PHASE1":6282,"PHASE2":6284,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6281,"activeCount":99},[],{"trials":6283,"activeCount":99},[],{"trials":6285,"activeCount":99},[6286],{"nctId":6287,"briefTitle":6288,"status":120,"phases":6289,"primaryCompletion":6290,"completion":6290,"start":6291,"enrollment":6292,"conditions":6293,"interventions":6297},"NCT03462459","Efficacy of Oral Vancomycin Prophylaxis for Prevention of Recurrent Clostridium Difficile Infection",[88],"2023-07-06","2018-05-21",79,[6294,5980,5982,5981,6295,6296],"Recurrent Clostridium Difficile Infection","C. Diff Colitis","C.Difficile Colitis",[6278],{"trials":6299,"activeCount":99},[],{"trials":6301,"activeCount":99},[],{"trials":6303,"activeCount":99},[],{"intervention":6305,"totalTrials":312,"cells":6306},"CGC-11047",{"EARLY_PHASE1":6307,"PHASE1":6309,"PHASE2":6311,"PHASE3":6321,"PHASE4":6323,"NA":6325},{"trials":6308,"activeCount":99},[],{"trials":6310,"activeCount":99},[],{"trials":6312,"activeCount":99},[6313],{"nctId":6314,"briefTitle":6315,"status":681,"phases":6316,"primaryCompletion":6317,"completion":5454,"start":6318,"enrollment":1156,"conditions":6319,"interventions":6320},"NCT00585416","Study of CGC-11047 in Patients With Metastatic Hormone Refractory Prostate Cancer",[88],"2007-11","2006-06",[18],[6305],{"trials":6322,"activeCount":99},[],{"trials":6324,"activeCount":99},[],{"trials":6326,"activeCount":99},[],{"intervention":1989,"totalTrials":312,"cells":6328},{"EARLY_PHASE1":6329,"PHASE1":6331,"PHASE2":6333,"PHASE3":6339,"PHASE4":6341,"NA":6343},{"trials":6330,"activeCount":99},[],{"trials":6332,"activeCount":99},[],{"trials":6334,"activeCount":99},[6335],{"nctId":1969,"briefTitle":1970,"status":120,"phases":6336,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":32,"conditions":6337,"interventions":6338},[88],[1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987],[1989,1990,1991,1992,1993,1994,1995],{"trials":6340,"activeCount":99},[],{"trials":6342,"activeCount":99},[],{"trials":6344,"activeCount":99},[],{"intervention":1991,"totalTrials":312,"cells":6346},{"EARLY_PHASE1":6347,"PHASE1":6349,"PHASE2":6351,"PHASE3":6357,"PHASE4":6359,"NA":6361},{"trials":6348,"activeCount":99},[],{"trials":6350,"activeCount":99},[],{"trials":6352,"activeCount":99},[6353],{"nctId":1969,"briefTitle":1970,"status":120,"phases":6354,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":32,"conditions":6355,"interventions":6356},[88],[1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987],[1989,1990,1991,1992,1993,1994,1995],{"trials":6358,"activeCount":99},[],{"trials":6360,"activeCount":99},[],{"trials":6362,"activeCount":99},[],{"intervention":6364,"totalTrials":312,"cells":6365},"R-CHOP+GM-CSF",{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6382,"PHASE4":6384,"NA":6386},{"trials":6367,"activeCount":99},[],{"trials":6369,"activeCount":99},[],{"trials":6371,"activeCount":99},[6372],{"nctId":6373,"briefTitle":6374,"status":120,"phases":6375,"primaryCompletion":6376,"completion":5048,"start":6377,"enrollment":6378,"conditions":6379,"interventions":6381},"NCT00582725","R-CHOP + GM-CSF for Previously Untreated LCL in Elderly",[88],"2005-12","2002-03",38,[6380],"Lymphoma, Large B-Cell, Diffuse",[6364],{"trials":6383,"activeCount":99},[],{"trials":6385,"activeCount":99},[],{"trials":6387,"activeCount":99},[],{"intervention":6389,"totalTrials":312,"cells":6390},"ZD4054",{"EARLY_PHASE1":6391,"PHASE1":6393,"PHASE2":6395,"PHASE3":6404,"PHASE4":6406,"NA":6408},{"trials":6392,"activeCount":99},[],{"trials":6394,"activeCount":99},[],{"trials":6396,"activeCount":99},[6397],{"nctId":6398,"briefTitle":6399,"status":681,"phases":6400,"primaryCompletion":6401,"completion":145,"start":146,"enrollment":592,"conditions":6402,"interventions":6403},"NCT01119118","ZD4054 With Positron Emission Tomography\u002FMagnetic Resonance Imaging (PET\u002FMRI) for Prostate Cancer",[88],"2011-08",[18],[6389],{"trials":6405,"activeCount":99},[],{"trials":6407,"activeCount":99},[],{"trials":6409,"activeCount":99},[],{"intervention":6411,"totalTrials":312,"cells":6412},"Active Nicotine Patch",{"EARLY_PHASE1":6413,"PHASE1":6415,"PHASE2":6417,"PHASE3":6428,"PHASE4":6430,"NA":6432},{"trials":6414,"activeCount":99},[],{"trials":6416,"activeCount":99},[],{"trials":6418,"activeCount":99},[6419],{"nctId":6420,"briefTitle":6421,"status":120,"phases":6422,"primaryCompletion":6423,"completion":6423,"start":6424,"enrollment":6425,"conditions":6426,"interventions":6427},"NCT04084210","Impact of Alternative Nicotine-Delivery Products on Combustible Cigarette Use",[88],"2022-05-23","2020-09-09",209,[31],[6411],{"trials":6429,"activeCount":99},[],{"trials":6431,"activeCount":99},[],{"trials":6433,"activeCount":99},[],{"intervention":6435,"totalTrials":312,"cells":6436},"Nasal Irrigation - Xylitol",{"EARLY_PHASE1":6437,"PHASE1":6439,"PHASE2":6441,"PHASE3":6454,"PHASE4":6456,"NA":6458},{"trials":6438,"activeCount":99},[],{"trials":6440,"activeCount":99},[],{"trials":6442,"activeCount":99},[6443],{"nctId":6444,"briefTitle":6445,"status":120,"phases":6446,"primaryCompletion":2609,"completion":6447,"start":5326,"enrollment":864,"conditions":6448,"interventions":6453},"NCT01700725","Gulf War Illness Nasal Irrigation Study",[88],"2017-05",[6449,6450,6451,6452],"Persian Gulf Syndrome","Chronic Sinusitis","Fatigue","Acute Sinusitis",[6435],{"trials":6455,"activeCount":99},[],{"trials":6457,"activeCount":99},[],{"trials":6459,"activeCount":99},[],{"intervention":6461,"totalTrials":312,"cells":6462},"Bupivicaine",{"EARLY_PHASE1":6463,"PHASE1":6465,"PHASE2":6467,"PHASE3":6479,"PHASE4":6481,"NA":6483},{"trials":6464,"activeCount":99},[],{"trials":6466,"activeCount":99},[],{"trials":6468,"activeCount":99},[6469],{"nctId":6470,"briefTitle":6471,"status":120,"phases":6472,"primaryCompletion":6473,"completion":4973,"start":6474,"enrollment":6475,"conditions":6476,"interventions":6478},"NCT01444924","Transversus Abdominis Plane Blocks for Patients Undergoing Robotic Gynecologic Oncology Surgery",[88],"2013-02","2011-09",75,[5956,6477],"Post-operative Pain",[6461],{"trials":6480,"activeCount":99},[],{"trials":6482,"activeCount":99},[],{"trials":6484,"activeCount":99},[],{"intervention":6486,"totalTrials":312,"cells":6487},"Belimumab",{"EARLY_PHASE1":6488,"PHASE1":6490,"PHASE2":6492,"PHASE3":6502,"PHASE4":6504,"NA":6506},{"trials":6489,"activeCount":99},[],{"trials":6491,"activeCount":99},[],{"trials":6493,"activeCount":99},[6494],{"nctId":6495,"briefTitle":6496,"status":681,"phases":6497,"primaryCompletion":6498,"completion":6498,"start":6499,"enrollment":778,"conditions":6500,"interventions":6501},"NCT03591380","CAMPath and BELimumab for Transplant Tolerance in Sensitized Kidney Transplant Recipients",[88],"2021-12-03","2019-05-14",[2177],[6486],{"trials":6503,"activeCount":99},[],{"trials":6505,"activeCount":99},[],{"trials":6507,"activeCount":99},[],{"intervention":6509,"totalTrials":312,"cells":6510},"IL2",{"EARLY_PHASE1":6511,"PHASE1":6513,"PHASE2":6515,"PHASE3":6526,"PHASE4":6528,"NA":6530},{"trials":6512,"activeCount":99},[],{"trials":6514,"activeCount":99},[],{"trials":6516,"activeCount":99},[6517],{"nctId":6518,"briefTitle":6519,"status":681,"phases":6520,"primaryCompletion":5482,"completion":6135,"start":6521,"enrollment":95,"conditions":6522,"interventions":6524},"NCT00582790","Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer",[88],"2003-08",[6523],"Kidney Cancer",[6509,6525],"Zoledronic acid",{"trials":6527,"activeCount":99},[],{"trials":6529,"activeCount":99},[],{"trials":6531,"activeCount":99},[],{"intervention":6525,"totalTrials":312,"cells":6533},{"EARLY_PHASE1":6534,"PHASE1":6536,"PHASE2":6538,"PHASE3":6544,"PHASE4":6546,"NA":6548},{"trials":6535,"activeCount":99},[],{"trials":6537,"activeCount":99},[],{"trials":6539,"activeCount":99},[6540],{"nctId":6518,"briefTitle":6519,"status":681,"phases":6541,"primaryCompletion":5482,"completion":6135,"start":6521,"enrollment":95,"conditions":6542,"interventions":6543},[88],[6523],[6509,6525],{"trials":6545,"activeCount":99},[],{"trials":6547,"activeCount":99},[],{"trials":6549,"activeCount":99},[],{"intervention":6551,"totalTrials":312,"cells":6552},"UCB-J",{"EARLY_PHASE1":6553,"PHASE1":6555,"PHASE2":6557,"PHASE3":6568,"PHASE4":6570,"NA":6572},{"trials":6554,"activeCount":99},[],{"trials":6556,"activeCount":99},[],{"trials":6558,"activeCount":99},[6559],{"nctId":6560,"briefTitle":6561,"status":120,"phases":6562,"primaryCompletion":6563,"completion":6564,"start":6565,"enrollment":496,"conditions":6566,"interventions":6567},"NCT04871074","The Synapse Project",[88],"2023-10-17","2025-05-01","2018-11-18",[1719],[6551],{"trials":6569,"activeCount":99},[],{"trials":6571,"activeCount":99},[],{"trials":6573,"activeCount":99},[],{"intervention":6575,"totalTrials":312,"cells":6576},"Akt\u002FERK Inhibitor ONC201",{"EARLY_PHASE1":6577,"PHASE1":6579,"PHASE2":6581,"PHASE3":6591,"PHASE4":6593,"NA":6595},{"trials":6578,"activeCount":99},[],{"trials":6580,"activeCount":99},[],{"trials":6582,"activeCount":99},[6583],{"nctId":6584,"briefTitle":6585,"status":681,"phases":6586,"primaryCompletion":6587,"completion":6587,"start":6588,"enrollment":317,"conditions":6589,"interventions":6590},"NCT03733119","ONC201 With a Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer",[88],"2021-02-13","2018-11-13",[357],[6575],{"trials":6592,"activeCount":99},[],{"trials":6594,"activeCount":99},[],{"trials":6596,"activeCount":99},[],{"intervention":6598,"totalTrials":312,"cells":6599},"[18F]Fluorofuranylnorprogesterone (FFNP) PET\u002FMR Imaging",{"EARLY_PHASE1":6600,"PHASE1":6602,"PHASE2":6604,"PHASE3":6615,"PHASE4":6617,"NA":6619},{"trials":6601,"activeCount":99},[],{"trials":6603,"activeCount":99},[],{"trials":6605,"activeCount":99},[6606],{"nctId":6607,"briefTitle":6608,"status":120,"phases":6609,"primaryCompletion":6610,"completion":6610,"start":6611,"enrollment":2580,"conditions":6612,"interventions":6614},"NCT03212170","FFNP-PET\u002FMR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer",[88],"2024-11-14","2017-12-13",[6613],"Invasive Breast Cancer",[6598],{"trials":6616,"activeCount":99},[],{"trials":6618,"activeCount":99},[],{"trials":6620,"activeCount":99},[],{"intervention":6622,"totalTrials":312,"cells":6623},"NVX-CoV2372",{"EARLY_PHASE1":6624,"PHASE1":6626,"PHASE2":6628,"PHASE3":6641,"PHASE4":6643,"NA":6645},{"trials":6625,"activeCount":99},[],{"trials":6627,"activeCount":99},[],{"trials":6629,"activeCount":99},[6630],{"nctId":6631,"briefTitle":6632,"status":120,"phases":6633,"primaryCompletion":6634,"completion":6635,"start":6636,"enrollment":2580,"conditions":6637,"interventions":6640},"NCT06027229","Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations",[88],"2024-04-24","2024-09-09","2023-11-20",[6638,6639],"Immunosuppression","COVID-19",[6622],{"trials":6642,"activeCount":99},[],{"trials":6644,"activeCount":99},[],{"trials":6646,"activeCount":99},[],{"intervention":6648,"totalTrials":312,"cells":6649},"PSMA-based 18F-DCFPyL PET tracer for PET\u002FCT exams",{"EARLY_PHASE1":6650,"PHASE1":6652,"PHASE2":6654,"PHASE3":6665,"PHASE4":6667,"NA":6669},{"trials":6651,"activeCount":99},[],{"trials":6653,"activeCount":99},[],{"trials":6655,"activeCount":99},[6656],{"nctId":6657,"briefTitle":6658,"status":681,"phases":6659,"primaryCompletion":6660,"completion":6660,"start":6661,"enrollment":1952,"conditions":6662,"interventions":6664},"NCT03387514","Functional Microscale Organotypic Assays to Predict Patient Response to Anti-Angiogenesis Therapies",[88],"2021-06-29","2018-12-08",[6663],"Renal Cell Carcinoma",[6648],{"trials":6666,"activeCount":99},[],{"trials":6668,"activeCount":99},[],{"trials":6670,"activeCount":99},[],{"intervention":6672,"totalTrials":312,"cells":6673},"Pycnogenol",{"EARLY_PHASE1":6674,"PHASE1":6676,"PHASE2":6678,"PHASE3":6688,"PHASE4":6690,"NA":6692},{"trials":6675,"activeCount":99},[],{"trials":6677,"activeCount":99},[],{"trials":6679,"activeCount":99},[6680],{"nctId":6681,"briefTitle":6682,"status":120,"phases":6683,"primaryCompletion":6684,"completion":6685,"start":6136,"enrollment":232,"conditions":6686,"interventions":6687},"NCT00214032","Pycnogenol for the Treatment of Lymphedema",[88],"2006-11","2007-01",[2761],[6672],{"trials":6689,"activeCount":99},[],{"trials":6691,"activeCount":99},[],{"trials":6693,"activeCount":99},[],{"intervention":6695,"totalTrials":312,"cells":6696},"Combination nicotine replacement therapy",{"EARLY_PHASE1":6697,"PHASE1":6699,"PHASE2":6701,"PHASE3":6712,"PHASE4":6714,"NA":6716},{"trials":6698,"activeCount":99},[],{"trials":6700,"activeCount":99},[],{"trials":6702,"activeCount":99},[6703],{"nctId":6704,"briefTitle":6705,"status":120,"phases":6706,"primaryCompletion":6707,"completion":6707,"start":6708,"enrollment":6709,"conditions":6710,"interventions":6711},"NCT04969198","UW Withdraw From Tobacco Study",[88],"2022-09-21","2021-07-13",232,[137],[6695],{"trials":6713,"activeCount":99},[],{"trials":6715,"activeCount":99},[],{"trials":6717,"activeCount":99},[],{"intervention":6719,"totalTrials":312,"cells":6720},"conditioning chemotherapy",{"EARLY_PHASE1":6721,"PHASE1":6723,"PHASE2":6725,"PHASE3":6735,"PHASE4":6737,"NA":6739},{"trials":6722,"activeCount":99},[],{"trials":6724,"activeCount":99},[],{"trials":6726,"activeCount":99},[6727],{"nctId":6728,"briefTitle":6729,"status":681,"phases":6730,"primaryCompletion":3068,"completion":3068,"start":5482,"enrollment":2759,"conditions":6731,"interventions":6734},"NCT00582816","Haploidentical Transplant With NK Cell Infusion for Pediatric Acute Leukemia and Solid Tumors",[87,88],[6732,6733],"Leukemia","Solid Tumors",[6719],{"trials":6736,"activeCount":99},[],{"trials":6738,"activeCount":99},[],{"trials":6740,"activeCount":99},[],{"intervention":5290,"totalTrials":312,"cells":6742},{"EARLY_PHASE1":6743,"PHASE1":6745,"PHASE2":6747,"PHASE3":6753,"PHASE4":6755,"NA":6757},{"trials":6744,"activeCount":99},[],{"trials":6746,"activeCount":99},[],{"trials":6748,"activeCount":99},[6749],{"nctId":5280,"briefTitle":5281,"status":120,"phases":6750,"primaryCompletion":5283,"completion":5284,"start":5285,"enrollment":695,"conditions":6751,"interventions":6752},[88],[5287],[5289,5290,5291],{"trials":6754,"activeCount":99},[],{"trials":6756,"activeCount":99},[],{"trials":6758,"activeCount":99},[],{"intervention":5291,"totalTrials":312,"cells":6760},{"EARLY_PHASE1":6761,"PHASE1":6763,"PHASE2":6765,"PHASE3":6771,"PHASE4":6773,"NA":6775},{"trials":6762,"activeCount":99},[],{"trials":6764,"activeCount":99},[],{"trials":6766,"activeCount":99},[6767],{"nctId":5280,"briefTitle":5281,"status":120,"phases":6768,"primaryCompletion":5283,"completion":5284,"start":5285,"enrollment":695,"conditions":6769,"interventions":6770},[88],[5287],[5289,5290,5291],{"trials":6772,"activeCount":99},[],{"trials":6774,"activeCount":99},[],{"trials":6776,"activeCount":99},[],{"intervention":647,"totalTrials":312,"cells":6778},{"EARLY_PHASE1":6779,"PHASE1":6781,"PHASE2":6783,"PHASE3":6789,"PHASE4":6791,"NA":6793},{"trials":6780,"activeCount":99},[],{"trials":6782,"activeCount":99},[],{"trials":6784,"activeCount":99},[6785],{"nctId":631,"briefTitle":632,"status":120,"phases":6786,"primaryCompletion":634,"completion":635,"start":636,"enrollment":637,"conditions":6787,"interventions":6788},[87,88],[639,640,641,642,643,644,645],[553,647],{"trials":6790,"activeCount":99},[],{"trials":6792,"activeCount":99},[],{"trials":6794,"activeCount":99},[],{"intervention":6796,"totalTrials":312,"cells":6797},"LBH589",{"EARLY_PHASE1":6798,"PHASE1":6800,"PHASE2":6802,"PHASE3":6812,"PHASE4":6814,"NA":6816},{"trials":6799,"activeCount":99},[],{"trials":6801,"activeCount":99},[],{"trials":6803,"activeCount":99},[6804],{"nctId":6805,"briefTitle":6806,"status":120,"phases":6807,"primaryCompletion":6808,"completion":295,"start":3241,"enrollment":1497,"conditions":6809,"interventions":6811},"NCT01013597","Trial of LBH589 in Metastatic Thyroid Cancer",[88],"2013-08",[6810],"Thyroid Carcinoma",[6796],{"trials":6813,"activeCount":99},[],{"trials":6815,"activeCount":99},[],{"trials":6817,"activeCount":99},[],{"intervention":6819,"totalTrials":312,"cells":6820},"Zometa",{"EARLY_PHASE1":6821,"PHASE1":6823,"PHASE2":6825,"PHASE3":6835,"PHASE4":6837,"NA":6839},{"trials":6822,"activeCount":99},[],{"trials":6824,"activeCount":99},[],{"trials":6826,"activeCount":99},[6827],{"nctId":6828,"briefTitle":6829,"status":120,"phases":6830,"primaryCompletion":5071,"completion":4973,"start":5284,"enrollment":6831,"conditions":6832,"interventions":6833},"NCT00582556","Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy",[88],44,[18],[6819,6834,6819],"zometa",{"trials":6836,"activeCount":99},[],{"trials":6838,"activeCount":99},[],{"trials":6840,"activeCount":99},[],{"intervention":6842,"totalTrials":312,"cells":6843},"All Subjects",{"EARLY_PHASE1":6844,"PHASE1":6846,"PHASE2":6848,"PHASE3":6859,"PHASE4":6861,"NA":6863},{"trials":6845,"activeCount":99},[],{"trials":6847,"activeCount":99},[],{"trials":6849,"activeCount":99},[6850],{"nctId":6851,"briefTitle":6852,"status":120,"phases":6853,"primaryCompletion":6854,"completion":6854,"start":6855,"enrollment":22,"conditions":6856,"interventions":6858},"NCT03919669","A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking",[88],"2022-05-19","2019-04-02",[1719,6857],"Mild Cognitive Impairment",[6842],{"trials":6860,"activeCount":99},[],{"trials":6862,"activeCount":99},[],{"trials":6864,"activeCount":99},[],{"intervention":6866,"totalTrials":312,"cells":6867},"docetaxel + cyclophosphamide + pegfilgrastim",{"EARLY_PHASE1":6868,"PHASE1":6870,"PHASE2":6872,"PHASE3":6880,"PHASE4":6882,"NA":6884},{"trials":6869,"activeCount":99},[],{"trials":6871,"activeCount":99},[],{"trials":6873,"activeCount":99},[6874],{"nctId":6875,"briefTitle":6876,"status":120,"phases":6877,"primaryCompletion":4196,"completion":4196,"start":3163,"enrollment":5142,"conditions":6878,"interventions":6879},"NCT01671319","Dose Dense TC + Pegfilgrastim Support for Breast Cancer",[88],[3243],[6866],{"trials":6881,"activeCount":99},[],{"trials":6883,"activeCount":99},[],{"trials":6885,"activeCount":99},[],{"intervention":6887,"totalTrials":312,"cells":6888},"(18F)FES",{"EARLY_PHASE1":6889,"PHASE1":6891,"PHASE2":6893,"PHASE3":6905,"PHASE4":6907,"NA":6909},{"trials":6890,"activeCount":99},[],{"trials":6892,"activeCount":99},[],{"trials":6894,"activeCount":99},[6895],{"nctId":6896,"briefTitle":6897,"status":120,"phases":6898,"primaryCompletion":6899,"completion":6899,"start":6900,"enrollment":95,"conditions":6901,"interventions":6903},"NCT03703492","Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS",[88],"2024-01-02","2019-01-03",[15,6902],"Ductal Carcinoma in Situ - Category",[6887,6904],"Gadobenate dimeglumine",{"trials":6906,"activeCount":99},[],{"trials":6908,"activeCount":99},[],{"trials":6910,"activeCount":99},[],{"intervention":6904,"totalTrials":312,"cells":6912},{"EARLY_PHASE1":6913,"PHASE1":6915,"PHASE2":6917,"PHASE3":6923,"PHASE4":6925,"NA":6927},{"trials":6914,"activeCount":99},[],{"trials":6916,"activeCount":99},[],{"trials":6918,"activeCount":99},[6919],{"nctId":6896,"briefTitle":6897,"status":120,"phases":6920,"primaryCompletion":6899,"completion":6899,"start":6900,"enrollment":95,"conditions":6921,"interventions":6922},[88],[15,6902],[6887,6904],{"trials":6924,"activeCount":99},[],{"trials":6926,"activeCount":99},[],{"trials":6928,"activeCount":99},[],{"intervention":6930,"totalTrials":312,"cells":6931},"Ibritumomab Tiuxetan (Zevalin) + Rituximab",{"EARLY_PHASE1":6932,"PHASE1":6934,"PHASE2":6936,"PHASE3":6946,"PHASE4":6948,"NA":6950},{"trials":6933,"activeCount":99},[],{"trials":6935,"activeCount":99},[],{"trials":6937,"activeCount":99},[6938],{"nctId":6939,"briefTitle":6940,"status":681,"phases":6941,"primaryCompletion":4973,"completion":4973,"start":6942,"enrollment":35,"conditions":6943,"interventions":6945},"NCT00582166","Ibritumomab Tiuxetan (Zevalin)+ Rituximab Maintenance",[88],"2005-01-25",[6944],"Non-Hodgkin's Lymphoma",[6930],{"trials":6947,"activeCount":99},[],{"trials":6949,"activeCount":99},[],{"trials":6951,"activeCount":99},[],{"intervention":5227,"totalTrials":312,"cells":6953},{"EARLY_PHASE1":6954,"PHASE1":6956,"PHASE2":6958,"PHASE3":6964,"PHASE4":6966,"NA":6968},{"trials":6955,"activeCount":99},[],{"trials":6957,"activeCount":99},[],{"trials":6959,"activeCount":99},[6960],{"nctId":5218,"briefTitle":5219,"status":120,"phases":6961,"primaryCompletion":5221,"completion":5222,"start":5223,"enrollment":397,"conditions":6962,"interventions":6963},[88],[5225],[1178,5227,1178],{"trials":6965,"activeCount":99},[],{"trials":6967,"activeCount":99},[],{"trials":6969,"activeCount":99},[],{"intervention":6971,"totalTrials":312,"cells":6972},"L-DOPA",{"EARLY_PHASE1":6973,"PHASE1":6975,"PHASE2":6977,"PHASE3":6989,"PHASE4":6991,"NA":6993},{"trials":6974,"activeCount":99},[],{"trials":6976,"activeCount":99},[],{"trials":6978,"activeCount":99},[6979],{"nctId":6980,"briefTitle":6981,"status":342,"phases":6982,"primaryCompletion":6983,"completion":6983,"start":6984,"enrollment":2033,"conditions":6985,"interventions":6988},"NCT04558112","Improving Therapeutic Learning for PTSD",[88],"2023-12","2021-02-18",[6986,6987],"PTSD","Post Traumatic Stress Disorder",[6971],{"trials":6990,"activeCount":99},[],{"trials":6992,"activeCount":99},[],{"trials":6994,"activeCount":99},[],{"intervention":5329,"totalTrials":312,"cells":6996},{"EARLY_PHASE1":6997,"PHASE1":6999,"PHASE2":7001,"PHASE3":7007,"PHASE4":7009,"NA":7011},{"trials":6998,"activeCount":99},[],{"trials":7000,"activeCount":99},[],{"trials":7002,"activeCount":99},[7003],{"nctId":5323,"briefTitle":5324,"status":120,"phases":7004,"primaryCompletion":5326,"completion":5326,"start":4822,"enrollment":35,"conditions":7005,"interventions":7006},[88],[5225],[5329,5236],{"trials":7008,"activeCount":99},[],{"trials":7010,"activeCount":99},[],{"trials":7012,"activeCount":99},[],{"intervention":7014,"totalTrials":312,"cells":7015},"Topical Phenylephrine Solution",{"EARLY_PHASE1":7016,"PHASE1":7018,"PHASE2":7020,"PHASE3":7034,"PHASE4":7036,"NA":7038},{"trials":7017,"activeCount":99},[],{"trials":7019,"activeCount":99},[],{"trials":7021,"activeCount":99},[7022],{"nctId":7023,"briefTitle":7024,"status":681,"phases":7025,"primaryCompletion":7026,"completion":7027,"start":7028,"enrollment":778,"conditions":7029,"interventions":7033},"NCT02434146","Topical Phenylephrine Solution in Preventing Oral Mucosa in Bone Marrow Transplant Patients Receiving Cyclophosphamide and Total Body Radiation Therapy",[87,88],"2016-04-27","2017-01-25","2015-05-14",[7030,7031,7032],"Neoplasm","Oral Mucosa","Transplant-Related Disorder",[7014],{"trials":7035,"activeCount":99},[],{"trials":7037,"activeCount":99},[],{"trials":7039,"activeCount":99},[],{"intervention":7041,"totalTrials":312,"cells":7042},"Sham device",{"EARLY_PHASE1":7043,"PHASE1":7045,"PHASE2":7047,"PHASE3":7057,"PHASE4":7059,"NA":7061},{"trials":7044,"activeCount":99},[],{"trials":7046,"activeCount":99},[],{"trials":7048,"activeCount":99},[7049],{"nctId":7050,"briefTitle":7051,"status":120,"phases":7052,"primaryCompletion":7053,"completion":7053,"start":3179,"enrollment":2491,"conditions":7054,"interventions":7056},"NCT01261780","MC-5A for Chemotherapy Induced Peripheral Neuropathy",[88],"2012-09",[7055],"Neuropathy, Paraneoplastic",[7041],{"trials":7058,"activeCount":99},[],{"trials":7060,"activeCount":99},[],{"trials":7062,"activeCount":99},[],{"intervention":7064,"totalTrials":312,"cells":7065},"FMT Capsule DE",{"EARLY_PHASE1":7066,"PHASE1":7068,"PHASE2":7070,"PHASE3":7080,"PHASE4":7082,"NA":7084},{"trials":7067,"activeCount":99},[],{"trials":7069,"activeCount":99},[],{"trials":7071,"activeCount":99},[7072],{"nctId":7073,"briefTitle":7074,"status":1013,"phases":7075,"primaryCompletion":7076,"completion":7077,"start":7076,"enrollment":99,"conditions":7078,"interventions":7079},"NCT03643887","Phase II Trial of Fecal Microbiota Transplant (FMT) for VRE and CRE Patients",[88],"2022-09-01","2025-06-30",[5980],[7064],{"trials":7081,"activeCount":99},[],{"trials":7083,"activeCount":99},[],{"trials":7085,"activeCount":99},[],{"intervention":7087,"totalTrials":312,"cells":7088},"FMT oral",{"EARLY_PHASE1":7089,"PHASE1":7091,"PHASE2":7093,"PHASE3":7107,"PHASE4":7109,"NA":7111},{"trials":7090,"activeCount":99},[],{"trials":7092,"activeCount":99},[],{"trials":7094,"activeCount":99},[7095],{"nctId":7096,"briefTitle":7097,"status":681,"phases":7098,"primaryCompletion":7099,"completion":7099,"start":7100,"enrollment":778,"conditions":7101,"interventions":7103},"NCT03617445","Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients",[88],"2023-06-01","2022-08-03",[7102],"Clostridium Difficile Infection Recurrence",[7087,7104,7105,7106],"Oral Vancomycin","FMT oral placebo","Oral Vancomycin placebo",{"trials":7108,"activeCount":99},[],{"trials":7110,"activeCount":99},[],{"trials":7112,"activeCount":99},[],{"intervention":7104,"totalTrials":312,"cells":7114},{"EARLY_PHASE1":7115,"PHASE1":7117,"PHASE2":7119,"PHASE3":7125,"PHASE4":7127,"NA":7129},{"trials":7116,"activeCount":99},[],{"trials":7118,"activeCount":99},[],{"trials":7120,"activeCount":99},[7121],{"nctId":7096,"briefTitle":7097,"status":681,"phases":7122,"primaryCompletion":7099,"completion":7099,"start":7100,"enrollment":778,"conditions":7123,"interventions":7124},[88],[7102],[7087,7104,7105,7106],{"trials":7126,"activeCount":99},[],{"trials":7128,"activeCount":99},[],{"trials":7130,"activeCount":99},[],{"intervention":7105,"totalTrials":312,"cells":7132},{"EARLY_PHASE1":7133,"PHASE1":7135,"PHASE2":7137,"PHASE3":7143,"PHASE4":7145,"NA":7147},{"trials":7134,"activeCount":99},[],{"trials":7136,"activeCount":99},[],{"trials":7138,"activeCount":99},[7139],{"nctId":7096,"briefTitle":7097,"status":681,"phases":7140,"primaryCompletion":7099,"completion":7099,"start":7100,"enrollment":778,"conditions":7141,"interventions":7142},[88],[7102],[7087,7104,7105,7106],{"trials":7144,"activeCount":99},[],{"trials":7146,"activeCount":99},[],{"trials":7148,"activeCount":99},[],{"intervention":7106,"totalTrials":312,"cells":7150},{"EARLY_PHASE1":7151,"PHASE1":7153,"PHASE2":7155,"PHASE3":7161,"PHASE4":7163,"NA":7165},{"trials":7152,"activeCount":99},[],{"trials":7154,"activeCount":99},[],{"trials":7156,"activeCount":99},[7157],{"nctId":7096,"briefTitle":7097,"status":681,"phases":7158,"primaryCompletion":7099,"completion":7099,"start":7100,"enrollment":778,"conditions":7159,"interventions":7160},[88],[7102],[7087,7104,7105,7106],{"trials":7162,"activeCount":99},[],{"trials":7164,"activeCount":99},[],{"trials":7166,"activeCount":99},[],{"intervention":7168,"totalTrials":312,"cells":7169},"angiotensin converting enzyme inhibitor",{"EARLY_PHASE1":7170,"PHASE1":7172,"PHASE2":7174,"PHASE3":7186,"PHASE4":7188,"NA":7190},{"trials":7171,"activeCount":99},[],{"trials":7173,"activeCount":99},[],{"trials":7175,"activeCount":99},[7176],{"nctId":7177,"briefTitle":7178,"status":120,"phases":7179,"primaryCompletion":3574,"completion":5550,"start":262,"enrollment":7180,"conditions":7181,"interventions":7184},"NCT00874432","Effect of ACE-inhibitors on Aortic Stiffness in Elderly Patients With Chronic Kidney Disease",[88],43,[7182,7183],"Cardiovascular Disease","Chronic Kidney Disease",[7168,7185],"lisinopril",{"trials":7187,"activeCount":99},[],{"trials":7189,"activeCount":99},[],{"trials":7191,"activeCount":99},[],{"intervention":7185,"totalTrials":312,"cells":7193},{"EARLY_PHASE1":7194,"PHASE1":7196,"PHASE2":7198,"PHASE3":7204,"PHASE4":7206,"NA":7208},{"trials":7195,"activeCount":99},[],{"trials":7197,"activeCount":99},[],{"trials":7199,"activeCount":99},[7200],{"nctId":7177,"briefTitle":7178,"status":120,"phases":7201,"primaryCompletion":3574,"completion":5550,"start":262,"enrollment":7180,"conditions":7202,"interventions":7203},[88],[7182,7183],[7168,7185],{"trials":7205,"activeCount":99},[],{"trials":7207,"activeCount":99},[],{"trials":7209,"activeCount":99},[],{"intervention":7211,"totalTrials":312,"cells":7212},"Onapristone",{"EARLY_PHASE1":7213,"PHASE1":7215,"PHASE2":7217,"PHASE3":7230,"PHASE4":7232,"NA":7234},{"trials":7214,"activeCount":99},[],{"trials":7216,"activeCount":99},[],{"trials":7218,"activeCount":99},[7219],{"nctId":7220,"briefTitle":7221,"status":681,"phases":7222,"primaryCompletion":7223,"completion":7224,"start":7225,"enrollment":1322,"conditions":7226,"interventions":7228},"NCT04738292","Onapristone and Fulvestrant for ER+ HER2- Metastatic Breast Cancer After Endocrine Therapy and CDK4\u002F6 Inhibitors (The SMILE Study)",[88],"2023-04-03","2023-05-15","2021-10-05",[7227,1499,653],"ER-positive Breast Cancer",[7211,7229],"Fulvestrant",{"trials":7231,"activeCount":99},[],{"trials":7233,"activeCount":99},[],{"trials":7235,"activeCount":99},[],{"intervention":7229,"totalTrials":312,"cells":7237},{"EARLY_PHASE1":7238,"PHASE1":7240,"PHASE2":7242,"PHASE3":7248,"PHASE4":7250,"NA":7252},{"trials":7239,"activeCount":99},[],{"trials":7241,"activeCount":99},[],{"trials":7243,"activeCount":99},[7244],{"nctId":7220,"briefTitle":7221,"status":681,"phases":7245,"primaryCompletion":7223,"completion":7224,"start":7225,"enrollment":1322,"conditions":7246,"interventions":7247},[88],[7227,1499,653],[7211,7229],{"trials":7249,"activeCount":99},[],{"trials":7251,"activeCount":99},[],{"trials":7253,"activeCount":99},[],{"intervention":7255,"totalTrials":312,"cells":7256},"Levodopa\u002Fcarbidopa",{"EARLY_PHASE1":7257,"PHASE1":7259,"PHASE2":7261,"PHASE3":7273,"PHASE4":7275,"NA":7277},{"trials":7258,"activeCount":99},[],{"trials":7260,"activeCount":99},[],{"trials":7262,"activeCount":99},[7263],{"nctId":7264,"briefTitle":7265,"status":681,"phases":7266,"primaryCompletion":7267,"completion":7267,"start":7268,"enrollment":32,"conditions":7269,"interventions":7272},"NCT01663935","Vision Response to Dopamine Replacement",[88],"2018-04-12","2012-10-17",[7270,7271],"Albinism","Oculocutaneous Albinism",[7255],{"trials":7274,"activeCount":99},[],{"trials":7276,"activeCount":99},[],{"trials":7278,"activeCount":99},[],{"intervention":7280,"totalTrials":312,"cells":7281},"antiperspirant",{"EARLY_PHASE1":7282,"PHASE1":7284,"PHASE2":7286,"PHASE3":7296,"PHASE4":7298,"NA":7300},{"trials":7283,"activeCount":99},[],{"trials":7285,"activeCount":99},[],{"trials":7287,"activeCount":99},[7288],{"nctId":7289,"briefTitle":7290,"status":120,"phases":7291,"primaryCompletion":7292,"completion":6685,"start":1069,"enrollment":2491,"conditions":7293,"interventions":7295},"NCT00213993","Topical Antiperspirant for Hand-Foot Syndrome",[88],"2006-10",[7294],"Palmar-plantar Erythrodysesthesia",[7280],{"trials":7297,"activeCount":99},[],{"trials":7299,"activeCount":99},[],{"trials":7301,"activeCount":99},[],{"intervention":7303,"totalTrials":312,"cells":7304},"PVC Suppression using Flecainide",{"EARLY_PHASE1":7305,"PHASE1":7307,"PHASE2":7309,"PHASE3":7320,"PHASE4":7322,"NA":7324},{"trials":7306,"activeCount":99},[],{"trials":7308,"activeCount":99},[],{"trials":7310,"activeCount":99},[7311],{"nctId":7312,"briefTitle":7313,"status":681,"phases":7314,"primaryCompletion":2609,"completion":2609,"start":6473,"enrollment":559,"conditions":7315,"interventions":7318},"NCT01833455","Premature Ventricular Contractions (PVCs) and Blood Pressure Control",[88],[7316,7317],"Ventricular Premature Complexes","Blood Pressure",[7303,7319],"No PVC Suppression using Placebo",{"trials":7321,"activeCount":99},[],{"trials":7323,"activeCount":99},[],{"trials":7325,"activeCount":99},[],{"intervention":7319,"totalTrials":312,"cells":7327},{"EARLY_PHASE1":7328,"PHASE1":7330,"PHASE2":7332,"PHASE3":7338,"PHASE4":7340,"NA":7342},{"trials":7329,"activeCount":99},[],{"trials":7331,"activeCount":99},[],{"trials":7333,"activeCount":99},[7334],{"nctId":7312,"briefTitle":7313,"status":681,"phases":7335,"primaryCompletion":2609,"completion":2609,"start":6473,"enrollment":559,"conditions":7336,"interventions":7337},[88],[7316,7317],[7303,7319],{"trials":7339,"activeCount":99},[],{"trials":7341,"activeCount":99},[],{"trials":7343,"activeCount":99},[],{"intervention":7345,"totalTrials":312,"cells":7346},"Immunization with inactivated bacteria",{"EARLY_PHASE1":7347,"PHASE1":7349,"PHASE2":7351,"PHASE3":7362,"PHASE4":7364,"NA":7366},{"trials":7348,"activeCount":99},[],{"trials":7350,"activeCount":99},[],{"trials":7352,"activeCount":99},[7353],{"nctId":7354,"briefTitle":7355,"status":120,"phases":7356,"completion":7357,"start":7358,"enrollment":6475,"conditions":7359,"interventions":7361},"NCT00261248","Vaccine for Recurrent Urinary Tract Infections in Women",[88],"2003-12","1996-11",[7360],"Recurrent Urinary Tract Infections in Women",[7345],{"trials":7363,"activeCount":99},[],{"trials":7365,"activeCount":99},[],{"trials":7367,"activeCount":99},[],{"intervention":7369,"totalTrials":312,"cells":7370},"panobinostat",{"EARLY_PHASE1":7371,"PHASE1":7373,"PHASE2":7375,"PHASE3":7383,"PHASE4":7385,"NA":7387},{"trials":7372,"activeCount":99},[],{"trials":7374,"activeCount":99},[],{"trials":7376,"activeCount":99},[7377],{"nctId":7378,"briefTitle":7379,"status":681,"phases":7380,"primaryCompletion":1912,"completion":1912,"start":1321,"enrollment":616,"conditions":7381,"interventions":7382},"NCT00985946","Study of Panobinostat in Patients With Neuroendocrine Tumors",[88],[1103],[7369],{"trials":7384,"activeCount":99},[],{"trials":7386,"activeCount":99},[],{"trials":7388,"activeCount":99},[],{"intervention":7390,"totalTrials":312,"cells":7391},"Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance",{"EARLY_PHASE1":7392,"PHASE1":7394,"PHASE2":7396,"PHASE3":7408,"PHASE4":7410,"NA":7412},{"trials":7393,"activeCount":99},[],{"trials":7395,"activeCount":99},[],{"trials":7397,"activeCount":99},[7398],{"nctId":7399,"briefTitle":7400,"status":1013,"phases":7401,"primaryCompletion":7402,"completion":7402,"start":7403,"enrollment":99,"conditions":7404,"interventions":7407},"NCT01754870","Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)",[88],"2014-08","2013-11",[7405,7406],"Chronic Lymphocytic Leukemia (CLL)","Small Lymphocytic Lymphoma (SLL)",[7390],{"trials":7409,"activeCount":99},[],{"trials":7411,"activeCount":99},[],{"trials":7413,"activeCount":99},[],{"intervention":7415,"totalTrials":312,"cells":7416},"Capecitabine and Oxaliplatin",{"EARLY_PHASE1":7417,"PHASE1":7419,"PHASE2":7421,"PHASE3":7430,"PHASE4":7432,"NA":7434},{"trials":7418,"activeCount":99},[],{"trials":7420,"activeCount":99},[],{"trials":7422,"activeCount":99},[7423],{"nctId":7424,"briefTitle":7425,"status":120,"phases":7426,"completion":6684,"start":3035,"enrollment":7427,"conditions":7428,"interventions":7429},"NCT00204776","XELOX for Metastatic Breast Cancer",[88],37,[1500],[7415],{"trials":7431,"activeCount":99},[],{"trials":7433,"activeCount":99},[],{"trials":7435,"activeCount":99},[],{"intervention":2180,"totalTrials":312,"cells":7437},{"EARLY_PHASE1":7438,"PHASE1":7440,"PHASE2":7442,"PHASE3":7448,"PHASE4":7450,"NA":7452},{"trials":7439,"activeCount":99},[],{"trials":7441,"activeCount":99},[],{"trials":7443,"activeCount":99},[7444],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7445,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7446,"interventions":7447},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7449,"activeCount":99},[],{"trials":7451,"activeCount":99},[],{"trials":7453,"activeCount":99},[],{"intervention":2181,"totalTrials":312,"cells":7455},{"EARLY_PHASE1":7456,"PHASE1":7458,"PHASE2":7460,"PHASE3":7466,"PHASE4":7468,"NA":7470},{"trials":7457,"activeCount":99},[],{"trials":7459,"activeCount":99},[],{"trials":7461,"activeCount":99},[7462],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7463,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7464,"interventions":7465},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7467,"activeCount":99},[],{"trials":7469,"activeCount":99},[],{"trials":7471,"activeCount":99},[],{"intervention":2182,"totalTrials":312,"cells":7473},{"EARLY_PHASE1":7474,"PHASE1":7476,"PHASE2":7478,"PHASE3":7484,"PHASE4":7486,"NA":7488},{"trials":7475,"activeCount":99},[],{"trials":7477,"activeCount":99},[],{"trials":7479,"activeCount":99},[7480],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7481,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7482,"interventions":7483},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7485,"activeCount":99},[],{"trials":7487,"activeCount":99},[],{"trials":7489,"activeCount":99},[],{"intervention":2183,"totalTrials":312,"cells":7491},{"EARLY_PHASE1":7492,"PHASE1":7494,"PHASE2":7496,"PHASE3":7502,"PHASE4":7504,"NA":7506},{"trials":7493,"activeCount":99},[],{"trials":7495,"activeCount":99},[],{"trials":7497,"activeCount":99},[7498],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7499,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7500,"interventions":7501},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7503,"activeCount":99},[],{"trials":7505,"activeCount":99},[],{"trials":7507,"activeCount":99},[],{"intervention":2184,"totalTrials":312,"cells":7509},{"EARLY_PHASE1":7510,"PHASE1":7512,"PHASE2":7514,"PHASE3":7520,"PHASE4":7522,"NA":7524},{"trials":7511,"activeCount":99},[],{"trials":7513,"activeCount":99},[],{"trials":7515,"activeCount":99},[7516],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7517,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7518,"interventions":7519},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7521,"activeCount":99},[],{"trials":7523,"activeCount":99},[],{"trials":7525,"activeCount":99},[],{"intervention":2185,"totalTrials":312,"cells":7527},{"EARLY_PHASE1":7528,"PHASE1":7530,"PHASE2":7532,"PHASE3":7538,"PHASE4":7540,"NA":7542},{"trials":7529,"activeCount":99},[],{"trials":7531,"activeCount":99},[],{"trials":7533,"activeCount":99},[7534],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7535,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7536,"interventions":7537},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7539,"activeCount":99},[],{"trials":7541,"activeCount":99},[],{"trials":7543,"activeCount":99},[],{"intervention":2186,"totalTrials":312,"cells":7545},{"EARLY_PHASE1":7546,"PHASE1":7548,"PHASE2":7550,"PHASE3":7556,"PHASE4":7558,"NA":7560},{"trials":7547,"activeCount":99},[],{"trials":7549,"activeCount":99},[],{"trials":7551,"activeCount":99},[7552],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7553,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7554,"interventions":7555},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7557,"activeCount":99},[],{"trials":7559,"activeCount":99},[],{"trials":7561,"activeCount":99},[],{"intervention":2187,"totalTrials":312,"cells":7563},{"EARLY_PHASE1":7564,"PHASE1":7566,"PHASE2":7568,"PHASE3":7574,"PHASE4":7576,"NA":7578},{"trials":7565,"activeCount":99},[],{"trials":7567,"activeCount":99},[],{"trials":7569,"activeCount":99},[7570],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7571,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7572,"interventions":7573},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7575,"activeCount":99},[],{"trials":7577,"activeCount":99},[],{"trials":7579,"activeCount":99},[],{"intervention":2188,"totalTrials":312,"cells":7581},{"EARLY_PHASE1":7582,"PHASE1":7584,"PHASE2":7586,"PHASE3":7592,"PHASE4":7594,"NA":7596},{"trials":7583,"activeCount":99},[],{"trials":7585,"activeCount":99},[],{"trials":7587,"activeCount":99},[7588],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7589,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7590,"interventions":7591},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7593,"activeCount":99},[],{"trials":7595,"activeCount":99},[],{"trials":7597,"activeCount":99},[],{"intervention":2189,"totalTrials":312,"cells":7599},{"EARLY_PHASE1":7600,"PHASE1":7602,"PHASE2":7604,"PHASE3":7610,"PHASE4":7612,"NA":7614},{"trials":7601,"activeCount":99},[],{"trials":7603,"activeCount":99},[],{"trials":7605,"activeCount":99},[7606],{"nctId":2171,"briefTitle":2172,"status":120,"phases":7607,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":7608,"interventions":7609},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":7611,"activeCount":99},[],{"trials":7613,"activeCount":99},[],{"trials":7615,"activeCount":99},[],{"intervention":7617,"totalTrials":312,"cells":7618},"hu14.18-IL2 fusion protein",{"EARLY_PHASE1":7619,"PHASE1":7621,"PHASE2":7623,"PHASE3":7633,"PHASE4":7635,"NA":7637},{"trials":7620,"activeCount":99},[],{"trials":7622,"activeCount":99},[],{"trials":7624,"activeCount":99},[7625],{"nctId":7626,"briefTitle":7627,"status":120,"phases":7628,"primaryCompletion":5634,"completion":7629,"start":1069,"enrollment":2491,"conditions":7630,"interventions":7632},"NCT00109863","Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma",[88],"2014-02",[7631],"Melanoma (Skin)",[7617],{"trials":7634,"activeCount":99},[],{"trials":7636,"activeCount":99},[],{"trials":7638,"activeCount":99},[],{"intervention":5429,"totalTrials":312,"cells":7640},{"EARLY_PHASE1":7641,"PHASE1":7643,"PHASE2":7645,"PHASE3":7651,"PHASE4":7653,"NA":7655},{"trials":7642,"activeCount":99},[],{"trials":7644,"activeCount":99},[],{"trials":7646,"activeCount":99},[7647],{"nctId":5422,"briefTitle":5423,"status":120,"phases":7648,"primaryCompletion":5425,"completion":5425,"start":5426,"enrollment":9,"conditions":7649,"interventions":7650},[88],[697],[5429,1239],{"trials":7652,"activeCount":99},[],{"trials":7654,"activeCount":99},[],{"trials":7656,"activeCount":99},[],{"intervention":7658,"totalTrials":312,"cells":7659},"Dasatinib",{"EARLY_PHASE1":7660,"PHASE1":7662,"PHASE2":7664,"PHASE3":7676,"PHASE4":7678,"NA":7680},{"trials":7661,"activeCount":99},[],{"trials":7663,"activeCount":99},[],{"trials":7665,"activeCount":99},[7666],{"nctId":7667,"briefTitle":7668,"status":681,"phases":7669,"primaryCompletion":7670,"completion":7671,"start":7672,"enrollment":1952,"conditions":7673,"interventions":7675},"NCT02720185","Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR",[88],"2020-07-02","2022-02-08","2017-05-03",[5026,7674],"Triple Negative Breast Neoplasms",[7658],{"trials":7677,"activeCount":99},[],{"trials":7679,"activeCount":99},[],{"trials":7681,"activeCount":99},[],{"intervention":7683,"totalTrials":312,"cells":7684},"Metoprolol",{"EARLY_PHASE1":7685,"PHASE1":7687,"PHASE2":7689,"PHASE3":7701,"PHASE4":7703,"NA":7705},{"trials":7686,"activeCount":99},[],{"trials":7688,"activeCount":99},[],{"trials":7690,"activeCount":99},[7691],{"nctId":7692,"briefTitle":7693,"status":120,"phases":7694,"primaryCompletion":7695,"completion":7695,"start":7696,"enrollment":602,"conditions":7697,"interventions":7699},"NCT03696758","Improving Right Ventricular Function in Young Adults Born Preterm",[88],"2020-02-24","2018-10-30",[7698],"Infant,Premature",[7683,7700],"Sildenafil",{"trials":7702,"activeCount":99},[],{"trials":7704,"activeCount":99},[],{"trials":7706,"activeCount":99},[],{"intervention":7700,"totalTrials":312,"cells":7708},{"EARLY_PHASE1":7709,"PHASE1":7711,"PHASE2":7713,"PHASE3":7719,"PHASE4":7721,"NA":7723},{"trials":7710,"activeCount":99},[],{"trials":7712,"activeCount":99},[],{"trials":7714,"activeCount":99},[7715],{"nctId":7692,"briefTitle":7693,"status":120,"phases":7716,"primaryCompletion":7695,"completion":7695,"start":7696,"enrollment":602,"conditions":7717,"interventions":7718},[88],[7698],[7683,7700],{"trials":7720,"activeCount":99},[],{"trials":7722,"activeCount":99},[],{"trials":7724,"activeCount":99},[],{"intervention":7726,"totalTrials":312,"cells":7727},"OnabotulinumtoxinA",{"EARLY_PHASE1":7728,"PHASE1":7730,"PHASE2":7732,"PHASE3":7742,"PHASE4":7744,"NA":7746},{"trials":7729,"activeCount":99},[],{"trials":7731,"activeCount":99},[],{"trials":7733,"activeCount":99},[7734],{"nctId":7735,"briefTitle":7736,"status":681,"phases":7737,"primaryCompletion":7738,"completion":7738,"start":7739,"enrollment":245,"conditions":7740,"interventions":7741},"NCT03922139","Botox for the Treatment of Chronic Exertional Compartment Syndrome",[87,88],"2021-12-15","2019-10-08",[4913],[7726],{"trials":7743,"activeCount":99},[],{"trials":7745,"activeCount":99},[],{"trials":7747,"activeCount":99},[],{"intervention":7749,"totalTrials":312,"cells":7750},"Gabapentin",{"EARLY_PHASE1":7751,"PHASE1":7753,"PHASE2":7755,"PHASE3":7765,"PHASE4":7767,"NA":7769},{"trials":7752,"activeCount":99},[],{"trials":7754,"activeCount":99},[],{"trials":7756,"activeCount":99},[7757],{"nctId":7758,"briefTitle":7759,"status":681,"phases":7760,"primaryCompletion":6023,"completion":212,"start":7761,"enrollment":1952,"conditions":7762,"interventions":7763},"NCT01533753","Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer",[88],"2012-02",[18],[7749,7764],"Venlafaxine",{"trials":7766,"activeCount":99},[],{"trials":7768,"activeCount":99},[],{"trials":7770,"activeCount":99},[],{"intervention":7764,"totalTrials":312,"cells":7772},{"EARLY_PHASE1":7773,"PHASE1":7775,"PHASE2":7777,"PHASE3":7783,"PHASE4":7785,"NA":7787},{"trials":7774,"activeCount":99},[],{"trials":7776,"activeCount":99},[],{"trials":7778,"activeCount":99},[7779],{"nctId":7758,"briefTitle":7759,"status":681,"phases":7780,"primaryCompletion":6023,"completion":212,"start":7761,"enrollment":1952,"conditions":7781,"interventions":7782},[88],[18],[7749,7764],{"trials":7784,"activeCount":99},[],{"trials":7786,"activeCount":99},[],{"trials":7788,"activeCount":99},[],{"intervention":7790,"totalTrials":312,"cells":7791},"modified Hyper-CVAD",{"EARLY_PHASE1":7792,"PHASE1":7794,"PHASE2":7796,"PHASE3":7806,"PHASE4":7808,"NA":7810},{"trials":7793,"activeCount":99},[],{"trials":7795,"activeCount":99},[],{"trials":7797,"activeCount":99},[7798],{"nctId":7799,"briefTitle":7800,"status":120,"phases":7801,"primaryCompletion":6318,"completion":7802,"start":7803,"enrollment":332,"conditions":7804,"interventions":7805},"NCT00581854","Phase 2 Hyper-CVAD\u002FRituximab for Untreated Mantle Cell Lymphoma",[88],"2010-03","2000-06",[1071],[7790],{"trials":7807,"activeCount":99},[],{"trials":7809,"activeCount":99},[],{"trials":7811,"activeCount":99},[],{"intervention":769,"totalTrials":312,"cells":7813},{"EARLY_PHASE1":7814,"PHASE1":7816,"PHASE2":7818,"PHASE3":7824,"PHASE4":7826,"NA":7828},{"trials":7815,"activeCount":99},[],{"trials":7817,"activeCount":99},[],{"trials":7819,"activeCount":99},[7820],{"nctId":761,"briefTitle":762,"status":681,"phases":7821,"primaryCompletion":764,"completion":764,"start":765,"enrollment":592,"conditions":7822,"interventions":7823},[88],[767],[769,700],{"trials":7825,"activeCount":99},[],{"trials":7827,"activeCount":99},[],{"trials":7829,"activeCount":99},[],{"intervention":7831,"totalTrials":312,"cells":7832},"Ixazomib Oral",{"EARLY_PHASE1":7833,"PHASE1":7835,"PHASE2":7837,"PHASE3":7848,"PHASE4":7850,"NA":7852},{"trials":7834,"activeCount":99},[],{"trials":7836,"activeCount":99},[],{"trials":7838,"activeCount":99},[7839],{"nctId":7840,"briefTitle":7841,"status":120,"phases":7842,"primaryCompletion":7843,"completion":7843,"start":7844,"enrollment":602,"conditions":7845,"interventions":7847},"NCT03213158","Ixazomib for Desensitization",[88],"2021-04-16","2017-09-15",[7846,1934],"Kidney Diseases",[7831],{"trials":7849,"activeCount":99},[],{"trials":7851,"activeCount":99},[],{"trials":7853,"activeCount":99},[],{"intervention":7855,"totalTrials":312,"cells":7856},"Platelet Rich Plasma - Group 1",{"EARLY_PHASE1":7857,"PHASE1":7859,"PHASE2":7861,"PHASE3":7873,"PHASE4":7875,"NA":7877},{"trials":7858,"activeCount":99},[],{"trials":7860,"activeCount":99},[],{"trials":7862,"activeCount":99},[7863],{"nctId":7864,"briefTitle":7865,"status":120,"phases":7866,"primaryCompletion":7867,"completion":7867,"start":7868,"enrollment":372,"conditions":7869,"interventions":7871},"NCT03072381","PEAK Platelet Rich Plasma Injection Treatment for Chronic Lateral Epicondylosis",[88],"2020-10-28","2017-01",[7870],"Chronic Lateral Epicondylosis",[7855,7872],"Corticosteroid Control - Group 2",{"trials":7874,"activeCount":99},[],{"trials":7876,"activeCount":99},[],{"trials":7878,"activeCount":99},[],{"intervention":7872,"totalTrials":312,"cells":7880},{"EARLY_PHASE1":7881,"PHASE1":7883,"PHASE2":7885,"PHASE3":7891,"PHASE4":7893,"NA":7895},{"trials":7882,"activeCount":99},[],{"trials":7884,"activeCount":99},[],{"trials":7886,"activeCount":99},[7887],{"nctId":7864,"briefTitle":7865,"status":120,"phases":7888,"primaryCompletion":7867,"completion":7867,"start":7868,"enrollment":372,"conditions":7889,"interventions":7890},[88],[7870],[7855,7872],{"trials":7892,"activeCount":99},[],{"trials":7894,"activeCount":99},[],{"trials":7896,"activeCount":99},[],{"intervention":7898,"totalTrials":312,"cells":7899},"docetaxel and cisplatin",{"EARLY_PHASE1":7900,"PHASE1":7902,"PHASE2":7904,"PHASE3":7913,"PHASE4":7915,"NA":7917},{"trials":7901,"activeCount":99},[],{"trials":7903,"activeCount":99},[],{"trials":7905,"activeCount":99},[7906],{"nctId":7907,"briefTitle":7908,"status":120,"phases":7909,"primaryCompletion":765,"completion":765,"start":156,"enrollment":317,"conditions":7910,"interventions":7912},"NCT00582634","Adjuvant Cisplatin and Docetaxel in Non Small Cell Lung Cancer",[88],[7911],"Non Small Cell Lung Cancer",[7898],{"trials":7914,"activeCount":99},[],{"trials":7916,"activeCount":99},[],{"trials":7918,"activeCount":99},[],{"intervention":844,"totalTrials":312,"cells":7920},{"EARLY_PHASE1":7921,"PHASE1":7923,"PHASE2":7925,"PHASE3":7931,"PHASE4":7933,"NA":7935},{"trials":7922,"activeCount":99},[],{"trials":7924,"activeCount":99},[],{"trials":7926,"activeCount":99},[7927],{"nctId":836,"briefTitle":837,"status":120,"phases":7928,"primaryCompletion":839,"completion":839,"start":840,"enrollment":841,"conditions":7929,"interventions":7930},[88],[18],[41,844],{"trials":7932,"activeCount":99},[],{"trials":7934,"activeCount":99},[],{"trials":7936,"activeCount":99},[],{"intervention":7938,"totalTrials":312,"cells":7939},"melphalan",{"EARLY_PHASE1":7940,"PHASE1":7942,"PHASE2":7944,"PHASE3":7954,"PHASE4":7956,"NA":7958},{"trials":7941,"activeCount":99},[],{"trials":7943,"activeCount":99},[],{"trials":7945,"activeCount":99},[7946],{"nctId":7947,"briefTitle":7948,"status":120,"phases":7949,"primaryCompletion":7950,"completion":5097,"start":7951,"enrollment":695,"conditions":7952,"interventions":7953},"NCT00002973","Melphalan and Whole-Body Hyperthermia in Treating Patients With Advanced Melanoma",[88],"2000-05","1995-12",[7631],[7938],{"trials":7955,"activeCount":99},[],{"trials":7957,"activeCount":99},[],{"trials":7959,"activeCount":99},[],{"intervention":7961,"totalTrials":312,"cells":7962},"Campath 1H®, Rituximab, mycophenolate mofetil",{"EARLY_PHASE1":7963,"PHASE1":7965,"PHASE2":7967,"PHASE3":7976,"PHASE4":7978,"NA":7980},{"trials":7964,"activeCount":99},[],{"trials":7966,"activeCount":99},[],{"trials":7968,"activeCount":99},[7969],{"nctId":7970,"briefTitle":7971,"status":120,"phases":7972,"primaryCompletion":2873,"completion":5426,"start":2648,"enrollment":19,"conditions":7973,"interventions":7975},"NCT00214266","A Pilot Study of Campath-1H Induction Therapy Combined With CellCept® Therapy to Allow for a Calcineurin Inhibitor Free Regimen After Renal Transplantation",[88],[7974],"Renal Transplantation",[7961],{"trials":7977,"activeCount":99},[],{"trials":7979,"activeCount":99},[],{"trials":7981,"activeCount":99},[],{"intervention":5255,"totalTrials":312,"cells":7983},{"EARLY_PHASE1":7984,"PHASE1":7986,"PHASE2":7988,"PHASE3":7994,"PHASE4":7996,"NA":7998},{"trials":7985,"activeCount":99},[],{"trials":7987,"activeCount":99},[],{"trials":7989,"activeCount":99},[7990],{"nctId":5248,"briefTitle":5249,"status":342,"phases":7991,"start":5251,"conditions":7992,"interventions":7993},[87,88],[5253,346],[5255,5256,5214],{"trials":7995,"activeCount":99},[],{"trials":7997,"activeCount":99},[],{"trials":7999,"activeCount":99},[],{"intervention":5256,"totalTrials":312,"cells":8001},{"EARLY_PHASE1":8002,"PHASE1":8004,"PHASE2":8006,"PHASE3":8012,"PHASE4":8014,"NA":8016},{"trials":8003,"activeCount":99},[],{"trials":8005,"activeCount":99},[],{"trials":8007,"activeCount":99},[8008],{"nctId":5248,"briefTitle":5249,"status":342,"phases":8009,"start":5251,"conditions":8010,"interventions":8011},[87,88],[5253,346],[5255,5256,5214],{"trials":8013,"activeCount":99},[],{"trials":8015,"activeCount":99},[],{"trials":8017,"activeCount":99},[],{"intervention":8019,"totalTrials":312,"cells":8020},"Doxazosin",{"EARLY_PHASE1":8021,"PHASE1":8023,"PHASE2":8025,"PHASE3":8036,"PHASE4":8038,"NA":8040},{"trials":8022,"activeCount":99},[],{"trials":8024,"activeCount":99},[],{"trials":8026,"activeCount":99},[8027],{"nctId":8028,"briefTitle":8029,"status":120,"phases":8030,"primaryCompletion":8031,"completion":8031,"start":8032,"enrollment":8033,"conditions":8034,"interventions":8035},"NCT02989493","Testing Doxazosin to Treat Stress Mechanisms in Alcoholism",[88],"2020-03-13","2017-04-12",61,[794],[8019],{"trials":8037,"activeCount":99},[],{"trials":8039,"activeCount":99},[],{"trials":8041,"activeCount":99},[],{"intervention":8043,"totalTrials":312,"cells":8044},"Vitamin C",{"EARLY_PHASE1":8045,"PHASE1":8047,"PHASE2":8049,"PHASE3":8060,"PHASE4":8062,"NA":8064},{"trials":8046,"activeCount":99},[],{"trials":8048,"activeCount":99},[],{"trials":8050,"activeCount":99},[8051],{"nctId":8052,"briefTitle":8053,"status":1013,"phases":8054,"primaryCompletion":6983,"completion":6983,"start":8055,"enrollment":99,"conditions":8056,"interventions":8059},"NCT04505878","Perioperative Vitamin C Lung Transplant",[88],"2023-04",[8057,8058],"Primary Graft Dysfunction","Lung Transplant; Complications",[8043],{"trials":8061,"activeCount":99},[],{"trials":8063,"activeCount":99},[],{"trials":8065,"activeCount":99},[],{"intervention":5315,"totalTrials":232,"cells":8067},{"EARLY_PHASE1":8068,"PHASE1":8070,"PHASE2":8089,"PHASE3":8091,"PHASE4":8093,"NA":8095},{"trials":8069,"activeCount":99},[],{"trials":8071,"activeCount":99},[8072,8085],{"nctId":8073,"briefTitle":8074,"status":120,"phases":8075,"primaryCompletion":8076,"start":8077,"conditions":8078,"interventions":8083},"NCT00036790","Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer",[87],"2005-10","2002-02",[15,8079,618,739,6732,346,1945,8080,8081,18,8082,5211],"Chronic Myeloproliferative Disorders","Multiple Myeloma and Plasma Cell Neoplasm","Myelodysplastic\u002FMyeloproliferative Diseases","Small Intestine Cancer",[5315,8084],"motexafin gadolinium",{"nctId":5309,"briefTitle":5310,"status":120,"phases":8086,"primaryCompletion":4154,"start":5312,"conditions":8087,"interventions":8088},[87],[5211],[5236,5315],{"trials":8090,"activeCount":99},[],{"trials":8092,"activeCount":99},[],{"trials":8094,"activeCount":99},[],{"trials":8096,"activeCount":99},[],{"intervention":8098,"totalTrials":312,"cells":8099},"Drug Trial 1",{"EARLY_PHASE1":8100,"PHASE1":8102,"PHASE2":8113,"PHASE3":8115,"PHASE4":8117,"NA":8119},{"trials":8101,"activeCount":99},[],{"trials":8103,"activeCount":99},[8104],{"nctId":8105,"briefTitle":8106,"status":681,"phases":8107,"primaryCompletion":8108,"completion":8108,"start":8109,"enrollment":559,"conditions":8110,"interventions":8111},"NCT02833207","Peripheral Vasodilation in Obese Humans",[87],"2021-11","2012-04-16",[24],[8098,8112],"Drug Trial 2",{"trials":8114,"activeCount":99},[],{"trials":8116,"activeCount":99},[],{"trials":8118,"activeCount":99},[],{"trials":8120,"activeCount":99},[],{"intervention":8112,"totalTrials":312,"cells":8122},{"EARLY_PHASE1":8123,"PHASE1":8125,"PHASE2":8131,"PHASE3":8133,"PHASE4":8135,"NA":8137},{"trials":8124,"activeCount":99},[],{"trials":8126,"activeCount":99},[8127],{"nctId":8105,"briefTitle":8106,"status":681,"phases":8128,"primaryCompletion":8108,"completion":8108,"start":8109,"enrollment":559,"conditions":8129,"interventions":8130},[87],[24],[8098,8112],{"trials":8132,"activeCount":99},[],{"trials":8134,"activeCount":99},[],{"trials":8136,"activeCount":99},[],{"trials":8138,"activeCount":99},[],{"intervention":8140,"totalTrials":312,"cells":8141},"BCG and CP-675,206",{"EARLY_PHASE1":8142,"PHASE1":8144,"PHASE2":8153,"PHASE3":8155,"PHASE4":8157,"NA":8159},{"trials":8143,"activeCount":99},[],{"trials":8145,"activeCount":99},[8146],{"nctId":8147,"briefTitle":8148,"status":1013,"phases":8149,"primaryCompletion":144,"start":5073,"enrollment":99,"conditions":8150,"interventions":8152},"NCT00880854","Study of CP-675,206 in Bacillus Calmette-Guerin (BCG)-Resistant Bladder Cancer",[87],[8151],"Bladder Cancer",[8140],{"trials":8154,"activeCount":99},[],{"trials":8156,"activeCount":99},[],{"trials":8158,"activeCount":99},[],{"trials":8160,"activeCount":99},[],{"intervention":8162,"totalTrials":312,"cells":8163},"CMV-specific T-cells",{"EARLY_PHASE1":8164,"PHASE1":8166,"PHASE2":8178,"PHASE3":8180,"PHASE4":8182,"NA":8184},{"trials":8165,"activeCount":99},[],{"trials":8167,"activeCount":99},[8168],{"nctId":8169,"briefTitle":8170,"status":681,"phases":8171,"primaryCompletion":614,"completion":614,"start":8172,"enrollment":778,"conditions":8173,"interventions":8177},"NCT03798301","Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells",[87],"2020-02-06",[8174,522,8175,8176],"CMV Infection","CMV Viremia","Opportunistic Infections",[8162],{"trials":8179,"activeCount":99},[],{"trials":8181,"activeCount":99},[],{"trials":8183,"activeCount":99},[],{"trials":8185,"activeCount":99},[],{"intervention":8187,"totalTrials":312,"cells":8188},"Campath 1H®",{"EARLY_PHASE1":8189,"PHASE1":8191,"PHASE2":8200,"PHASE3":8202,"PHASE4":8204,"NA":8206},{"trials":8190,"activeCount":99},[],{"trials":8192,"activeCount":99},[8193],{"nctId":8194,"briefTitle":8195,"status":1013,"phases":8196,"start":8076,"enrollment":99,"conditions":8197,"interventions":8199},"NCT00214214","A Pilot Study to Determine the Safety of Campath-1H (Anti-CD52 Antibody) Therapy in Newly Diagnosed Subjects With Type 1 Diabetes Mellitus",[87],[8198],"New Onset Type 1 Diabetes Mellitus",[8187],{"trials":8201,"activeCount":99},[],{"trials":8203,"activeCount":99},[],{"trials":8205,"activeCount":99},[],{"trials":8207,"activeCount":99},[],{"intervention":8209,"totalTrials":312,"cells":8210},"Linaclotide",{"EARLY_PHASE1":8211,"PHASE1":8213,"PHASE2":8227,"PHASE3":8229,"PHASE4":8231,"NA":8233},{"trials":8212,"activeCount":99},[],{"trials":8214,"activeCount":99},[8215],{"nctId":8216,"briefTitle":8217,"status":120,"phases":8218,"primaryCompletion":8219,"completion":8219,"start":8220,"enrollment":7180,"conditions":8221,"interventions":8225},"NCT05107219","GCC Agonist Signal in the Small Intestine",[87],"2026-02-06","2022-11-30",[8222,8223,8224],"Barrett Esophagus","Gastroesophageal Reflux Disease","Malignant Digestive System Neoplasm",[8209,8226],"Plecanatide",{"trials":8228,"activeCount":99},[],{"trials":8230,"activeCount":99},[],{"trials":8232,"activeCount":99},[],{"trials":8234,"activeCount":99},[],{"intervention":8226,"totalTrials":312,"cells":8236},{"EARLY_PHASE1":8237,"PHASE1":8239,"PHASE2":8245,"PHASE3":8247,"PHASE4":8249,"NA":8251},{"trials":8238,"activeCount":99},[],{"trials":8240,"activeCount":99},[8241],{"nctId":8216,"briefTitle":8217,"status":120,"phases":8242,"primaryCompletion":8219,"completion":8219,"start":8220,"enrollment":7180,"conditions":8243,"interventions":8244},[87],[8222,8223,8224],[8209,8226],{"trials":8246,"activeCount":99},[],{"trials":8248,"activeCount":99},[],{"trials":8250,"activeCount":99},[],{"trials":8252,"activeCount":99},[],{"intervention":8254,"totalTrials":312,"cells":8255},"19 nor vitamin d",{"EARLY_PHASE1":8256,"PHASE1":8258,"PHASE2":8268,"PHASE3":8270,"PHASE4":8272,"NA":8274},{"trials":8257,"activeCount":99},[],{"trials":8259,"activeCount":99},[8260],{"nctId":8261,"briefTitle":8262,"status":120,"phases":8263,"primaryCompletion":8264,"completion":7803,"start":5575,"conditions":8265,"interventions":8267},"NCT01257958","Vitamin D Pilot Study in Patients With Multiple Sclerosis",[87],"2000-02",[8266],"Relapsing Remitting Multiple Sclerosis",[8254],{"trials":8269,"activeCount":99},[],{"trials":8271,"activeCount":99},[],{"trials":8273,"activeCount":99},[],{"trials":8275,"activeCount":99},[],{"intervention":8277,"totalTrials":312,"cells":8278},"erlotinib, sunitinib",{"EARLY_PHASE1":8279,"PHASE1":8281,"PHASE2":8289,"PHASE3":8291,"PHASE4":8293,"NA":8295},{"trials":8280,"activeCount":99},[],{"trials":8282,"activeCount":99},[8283],{"nctId":8284,"briefTitle":8285,"status":120,"phases":8286,"primaryCompletion":2174,"completion":6401,"start":2873,"enrollment":1322,"conditions":8287,"interventions":8288},"NCT00581789","Erlotinib and Sunitinib in NSCLC",[87],[7911],[8277],{"trials":8290,"activeCount":99},[],{"trials":8292,"activeCount":99},[],{"trials":8294,"activeCount":99},[],{"trials":8296,"activeCount":99},[],{"intervention":8298,"totalTrials":312,"cells":8299},"TAK700",{"EARLY_PHASE1":8300,"PHASE1":8302,"PHASE2":8312,"PHASE3":8314,"PHASE4":8316,"NA":8318},{"trials":8301,"activeCount":99},[],{"trials":8303,"activeCount":99},[8304],{"nctId":8305,"briefTitle":8306,"status":120,"phases":8307,"primaryCompletion":4404,"completion":8308,"start":1067,"enrollment":559,"conditions":8309,"interventions":8311},"NCT01808040","A Phase 1b Study of TAK-700 in Postmenopausal Women With Hormone-receptor Positive Metastatic Breast Cancer",[87],"2016-12-09",[8310],"Post Menopausal, Hormone Receptor Positive Breast Cancer",[8298],{"trials":8313,"activeCount":99},[],{"trials":8315,"activeCount":99},[],{"trials":8317,"activeCount":99},[],{"trials":8319,"activeCount":99},[],{"intervention":8321,"totalTrials":312,"cells":8322},"CMV specific T-cells",{"EARLY_PHASE1":8323,"PHASE1":8325,"PHASE2":8336,"PHASE3":8338,"PHASE4":8340,"NA":8342},{"trials":8324,"activeCount":99},[],{"trials":8326,"activeCount":99},[8327],{"nctId":8328,"briefTitle":8329,"status":681,"phases":8330,"primaryCompletion":8331,"completion":8331,"start":8332,"enrollment":232,"conditions":8333,"interventions":8335},"NCT03950414","A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients",[87],"2022-07-11","2019-09-27",[522,8334],"Solid Organ Transplant",[8321],{"trials":8337,"activeCount":99},[],{"trials":8339,"activeCount":99},[],{"trials":8341,"activeCount":99},[],{"trials":8343,"activeCount":99},[],{"intervention":8345,"totalTrials":312,"cells":8346},"perifosine",{"EARLY_PHASE1":8347,"PHASE1":8349,"PHASE2":8357,"PHASE3":8359,"PHASE4":8361,"NA":8363},{"trials":8348,"activeCount":99},[],{"trials":8350,"activeCount":99},[8351],{"nctId":8352,"briefTitle":8353,"status":120,"phases":8354,"completion":5721,"start":8264,"conditions":8355,"interventions":8356},"NCT00005794","Perifosine in Treating Patients With Advanced Solid Tumors",[87],[5211],[8345],{"trials":8358,"activeCount":99},[],{"trials":8360,"activeCount":99},[],{"trials":8362,"activeCount":99},[],{"trials":8364,"activeCount":99},[],{"intervention":8366,"totalTrials":312,"cells":8367},"recombinant human endostatin",{"EARLY_PHASE1":8368,"PHASE1":8370,"PHASE2":8379,"PHASE3":8381,"PHASE4":8383,"NA":8385},{"trials":8369,"activeCount":99},[],{"trials":8371,"activeCount":99},[8372],{"nctId":8373,"briefTitle":8374,"status":120,"phases":8375,"start":8376,"conditions":8377,"interventions":8378},"NCT00004872","Endostatin in Treating Patients With Advanced Refractory Solid Tumors",[87],"2000-03",[5211],[8366],{"trials":8380,"activeCount":99},[],{"trials":8382,"activeCount":99},[],{"trials":8384,"activeCount":99},[],{"trials":8386,"activeCount":99},[],{"intervention":8388,"totalTrials":312,"cells":8389},"gp100 antigen",{"EARLY_PHASE1":8390,"PHASE1":8392,"PHASE2":8404,"PHASE3":8406,"PHASE4":8408,"NA":8410},{"trials":8391,"activeCount":99},[],{"trials":8393,"activeCount":99},[8394],{"nctId":8395,"briefTitle":8396,"status":120,"phases":8397,"primaryCompletion":8398,"completion":8399,"start":8400,"enrollment":35,"conditions":8401,"interventions":8402},"NCT00003897","Vaccine Therapy With gp100 and\u002For Sargramostim in Treating Patients With Malignant Melanoma",[87],"2001-03","2006-12","1999-05",[7631],[8388,8403],"sargramostim",{"trials":8405,"activeCount":99},[],{"trials":8407,"activeCount":99},[],{"trials":8409,"activeCount":99},[],{"trials":8411,"activeCount":99},[],{"intervention":8403,"totalTrials":312,"cells":8413},{"EARLY_PHASE1":8414,"PHASE1":8416,"PHASE2":8422,"PHASE3":8424,"PHASE4":8426,"NA":8428},{"trials":8415,"activeCount":99},[],{"trials":8417,"activeCount":99},[8418],{"nctId":8395,"briefTitle":8396,"status":120,"phases":8419,"primaryCompletion":8398,"completion":8399,"start":8400,"enrollment":35,"conditions":8420,"interventions":8421},[87],[7631],[8388,8403],{"trials":8423,"activeCount":99},[],{"trials":8425,"activeCount":99},[],{"trials":8427,"activeCount":99},[],{"trials":8429,"activeCount":99},[],{"intervention":8431,"totalTrials":312,"cells":8432},"lanthanum carbonate",{"EARLY_PHASE1":8433,"PHASE1":8435,"PHASE2":8445,"PHASE3":8447,"PHASE4":8449,"NA":8451},{"trials":8434,"activeCount":99},[],{"trials":8436,"activeCount":99},[8437],{"nctId":8438,"briefTitle":8439,"status":120,"phases":8440,"primaryCompletion":4973,"completion":4997,"start":144,"enrollment":95,"conditions":8441,"interventions":8443},"NCT01289626","Efficacy of Lanthanum Carbonate in Calciphylaxis",[87],[8442],"Calciphylaxis",[8431,8444],"Lanthanum for calciphylaxis",{"trials":8446,"activeCount":99},[],{"trials":8448,"activeCount":99},[],{"trials":8450,"activeCount":99},[],{"trials":8452,"activeCount":99},[],{"intervention":8444,"totalTrials":312,"cells":8454},{"EARLY_PHASE1":8455,"PHASE1":8457,"PHASE2":8463,"PHASE3":8465,"PHASE4":8467,"NA":8469},{"trials":8456,"activeCount":99},[],{"trials":8458,"activeCount":99},[8459],{"nctId":8438,"briefTitle":8439,"status":120,"phases":8460,"primaryCompletion":4973,"completion":4997,"start":144,"enrollment":95,"conditions":8461,"interventions":8462},[87],[8442],[8431,8444],{"trials":8464,"activeCount":99},[],{"trials":8466,"activeCount":99},[],{"trials":8468,"activeCount":99},[],{"trials":8470,"activeCount":99},[],{"intervention":5213,"totalTrials":312,"cells":8472},{"EARLY_PHASE1":8473,"PHASE1":8475,"PHASE2":8481,"PHASE3":8483,"PHASE4":8485,"NA":8487},{"trials":8474,"activeCount":99},[],{"trials":8476,"activeCount":99},[8477],{"nctId":5205,"briefTitle":5206,"status":120,"phases":8478,"primaryCompletion":5208,"completion":5208,"start":5209,"enrollment":2491,"conditions":8479,"interventions":8480},[87],[5211],[5213,5214],{"trials":8482,"activeCount":99},[],{"trials":8484,"activeCount":99},[],{"trials":8486,"activeCount":99},[],{"trials":8488,"activeCount":99},[],{"intervention":8490,"totalTrials":312,"cells":8491},"autologous CD133+ cells",{"EARLY_PHASE1":8492,"PHASE1":8494,"PHASE2":8506,"PHASE3":8508,"PHASE4":8510,"NA":8512},{"trials":8493,"activeCount":99},[],{"trials":8495,"activeCount":99},[8496],{"nctId":8497,"briefTitle":8498,"status":681,"phases":8499,"primaryCompletion":8500,"completion":8500,"start":5626,"enrollment":602,"conditions":8501,"interventions":8505},"NCT00913900","Safety Study of Adult Stem Cells to Treat Patients With Severe Leg Artery Disease",[87],"2013-12",[8502,8503,8504],"Critical Limb Ischemia","Arterial Occlusive Disease","Vascular Diseases",[8490],{"trials":8507,"activeCount":99},[],{"trials":8509,"activeCount":99},[],{"trials":8511,"activeCount":99},[],{"trials":8513,"activeCount":99},[],{"intervention":8515,"totalTrials":312,"cells":8516},"NOS Inhibition",{"EARLY_PHASE1":8517,"PHASE1":8519,"PHASE2":8535,"PHASE3":8537,"PHASE4":8539,"NA":8541},{"trials":8518,"activeCount":99},[],{"trials":8520,"activeCount":99},[8521],{"nctId":8522,"briefTitle":8523,"status":120,"phases":8524,"primaryCompletion":8525,"completion":8526,"start":8527,"enrollment":8528,"conditions":8529,"interventions":8531},"NCT02936687","Mechanisms of Cerebrovascular Control",[87],"2021-07-01","2021-09-30","2017-01-31",59,[8530],"Metabolic Syndrome X",[8515,8532,8533,8534],"ET-1 Inhibition","NOS Inhibition Placebo","ET-1 Inhibition Placebo",{"trials":8536,"activeCount":99},[],{"trials":8538,"activeCount":99},[],{"trials":8540,"activeCount":99},[],{"trials":8542,"activeCount":99},[],{"intervention":8532,"totalTrials":312,"cells":8544},{"EARLY_PHASE1":8545,"PHASE1":8547,"PHASE2":8553,"PHASE3":8555,"PHASE4":8557,"NA":8559},{"trials":8546,"activeCount":99},[],{"trials":8548,"activeCount":99},[8549],{"nctId":8522,"briefTitle":8523,"status":120,"phases":8550,"primaryCompletion":8525,"completion":8526,"start":8527,"enrollment":8528,"conditions":8551,"interventions":8552},[87],[8530],[8515,8532,8533,8534],{"trials":8554,"activeCount":99},[],{"trials":8556,"activeCount":99},[],{"trials":8558,"activeCount":99},[],{"trials":8560,"activeCount":99},[],{"intervention":8533,"totalTrials":312,"cells":8562},{"EARLY_PHASE1":8563,"PHASE1":8565,"PHASE2":8571,"PHASE3":8573,"PHASE4":8575,"NA":8577},{"trials":8564,"activeCount":99},[],{"trials":8566,"activeCount":99},[8567],{"nctId":8522,"briefTitle":8523,"status":120,"phases":8568,"primaryCompletion":8525,"completion":8526,"start":8527,"enrollment":8528,"conditions":8569,"interventions":8570},[87],[8530],[8515,8532,8533,8534],{"trials":8572,"activeCount":99},[],{"trials":8574,"activeCount":99},[],{"trials":8576,"activeCount":99},[],{"trials":8578,"activeCount":99},[],{"intervention":8534,"totalTrials":312,"cells":8580},{"EARLY_PHASE1":8581,"PHASE1":8583,"PHASE2":8589,"PHASE3":8591,"PHASE4":8593,"NA":8595},{"trials":8582,"activeCount":99},[],{"trials":8584,"activeCount":99},[8585],{"nctId":8522,"briefTitle":8523,"status":120,"phases":8586,"primaryCompletion":8525,"completion":8526,"start":8527,"enrollment":8528,"conditions":8587,"interventions":8588},[87],[8530],[8515,8532,8533,8534],{"trials":8590,"activeCount":99},[],{"trials":8592,"activeCount":99},[],{"trials":8594,"activeCount":99},[],{"trials":8596,"activeCount":99},[],{"intervention":8598,"totalTrials":312,"cells":8599},"phenylephrine solution",{"EARLY_PHASE1":8600,"PHASE1":8602,"PHASE2":8612,"PHASE3":8614,"PHASE4":8616,"NA":8618},{"trials":8601,"activeCount":99},[],{"trials":8603,"activeCount":99},[8604],{"nctId":8605,"briefTitle":8606,"status":681,"phases":8607,"primaryCompletion":5048,"completion":3179,"start":7802,"enrollment":312,"conditions":8608,"interventions":8611},"NCT01092975","Safety of Phenylephrine for Oral Mucositis Prevention",[87],[8609,8610],"Mucositis","Stomatitis",[8598],{"trials":8613,"activeCount":99},[],{"trials":8615,"activeCount":99},[],{"trials":8617,"activeCount":99},[],{"trials":8619,"activeCount":99},[],{"intervention":8621,"totalTrials":312,"cells":8622},"Oral Psilocybin",{"EARLY_PHASE1":8623,"PHASE1":8625,"PHASE2":8636,"PHASE3":8638,"PHASE4":8640,"NA":8642},{"trials":8624,"activeCount":99},[],{"trials":8626,"activeCount":99},[8627],{"nctId":8628,"briefTitle":8629,"status":1013,"phases":8630,"primaryCompletion":8631,"completion":8631,"start":8632,"enrollment":99,"conditions":8633,"interventions":8634},"NCT05467761","Bioavailability Study of Psilocybin in Normal Adults",[87],"2024-03","2023-06",[21],[8621,8635],"IV Psilocybin",{"trials":8637,"activeCount":99},[],{"trials":8639,"activeCount":99},[],{"trials":8641,"activeCount":99},[],{"trials":8643,"activeCount":99},[],{"intervention":8635,"totalTrials":312,"cells":8645},{"EARLY_PHASE1":8646,"PHASE1":8648,"PHASE2":8654,"PHASE3":8656,"PHASE4":8658,"NA":8660},{"trials":8647,"activeCount":99},[],{"trials":8649,"activeCount":99},[8650],{"nctId":8628,"briefTitle":8629,"status":1013,"phases":8651,"primaryCompletion":8631,"completion":8631,"start":8632,"enrollment":99,"conditions":8652,"interventions":8653},[87],[21],[8621,8635],{"trials":8655,"activeCount":99},[],{"trials":8657,"activeCount":99},[],{"trials":8659,"activeCount":99},[],{"trials":8661,"activeCount":99},[],{"intervention":8084,"totalTrials":312,"cells":8663},{"EARLY_PHASE1":8664,"PHASE1":8666,"PHASE2":8672,"PHASE3":8674,"PHASE4":8676,"NA":8678},{"trials":8665,"activeCount":99},[],{"trials":8667,"activeCount":99},[8668],{"nctId":8073,"briefTitle":8074,"status":120,"phases":8669,"primaryCompletion":8076,"start":8077,"conditions":8670,"interventions":8671},[87],[15,8079,618,739,6732,346,1945,8080,8081,18,8082,5211],[5315,8084],{"trials":8673,"activeCount":99},[],{"trials":8675,"activeCount":99},[],{"trials":8677,"activeCount":99},[],{"trials":8679,"activeCount":99},[],{"intervention":8681,"totalTrials":312,"cells":8682},"Bicalutamide and CP-675,206",{"EARLY_PHASE1":8683,"PHASE1":8685,"PHASE2":8695,"PHASE3":8697,"PHASE4":8699,"NA":8701},{"trials":8684,"activeCount":99},[],{"trials":8686,"activeCount":99},[8687],{"nctId":8688,"briefTitle":8689,"status":681,"phases":8690,"primaryCompletion":6474,"completion":4973,"start":8691,"enrollment":95,"conditions":8692,"interventions":8693},"NCT00702923","CP-675,206 in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer",[87],"2008-07",[18],[8681,8694,8694,8694,8694],"Bicalutamide, CP-675,206",{"trials":8696,"activeCount":99},[],{"trials":8698,"activeCount":99},[],{"trials":8700,"activeCount":99},[],{"trials":8702,"activeCount":99},[],{"intervention":8694,"totalTrials":312,"cells":8704},{"EARLY_PHASE1":8705,"PHASE1":8707,"PHASE2":8713,"PHASE3":8715,"PHASE4":8717,"NA":8719},{"trials":8706,"activeCount":99},[],{"trials":8708,"activeCount":99},[8709],{"nctId":8688,"briefTitle":8689,"status":681,"phases":8710,"primaryCompletion":6474,"completion":4973,"start":8691,"enrollment":95,"conditions":8711,"interventions":8712},[87],[18],[8681,8694,8694,8694,8694],{"trials":8714,"activeCount":99},[],{"trials":8716,"activeCount":99},[],{"trials":8718,"activeCount":99},[],{"trials":8720,"activeCount":99},[],{"intervention":8722,"totalTrials":312,"cells":8723},"Durvalumab",{"EARLY_PHASE1":8724,"PHASE1":8726,"PHASE2":8738,"PHASE3":8740,"PHASE4":8742,"NA":8744},{"trials":8725,"activeCount":99},[],{"trials":8727,"activeCount":99},[8728],{"nctId":8729,"briefTitle":8730,"status":681,"phases":8731,"primaryCompletion":8732,"completion":8732,"start":4756,"enrollment":2298,"conditions":8733,"interventions":8736},"NCT03275597","Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition",[87],"2020-07-01",[8734,8735],"Non-small Cell Lung Cancer","Non-small Cell Lung Cancer Stage IV",[8722,8737],"Tremelimumab",{"trials":8739,"activeCount":99},[],{"trials":8741,"activeCount":99},[],{"trials":8743,"activeCount":99},[],{"trials":8745,"activeCount":99},[],{"intervention":8737,"totalTrials":312,"cells":8747},{"EARLY_PHASE1":8748,"PHASE1":8750,"PHASE2":8756,"PHASE3":8758,"PHASE4":8760,"NA":8762},{"trials":8749,"activeCount":99},[],{"trials":8751,"activeCount":99},[8752],{"nctId":8729,"briefTitle":8730,"status":681,"phases":8753,"primaryCompletion":8732,"completion":8732,"start":4756,"enrollment":2298,"conditions":8754,"interventions":8755},[87],[8734,8735],[8722,8737],{"trials":8757,"activeCount":99},[],{"trials":8759,"activeCount":99},[],{"trials":8761,"activeCount":99},[],{"trials":8763,"activeCount":99},[],{"intervention":3207,"totalTrials":312,"cells":8765},{"EARLY_PHASE1":8766,"PHASE1":8768,"PHASE2":8774,"PHASE3":8776,"PHASE4":8778,"NA":8780},{"trials":8767,"activeCount":99},[],{"trials":8769,"activeCount":99},[8770],{"nctId":3198,"briefTitle":3199,"status":1013,"phases":8771,"primaryCompletion":3201,"completion":3201,"start":3202,"enrollment":99,"conditions":8772,"interventions":8773},[87],[3204,3205],[3207,3208,3191],{"trials":8775,"activeCount":99},[],{"trials":8777,"activeCount":99},[],{"trials":8779,"activeCount":99},[],{"trials":8781,"activeCount":99},[],{"intervention":3208,"totalTrials":312,"cells":8783},{"EARLY_PHASE1":8784,"PHASE1":8786,"PHASE2":8792,"PHASE3":8794,"PHASE4":8796,"NA":8798},{"trials":8785,"activeCount":99},[],{"trials":8787,"activeCount":99},[8788],{"nctId":3198,"briefTitle":3199,"status":1013,"phases":8789,"primaryCompletion":3201,"completion":3201,"start":3202,"enrollment":99,"conditions":8790,"interventions":8791},[87],[3204,3205],[3207,3208,3191],{"trials":8793,"activeCount":99},[],{"trials":8795,"activeCount":99},[],{"trials":8797,"activeCount":99},[],{"trials":8799,"activeCount":99},[],{"intervention":8801,"totalTrials":312,"cells":8802},"RG-HRV16",{"EARLY_PHASE1":8803,"PHASE1":8805,"PHASE2":8814,"PHASE3":8816,"PHASE4":8818,"NA":8820},{"trials":8804,"activeCount":99},[],{"trials":8806,"activeCount":99},[8807],{"nctId":8808,"briefTitle":8809,"status":120,"phases":8810,"primaryCompletion":5930,"completion":224,"start":1911,"enrollment":296,"conditions":8811,"interventions":8813},"NCT01769573","A First-in-Human Safety and Dose-Finding Study of New Type-16 Human Rhinovirus (RG-HRV16) Inoculum in Healthy Volunteers",[87],[8812],"Healthy Volunteers",[8801],{"trials":8815,"activeCount":99},[],{"trials":8817,"activeCount":99},[],{"trials":8819,"activeCount":99},[],{"trials":8821,"activeCount":99},[],{"intervention":8823,"totalTrials":312,"cells":8824},"ZD6474",{"EARLY_PHASE1":8825,"PHASE1":8827,"PHASE2":8836,"PHASE3":8838,"PHASE4":8840,"NA":8842},{"trials":8826,"activeCount":99},[],{"trials":8828,"activeCount":99},[8829],{"nctId":8830,"briefTitle":8831,"status":1013,"phases":8832,"primaryCompletion":5048,"completion":5072,"start":764,"enrollment":99,"conditions":8833,"interventions":8834},"NCT01004419","Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer",[87],[5225],[8823,8835],"Faslodex",{"trials":8837,"activeCount":99},[],{"trials":8839,"activeCount":99},[],{"trials":8841,"activeCount":99},[],{"trials":8843,"activeCount":99},[],{"intervention":8835,"totalTrials":312,"cells":8845},{"EARLY_PHASE1":8846,"PHASE1":8848,"PHASE2":8854,"PHASE3":8856,"PHASE4":8858,"NA":8860},{"trials":8847,"activeCount":99},[],{"trials":8849,"activeCount":99},[8850],{"nctId":8830,"briefTitle":8831,"status":1013,"phases":8851,"primaryCompletion":5048,"completion":5072,"start":764,"enrollment":99,"conditions":8852,"interventions":8853},[87],[5225],[8823,8835],{"trials":8855,"activeCount":99},[],{"trials":8857,"activeCount":99},[],{"trials":8859,"activeCount":99},[],{"trials":8861,"activeCount":99},[],{"intervention":8863,"totalTrials":312,"cells":8864},"Heparin",{"EARLY_PHASE1":8865,"PHASE1":8867,"PHASE2":8880,"PHASE3":8882,"PHASE4":8884,"NA":8886},{"trials":8866,"activeCount":99},[],{"trials":8868,"activeCount":99},[8869],{"nctId":8870,"briefTitle":8871,"status":342,"phases":8872,"primaryCompletion":8873,"completion":8874,"start":8875,"enrollment":2164,"conditions":8876,"interventions":8878},"NCT02435732","CINRYZE as a Donor Pre-treatment Strategy in Kidney Recipients of KDPI>60%",[87],"2021-05","2022-05","2020-12",[8877],"Kidney Failure",[8863,8879],"CINRYZE",{"trials":8881,"activeCount":99},[],{"trials":8883,"activeCount":99},[],{"trials":8885,"activeCount":99},[],{"trials":8887,"activeCount":99},[],{"intervention":8879,"totalTrials":312,"cells":8889},{"EARLY_PHASE1":8890,"PHASE1":8892,"PHASE2":8898,"PHASE3":8900,"PHASE4":8902,"NA":8904},{"trials":8891,"activeCount":99},[],{"trials":8893,"activeCount":99},[8894],{"nctId":8870,"briefTitle":8871,"status":342,"phases":8895,"primaryCompletion":8873,"completion":8874,"start":8875,"enrollment":2164,"conditions":8896,"interventions":8897},[87],[8877],[8863,8879],{"trials":8899,"activeCount":99},[],{"trials":8901,"activeCount":99},[],{"trials":8903,"activeCount":99},[],{"trials":8905,"activeCount":99},[],{"intervention":1142,"totalTrials":312,"cells":8907},{"EARLY_PHASE1":8908,"PHASE1":8910,"PHASE2":8916,"PHASE3":8918,"PHASE4":8920,"NA":8922},{"trials":8909,"activeCount":99},[],{"trials":8911,"activeCount":99},[8912],{"nctId":1132,"briefTitle":1133,"status":1013,"phases":8913,"primaryCompletion":1135,"completion":1135,"start":790,"enrollment":99,"conditions":8914,"interventions":8915},[87],[1137,1138,1139,1140],[1142,1143],{"trials":8917,"activeCount":99},[],{"trials":8919,"activeCount":99},[],{"trials":8921,"activeCount":99},[],{"trials":8923,"activeCount":99},[],{"intervention":8925,"totalTrials":312,"cells":8926},"CLR 131",{"EARLY_PHASE1":8927,"PHASE1":8929,"PHASE2":8940,"PHASE3":8942,"PHASE4":8944,"NA":8946},{"trials":8928,"activeCount":99},[],{"trials":8930,"activeCount":99},[8931],{"nctId":8932,"briefTitle":8933,"status":120,"phases":8934,"primaryCompletion":8935,"completion":8936,"start":8937,"enrollment":95,"conditions":8938,"interventions":8939},"NCT04105543","CLR 131 Combined With Radiation for Head and Neck Cancer",[87],"2022-09-19","2024-02-01","2019-12-20",[739],[8925],{"trials":8941,"activeCount":99},[],{"trials":8943,"activeCount":99},[],{"trials":8945,"activeCount":99},[],{"trials":8947,"activeCount":99},[],{"intervention":8949,"totalTrials":312,"cells":8950},"Thiazolidinedione",{"EARLY_PHASE1":8951,"PHASE1":8953,"PHASE2":8963,"PHASE3":8965,"PHASE4":8967,"NA":8969},{"trials":8952,"activeCount":99},[],{"trials":8954,"activeCount":99},[8955],{"nctId":8956,"briefTitle":8957,"status":120,"phases":8958,"primaryCompletion":8959,"completion":8959,"start":8077,"enrollment":2491,"conditions":8960,"interventions":8962},"NCT00214253","Islet Transplantation in Type 1 Diabetic Patients",[87],"2011-10",[8961],"Type 1 Diabetes",[8949],{"trials":8964,"activeCount":99},[],{"trials":8966,"activeCount":99},[],{"trials":8968,"activeCount":99},[],{"trials":8970,"activeCount":99},[],{"intervention":8972,"totalTrials":312,"cells":8973},"axitinib",{"EARLY_PHASE1":8974,"PHASE1":8976,"PHASE2":8988,"PHASE3":8990,"PHASE4":8992,"NA":8994},{"trials":8975,"activeCount":99},[],{"trials":8977,"activeCount":99},[8978],{"nctId":8979,"briefTitle":8980,"status":120,"phases":8981,"primaryCompletion":5209,"completion":8982,"start":8983,"enrollment":1675,"conditions":8984,"interventions":8987},"NCT01540526","Pharmacodynamic Study With FLT-PET\u002FCT in Patients With Prostate\u002FOther Solid Malignancies Treated With High Dose Axitinib",[87],"2014-12","2012-03",[8985,8986],"Solid Malignancies","Metastatic Castrate-resistant Prostate Cancer",[8972],{"trials":8989,"activeCount":99},[],{"trials":8991,"activeCount":99},[],{"trials":8993,"activeCount":99},[],{"trials":8995,"activeCount":99},[],{"intervention":8997,"totalTrials":312,"cells":8998},"Fecal Microbiota Transplant",{"EARLY_PHASE1":8999,"PHASE1":9001,"PHASE2":9011,"PHASE3":9013,"PHASE4":9015,"NA":9017},{"trials":9000,"activeCount":99},[],{"trials":9002,"activeCount":99},[9003],{"nctId":9004,"briefTitle":9005,"status":681,"phases":9006,"primaryCompletion":9007,"completion":9007,"start":9008,"enrollment":1952,"conditions":9009,"interventions":9010},"NCT03998423","Oral Fecal Microbiota Transplant Feasibility Study in Alzheimer's Disease",[87],"2020-07-14","2019-11-14",[1719],[8997],{"trials":9012,"activeCount":99},[],{"trials":9014,"activeCount":99},[],{"trials":9016,"activeCount":99},[],{"trials":9018,"activeCount":99},[],{"intervention":9020,"totalTrials":312,"cells":9021},"Psilocybin and Midazolam",{"EARLY_PHASE1":9022,"PHASE1":9024,"PHASE2":9035,"PHASE3":9037,"PHASE4":9039,"NA":9041},{"trials":9023,"activeCount":99},[],{"trials":9025,"activeCount":99},[9026],{"nctId":9027,"briefTitle":9028,"status":120,"phases":9029,"primaryCompletion":9030,"completion":9030,"start":9031,"enrollment":559,"conditions":9032,"interventions":9034},"NCT04842045","Pilot RECAP Study in Healthy Volunteers",[87],"2022-11-17","2021-05-21",[2025,9033],"Amnesia",[9020],{"trials":9036,"activeCount":99},[],{"trials":9038,"activeCount":99},[],{"trials":9040,"activeCount":99},[],{"trials":9042,"activeCount":99},[],{"intervention":9044,"totalTrials":312,"cells":9045},"Alendronate",{"EARLY_PHASE1":9046,"PHASE1":9048,"PHASE2":9058,"PHASE3":9060,"PHASE4":9062,"NA":9064},{"trials":9047,"activeCount":99},[],{"trials":9049,"activeCount":99},[9050],{"nctId":9051,"briefTitle":9052,"status":681,"phases":9053,"primaryCompletion":9054,"completion":9054,"start":9055,"enrollment":592,"conditions":9056,"interventions":9057},"NCT02781805","Pilot Study of Bisphosphonates for Breast Cancer",[87],"2018-12-12","2016-08-05",[5026],[9044],{"trials":9059,"activeCount":99},[],{"trials":9061,"activeCount":99},[],{"trials":9063,"activeCount":99},[],{"trials":9065,"activeCount":99},[],{"intervention":9067,"totalTrials":312,"cells":9068},"interleukin-12 gene",{"EARLY_PHASE1":9069,"PHASE1":9071,"PHASE2":9080,"PHASE3":9082,"PHASE4":9084,"NA":9086},{"trials":9070,"activeCount":99},[],{"trials":9072,"activeCount":99},[9073],{"nctId":9074,"briefTitle":9075,"status":681,"phases":9076,"start":9077,"conditions":9078,"interventions":9079},"NCT00028652","Interleukin-12 Gene Therapy in Treating Patients With Skin Metastases",[87],"2002-01",[653],[9067],{"trials":9081,"activeCount":99},[],{"trials":9083,"activeCount":99},[],{"trials":9085,"activeCount":99},[],{"trials":9087,"activeCount":99},[],{"intervention":9089,"totalTrials":312,"cells":9090},"BK-specific T cells from Donor Lymphocytes",{"EARLY_PHASE1":9091,"PHASE1":9093,"PHASE2":9103,"PHASE3":9105,"PHASE4":9107,"NA":9109},{"trials":9092,"activeCount":99},[],{"trials":9094,"activeCount":99},[9095],{"nctId":9096,"briefTitle":9097,"status":120,"phases":9098,"primaryCompletion":9099,"completion":9099,"start":576,"enrollment":778,"conditions":9100,"interventions":9102},"NCT05042076","BK With VST for Kidney Transplant Patients",[87],"2024-05-14",[523,9101],"BK Virus Infection",[9089],{"trials":9104,"activeCount":99},[],{"trials":9106,"activeCount":99},[],{"trials":9108,"activeCount":99},[],{"trials":9110,"activeCount":99},[],{"intervention":9112,"totalTrials":312,"cells":9113},"Helminth ova",{"EARLY_PHASE1":9114,"PHASE1":9116,"PHASE2":9125,"PHASE3":9127,"PHASE4":9129,"NA":9131},{"trials":9115,"activeCount":99},[],{"trials":9117,"activeCount":99},[9118],{"nctId":9119,"briefTitle":9120,"status":120,"phases":9121,"primaryCompletion":9122,"completion":9122,"start":8691,"enrollment":2298,"conditions":9123,"interventions":9124},"NCT00645749","Helminth-induced Immunomodulation Therapy (HINT) in Relapsing-remitting Multiple Sclerosis",[87],"2015-08-13",[8266],[9112],{"trials":9126,"activeCount":99},[],{"trials":9128,"activeCount":99},[],{"trials":9130,"activeCount":99},[],{"trials":9132,"activeCount":99},[],{"intervention":9134,"totalTrials":312,"cells":9135},"pentoxifylline",{"EARLY_PHASE1":9136,"PHASE1":9138,"PHASE2":9147,"PHASE3":9149,"PHASE4":9151,"NA":9153},{"trials":9137,"activeCount":99},[],{"trials":9139,"activeCount":99},[9140],{"nctId":9141,"briefTitle":9142,"status":681,"phases":9143,"primaryCompletion":6684,"completion":6684,"start":3035,"enrollment":317,"conditions":9144,"interventions":9146},"NCT00205049","Pentoxifylline for Acute Alcoholic Hepatitis (AAH)",[87],[9145],"Hepatitis, Alcoholic",[9134],{"trials":9148,"activeCount":99},[],{"trials":9150,"activeCount":99},[],{"trials":9152,"activeCount":99},[],{"trials":9154,"activeCount":99},[],{"intervention":9156,"totalTrials":312,"cells":9157},"I124-NM404",{"EARLY_PHASE1":9158,"PHASE1":9160,"PHASE2":9170,"PHASE3":9172,"PHASE4":9174,"NA":9176},{"trials":9159,"activeCount":99},[],{"trials":9161,"activeCount":99},[9162],{"nctId":9163,"briefTitle":9164,"status":120,"phases":9165,"primaryCompletion":9166,"completion":9166,"start":9167,"enrollment":2580,"conditions":9168,"interventions":9169},"NCT00582283","NM404 as an Imaging Agent in Patients With NSCLC",[87],"2014-08-01","2004-01-14",[7911],[9156],{"trials":9171,"activeCount":99},[],{"trials":9173,"activeCount":99},[],{"trials":9175,"activeCount":99},[],{"trials":9177,"activeCount":99},[],{"intervention":9179,"totalTrials":312,"cells":9180},"calcium formate",{"EARLY_PHASE1":9181,"PHASE1":9183,"PHASE2":9192,"PHASE3":9194,"PHASE4":9196,"NA":9198},{"trials":9182,"activeCount":99},[],{"trials":9184,"activeCount":99},[9185],{"nctId":9186,"briefTitle":9187,"status":120,"phases":9188,"primaryCompletion":9189,"completion":9189,"start":5721,"enrollment":95,"conditions":9190,"interventions":9191},"NCT00204893","Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects",[87],"2007-03",[21],[9179],{"trials":9193,"activeCount":99},[],{"trials":9195,"activeCount":99},[],{"trials":9197,"activeCount":99},[],{"trials":9199,"activeCount":99},[],{"intervention":9201,"totalTrials":312,"cells":9202},"etaracizumab",{"EARLY_PHASE1":9203,"PHASE1":9205,"PHASE2":9213,"PHASE3":9215,"PHASE4":9217,"NA":9219},{"trials":9204,"activeCount":99},[],{"trials":9206,"activeCount":99},[9207],{"nctId":9208,"briefTitle":9209,"status":120,"phases":9210,"primaryCompletion":5241,"completion":5241,"start":4153,"conditions":9211,"interventions":9212},"NCT00049712","Monoclonal Antibody Therapy in Treating Patients With Refractory Advanced Solid Tumors or Lymphoma",[87],[1945,8082,5211],[9201],{"trials":9214,"activeCount":99},[],{"trials":9216,"activeCount":99},[],{"trials":9218,"activeCount":99},[],{"trials":9220,"activeCount":99},[],{"intervention":1107,"totalTrials":312,"cells":9222},{"EARLY_PHASE1":9223,"PHASE1":9225,"PHASE2":9231,"PHASE3":9233,"PHASE4":9235,"NA":9237},{"trials":9224,"activeCount":99},[],{"trials":9226,"activeCount":99},[9227],{"nctId":1096,"briefTitle":1097,"status":681,"phases":9228,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":35,"conditions":9229,"interventions":9230},[87],[1103,1104,309,1105],[1107,1108,362,361],{"trials":9232,"activeCount":99},[],{"trials":9234,"activeCount":99},[],{"trials":9236,"activeCount":99},[],{"trials":9238,"activeCount":99},[],{"intervention":1108,"totalTrials":312,"cells":9240},{"EARLY_PHASE1":9241,"PHASE1":9243,"PHASE2":9249,"PHASE3":9251,"PHASE4":9253,"NA":9255},{"trials":9242,"activeCount":99},[],{"trials":9244,"activeCount":99},[9245],{"nctId":1096,"briefTitle":1097,"status":681,"phases":9246,"primaryCompletion":1099,"completion":1100,"start":1101,"enrollment":35,"conditions":9247,"interventions":9248},[87],[1103,1104,309,1105],[1107,1108,362,361],{"trials":9250,"activeCount":99},[],{"trials":9252,"activeCount":99},[],{"trials":9254,"activeCount":99},[],{"trials":9256,"activeCount":99},[],{"intervention":9258,"totalTrials":312,"cells":9259},"AG-013736",{"EARLY_PHASE1":9260,"PHASE1":9262,"PHASE2":9271,"PHASE3":9273,"PHASE4":9275,"NA":9277},{"trials":9261,"activeCount":99},[],{"trials":9263,"activeCount":99},[9264],{"nctId":9265,"briefTitle":9266,"status":120,"phases":9267,"primaryCompletion":4997,"completion":8982,"start":9268,"enrollment":241,"conditions":9269,"interventions":9270},"NCT00859118","Pharmacodynamic Study of Axitinib in Patients With Advanced Solid Malignancies",[87],"2009-02",[1104],[9258,9258],{"trials":9272,"activeCount":99},[],{"trials":9274,"activeCount":99},[],{"trials":9276,"activeCount":99},[],{"trials":9278,"activeCount":99},[],{"intervention":9280,"totalTrials":312,"cells":9281},"rhC1INH",{"EARLY_PHASE1":9282,"PHASE1":9284,"PHASE2":9294,"PHASE3":9296,"PHASE4":9298,"NA":9300},{"trials":9283,"activeCount":99},[],{"trials":9285,"activeCount":99},[9286],{"nctId":9287,"briefTitle":9288,"status":342,"phases":9289,"primaryCompletion":9290,"completion":9290,"start":9291,"enrollment":32,"conditions":9292,"interventions":9293},"NCT03791476","RUCONEST® as a Therapeutic Strategy to Reduce the Incidence of Delayed Graft Function",[87],"2022-01","2019-06-21",[8877],[9280],{"trials":9295,"activeCount":99},[],{"trials":9297,"activeCount":99},[],{"trials":9299,"activeCount":99},[],{"trials":9301,"activeCount":99},[],{"intervention":9303,"totalTrials":312,"cells":9304},"Propranolol",{"EARLY_PHASE1":9305,"PHASE1":9307,"PHASE2":9316,"PHASE3":9318,"PHASE4":9320,"NA":9322},{"trials":9306,"activeCount":99},[],{"trials":9308,"activeCount":99},[9309],{"nctId":9310,"briefTitle":9311,"status":120,"phases":9312,"primaryCompletion":2064,"completion":2064,"start":7761,"enrollment":2759,"conditions":9313,"interventions":9315},"NCT01535495","Propranolol for Diabetic Retinopathy",[87],[9314],"Proliferative Diabetic Retinopathy",[9303],{"trials":9317,"activeCount":99},[],{"trials":9319,"activeCount":99},[],{"trials":9321,"activeCount":99},[],{"trials":9323,"activeCount":99},[],{"intervention":9325,"totalTrials":312,"cells":9326},"SLN mapping using technetium-99m +\u002F- isosulfan blue dye",{"EARLY_PHASE1":9327,"PHASE1":9336,"PHASE2":9338,"PHASE3":9340,"PHASE4":9342,"NA":9344},{"trials":9328,"activeCount":99},[9329],{"nctId":9330,"briefTitle":9331,"status":120,"phases":9332,"primaryCompletion":7099,"completion":7099,"start":9333,"enrollment":602,"conditions":9334,"interventions":9335},"NCT05859971","ICG and SLN Mapping",[86],"2023-04-13",[15],[9325],{"trials":9337,"activeCount":99},[],{"trials":9339,"activeCount":99},[],{"trials":9341,"activeCount":99},[],{"trials":9343,"activeCount":99},[],{"trials":9345,"activeCount":99},[],{"intervention":9347,"totalTrials":312,"cells":9348},"Indomethacin 25 MG\u002F50 MG",{"EARLY_PHASE1":9349,"PHASE1":9365,"PHASE2":9367,"PHASE3":9369,"PHASE4":9371,"NA":9373},{"trials":9350,"activeCount":99},[9351],{"nctId":9352,"briefTitle":9353,"status":120,"phases":9354,"primaryCompletion":9355,"completion":1044,"start":9356,"enrollment":9357,"conditions":9358,"interventions":9360},"NCT04265053","Human Cerebral Blood Flow Regulation",[86],"2025-03-31","2021-04-12",110,[9359],"Cerebral Arterial Diseases",[9347,9361,9362,9363,9364],"Ganirelix Acetate","Testosterone Transdermal Product","Estradiol Topical","Antacid",{"trials":9366,"activeCount":99},[],{"trials":9368,"activeCount":99},[],{"trials":9370,"activeCount":99},[],{"trials":9372,"activeCount":99},[],{"trials":9374,"activeCount":99},[],{"intervention":9361,"totalTrials":312,"cells":9376},{"EARLY_PHASE1":9377,"PHASE1":9383,"PHASE2":9385,"PHASE3":9387,"PHASE4":9389,"NA":9391},{"trials":9378,"activeCount":99},[9379],{"nctId":9352,"briefTitle":9353,"status":120,"phases":9380,"primaryCompletion":9355,"completion":1044,"start":9356,"enrollment":9357,"conditions":9381,"interventions":9382},[86],[9359],[9347,9361,9362,9363,9364],{"trials":9384,"activeCount":99},[],{"trials":9386,"activeCount":99},[],{"trials":9388,"activeCount":99},[],{"trials":9390,"activeCount":99},[],{"trials":9392,"activeCount":99},[],{"intervention":9362,"totalTrials":312,"cells":9394},{"EARLY_PHASE1":9395,"PHASE1":9401,"PHASE2":9403,"PHASE3":9405,"PHASE4":9407,"NA":9409},{"trials":9396,"activeCount":99},[9397],{"nctId":9352,"briefTitle":9353,"status":120,"phases":9398,"primaryCompletion":9355,"completion":1044,"start":9356,"enrollment":9357,"conditions":9399,"interventions":9400},[86],[9359],[9347,9361,9362,9363,9364],{"trials":9402,"activeCount":99},[],{"trials":9404,"activeCount":99},[],{"trials":9406,"activeCount":99},[],{"trials":9408,"activeCount":99},[],{"trials":9410,"activeCount":99},[],{"intervention":9363,"totalTrials":312,"cells":9412},{"EARLY_PHASE1":9413,"PHASE1":9419,"PHASE2":9421,"PHASE3":9423,"PHASE4":9425,"NA":9427},{"trials":9414,"activeCount":99},[9415],{"nctId":9352,"briefTitle":9353,"status":120,"phases":9416,"primaryCompletion":9355,"completion":1044,"start":9356,"enrollment":9357,"conditions":9417,"interventions":9418},[86],[9359],[9347,9361,9362,9363,9364],{"trials":9420,"activeCount":99},[],{"trials":9422,"activeCount":99},[],{"trials":9424,"activeCount":99},[],{"trials":9426,"activeCount":99},[],{"trials":9428,"activeCount":99},[],{"intervention":9364,"totalTrials":312,"cells":9430},{"EARLY_PHASE1":9431,"PHASE1":9437,"PHASE2":9439,"PHASE3":9441,"PHASE4":9443,"NA":9445},{"trials":9432,"activeCount":99},[9433],{"nctId":9352,"briefTitle":9353,"status":120,"phases":9434,"primaryCompletion":9355,"completion":1044,"start":9356,"enrollment":9357,"conditions":9435,"interventions":9436},[86],[9359],[9347,9361,9362,9363,9364],{"trials":9438,"activeCount":99},[],{"trials":9440,"activeCount":99},[],{"trials":9442,"activeCount":99},[],{"trials":9444,"activeCount":99},[],{"trials":9446,"activeCount":99},[],{"intervention":9448,"totalTrials":312,"cells":9449},"18F-DCFPyL PET",{"EARLY_PHASE1":9450,"PHASE1":9462,"PHASE2":9464,"PHASE3":9466,"PHASE4":9468,"NA":9470},{"trials":9451,"activeCount":99},[9452],{"nctId":9453,"briefTitle":9454,"status":120,"phases":9455,"primaryCompletion":9456,"completion":9456,"start":9457,"enrollment":9458,"conditions":9459,"interventions":9461},"NCT03232164","PSMA-based 18F-DCFPyL PET\u002FCT and PET\u002FMRI Pilot Studies in Prostate Cancer",[86],"2024-11-01","2017-02-02",126,[18,9460],"Prostate Neoplasm",[9448],{"trials":9463,"activeCount":99},[],{"trials":9465,"activeCount":99},[],{"trials":9467,"activeCount":99},[],{"trials":9469,"activeCount":99},[],{"trials":9471,"activeCount":99},[],{"intervention":9473,"totalTrials":312,"cells":9474},"10% Povidone-iodine nasal decolonization swab plus 0.12% CHG oral rinse",{"EARLY_PHASE1":9475,"PHASE1":9486,"PHASE2":9488,"PHASE3":9490,"PHASE4":9492,"NA":9494},{"trials":9476,"activeCount":99},[9477],{"nctId":9478,"briefTitle":9479,"status":120,"phases":9480,"primaryCompletion":1894,"completion":1894,"start":9481,"enrollment":9482,"conditions":9483,"interventions":9485},"NCT04478019","SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding",[86],"2020-07-07",245,[6639,9484],"SARS-CoV 2",[9473],{"trials":9487,"activeCount":99},[],{"trials":9489,"activeCount":99},[],{"trials":9491,"activeCount":99},[],{"trials":9493,"activeCount":99},[],{"trials":9495,"activeCount":99},[],{"intervention":9497,"totalTrials":312,"cells":9498},"Lamivudine 300 MG",{"EARLY_PHASE1":9499,"PHASE1":9510,"PHASE2":9512,"PHASE3":9514,"PHASE4":9516,"NA":9518},{"trials":9500,"activeCount":99},[9501],{"nctId":9502,"briefTitle":9503,"status":681,"phases":9504,"primaryCompletion":9505,"completion":9505,"start":9506,"enrollment":232,"conditions":9507,"interventions":9509},"NCT06056596","Lamivudine and Plasma Markers of Inflammation in Retinal Detachment",[86],"2024-09-06","2024-01-30",[710,9508],"Rhegmatogenous Retinal Detachment",[9497],{"trials":9511,"activeCount":99},[],{"trials":9513,"activeCount":99},[],{"trials":9515,"activeCount":99},[],{"trials":9517,"activeCount":99},[],{"trials":9519,"activeCount":99},[],{"intervention":9521,"totalTrials":312,"cells":9522},"Misoprostol Oral Product",{"EARLY_PHASE1":9523,"PHASE1":9537,"PHASE2":9539,"PHASE3":9541,"PHASE4":9543,"NA":9545},{"trials":9524,"activeCount":99},[9525],{"nctId":9526,"briefTitle":9527,"status":120,"phases":9528,"primaryCompletion":9529,"completion":9529,"start":9530,"enrollment":9531,"conditions":9532,"interventions":9535},"NCT04478942","PROMMO Trial: Oral Misoprostol vs IV Oxytocin",[86],"2025-01-14","2020-10-26",138,[9533,9534],"Premature Rupture of Membrane","Induction of Labor Affected Fetus \u002F Newborn",[9521,9536],"Intravenous Oxytocin",{"trials":9538,"activeCount":99},[],{"trials":9540,"activeCount":99},[],{"trials":9542,"activeCount":99},[],{"trials":9544,"activeCount":99},[],{"trials":9546,"activeCount":99},[],{"intervention":9536,"totalTrials":312,"cells":9548},{"EARLY_PHASE1":9549,"PHASE1":9555,"PHASE2":9557,"PHASE3":9559,"PHASE4":9561,"NA":9563},{"trials":9550,"activeCount":99},[9551],{"nctId":9526,"briefTitle":9527,"status":120,"phases":9552,"primaryCompletion":9529,"completion":9529,"start":9530,"enrollment":9531,"conditions":9553,"interventions":9554},[86],[9533,9534],[9521,9536],{"trials":9556,"activeCount":99},[],{"trials":9558,"activeCount":99},[],{"trials":9560,"activeCount":99},[],{"trials":9562,"activeCount":99},[],{"trials":9564,"activeCount":99},[],{"intervention":9566,"totalTrials":312,"cells":9567},"mannitol",{"EARLY_PHASE1":9568,"PHASE1":9577,"PHASE2":9579,"PHASE3":9581,"PHASE4":9583,"NA":9585},{"trials":9569,"activeCount":99},[9570],{"nctId":9571,"briefTitle":9572,"status":120,"phases":9573,"primaryCompletion":9574,"completion":9574,"start":765,"enrollment":637,"conditions":9575,"interventions":9576},"NCT00585260","Mannitol Bronchoprovocation Challenge Ancillary Study\u002FACRN",[86],"2010-02-16",[34],[9566],{"trials":9578,"activeCount":99},[],{"trials":9580,"activeCount":99},[],{"trials":9582,"activeCount":99},[],{"trials":9584,"activeCount":99},[],{"trials":9586,"activeCount":99},[],{"intervention":9588,"totalTrials":312,"cells":9589},"Delta-9-THC",{"EARLY_PHASE1":9590,"PHASE1":9604,"PHASE2":9606,"PHASE3":9608,"PHASE4":9610,"NA":9612},{"trials":9591,"activeCount":99},[9592],{"nctId":9593,"briefTitle":9594,"status":120,"phases":9595,"primaryCompletion":9596,"completion":9596,"start":9597,"enrollment":1952,"conditions":9598,"interventions":9602},"NCT06236815","High Confusion: Cannabis & Driving",[86],"2025-09-16","2025-01-25",[9599,9600,9601],"Impairment, Cognitive","Impairment of Attention","Impairment, Psychomotor",[9588,9603],"Delta-8-THC",{"trials":9605,"activeCount":99},[],{"trials":9607,"activeCount":99},[],{"trials":9609,"activeCount":99},[],{"trials":9611,"activeCount":99},[],{"trials":9613,"activeCount":99},[],{"intervention":9603,"totalTrials":312,"cells":9615},{"EARLY_PHASE1":9616,"PHASE1":9622,"PHASE2":9624,"PHASE3":9626,"PHASE4":9628,"NA":9630},{"trials":9617,"activeCount":99},[9618],{"nctId":9593,"briefTitle":9594,"status":120,"phases":9619,"primaryCompletion":9596,"completion":9596,"start":9597,"enrollment":1952,"conditions":9620,"interventions":9621},[86],[9599,9600,9601],[9588,9603],{"trials":9623,"activeCount":99},[],{"trials":9625,"activeCount":99},[],{"trials":9627,"activeCount":99},[],{"trials":9629,"activeCount":99},[],{"trials":9631,"activeCount":99},[],{"intervention":9633,"totalTrials":312,"cells":9634},"VSL#3",{"EARLY_PHASE1":9635,"PHASE1":9646,"PHASE2":9648,"PHASE3":9650,"PHASE4":9652,"NA":9654},{"trials":9636,"activeCount":99},[9637],{"nctId":9638,"briefTitle":9639,"status":120,"phases":9640,"primaryCompletion":9641,"completion":9641,"start":9642,"enrollment":2759,"conditions":9643,"interventions":9645},"NCT03682094","Impact of Probiotics on Oral Microbiota in Older Adults With Dysphagia",[86],"2020-01-21","2018-08-27",[9644],"Dysphagia",[9633],{"trials":9647,"activeCount":99},[],{"trials":9649,"activeCount":99},[],{"trials":9651,"activeCount":99},[],{"trials":9653,"activeCount":99},[],{"trials":9655,"activeCount":99},[],{"intervention":9657,"totalTrials":2759,"cells":9658},"Influenza vaccine",{"EARLY_PHASE1":9659,"PHASE1":9661,"PHASE2":9663,"PHASE3":9665,"PHASE4":9667,"NA":9676},{"trials":9660,"activeCount":99},[],{"trials":9662,"activeCount":99},[],{"trials":9664,"activeCount":99},[],{"trials":9666,"activeCount":99},[],{"trials":9668,"activeCount":99},[9669],{"nctId":9670,"briefTitle":9671,"status":120,"phases":9672,"primaryCompletion":4996,"completion":239,"start":5209,"enrollment":1234,"conditions":9673,"interventions":9675},"NCT02268500","VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)",[90],[9674],"Chronic Heart Failure",[9657],{"trials":9677,"activeCount":99},[9678,9685,9694,9700,9707,9713,9721,9729],{"nctId":9679,"briefTitle":9680,"status":120,"phases":9681,"primaryCompletion":202,"completion":202,"start":978,"enrollment":1675,"conditions":9682,"interventions":9684},"NCT04533061","Influenza Vaccine in Lung Transplant Patients - T Cells",[],[9683],"Influenza",[9657],{"nctId":9686,"briefTitle":9687,"status":120,"phases":9688,"primaryCompletion":9689,"completion":9689,"start":9690,"enrollment":4325,"conditions":9691,"interventions":9692},"NCT05584735","Determining the Relationship Between Gut Microbiota and Immune Response to Influenza or COVID-19 Vaccine",[],"2025-03-20","2023-11-03",[3301],[9657,9693],"COVID-19 vaccine",{"nctId":9695,"briefTitle":9696,"status":120,"phases":9697,"primaryCompletion":202,"completion":202,"start":978,"enrollment":6292,"conditions":9698,"interventions":9699},"NCT04531657","Influenza Vaccine in Lung Transplant Patients - Seroprotection",[],[9683],[9657],{"nctId":9701,"briefTitle":9702,"status":120,"phases":9703,"primaryCompletion":202,"completion":202,"start":978,"enrollment":9704,"conditions":9705,"interventions":9706},"NCT04533139","Influenza Vaccine in Lung Transplant Patients - Antibody",[],122,[9683],[9657],{"nctId":9708,"briefTitle":9709,"status":120,"phases":9710,"primaryCompletion":202,"completion":202,"start":978,"enrollment":496,"conditions":9711,"interventions":9712},"NCT04530786","Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies Beyond the Season",[],[9683],[9657],{"nctId":9714,"briefTitle":9715,"status":120,"phases":9716,"primaryCompletion":6318,"completion":6318,"start":9717,"enrollment":241,"conditions":9718,"interventions":9720},"NCT00214071","Immunological Consequences of Obstructive Sleep Apnea",[91],"2004-10",[9719],"Obstructive Sleep Apnea",[9657],{"nctId":9722,"briefTitle":9723,"status":120,"phases":9724,"primaryCompletion":202,"completion":202,"start":9725,"enrollment":9726,"conditions":9727,"interventions":9728},"NCT04531787","Influenza Vaccine in Lung Transplant Patients - Persistence of Antibodies",[],"2004-08",139,[9683],[9657],{"nctId":9730,"briefTitle":9731,"status":120,"phases":9732,"primaryCompletion":202,"completion":202,"start":978,"enrollment":9458,"conditions":9733,"interventions":9734},"NCT00205270","Influenza Vaccine in Lung Transplant Patients",[],[9683],[9657],{"intervention":500,"totalTrials":317,"cells":9736},{"EARLY_PHASE1":9737,"PHASE1":9739,"PHASE2":9741,"PHASE3":9751,"PHASE4":9753,"NA":9759},{"trials":9738,"activeCount":99},[],{"trials":9740,"activeCount":99},[],{"trials":9742,"activeCount":99},[9743,9747],{"nctId":1969,"briefTitle":1970,"status":120,"phases":9744,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":32,"conditions":9745,"interventions":9746},[88],[1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987],[1989,1990,1991,1992,1993,1994,1995],{"nctId":2171,"briefTitle":2172,"status":120,"phases":9748,"primaryCompletion":2174,"completion":2174,"start":2175,"enrollment":602,"conditions":9749,"interventions":9750},[87,88],[2177,2178],[2180,2152,500,2181,2182,2183,2184,2185,2186,2187,2188,2189],{"trials":9752,"activeCount":99},[],{"trials":9754,"activeCount":99},[9755],{"nctId":491,"briefTitle":492,"status":120,"phases":9756,"primaryCompletion":494,"completion":494,"start":495,"enrollment":496,"conditions":9757,"interventions":9758},[90],[498],[469,500],{"trials":9760,"activeCount":99},[9761],{"nctId":1938,"briefTitle":1939,"status":120,"phases":9762,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1322,"conditions":9763,"interventions":9764},[91],[1945],[1947,1948,360,1949,1950,500,65],{"intervention":1994,"totalTrials":778,"cells":9766},{"EARLY_PHASE1":9767,"PHASE1":9769,"PHASE2":9771,"PHASE3":9777,"PHASE4":9779,"NA":9781},{"trials":9768,"activeCount":99},[],{"trials":9770,"activeCount":99},[],{"trials":9772,"activeCount":99},[9773],{"nctId":1969,"briefTitle":1970,"status":120,"phases":9774,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":32,"conditions":9775,"interventions":9776},[88],[1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987],[1989,1990,1991,1992,1993,1994,1995],{"trials":9778,"activeCount":99},[],{"trials":9780,"activeCount":99},[],{"trials":9782,"activeCount":99},[9783,9790],{"nctId":9784,"briefTitle":9785,"status":1013,"phases":9786,"enrollment":99,"conditions":9787,"interventions":9789},"NCT00849238","Mycophenolate Mofetil Maintenance Therapy for Liver Transplantation",[91],[9788],"Primary Liver Transplant",[1994],{"nctId":1938,"briefTitle":1939,"status":120,"phases":9791,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1322,"conditions":9792,"interventions":9793},[91],[1945],[1947,1948,360,1949,1950,500,65],{"intervention":9795,"totalTrials":778,"cells":9796},"Vitamin D",{"EARLY_PHASE1":9797,"PHASE1":9799,"PHASE2":9801,"PHASE3":9803,"PHASE4":9805,"NA":9817},{"trials":9798,"activeCount":99},[],{"trials":9800,"activeCount":99},[],{"trials":9802,"activeCount":99},[],{"trials":9804,"activeCount":99},[],{"trials":9806,"activeCount":99},[9807],{"nctId":9808,"briefTitle":9809,"status":120,"phases":9810,"primaryCompletion":8691,"completion":4822,"start":2648,"enrollment":567,"conditions":9811,"interventions":9816},"NCT00581828","Does Treatment of Hypovitaminosis D Increase Calcium Absorption?",[90],[3046,4131,9812,9813,9814,9815],"Vitamin D Deficiency","Hypoparathyroidism","Hypercalciuria","Hypercalcemia",[9795],{"trials":9818,"activeCount":99},[9819,9827],{"nctId":9820,"briefTitle":9821,"status":681,"phases":9822,"primaryCompletion":6401,"completion":6401,"start":2873,"enrollment":9,"conditions":9823,"interventions":9825},"NCT00715429","Vitamin D for Painful Nocturnal Leg Cramps",[91],[9824],"Leg Cramps, Nocturnal",[9826],"vitamin d",{"nctId":9828,"briefTitle":9829,"status":120,"phases":9830,"primaryCompletion":9831,"completion":9832,"start":5312,"enrollment":9833,"conditions":9834,"interventions":9835},"NCT00204919","Vitamin D Administration in the Nursing Home",[91],"2004-05","2004-11",96,[9812,3046],[9795],{"intervention":9837,"totalTrials":232,"cells":9838},"NM404",{"EARLY_PHASE1":9839,"PHASE1":9841,"PHASE2":9843,"PHASE3":9845,"PHASE4":9847,"NA":9849},{"trials":9840,"activeCount":99},[],{"trials":9842,"activeCount":99},[],{"trials":9844,"activeCount":99},[],{"trials":9846,"activeCount":99},[],{"trials":9848,"activeCount":99},[],{"trials":9850,"activeCount":99},[9851,9860],{"nctId":9852,"briefTitle":9853,"status":120,"phases":9854,"primaryCompletion":9855,"completion":9855,"start":5550,"enrollment":567,"conditions":9856,"interventions":9859},"NCT01516905","PET\u002FCT Imaging of Malignant Brain Tumors With 124I-NM404",[],"2016-05-17",[9857,9858],"Glioblastoma","Brain Metastases",[9837],{"nctId":9861,"briefTitle":9862,"status":120,"phases":9863,"primaryCompletion":240,"completion":240,"start":8983,"enrollment":95,"conditions":9864,"interventions":9866},"NCT01540513","PET\u002FCT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404",[91],[9865,9858],"Glioblastoma Multiforme",[9837,9837],{"intervention":9868,"totalTrials":232,"cells":9869},"Azithromycin",{"EARLY_PHASE1":9870,"PHASE1":9872,"PHASE2":9874,"PHASE3":9876,"PHASE4":9886,"NA":9888},{"trials":9871,"activeCount":99},[],{"trials":9873,"activeCount":99},[],{"trials":9875,"activeCount":99},[],{"trials":9877,"activeCount":99},[9878],{"nctId":9879,"briefTitle":9880,"status":120,"phases":9881,"primaryCompletion":5048,"completion":5048,"start":9882,"enrollment":9883,"conditions":9884,"interventions":9885},"NCT00266851","AZMATICS: AZithroMycin\u002FAsthma Trial In Community Settings",[89],"2006-01",97,[34],[9868],{"trials":9887,"activeCount":99},[],{"trials":9889,"activeCount":99},[9890],{"nctId":9891,"briefTitle":9892,"status":120,"phases":9893,"primaryCompletion":155,"completion":155,"start":5284,"enrollment":9894,"conditions":9895,"interventions":9897},"NCT00214331","Pharmacokinetics and Pharmacodynamics and Selected Antibiotics During Pregnancy",[],150,[9896],"Pregnancy",[9898,9899,9900],"ciprofloxacin","azithromycin","gentamicin",{"intervention":9902,"totalTrials":232,"cells":9903},"Ferumoxytol",{"EARLY_PHASE1":9904,"PHASE1":9915,"PHASE2":9917,"PHASE3":9919,"PHASE4":9921,"NA":9923},{"trials":9905,"activeCount":99},[9906],{"nctId":9907,"briefTitle":9908,"status":120,"phases":9909,"primaryCompletion":9910,"completion":9910,"start":9911,"enrollment":778,"conditions":9912,"interventions":9914},"NCT04839185","Placental Lesions in Fetal Growth Restrictions",[86],"2021-10-06","2021-04-15",[9913],"Fetal Growth Retardation",[9902],{"trials":9916,"activeCount":99},[],{"trials":9918,"activeCount":99},[],{"trials":9920,"activeCount":99},[],{"trials":9922,"activeCount":99},[],{"trials":9924,"activeCount":99},[9925],{"nctId":9926,"briefTitle":9927,"status":120,"phases":9928,"primaryCompletion":9929,"completion":9929,"start":8527,"enrollment":9930,"conditions":9931,"interventions":9933},"NCT02791568","Advanced MRI for Uteroplacental Flow, Perfusion, Oxygenation & Inflammation",[],"2020-07-31",121,[9896,24,9932],"Preeclampsia",[9902],{"intervention":6270,"totalTrials":232,"cells":9935},{"EARLY_PHASE1":9936,"PHASE1":9938,"PHASE2":9940,"PHASE3":9946,"PHASE4":9948,"NA":9950},{"trials":9937,"activeCount":99},[],{"trials":9939,"activeCount":99},[],{"trials":9941,"activeCount":99},[9942],{"nctId":6263,"briefTitle":6264,"status":120,"phases":9943,"primaryCompletion":2903,"completion":2903,"start":5223,"enrollment":6266,"conditions":9944,"interventions":9945},[88],[6268,3602],[6254,6270],{"trials":9947,"activeCount":99},[],{"trials":9949,"activeCount":99},[],{"trials":9951,"activeCount":99},[9952],{"nctId":9953,"briefTitle":9954,"status":1013,"phases":9955,"enrollment":99,"conditions":9956,"interventions":9957},"NCT00214084","Vascular Pathophysiology in Obstructive Sleep Apnea",[91],[9719],[6270],{"intervention":1990,"totalTrials":232,"cells":9959},{"EARLY_PHASE1":9960,"PHASE1":9962,"PHASE2":9964,"PHASE3":9970,"PHASE4":9972,"NA":9974},{"trials":9961,"activeCount":99},[],{"trials":9963,"activeCount":99},[],{"trials":9965,"activeCount":99},[9966],{"nctId":1969,"briefTitle":1970,"status":120,"phases":9967,"primaryCompletion":1972,"completion":1973,"start":1974,"enrollment":32,"conditions":9968,"interventions":9969},[88],[1976,1977,1978,1979,1980,1981,1982,1983,1984,1985,1986,1987],[1989,1990,1991,1992,1993,1994,1995],{"trials":9971,"activeCount":99},[],{"trials":9973,"activeCount":99},[],{"trials":9975,"activeCount":99},[9976],{"nctId":1938,"briefTitle":1939,"status":120,"phases":9977,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1322,"conditions":9978,"interventions":9979},[91],[1945],[1947,1948,360,1949,1950,500,65],{"intervention":9981,"totalTrials":232,"cells":9982},"Chemotherapy",{"EARLY_PHASE1":9983,"PHASE1":9985,"PHASE2":9987,"PHASE3":9999,"PHASE4":10001,"NA":10003},{"trials":9984,"activeCount":99},[],{"trials":9986,"activeCount":99},[],{"trials":9988,"activeCount":99},[9989],{"nctId":9990,"briefTitle":9991,"status":120,"phases":9992,"primaryCompletion":9993,"completion":9993,"start":9994,"enrollment":9995,"conditions":9996,"interventions":9997},"NCT00205322","Oxaliplatin, 5-FU and Leucovorin in Combination With Oral Capecitabine for Metastatic Colorectal Cancer",[88],"2007-10","2004-04",45,[697],[9998],"chemotherapy",{"trials":10000,"activeCount":99},[],{"trials":10002,"activeCount":99},[],{"trials":10004,"activeCount":99},[10005],{"nctId":10006,"briefTitle":10007,"status":681,"phases":10008,"primaryCompletion":10009,"completion":10009,"start":10010,"enrollment":1952,"conditions":10011,"interventions":10012},"NCT03393741","Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy",[],"2024-02-11","2018-01-29",[15,5026],[10013,10014,10015,10016,9981],"Taxane","Vinorelbine","Ixabepilone","Eribulin",{"intervention":10018,"totalTrials":232,"cells":10019},"Buprenorphine",{"EARLY_PHASE1":10020,"PHASE1":10022,"PHASE2":10024,"PHASE3":10026,"PHASE4":10032,"NA":10034},{"trials":10021,"activeCount":99},[],{"trials":10023,"activeCount":99},[],{"trials":10025,"activeCount":99},[],{"trials":10027,"activeCount":99},[10028],{"nctId":5068,"briefTitle":5069,"status":120,"phases":10029,"primaryCompletion":5071,"completion":5072,"start":5073,"enrollment":5074,"conditions":10030,"interventions":10031},[88,89],[4975],[5057,5077],{"trials":10033,"activeCount":99},[],{"trials":10035,"activeCount":99},[10036],{"nctId":10037,"briefTitle":10038,"status":681,"phases":10039,"primaryCompletion":10040,"completion":2064,"start":3178,"enrollment":27,"conditions":10041,"interventions":10046},"NCT01583179","Duration of Analgesic Effect for Ultrasound Guided Supraclavicular Blocks With the Addition of Buprenorphine to Local Anesthetic Solution",[91],"2014-03",[10042,10043,10044,10045],"Regional Block for Pain Control","Supraclavicular Block","Ultrasound Guided Block","Block Additive",[10018],{"intervention":10048,"totalTrials":232,"cells":10049},"atorvastatin",{"EARLY_PHASE1":10050,"PHASE1":10052,"PHASE2":10054,"PHASE3":10062,"PHASE4":10064,"NA":10066},{"trials":10051,"activeCount":99},[],{"trials":10053,"activeCount":99},[],{"trials":10055,"activeCount":99},[10056],{"nctId":10057,"briefTitle":10058,"status":120,"phases":10059,"primaryCompletion":5888,"completion":5888,"start":6318,"enrollment":5074,"conditions":10060,"interventions":10061},"NCT00751907","Cerebral and Peripheral Perfusion Pilot Study",[88],[3601],[10048],{"trials":10063,"activeCount":99},[],{"trials":10065,"activeCount":99},[],{"trials":10067,"activeCount":99},[10068],{"nctId":10069,"briefTitle":10070,"status":681,"phases":10071,"primaryCompletion":10072,"completion":10072,"start":6376,"enrollment":312,"conditions":10073,"interventions":10075},"NCT00585611","Effects of Statin Therapy on Vascular Properties and Outcomes in Diastolic Heart Failure Patients",[91],"2008-06",[10074],"Diastolic Heart Failure",[10076],"Atorvastatin",{"intervention":4470,"totalTrials":232,"cells":10078},{"EARLY_PHASE1":10079,"PHASE1":10081,"PHASE2":10083,"PHASE3":10085,"PHASE4":10087,"NA":10093},{"trials":10080,"activeCount":99},[],{"trials":10082,"activeCount":99},[],{"trials":10084,"activeCount":99},[],{"trials":10086,"activeCount":99},[],{"trials":10088,"activeCount":99},[10089],{"nctId":4462,"briefTitle":4463,"status":1013,"phases":10090,"primaryCompletion":4465,"completion":4465,"start":4466,"enrollment":99,"conditions":10091,"interventions":10092},[90],[1934,4468],[4470,4449,4471,4472,4473],{"trials":10094,"activeCount":99},[10095],{"nctId":10096,"briefTitle":10097,"status":1013,"phases":10098,"primaryCompletion":123,"completion":123,"start":1232,"enrollment":99,"conditions":10099,"interventions":10102},"NCT01033500","Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients",[91],[10100,10101,2177],"Islets of Langerhans Transplantation","Diabetes Mellitus, Type 1",[4470],{"intervention":10104,"totalTrials":312,"cells":10105},"CMV Immune globulin",{"EARLY_PHASE1":10106,"PHASE1":10108,"PHASE2":10110,"PHASE3":10112,"PHASE4":10114,"NA":10116},{"trials":10107,"activeCount":99},[],{"trials":10109,"activeCount":99},[],{"trials":10111,"activeCount":99},[],{"trials":10113,"activeCount":99},[],{"trials":10115,"activeCount":99},[],{"trials":10117,"activeCount":99},[10118],{"nctId":10119,"briefTitle":10120,"status":120,"phases":10121,"primaryCompletion":5888,"completion":5888,"start":2141,"enrollment":4889,"conditions":10122,"interventions":10124},"NCT00214240","The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney\u002FPancreas Transplant Recipients With Clinical CMV Disease",[91],[10123],"Cytomegalovirus",[10104],{"intervention":10126,"totalTrials":312,"cells":10127},"epidural catheter",{"EARLY_PHASE1":10128,"PHASE1":10130,"PHASE2":10132,"PHASE3":10134,"PHASE4":10136,"NA":10138},{"trials":10129,"activeCount":99},[],{"trials":10131,"activeCount":99},[],{"trials":10133,"activeCount":99},[],{"trials":10135,"activeCount":99},[],{"trials":10137,"activeCount":99},[],{"trials":10139,"activeCount":99},[10140],{"nctId":10141,"briefTitle":10142,"status":681,"phases":10143,"primaryCompletion":8982,"completion":8982,"start":1911,"enrollment":232,"conditions":10144,"interventions":10146},"NCT01900626","Single vs Double Epidural Catheter Analgesia for Scoliosis Surgery",[91],[10145],"Adolescent Idiopathic Scoliosis",[10126],{"intervention":10148,"totalTrials":312,"cells":10149},"Segmental Allergen Challenge",{"EARLY_PHASE1":10150,"PHASE1":10152,"PHASE2":10154,"PHASE3":10156,"PHASE4":10158,"NA":10160},{"trials":10151,"activeCount":99},[],{"trials":10153,"activeCount":99},[],{"trials":10155,"activeCount":99},[],{"trials":10157,"activeCount":99},[],{"trials":10159,"activeCount":99},[],{"trials":10161,"activeCount":99},[10162],{"nctId":10163,"briefTitle":10164,"status":120,"phases":10165,"primaryCompletion":10166,"completion":10166,"start":10167,"enrollment":19,"conditions":10168,"interventions":10169},"NCT01026532","Functional Activity of Airway Eosinophils in Allergic Disease",[],"2017-03-31","2011-08-24",[34],[10148],{"intervention":10171,"totalTrials":312,"cells":10172},"NRTI\u002FNNRTI\u002F Kaletra",{"EARLY_PHASE1":10173,"PHASE1":10175,"PHASE2":10177,"PHASE3":10179,"PHASE4":10181,"NA":10183},{"trials":10174,"activeCount":99},[],{"trials":10176,"activeCount":99},[],{"trials":10178,"activeCount":99},[],{"trials":10180,"activeCount":99},[],{"trials":10182,"activeCount":99},[],{"trials":10184,"activeCount":99},[10185],{"nctId":10186,"briefTitle":10187,"status":120,"phases":10188,"primaryCompletion":2174,"completion":2174,"start":8691,"enrollment":2023,"conditions":10189,"interventions":10191},"NCT00585793","Relationship Between HIV-1 Subtype and ARV Response",[],[10190],"HIV Infections",[10171],{"intervention":10193,"totalTrials":312,"cells":10194},"ProLab 200mg caffeine",{"EARLY_PHASE1":10195,"PHASE1":10197,"PHASE2":10199,"PHASE3":10201,"PHASE4":10203,"NA":10205},{"trials":10196,"activeCount":99},[],{"trials":10198,"activeCount":99},[],{"trials":10200,"activeCount":99},[],{"trials":10202,"activeCount":99},[],{"trials":10204,"activeCount":99},[],{"trials":10206,"activeCount":99},[10207],{"nctId":10208,"briefTitle":10209,"status":120,"phases":10210,"primaryCompletion":10211,"completion":10211,"start":10212,"enrollment":10213,"conditions":10214,"interventions":10216},"NCT02411318","Influence of Lifestyle Factors on Neutrophil Migration Pilot Study",[91],"2019-12-31","2014-09-25",47,[10215],"Neutrophil Chemotactic Response",[10193,10217],"Glucose Tolerance Drink",{"intervention":10217,"totalTrials":312,"cells":10219},{"EARLY_PHASE1":10220,"PHASE1":10222,"PHASE2":10224,"PHASE3":10226,"PHASE4":10228,"NA":10230},{"trials":10221,"activeCount":99},[],{"trials":10223,"activeCount":99},[],{"trials":10225,"activeCount":99},[],{"trials":10227,"activeCount":99},[],{"trials":10229,"activeCount":99},[],{"trials":10231,"activeCount":99},[10232],{"nctId":10208,"briefTitle":10209,"status":120,"phases":10233,"primaryCompletion":10211,"completion":10211,"start":10212,"enrollment":10213,"conditions":10234,"interventions":10235},[91],[10215],[10193,10217],{"intervention":9693,"totalTrials":312,"cells":10237},{"EARLY_PHASE1":10238,"PHASE1":10240,"PHASE2":10242,"PHASE3":10244,"PHASE4":10246,"NA":10248},{"trials":10239,"activeCount":99},[],{"trials":10241,"activeCount":99},[],{"trials":10243,"activeCount":99},[],{"trials":10245,"activeCount":99},[],{"trials":10247,"activeCount":99},[],{"trials":10249,"activeCount":99},[10250],{"nctId":9686,"briefTitle":9687,"status":120,"phases":10251,"primaryCompletion":9689,"completion":9689,"start":9690,"enrollment":4325,"conditions":10252,"interventions":10253},[],[3301],[9657,9693],{"intervention":10255,"totalTrials":312,"cells":10256},"Terbutaline plus Metoprolol or carvedilol",{"EARLY_PHASE1":10257,"PHASE1":10259,"PHASE2":10261,"PHASE3":10263,"PHASE4":10265,"NA":10267},{"trials":10258,"activeCount":99},[],{"trials":10260,"activeCount":99},[],{"trials":10262,"activeCount":99},[],{"trials":10264,"activeCount":99},[],{"trials":10266,"activeCount":99},[],{"trials":10268,"activeCount":99},[10269],{"nctId":10270,"briefTitle":10271,"status":120,"phases":10272,"completion":10273,"start":2648,"enrollment":10274,"conditions":10275,"interventions":10277},"NCT00214318","Beta-2 Polymorphisms and Beta Receptor Selectivity",[91],"2007-02",25,[10276],"Heart Failure",[10255],{"intervention":10279,"totalTrials":312,"cells":10280},"Calcineurin inhibitor withdrawal",{"EARLY_PHASE1":10281,"PHASE1":10283,"PHASE2":10285,"PHASE3":10287,"PHASE4":10289,"NA":10291},{"trials":10282,"activeCount":99},[],{"trials":10284,"activeCount":99},[],{"trials":10286,"activeCount":99},[],{"trials":10288,"activeCount":99},[],{"trials":10290,"activeCount":99},[],{"trials":10292,"activeCount":99},[10293],{"nctId":10294,"briefTitle":10295,"status":120,"phases":10296,"primaryCompletion":5626,"completion":5626,"start":5233,"enrollment":864,"conditions":10297,"interventions":10299},"NCT00214201","Campath-1H Induction to Allow Discontinuation of Calcineurin Inhibitors After Renal Transplantation",[91],[10298],"Primary Renal Transplant",[10279],{"intervention":10301,"totalTrials":312,"cells":10302},"salmeterol",{"EARLY_PHASE1":10303,"PHASE1":10305,"PHASE2":10307,"PHASE3":10309,"PHASE4":10311,"NA":10313},{"trials":10304,"activeCount":99},[],{"trials":10306,"activeCount":99},[],{"trials":10308,"activeCount":99},[],{"trials":10310,"activeCount":99},[],{"trials":10312,"activeCount":99},[],{"trials":10314,"activeCount":99},[10315],{"nctId":10316,"briefTitle":10317,"status":120,"phases":10318,"primaryCompletion":4823,"completion":4823,"start":2175,"enrollment":296,"conditions":10319,"interventions":10321},"NCT00214019","The Effect of Salmeterol on Eosinophil (EOS) Function",[91],[10320],"Allergic Asthma",[10301,10322],"Fluticasone",{"intervention":10322,"totalTrials":312,"cells":10324},{"EARLY_PHASE1":10325,"PHASE1":10327,"PHASE2":10329,"PHASE3":10331,"PHASE4":10333,"NA":10335},{"trials":10326,"activeCount":99},[],{"trials":10328,"activeCount":99},[],{"trials":10330,"activeCount":99},[],{"trials":10332,"activeCount":99},[],{"trials":10334,"activeCount":99},[],{"trials":10336,"activeCount":99},[10337],{"nctId":10316,"briefTitle":10317,"status":120,"phases":10338,"primaryCompletion":4823,"completion":4823,"start":2175,"enrollment":296,"conditions":10339,"interventions":10340},[91],[10320],[10301,10322],{"intervention":10342,"totalTrials":312,"cells":10343},"Anti-Hypertensive",{"EARLY_PHASE1":10344,"PHASE1":10346,"PHASE2":10348,"PHASE3":10350,"PHASE4":10352,"NA":10354},{"trials":10345,"activeCount":99},[],{"trials":10347,"activeCount":99},[],{"trials":10349,"activeCount":99},[],{"trials":10351,"activeCount":99},[],{"trials":10353,"activeCount":99},[],{"trials":10355,"activeCount":99},[10356],{"nctId":10357,"briefTitle":10358,"status":120,"phases":10359,"primaryCompletion":191,"completion":10360,"start":10361,"enrollment":6225,"conditions":10362,"interventions":10363},"NCT05479097","Feasibility Study of a Novel mHealth Application to Enable Community Health Workers to Manage",[91],"2023-12-31","2023-02-06",[3602],[10342],{"intervention":10365,"totalTrials":312,"cells":10366},"Dobutamine",{"EARLY_PHASE1":10367,"PHASE1":10369,"PHASE2":10371,"PHASE3":10373,"PHASE4":10375,"NA":10377},{"trials":10368,"activeCount":99},[],{"trials":10370,"activeCount":99},[],{"trials":10372,"activeCount":99},[],{"trials":10374,"activeCount":99},[],{"trials":10376,"activeCount":99},[],{"trials":10378,"activeCount":99},[10379],{"nctId":10380,"briefTitle":10381,"status":120,"phases":10382,"primaryCompletion":8500,"completion":8500,"start":3179,"enrollment":2491,"conditions":10383,"interventions":10387},"NCT01354613","Reduced Contractile Reserve: a Therapeutic Target in Heart Failure With Preserved Ejection Fraction(HFpEF)",[91],[10384,10385,10386],"Heart Failure With Preserved Ejection Fraction","Pulmonary Disease","Left Ventricular Hypertrophy\u002FHypertension",[10365,10388],"Amlodipine",{"intervention":10388,"totalTrials":312,"cells":10390},{"EARLY_PHASE1":10391,"PHASE1":10393,"PHASE2":10395,"PHASE3":10397,"PHASE4":10399,"NA":10401},{"trials":10392,"activeCount":99},[],{"trials":10394,"activeCount":99},[],{"trials":10396,"activeCount":99},[],{"trials":10398,"activeCount":99},[],{"trials":10400,"activeCount":99},[],{"trials":10402,"activeCount":99},[10403],{"nctId":10380,"briefTitle":10381,"status":120,"phases":10404,"primaryCompletion":8500,"completion":8500,"start":3179,"enrollment":2491,"conditions":10405,"interventions":10406},[91],[10384,10385,10386],[10365,10388],{"intervention":10408,"totalTrials":312,"cells":10409},"mepolizumab",{"EARLY_PHASE1":10410,"PHASE1":10412,"PHASE2":10414,"PHASE3":10416,"PHASE4":10418,"NA":10420},{"trials":10411,"activeCount":99},[],{"trials":10413,"activeCount":99},[],{"trials":10415,"activeCount":99},[],{"trials":10417,"activeCount":99},[],{"trials":10419,"activeCount":99},[],{"trials":10421,"activeCount":99},[10422],{"nctId":10423,"briefTitle":10424,"status":120,"phases":10425,"primaryCompletion":10426,"completion":10426,"start":10427,"enrollment":6378,"conditions":10428,"interventions":10429},"NCT00802438","Eosinophilic Airway Inflammation and Mepolizumab",[91],"2013-03-01","2008-06-01",[34],[10408],{"intervention":10431,"totalTrials":312,"cells":10432},"etanercept",{"EARLY_PHASE1":10433,"PHASE1":10435,"PHASE2":10437,"PHASE3":10439,"PHASE4":10441,"NA":10443},{"trials":10434,"activeCount":99},[],{"trials":10436,"activeCount":99},[],{"trials":10438,"activeCount":99},[],{"trials":10440,"activeCount":99},[],{"trials":10442,"activeCount":99},[],{"trials":10444,"activeCount":99},[10445],{"nctId":10446,"briefTitle":10447,"status":120,"phases":10448,"primaryCompletion":10449,"completion":10449,"start":6136,"enrollment":10274,"conditions":10450,"interventions":10451},"NCT00205231","A Pilot Study to Examine the Feasibility and Effect of Tumor Necrosis Factor (TNF) Inhibition on HIV Disease",[91],"2004-05-01",[10190],[10431],{"intervention":10453,"totalTrials":312,"cells":10454},"montelukast",{"EARLY_PHASE1":10455,"PHASE1":10457,"PHASE2":10459,"PHASE3":10461,"PHASE4":10463,"NA":10465},{"trials":10456,"activeCount":99},[],{"trials":10458,"activeCount":99},[],{"trials":10460,"activeCount":99},[],{"trials":10462,"activeCount":99},[],{"trials":10464,"activeCount":99},[],{"trials":10466,"activeCount":99},[10467],{"nctId":10468,"briefTitle":10469,"status":120,"phases":10470,"primaryCompletion":262,"completion":262,"start":7292,"enrollment":10274,"conditions":10471,"interventions":10472},"NCT00359073","Effect of Montelukast on Experimentally-Induced RV16 Infection in Asthma",[91],[34],[10453],{"intervention":10474,"totalTrials":312,"cells":10475},"Xeloda",{"EARLY_PHASE1":10476,"PHASE1":10478,"PHASE2":10480,"PHASE3":10482,"PHASE4":10484,"NA":10486},{"trials":10477,"activeCount":99},[],{"trials":10479,"activeCount":99},[],{"trials":10481,"activeCount":99},[],{"trials":10483,"activeCount":99},[],{"trials":10485,"activeCount":99},[],{"trials":10487,"activeCount":99},[10488],{"nctId":10489,"briefTitle":10490,"status":120,"phases":10491,"primaryCompletion":10492,"completion":10492,"start":3239,"enrollment":559,"conditions":10493,"interventions":10494},"NCT01828554","Capecitabine Pharmacokinetics(PK)-Actual Versus Ideal Body Weight",[91],"2018-04",[24,1104],[10474],{"intervention":10496,"totalTrials":312,"cells":10497},"Hypoxyprobe-1",{"EARLY_PHASE1":10498,"PHASE1":10500,"PHASE2":10502,"PHASE3":10504,"PHASE4":10506,"NA":10508},{"trials":10499,"activeCount":99},[],{"trials":10501,"activeCount":99},[],{"trials":10503,"activeCount":99},[],{"trials":10505,"activeCount":99},[],{"trials":10507,"activeCount":99},[],{"trials":10509,"activeCount":99},[10510],{"nctId":10511,"briefTitle":10512,"status":120,"phases":10513,"primaryCompletion":10514,"completion":10515,"start":10516,"enrollment":559,"conditions":10517,"interventions":10518},"NCT01674465","Role of Nox2 in CNI-induced Renal Fibrosis",[],"2018-08-09","2019-10-10","2012-11-30",[2178],[10496],{"intervention":10520,"totalTrials":312,"cells":10521},"Corticosteroid withdrawal",{"EARLY_PHASE1":10522,"PHASE1":10524,"PHASE2":10526,"PHASE3":10528,"PHASE4":10530,"NA":10532},{"trials":10523,"activeCount":99},[],{"trials":10525,"activeCount":99},[],{"trials":10527,"activeCount":99},[],{"trials":10529,"activeCount":99},[],{"trials":10531,"activeCount":99},[],{"trials":10533,"activeCount":99},[10534],{"nctId":10535,"briefTitle":10536,"status":120,"phases":10537,"primaryCompletion":6317,"completion":6317,"start":6136,"enrollment":6225,"conditions":10538,"interventions":10539},"NCT00214279","MMF Monotherapy and Immune Regulation in Kidney Transplant Recipients: Part 1 Steroid Withdrawal",[91],[7974],[10520],{"intervention":10541,"totalTrials":312,"cells":10542},"House Dust Mite SLIT",{"EARLY_PHASE1":10543,"PHASE1":10545,"PHASE2":10547,"PHASE3":10549,"PHASE4":10551,"NA":10553},{"trials":10544,"activeCount":99},[],{"trials":10546,"activeCount":99},[],{"trials":10548,"activeCount":99},[],{"trials":10550,"activeCount":99},[],{"trials":10552,"activeCount":99},[],{"trials":10554,"activeCount":99},[10555],{"nctId":10556,"briefTitle":10557,"status":120,"phases":10558,"primaryCompletion":10559,"completion":10559,"start":9882,"enrollment":19,"conditions":10560,"interventions":10561},"NCT00200850","Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy",[91],"2008-10",[34],[10541,10562],"High dose SLIT",{"intervention":10562,"totalTrials":312,"cells":10564},{"EARLY_PHASE1":10565,"PHASE1":10567,"PHASE2":10569,"PHASE3":10571,"PHASE4":10573,"NA":10575},{"trials":10566,"activeCount":99},[],{"trials":10568,"activeCount":99},[],{"trials":10570,"activeCount":99},[],{"trials":10572,"activeCount":99},[],{"trials":10574,"activeCount":99},[],{"trials":10576,"activeCount":99},[10577],{"nctId":10556,"briefTitle":10557,"status":120,"phases":10578,"primaryCompletion":10559,"completion":10559,"start":9882,"enrollment":19,"conditions":10579,"interventions":10580},[91],[34],[10541,10562],{"intervention":1948,"totalTrials":312,"cells":10582},{"EARLY_PHASE1":10583,"PHASE1":10585,"PHASE2":10587,"PHASE3":10589,"PHASE4":10591,"NA":10593},{"trials":10584,"activeCount":99},[],{"trials":10586,"activeCount":99},[],{"trials":10588,"activeCount":99},[],{"trials":10590,"activeCount":99},[],{"trials":10592,"activeCount":99},[],{"trials":10594,"activeCount":99},[10595],{"nctId":1938,"briefTitle":1939,"status":120,"phases":10596,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1322,"conditions":10597,"interventions":10598},[91],[1945],[1947,1948,360,1949,1950,500,65],{"intervention":1949,"totalTrials":312,"cells":10600},{"EARLY_PHASE1":10601,"PHASE1":10603,"PHASE2":10605,"PHASE3":10607,"PHASE4":10609,"NA":10611},{"trials":10602,"activeCount":99},[],{"trials":10604,"activeCount":99},[],{"trials":10606,"activeCount":99},[],{"trials":10608,"activeCount":99},[],{"trials":10610,"activeCount":99},[],{"trials":10612,"activeCount":99},[10613],{"nctId":1938,"briefTitle":1939,"status":120,"phases":10614,"primaryCompletion":1941,"completion":1942,"start":1943,"enrollment":1322,"conditions":10615,"interventions":10616},[91],[1945],[1947,1948,360,1949,1950,500,65],{"intervention":10618,"totalTrials":312,"cells":10619},"cytogenetic analysis",{"EARLY_PHASE1":10620,"PHASE1":10622,"PHASE2":10624,"PHASE3":10626,"PHASE4":10628,"NA":10630},{"trials":10621,"activeCount":99},[],{"trials":10623,"activeCount":99},[],{"trials":10625,"activeCount":99},[],{"trials":10627,"activeCount":99},[],{"trials":10629,"activeCount":99},[],{"trials":10631,"activeCount":99},[10632],{"nctId":10633,"briefTitle":10634,"status":342,"phases":10635,"conditions":10636,"interventions":10637},"NCT01004796","Study of Biomarkers in Tissue Samples From Patients With Breast Cancer",[],[15],[10618,10638,10639],"microarray analysis","mutation analysis",{"intervention":10638,"totalTrials":312,"cells":10641},{"EARLY_PHASE1":10642,"PHASE1":10644,"PHASE2":10646,"PHASE3":10648,"PHASE4":10650,"NA":10652},{"trials":10643,"activeCount":99},[],{"trials":10645,"activeCount":99},[],{"trials":10647,"activeCount":99},[],{"trials":10649,"activeCount":99},[],{"trials":10651,"activeCount":99},[],{"trials":10653,"activeCount":99},[10654],{"nctId":10633,"briefTitle":10634,"status":342,"phases":10655,"conditions":10656,"interventions":10657},[],[15],[10618,10638,10639],{"intervention":10639,"totalTrials":312,"cells":10659},{"EARLY_PHASE1":10660,"PHASE1":10662,"PHASE2":10664,"PHASE3":10666,"PHASE4":10668,"NA":10670},{"trials":10661,"activeCount":99},[],{"trials":10663,"activeCount":99},[],{"trials":10665,"activeCount":99},[],{"trials":10667,"activeCount":99},[],{"trials":10669,"activeCount":99},[],{"trials":10671,"activeCount":99},[10672],{"nctId":10633,"briefTitle":10634,"status":342,"phases":10673,"conditions":10674,"interventions":10675},[],[15],[10618,10638,10639],{"intervention":10013,"totalTrials":312,"cells":10677},{"EARLY_PHASE1":10678,"PHASE1":10680,"PHASE2":10682,"PHASE3":10684,"PHASE4":10686,"NA":10688},{"trials":10679,"activeCount":99},[],{"trials":10681,"activeCount":99},[],{"trials":10683,"activeCount":99},[],{"trials":10685,"activeCount":99},[],{"trials":10687,"activeCount":99},[],{"trials":10689,"activeCount":99},[10690],{"nctId":10006,"briefTitle":10007,"status":681,"phases":10691,"primaryCompletion":10009,"completion":10009,"start":10010,"enrollment":1952,"conditions":10692,"interventions":10693},[],[15,5026],[10013,10014,10015,10016,9981],{"intervention":10014,"totalTrials":312,"cells":10695},{"EARLY_PHASE1":10696,"PHASE1":10698,"PHASE2":10700,"PHASE3":10702,"PHASE4":10704,"NA":10706},{"trials":10697,"activeCount":99},[],{"trials":10699,"activeCount":99},[],{"trials":10701,"activeCount":99},[],{"trials":10703,"activeCount":99},[],{"trials":10705,"activeCount":99},[],{"trials":10707,"activeCount":99},[10708],{"nctId":10006,"briefTitle":10007,"status":681,"phases":10709,"primaryCompletion":10009,"completion":10009,"start":10010,"enrollment":1952,"conditions":10710,"interventions":10711},[],[15,5026],[10013,10014,10015,10016,9981],{"intervention":10015,"totalTrials":312,"cells":10713},{"EARLY_PHASE1":10714,"PHASE1":10716,"PHASE2":10718,"PHASE3":10720,"PHASE4":10722,"NA":10724},{"trials":10715,"activeCount":99},[],{"trials":10717,"activeCount":99},[],{"trials":10719,"activeCount":99},[],{"trials":10721,"activeCount":99},[],{"trials":10723,"activeCount":99},[],{"trials":10725,"activeCount":99},[10726],{"nctId":10006,"briefTitle":10007,"status":681,"phases":10727,"primaryCompletion":10009,"completion":10009,"start":10010,"enrollment":1952,"conditions":10728,"interventions":10729},[],[15,5026],[10013,10014,10015,10016,9981],{"intervention":10016,"totalTrials":312,"cells":10731},{"EARLY_PHASE1":10732,"PHASE1":10734,"PHASE2":10736,"PHASE3":10738,"PHASE4":10740,"NA":10742},{"trials":10733,"activeCount":99},[],{"trials":10735,"activeCount":99},[],{"trials":10737,"activeCount":99},[],{"trials":10739,"activeCount":99},[],{"trials":10741,"activeCount":99},[],{"trials":10743,"activeCount":99},[10744],{"nctId":10006,"briefTitle":10007,"status":681,"phases":10745,"primaryCompletion":10009,"completion":10009,"start":10010,"enrollment":1952,"conditions":10746,"interventions":10747},[],[15,5026],[10013,10014,10015,10016,9981],{"intervention":10749,"totalTrials":312,"cells":10750},"Nicotine replacement therapy sampling",{"EARLY_PHASE1":10751,"PHASE1":10753,"PHASE2":10755,"PHASE3":10757,"PHASE4":10759,"NA":10761},{"trials":10752,"activeCount":99},[],{"trials":10754,"activeCount":99},[],{"trials":10756,"activeCount":99},[],{"trials":10758,"activeCount":99},[],{"trials":10760,"activeCount":99},[],{"trials":10762,"activeCount":99},[10763],{"nctId":10764,"briefTitle":10765,"status":120,"phases":10766,"primaryCompletion":10767,"completion":10767,"start":10768,"enrollment":10769,"conditions":10770,"interventions":10772},"NCT05683821","BREATHE 2 Clinic Stop-Smoking Treatment Outreach Study",[91],"2025-05-07","2023-07-24",12376,[10771,26,279],"Quitting Smoking",[10749,10773,10774,10775],"Wisconsin Tobacco QuitLine Referral","Referral to Primary Care Provider","BREATHE 2 Cessation Study",{"intervention":10773,"totalTrials":312,"cells":10777},{"EARLY_PHASE1":10778,"PHASE1":10780,"PHASE2":10782,"PHASE3":10784,"PHASE4":10786,"NA":10788},{"trials":10779,"activeCount":99},[],{"trials":10781,"activeCount":99},[],{"trials":10783,"activeCount":99},[],{"trials":10785,"activeCount":99},[],{"trials":10787,"activeCount":99},[],{"trials":10789,"activeCount":99},[10790],{"nctId":10764,"briefTitle":10765,"status":120,"phases":10791,"primaryCompletion":10767,"completion":10767,"start":10768,"enrollment":10769,"conditions":10792,"interventions":10793},[91],[10771,26,279],[10749,10773,10774,10775],{"intervention":10774,"totalTrials":312,"cells":10795},{"EARLY_PHASE1":10796,"PHASE1":10798,"PHASE2":10800,"PHASE3":10802,"PHASE4":10804,"NA":10806},{"trials":10797,"activeCount":99},[],{"trials":10799,"activeCount":99},[],{"trials":10801,"activeCount":99},[],{"trials":10803,"activeCount":99},[],{"trials":10805,"activeCount":99},[],{"trials":10807,"activeCount":99},[10808],{"nctId":10764,"briefTitle":10765,"status":120,"phases":10809,"primaryCompletion":10767,"completion":10767,"start":10768,"enrollment":10769,"conditions":10810,"interventions":10811},[91],[10771,26,279],[10749,10773,10774,10775],{"intervention":10775,"totalTrials":312,"cells":10813},{"EARLY_PHASE1":10814,"PHASE1":10816,"PHASE2":10818,"PHASE3":10820,"PHASE4":10822,"NA":10824},{"trials":10815,"activeCount":99},[],{"trials":10817,"activeCount":99},[],{"trials":10819,"activeCount":99},[],{"trials":10821,"activeCount":99},[],{"trials":10823,"activeCount":99},[],{"trials":10825,"activeCount":99},[10826],{"nctId":10764,"briefTitle":10765,"status":120,"phases":10827,"primaryCompletion":10767,"completion":10767,"start":10768,"enrollment":10769,"conditions":10828,"interventions":10829},[91],[10771,26,279],[10749,10773,10774,10775],{"intervention":10831,"totalTrials":312,"cells":10832},"Campath-1H, rituximab, myfortic",{"EARLY_PHASE1":10833,"PHASE1":10835,"PHASE2":10837,"PHASE3":10839,"PHASE4":10841,"NA":10843},{"trials":10834,"activeCount":99},[],{"trials":10836,"activeCount":99},[],{"trials":10838,"activeCount":99},[],{"trials":10840,"activeCount":99},[],{"trials":10842,"activeCount":99},[],{"trials":10844,"activeCount":99},[10845],{"nctId":10846,"briefTitle":10847,"status":681,"phases":10848,"primaryCompletion":9189,"completion":5888,"start":10849,"enrollment":1322,"conditions":10850,"interventions":10852},"NCT00579592","Campath, Rituximab, and Myfortic With Short-Course Calcineurin Inhibitor Therapy in Renal Transplanation",[91],"2006-04",[10851,7974],"Acute Rejection",[10831],{"intervention":10854,"totalTrials":312,"cells":10855},"124I-NM404",{"EARLY_PHASE1":10856,"PHASE1":10858,"PHASE2":10860,"PHASE3":10862,"PHASE4":10864,"NA":10866},{"trials":10857,"activeCount":99},[],{"trials":10859,"activeCount":99},[],{"trials":10861,"activeCount":99},[],{"trials":10863,"activeCount":99},[],{"trials":10865,"activeCount":99},[],{"trials":10867,"activeCount":99},[10868],{"nctId":10869,"briefTitle":10870,"status":681,"phases":10871,"primaryCompletion":239,"completion":239,"start":10872,"enrollment":95,"conditions":10873,"interventions":10875},"NCT01662284","Study of 124I-NM404 in Advanced Solid Malignancies",[],"2012-07",[10874],"Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer",[10854],{"intervention":10877,"totalTrials":312,"cells":10878},"FP 220 mcg 2 puffs BID",{"EARLY_PHASE1":10879,"PHASE1":10881,"PHASE2":10883,"PHASE3":10885,"PHASE4":10887,"NA":10889},{"trials":10880,"activeCount":99},[],{"trials":10882,"activeCount":99},[],{"trials":10884,"activeCount":99},[],{"trials":10886,"activeCount":99},[],{"trials":10888,"activeCount":99},[],{"trials":10890,"activeCount":99},[10891],{"nctId":10892,"briefTitle":10893,"status":120,"phases":10894,"primaryCompletion":144,"completion":144,"start":5454,"enrollment":296,"conditions":10895,"interventions":10897},"NCT01184118","DREAM: Does Inhaled Fluticasone REsult in Obstructive Sleep Apnea Manifestations?",[91],[10896],"Lung Disease",[10877],{"intervention":10899,"totalTrials":312,"cells":10900},"solifenacin",{"EARLY_PHASE1":10901,"PHASE1":10903,"PHASE2":10905,"PHASE3":10907,"PHASE4":10909,"NA":10911},{"trials":10902,"activeCount":99},[],{"trials":10904,"activeCount":99},[],{"trials":10906,"activeCount":99},[],{"trials":10908,"activeCount":99},[],{"trials":10910,"activeCount":99},[],{"trials":10912,"activeCount":99},[10913],{"nctId":10914,"briefTitle":10915,"status":120,"phases":10916,"primaryCompletion":10917,"completion":10917,"start":145,"enrollment":10918,"conditions":10919,"interventions":10922},"NCT01470001","The Effect of Solifenacin on Post Void Dribbling in Women",[91],"2015-09",118,[10920,10921],"Post-micturition Incontinence","Incontinence",[10899],{"intervention":9898,"totalTrials":312,"cells":10924},{"EARLY_PHASE1":10925,"PHASE1":10927,"PHASE2":10929,"PHASE3":10931,"PHASE4":10933,"NA":10935},{"trials":10926,"activeCount":99},[],{"trials":10928,"activeCount":99},[],{"trials":10930,"activeCount":99},[],{"trials":10932,"activeCount":99},[],{"trials":10934,"activeCount":99},[],{"trials":10936,"activeCount":99},[10937],{"nctId":9891,"briefTitle":9892,"status":120,"phases":10938,"primaryCompletion":155,"completion":155,"start":5284,"enrollment":9894,"conditions":10939,"interventions":10940},[],[9896],[9898,9899,9900],{"intervention":9900,"totalTrials":312,"cells":10942},{"EARLY_PHASE1":10943,"PHASE1":10945,"PHASE2":10947,"PHASE3":10949,"PHASE4":10951,"NA":10953},{"trials":10944,"activeCount":99},[],{"trials":10946,"activeCount":99},[],{"trials":10948,"activeCount":99},[],{"trials":10950,"activeCount":99},[],{"trials":10952,"activeCount":99},[],{"trials":10954,"activeCount":99},[10955],{"nctId":9891,"briefTitle":9892,"status":120,"phases":10956,"primaryCompletion":155,"completion":155,"start":5284,"enrollment":9894,"conditions":10957,"interventions":10958},[],[9896],[9898,9899,9900],{"intervention":10960,"totalTrials":312,"cells":10961},"Whole lung antigen challenge, segmental allergen challenge",{"EARLY_PHASE1":10962,"PHASE1":10964,"PHASE2":10966,"PHASE3":10968,"PHASE4":10970,"NA":10972},{"trials":10963,"activeCount":99},[],{"trials":10965,"activeCount":99},[],{"trials":10967,"activeCount":99},[],{"trials":10969,"activeCount":99},[],{"trials":10971,"activeCount":99},[],{"trials":10973,"activeCount":99},[10974],{"nctId":10975,"briefTitle":10976,"status":120,"phases":10977,"primaryCompletion":10978,"completion":10978,"start":10979,"enrollment":7180,"conditions":10980,"interventions":10981},"NCT02764437","AsthMatic Inflammation and Neurocircuitry Activation (MINA)",[],"2020-03-31","2016-07-28",[10320],[10960],{"intervention":10983,"totalTrials":312,"cells":10984},"Venlafaxine ERT",{"EARLY_PHASE1":10985,"PHASE1":10987,"PHASE2":10989,"PHASE3":10991,"PHASE4":10993,"NA":10995},{"trials":10986,"activeCount":99},[],{"trials":10988,"activeCount":99},[],{"trials":10990,"activeCount":99},[],{"trials":10992,"activeCount":99},[],{"trials":10994,"activeCount":99},[],{"trials":10996,"activeCount":99},[10997],{"nctId":10998,"briefTitle":10999,"status":120,"phases":11000,"primaryCompletion":3574,"completion":3574,"start":11001,"enrollment":372,"conditions":11002,"interventions":11004},"NCT00909155","Brain Imaging Techniques That Predict Antidepressant Responsiveness",[91],"2002-07",[11003],"Major Depressive Disorder",[10983,11005],"Fluoxetine",{"intervention":11005,"totalTrials":312,"cells":11007},{"EARLY_PHASE1":11008,"PHASE1":11010,"PHASE2":11012,"PHASE3":11014,"PHASE4":11016,"NA":11018},{"trials":11009,"activeCount":99},[],{"trials":11011,"activeCount":99},[],{"trials":11013,"activeCount":99},[],{"trials":11015,"activeCount":99},[],{"trials":11017,"activeCount":99},[],{"trials":11019,"activeCount":99},[11020],{"nctId":10998,"briefTitle":10999,"status":120,"phases":11021,"primaryCompletion":3574,"completion":3574,"start":11001,"enrollment":372,"conditions":11022,"interventions":11023},[91],[11003],[10983,11005],{"intervention":11025,"totalTrials":312,"cells":11026},"Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy",{"EARLY_PHASE1":11027,"PHASE1":11029,"PHASE2":11031,"PHASE3":11033,"PHASE4":11035,"NA":11037},{"trials":11028,"activeCount":99},[],{"trials":11030,"activeCount":99},[],{"trials":11032,"activeCount":99},[],{"trials":11034,"activeCount":99},[],{"trials":11036,"activeCount":99},[],{"trials":11038,"activeCount":99},[11039],{"nctId":11040,"briefTitle":11041,"status":681,"phases":11042,"primaryCompletion":171,"completion":5223,"start":145,"enrollment":1322,"conditions":11043,"interventions":11045},"NCT01230502","Mycophenolic Acid (MPA) Monotherapy in Liver Transplantation",[91],[11044],"Liver Transplant",[11025],{"intervention":11047,"totalTrials":312,"cells":11048},"Caffeine",{"EARLY_PHASE1":11049,"PHASE1":11051,"PHASE2":11053,"PHASE3":11055,"PHASE4":11057,"NA":11059},{"trials":11050,"activeCount":99},[],{"trials":11052,"activeCount":99},[],{"trials":11054,"activeCount":99},[],{"trials":11056,"activeCount":99},[],{"trials":11058,"activeCount":99},[],{"trials":11060,"activeCount":99},[11061],{"nctId":11062,"briefTitle":11063,"status":120,"phases":11064,"primaryCompletion":978,"completion":978,"start":11065,"enrollment":372,"conditions":11066,"interventions":11068},"NCT00205166","Does Caffeine Affect the Sensitivity of Adenosine Perfusion Scans?",[91],"1999-06",[11067],"Coronary Artery Disease",[11047,11047],{"intervention":11070,"totalTrials":312,"cells":11071},"Nelfinavir",{"EARLY_PHASE1":11072,"PHASE1":11074,"PHASE2":11076,"PHASE3":11078,"PHASE4":11080,"NA":11082},{"trials":11073,"activeCount":99},[],{"trials":11075,"activeCount":99},[],{"trials":11077,"activeCount":99},[],{"trials":11079,"activeCount":99},[],{"trials":11081,"activeCount":99},[],{"trials":11083,"activeCount":99},[11084],{"nctId":11085,"briefTitle":11086,"status":120,"phases":11087,"primaryCompletion":11088,"completion":11088,"start":6521,"enrollment":32,"conditions":11089,"interventions":11090},"NCT00205283","Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection",[91],"2005-08-01",[10190],[11070],{"intervention":11092,"totalTrials":312,"cells":11093},"Adductor Canal Block",{"EARLY_PHASE1":11094,"PHASE1":11096,"PHASE2":11098,"PHASE3":11100,"PHASE4":11102,"NA":11104},{"trials":11095,"activeCount":99},[],{"trials":11097,"activeCount":99},[],{"trials":11099,"activeCount":99},[],{"trials":11101,"activeCount":99},[],{"trials":11103,"activeCount":99},[],{"trials":11105,"activeCount":99},[11106],{"nctId":11107,"briefTitle":11108,"status":120,"phases":11109,"primaryCompletion":11110,"completion":11110,"start":1068,"enrollment":577,"conditions":11111,"interventions":11113},"NCT02453360","Adductor Canal Block for Total Knee Arthroplasty",[91],"2017-07",[11112,3369],"Arthroplasty, Replacement, Knee",[11092],{"intervention":11115,"totalTrials":312,"cells":11116},"Amoxicillin-Potassium Clavulanate Combination",{"EARLY_PHASE1":11117,"PHASE1":11119,"PHASE2":11121,"PHASE3":11123,"PHASE4":11125,"NA":11127},{"trials":11118,"activeCount":99},[],{"trials":11120,"activeCount":99},[],{"trials":11122,"activeCount":99},[],{"trials":11124,"activeCount":99},[],{"trials":11126,"activeCount":99},[],{"trials":11128,"activeCount":99},[11129],{"nctId":11130,"briefTitle":11131,"status":120,"phases":11132,"primaryCompletion":295,"completion":295,"start":5048,"enrollment":11133,"conditions":11134,"interventions":11136},"NCT01166945","Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children",[91],98,[11135],"Sinusitis",[11115],{"intervention":11138,"totalTrials":312,"cells":11139},"olopatadine",{"EARLY_PHASE1":11140,"PHASE1":11142,"PHASE2":11144,"PHASE3":11146,"PHASE4":11148,"NA":11150},{"trials":11141,"activeCount":99},[],{"trials":11143,"activeCount":99},[],{"trials":11145,"activeCount":99},[],{"trials":11147,"activeCount":99},[],{"trials":11149,"activeCount":99},[],{"trials":11151,"activeCount":99},[11152],{"nctId":11153,"briefTitle":11154,"status":120,"phases":11155,"primaryCompletion":764,"completion":764,"start":11156,"enrollment":2580,"conditions":11157,"interventions":11159},"NCT00609128","Effect of Olopatadine on Allergic Tear Mediators",[91],"2000-09",[11158],"Allergic Conjunctivitis",[11138],{"intervention":11161,"totalTrials":312,"cells":11162},"Instilled 1% Lidocaine",{"EARLY_PHASE1":11163,"PHASE1":11165,"PHASE2":11167,"PHASE3":11169,"PHASE4":11171,"NA":11173},{"trials":11164,"activeCount":99},[],{"trials":11166,"activeCount":99},[],{"trials":11168,"activeCount":99},[],{"trials":11170,"activeCount":99},[],{"trials":11172,"activeCount":99},[],{"trials":11174,"activeCount":99},[11175],{"nctId":11176,"briefTitle":11177,"status":120,"phases":11178,"primaryCompletion":11179,"completion":11179,"start":9717,"enrollment":616,"conditions":11180,"interventions":11182},"NCT00585325","Instilled Lidocaine vs Placebo for Pain Management During Vacuum Assisted Closure (VAC) Dressing Changes",[91],"2008-11",[11181],"Burn",[11161],{"intervention":11184,"totalTrials":312,"cells":11185},"Propofol-Fentanyl",{"EARLY_PHASE1":11186,"PHASE1":11188,"PHASE2":11190,"PHASE3":11192,"PHASE4":11194,"NA":11196},{"trials":11187,"activeCount":99},[],{"trials":11189,"activeCount":99},[],{"trials":11191,"activeCount":99},[],{"trials":11193,"activeCount":99},[],{"trials":11195,"activeCount":99},[],{"trials":11197,"activeCount":99},[11198],{"nctId":11199,"briefTitle":11200,"status":120,"phases":11201,"completion":6318,"start":5232,"enrollment":864,"conditions":11202,"interventions":11203},"NCT00214370","Propofol Versus Propofol-Fentanyl as Sedation For Lumbar Puncture in Children With Acute Leukemia\u002FLymphoma",[91],[6732,1945],[11184,11204],"Propofol alone",{"intervention":11204,"totalTrials":312,"cells":11206},{"EARLY_PHASE1":11207,"PHASE1":11209,"PHASE2":11211,"PHASE3":11213,"PHASE4":11215,"NA":11217},{"trials":11208,"activeCount":99},[],{"trials":11210,"activeCount":99},[],{"trials":11212,"activeCount":99},[],{"trials":11214,"activeCount":99},[],{"trials":11216,"activeCount":99},[],{"trials":11218,"activeCount":99},[11219],{"nctId":11199,"briefTitle":11200,"status":120,"phases":11220,"completion":6318,"start":5232,"enrollment":864,"conditions":11221,"interventions":11222},[91],[6732,1945],[11184,11204],{"intervention":11224,"totalTrials":312,"cells":11225},"Intravenous Ascorbic Acid",{"EARLY_PHASE1":11226,"PHASE1":11228,"PHASE2":11230,"PHASE3":11232,"PHASE4":11234,"NA":11236},{"trials":11227,"activeCount":99},[],{"trials":11229,"activeCount":99},[],{"trials":11231,"activeCount":99},[],{"trials":11233,"activeCount":99},[],{"trials":11235,"activeCount":99},[],{"trials":11237,"activeCount":99},[11238],{"nctId":11239,"briefTitle":11240,"status":120,"phases":11241,"primaryCompletion":11242,"completion":11242,"start":11243,"enrollment":11244,"conditions":11245,"interventions":11248},"NCT03913468","Outcomes of Septic Shock Patients Treated With a Metabolic Resuscitation Bundle Consisting of Intravenous Hydrocortisone, Ascorbic Acid and Thiamine.",[],"2019-12-01","2019-01-01",206,[11246,11247],"Septic Shock","Ascorbic Acid Deficiency",[11224],{"intervention":11250,"totalTrials":312,"cells":11251},"Naltrexone, then placebo",{"EARLY_PHASE1":11252,"PHASE1":11254,"PHASE2":11256,"PHASE3":11258,"PHASE4":11260,"NA":11262},{"trials":11253,"activeCount":99},[],{"trials":11255,"activeCount":99},[],{"trials":11257,"activeCount":99},[],{"trials":11259,"activeCount":99},[],{"trials":11261,"activeCount":99},[],{"trials":11263,"activeCount":99},[11264],{"nctId":11265,"briefTitle":11266,"status":120,"phases":11267,"primaryCompletion":11268,"completion":11268,"start":261,"enrollment":577,"conditions":11269,"interventions":11270},"NCT01220414","Attenuation of Pain in Men and Women",[91],"2013-01",[2839],[11250],{"intervention":11272,"totalTrials":312,"cells":11273},"oral hydralazine and intravenous nesiritide",{"EARLY_PHASE1":11274,"PHASE1":11276,"PHASE2":11278,"PHASE3":11280,"PHASE4":11282,"NA":11284},{"trials":11275,"activeCount":99},[],{"trials":11277,"activeCount":99},[],{"trials":11279,"activeCount":99},[],{"trials":11281,"activeCount":99},[],{"trials":11283,"activeCount":99},[],{"trials":11285,"activeCount":99},[11286],{"nctId":11287,"briefTitle":11288,"status":120,"phases":11289,"primaryCompletion":11290,"completion":11290,"start":1069,"enrollment":2298,"conditions":11291,"interventions":11293},"NCT00204984","Heart and Blood Pressure Study: The Effect of Aortic Impedance on Myocardial Relaxation",[91],"2006-12-20",[11292],"High Blood Pressure",[11272],{"intervention":11295,"totalTrials":312,"cells":11296},"nesiritide",{"EARLY_PHASE1":11297,"PHASE1":11299,"PHASE2":11301,"PHASE3":11303,"PHASE4":11305,"NA":11307},{"trials":11298,"activeCount":99},[],{"trials":11300,"activeCount":99},[],{"trials":11302,"activeCount":99},[],{"trials":11304,"activeCount":99},[],{"trials":11306,"activeCount":99},[],{"trials":11308,"activeCount":99},[11309],{"nctId":11310,"briefTitle":11311,"status":120,"phases":11312,"primaryCompletion":11313,"completion":11313,"start":5462,"enrollment":616,"conditions":11314,"interventions":11316},"NCT00204945","Catheterization Laboratory Study: Acute Responses in Diastolic Heart Failure",[91],"2007-06-20",[11315],"Heart Failure, Congestive",[11295],{"intervention":11318,"totalTrials":312,"cells":11319},"Arnica montana",{"EARLY_PHASE1":11320,"PHASE1":11322,"PHASE2":11324,"PHASE3":11326,"PHASE4":11328,"NA":11330},{"trials":11321,"activeCount":99},[],{"trials":11323,"activeCount":99},[],{"trials":11325,"activeCount":99},[],{"trials":11327,"activeCount":99},[],{"trials":11329,"activeCount":99},[],{"trials":11331,"activeCount":99},[11332],{"nctId":11333,"briefTitle":11334,"status":120,"phases":11335,"primaryCompletion":123,"completion":123,"start":213,"enrollment":4889,"conditions":11336,"interventions":11338},"NCT01164644","The Utility of Peri-operative Arnica Montana for Reduction of Ecchymosis in Rhinoplasty Surgery",[91],[11337],"Ecchymosis",[11318]]